BackgroundHuman	O
embryonic	O
stem	O
cells	O
provide	O
access	O
to	O
the	O
earliest	O
stages	O
of	O
human	O
development	O
and	O
may	O
serve	O
as	O
a	O
source	O
of	O
specialized	O
cells	O
for	O
regenerative	O
medicine	O
.	O

Thus	O
,	O
it	O
becomes	O
crucial	O
to	O
develop	O
protocols	O
for	O
the	O
directed	O
differentiation	O
of	O
embryonic	O
stem	O
cells	O
into	O
tissue	O
-	O
restricted	O
precursors	O
.	O

Methods	O
and	O
FindingsHere	O
,	O
we	O
present	O
culture	O
conditions	O
for	O
the	O
derivation	O
of	O
unlimited	O
numbers	O
of	O
pure	O
mesenchymal	O
precursors	O
from	O
human	O
embryonic	O
stem	O
cells	O
and	O
demonstrate	O
multilineage	O
differentiation	O
into	O
fat	O
,	O
cartilage	O
,	O
bone	O
,	O
and	O
skeletal	O
muscle	O
cells	O
.	O

ConclusionOur	O
findings	O
will	O
help	O
to	O
elucidate	O
the	O
mechanism	O
of	O
mesoderm	O
specification	O
during	O
embryonic	O
stem	O
cell	O
differentiation	O
and	O
provide	O
a	O
platform	O
to	O
efficiently	O
generate	O
specialized	O
human	O
mesenchymal	O
cell	O
types	O
for	O
future	O
clinical	O
applications	O
.	O

Lorenz	O
Studer	O
and	O
colleagues	O
describe	O
the	O
use	O
of	O
embryonic	O
stem	O
cells	O
to	O
derive	O
mesenchymal	O
precursors	O
and	O
then	O
fat	O
,	O
cartilage	O
,	O
bone	O
,	O
and	O
skeletal	O
muscle	O
cells	O
.	O

Embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
are	O
pluripotent	O
cells	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
that	O
can	O
be	O
maintained	O
in	O
culture	O
for	O
an	O
extended	O
period	O
of	O
time	O
without	O
losing	O
differentiation	O
potential	O
.	O

The	O
successful	O
isolation	O
of	O
human	O
ES	O
cells	O
(	O
hESCs	O
)	O
has	O
raised	O
the	O
hope	O
that	O
these	O
cells	O
may	O
provide	O
a	O
universal	O
tissue	O
source	O
to	O
treat	O
many	O
human	O
diseases	O
.	O

However	O
,	O
directed	O
differentiation	O
of	O
hESCs	O
into	O
specific	O
tissue	O
types	O
poses	O
a	O
formidable	O
challenge	O
.	O

Protocols	O
are	O
currently	O
available	O
for	O
only	O
a	O
few	O
cell	O
types	O
,	O
mostly	O
of	O
neural	O
identity	O
[	O
1–3	O
]	O
,	O
and	O
differentiation	O
into	O
many	O
of	O
the	O
cell	O
types	O
derived	O
from	O
the	O
paraxial	O
mesoderm	O
has	O
not	O
been	O
reported	O
,	O
with	O
the	O
exception	O
of	O
a	O
recent	O
study	O
indicating	O
osteoblastic	O
differentiation	O
[	O
4	O
]	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
been	O
isolated	O
from	O
the	O
adult	O
bone	O
marrow	O
[	O
5	O
]	O
,	O
adipose	O
tissue	O
[	O
6	O
]	O
,	O
and	O
dermis	O
and	O
other	O
connective	O
tissues	O
[	O
7	O
]	O
.	O

Harvesting	O
MSCs	O
from	O
any	O
of	O
these	O
sources	O
requires	O
invasive	O
procedures	O
and	O
the	O
availability	O
of	O
a	O
suitable	O
donor	O
.	O

The	O
number	O
of	O
MSCs	O
that	O
can	O
be	O
obtained	O
from	O
a	O
single	O
donor	O
is	O
limited	O
,	O
and	O
the	O
capacity	O
of	O
these	O
cells	O
for	O
long	O
-	O
term	O
proliferation	O
is	O
rather	O
poor	O
.	O

In	O
contrast	O
,	O
hESCs	O
could	O
provide	O
an	O
unlimited	O
number	O
of	O
specialized	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
techniques	O
for	O
the	O
generation	O
and	O
purification	O
of	O
mesenchymal	O
precursors	O
from	O
hESCs	O
and	O
their	O
directed	O
differentiation	O
in	O
vitro	O
into	O
various	O
mesenchymal	O
derivatives	O
,	O
including	O
skeletal	O
myoblasts	O
.	O

Our	O
isolation	O
method	O
for	O
mesenchymal	O
precursors	O
is	O
the	O
first	O
example	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
efficiently	O
deriving	O
structures	O
of	O
the	O
paraxial	O
mesoderm	O
from	O
ES	O
cells	O
,	O
and	O
further	O
highlights	O
the	O
potential	O
of	O
hESCs	O
for	O
basic	O
biology	O
and	O
regenerative	O
medicine	O
.	O

Cell	O
Culture	O
and	O
FACSUndifferentiated	O
hESCs	O
,	O
H1	O
(	O
WA-01	O
,	O
XY	O
,	O
passages	O
40–65	O
)	O
and	O
H9	O
(	O
WA-09	O
,	O
XX	O
,	O
passages	O
35–45	O
)	O
,	O
were	O
cultured	O
on	O
mitotically	O
inactivated	O
mouse	O
embryonic	O
fibroblasts	O
(	O
Specialty	O
Media	O
,	O
Phillipsburg	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
and	O
maintained	O
under	O
growth	O
conditions	O
and	O
passaging	O
techniques	O
described	O
previously	O
[	O
3	O
]	O
.	O

OP9	O
cells	O
were	O
maintained	O
in	O
alpha	O
MEM	O
medium	O
containing	O
20	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
2	O
mM	O
L	O
-	O
glutamine	O
.	O

Mesenchymal	O
differentiation	O
was	O
induced	O
by	O
plating	O
10	O
×	O
103	O
to	O
25	O
×	O
103	O
cells	O
/	O
cm2	O
on	O
a	O
monolayer	O
of	O
OP9	O
cells	O
in	O
the	O
presence	O
of	O
20	O
%	O
heat	O
-	O
inactivated	O
FBS	O
in	O
alpha	O
MEM	O
medium	O
.	O

Flow	O
-	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
(	O
CD73-PE	B
;	O
PharMingen	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
was	O
performed	O
on	O
a	O
MoFlo	O
(	O
Cytomation	O
,	O
Fort	O
Collins	O
,	O
Colorado	O
,	O
United	O
States	O
)	O
.	O

All	O
human	O
ES	O
cell	O
–	O
derived	O
mesenchymal	O
precursor	O
cell	O
(	O
hESMPC	O
)	O
lines	O
in	O
this	O
study	O
are	O
of	O
polyclonal	O
origin	O
.	O

Primary	O
human	O
bone	O
marrow	O
–	O
derived	O
MSCs	O
and	O
primary	O
human	O
foreskin	O
fibroblasts	O
(	O
both	O
from	O
Poietics	O
,	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
were	O
grown	O
in	O
alpha	O
MEM	O
medium	O
containing	O
10	O
%	O
FBS	O
and	O
2	O
mM	O
L	O
-	O
glutamine	O
.	O

Adipocytic	O
DifferentiationhESMPCs	O
are	O
grown	O
to	O
confluence	O
followed	O
by	O
exposure	O
to	O
1	O
mM	O
dexamethasone	O
,	O
10	O
μg	O
/	O
ml	O
insulin	O
,	O
and	O
0.5	O
mM	O
isobutylxanthine	O
(	O
all	O
from	O
Sigma	O
,	O
St.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
in	O
alpha	O
MEM	O
medium	O
containing	O
10	O
%	O
FBS	O
for	O
2–4	O
wk	O
.	O

Data	O
were	O
confirmed	O
in	O
hESMPC	O
-	O
H1.1	O
,	O
-H1.2	O
,	O
-H1.3	O
,	O
and	O
-H9.1	O
(	O
hESMPC	O
-	O
H1.4	O
was	O
not	O
tested	O
)	O
.	O

Chondrocytic	O
DifferentiationDifferentiation	O
of	O
hESMPCs	O
was	O
induced	O
in	O
pellet	O
culture	O
[	O
5	O
]	O
by	O
exposure	O
to	O
10	O
ng	O
/	O
ml	O
TGF	B
-	I
β3	I
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
Minnesota	O
,	O
United	O
States	O
)	O
and	O
200	O
μM	O
ascorbic	O
acid	O
(	O
Sigma	O
)	O
in	O
alpha	O
MEM	O
medium	O
containing	O
10	O
%	O
FBS	O
for	O
3–4	O
wk	O
.	O

Data	O
were	O
confirmed	O
in	O
hESMPC	O
-	O
H1.1	O
,	O
-H1.3	O
,	O
and	O
-H9.1	O
(	O
hESMPC	O
-	O
H1.2	O
and	O
-H1.4	O
were	O
not	O
tested	O
)	O
.	O

Osteogenic	O
DifferentiationhESMPCs	O
were	O
plated	O
at	O
low	O
density	O
(	O
1	O
×	O
103	O
to	O
2.5	O
×	O
103	O
cells	O
/	O
cm2	O
)	O
on	O
tissue	O
-	O
culture	O
-	O
treated	O
dishes	O
in	O
the	O
presence	O
of	O
10	O
mM	O
β	O
-	O
glycerol	O
phosphate	O
(	O
Sigma	O
)	O
,	O
0.1	O
μM	O
dexamethasone	O
,	O
and	O
200	O
μM	O
ascorbic	O
acid	O
in	O
alpha	O
MEM	O
medium	O
containing	O
10	O
%	O
FBS	O
for	O
3–4	O
wk	O
.	O

Data	O
were	O
confirmed	O
in	O
hESMPC	O
-	O
H1.1	O
,	O
-H1.3	O
,	O
and	O
-H9.1	O
(	O
hESMPC	O
-	O
H1.2	O
and	O
-H1.4	O
were	O
not	O
tested	O
)	O
.	O

Myogenic	O
DifferentiationConfluent	O
hESMPCs	O
were	O
maintained	O
for	O
2–3	O
wk	O
in	O
alpha	O
MEM	O
medium	O
with	O
20	O
%	O
heat	O
-	O
inactivated	O
FBS	O
.	O

More	O
rapid	O
induction	O
was	O
observed	O
in	O
the	O
presence	O
of	O
medium	O
conditioned	O
for	O
24	O
h	O
by	O
differentiated	O
C2C12	O
cells	O
.	O

Coculture	O
of	O
hESMPCs	O
and	O
C2C12	O
cells	O
was	O
carried	O
out	O
in	O
alpha	O
MEM	O
with	O
3	O
%	O
horse	O
serum	O
and	O
1	O
%	O
FBS	O
[	O
8	O
]	O
.	O

Data	O
were	O
confirmed	O
in	O
hESMPC	O
-	O
H1.3	O
,	O
-H1.4	O
,	O
and	O
-H9.1	O
(	O
hESMPC	O
-	O
H1.1	O
and	O
-H1.2	O
were	O
not	O
tested	O
)	O
.	O

CytochemistryImmunocytochemistry	O
for	O
all	O
surface	O
markers	O
was	O
performed	O
on	O
live	O
cells	O
.	O

Monoclonal	O
antibodies	O
VCAM	B
,	O
STRO-1	B
,	O
ICAM-1	B
(	O
CD54	B
)	O
,	O
CD105	B
,	O
CD29	B
,	O
and	O
MF20	B
were	O
from	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
(	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
Iowa	O
,	O
United	O
States	O
)	O
;	O
CD73	B
,	O
CD44	B
,	O
and	O
ALCAM	B
(	O
CD166	B
)	O
were	O
from	O
BD	O
Biosciences	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

All	O
other	O
immunocytochemical	O
analyses	O
were	O
performed	O
after	O
fixation	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
0.15	O
%	O
picric	O
acid	O
,	O
followed	O
by	O
permeabilization	O
in	O
0.3	O
%	O
Triton	O
X100	O
.	O

Polyclonal	O
antibodies	O
used	O
were	O
MyoD	B
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
nestin	B
(	O
gift	O
from	O
R.	O
McKay	O
)	O
;	O
monoclonal	O
antibodies	O
were	O
vimentin	B
,	O
alpha	B
smooth	I
muscle	I
actin	I
,	O
fast	B
-	I
switch	I
myosin	I
,	O
pan	B
-	I
cytokeratin	I
(	O
all	O
from	O
Sigma	O
)	O
,	O
and	O
human	B
nuclear	I
antigen	I
(	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
United	O
States	O
)	O
.Alkaline	O
phosphatase	B
reaction	O
was	O
performed	O
using	O
a	O
commercially	O
available	O
kit	O
(	O
Kit-86	O
;	O
Sigma	O
)	O
and	O
the	O
mineral	O
was	O
stained	O
with	O
silver	O
nitrate	O
according	O
to	O
the	O
von	O
Kossa	O
method	O
.	O

Fat	O
granules	O
were	O
visualized	O
by	O
Oil	O
Red	O
O	O
staining	O
solution	O
(	O
Sigma	O
)	O
.	O

Alcian	O
Blue	O
(	O
Sigma	O
)	O
was	O
used	O
to	O
detect	O
extracellular	B
matrix	I
proteoglycans	I
in	O
chondrogenic	O
cultures	O
.	O

Gene	O
-	O
Expression	O
AnalysesRT	O
-	O
PCR	O
analysisTotal	O
RNA	O
was	O
extracted	O
by	O
using	O
the	O
RNeasy	O
kit	O
and	O
DNase	O
I	O
treatment	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Total	O
RNA	O
(	O
2	O
μg	O
each	O
)	O
was	O
reverse	O
transcribed	O
(	O
SuperScript	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

PCR	O
conditions	O
were	O
optimized	O
and	O
linear	O
amplification	O
range	O
was	O
determined	O
for	O
each	O
primer	O
by	O
varying	O
annealing	O
temperature	O
and	O
cycle	O
number	O
.	O

PCR	O
products	O
were	O
identified	O
by	O
size	O
,	O
and	O
identity	O
was	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Primer	O
sequences	O
,	O
cycle	O
numbers	O
,	O
and	O
annealing	O
temperatures	O
are	O
provided	O
in	O
Table	O
S1.Affymetrix	O
analysisTotal	O
RNA	O
(	O
5	O
μg	O
)	O
from	O
primary	O
MSCs	O
,	O
from	O
hESMPC	O
-	O
H9.1	O
,	O
hESMPC	O
-	O
H1.2	O
,	O
and	O
three	O
samples	O
of	O
undifferentiated	O
hESCs	O
(	O
H1	O
;	O
passages	O
42–46	O
)	O
,	O
were	O
processed	O
by	O
the	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
Genomics	O
Core	O
Facility	O
and	O
hybridized	O
on	O
Affymetrix	O
(	O
Santa	O
Clara	O
,	O
California	O
,	O
United	O
States	O
)	O
U133A	O
human	O
oligonucleotide	O
arrays	O
.	O

Data	O
were	O
analyzed	O
using	O
MAS5.0	O
(	O
Affymetrix	O
)	O
software	O
.	O

Transcripts	O
selectively	O
expressed	O
in	O
each	O
of	O
the	O
mesenchymal	O
cell	O
populations	O
(	O
MSC	O
,	O
hESMPC	O
-	O
H9.1	O
,	O
and	O
hESMPC	O
-	O
H1.2	O
)	O
were	O
defined	O
as	O
those	O
called	O
""""	O
increased	O
""""	O
by	O
the	O
MAS5.0	O
algorithm	O
in	O
each	O
of	O
three	O
comparisons	O
with	O
independent	O
samples	O
of	O
undifferentiated	O
hESCs	O
.	O

A	O
Venn	O
diagram	O
was	O
generated	O
to	O
visualize	O
overlap	O
in	O
gene	O
expression	O
.	O

Further	O
statistical	O
analyses	O
were	O
performed	O
as	O
described	O
below	O
.	O

Mesenchymal	O
differentiation	O
of	O
hESCs	O
(	O
lines	O
H1	O
[	O
WA-01	O
]	O
and	O
H9	O
[	O
WA-09	O
]	O
)	O
[	O
9	O
]	O
was	O
induced	O
by	O
plating	O
undifferentiated	O
hESCs	O
on	O
a	O
monolayer	O
of	O
murine	O
OP9	O
stromal	O
cells	O
[	O
10	O
]	O
,	O
in	O
the	O
presence	O
of	O
20	O
%	O
heat	O
-	O
inactivated	O
FBS	O
in	O
alpha	O
MEM	O
medium	O
.	O

OP9	O
cells	O
have	O
been	O
previously	O
shown	O
to	O
induce	O
blood	O
cell	O
differentiation	O
from	O
mouse	O
ES	O
cells	O
[	O
11	O
]	O
.	O

After	O
40	O
d	O
of	O
coculture	O
,	O
cells	O
were	O
harvested	O
and	O
sorted	O
by	O
FACS	O
for	O
CD73	B
,	O
a	O
surface	O
marker	O
expressed	O
in	O
adult	O
MSCs	O
[	O
5	O
]	O
(	O
Figure	O
1A	O
)	O
.	O

An	O
average	O
of	O
5	O
%	O
CD73	B
+	O
cells	O
was	O
obtained	O
from	O
the	O
mixed	O
culture	O
of	O
OP9	O
and	O
differentiated	O
hESC	O
progeny	O
.	O

CD73	B
+	O
cells	O
were	O
replated	O
in	O
the	O
absence	O
of	O
stromal	O
feeders	O
on	O
tissue	O
culture	O
plates	O
and	O
expanded	O
in	O
alpha	O
MEM	O
medium	O
with	O
20	O
%	O
FBS	O
for	O
7–14	O
d.	O

We	O
next	O
established	O
the	O
membrane	O
antigen	O
profile	O
of	O
the	O
resulting	O
population	O
of	O
flat	O
spindle	O
-	O
like	O
cells	O
.	O

The	O
H1-	O
and	O
H9-derived	O
CD73	B
+	O
cells	O
expressed	O
a	O
comprehensive	O
set	O
of	O
markers	O
that	O
are	O
considered	O
to	O
define	O
adult	O
MSCs	O
,	O
including	O
CD105	B
(	O
SH2	B
)	O
,	O
STRO-1	B
,	O
VCAM	B
(	O
CD106	B
)	O
,	O
CD29	B
(	O
integrin	B
β1	I
)	O
,	O
CD44	B
,	O
ICAM	B
-1	I
(	O
CD54	B
)	O
,	O
ALCAM	B
(	O
CD166	B
)	O
,	O
vimentin	B
,	O
and	O
alpha	B
smooth	I
muscle	I
actin	I
(	O
Figure	O
1B	O
and	O
1C	O
)	O
.	O

The	O
cells	O
were	O
negative	O
for	O
hematopoietic	O
markers	O
such	O
as	O
CD34	B
,	O
CD45	B
,	O
and	O
CD14	B
.	O

They	O
were	O
also	O
negative	O
for	O
neuroectodermal	O
,	O
epithelial	O
,	O
and	O
muscle	O
cell	O
markers	O
including	O
nestin	B
,	O
pancytokeratin	B
,	O
and	O
desmin	B
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
human	O
identity	O
of	O
these	O
presumed	O
mesenchymal	O
cells	O
(	O
termed	O
hESMPC	O
-	O
H1.1	O
,	O
-H1.2	O
,	O
-H1.3	O
,	O
-H1.4	O
,	O
and	O
-H9.1	O
)	O
was	O
confirmed	O
for	O
all	O
experiments	O
by	O
immunocytochemistry	O
for	O
human	B
nuclear	I
antigen	I
to	O
rule	O
out	O
the	O
possibility	O
of	O
contamination	O
with	O
OP9	O
cells	O
(	O
Figure	O
S1	O
)	O
.	O

To	O
further	O
characterize	O
hESMPCs	O
,	O
we	O
performed	O
genome	O
-	O
wide	O
expression	O
analysis	O
using	O
oligonucleotide	O
arrays	O
(	O
Affymetrix	O
U133A	O
)	O
.	O

The	O
expression	O
profiles	O
of	O
hESMPC	O
-	O
H1.2	O
and	O
hESMPC	O
-	O
H9.1	O
were	O
compared	O
with	O
that	O
of	O
human	O
primary	O
adult	O
MSCs	O
.	O

Housekeeping	B
genes	I
for	O
each	O
of	O
the	O
mesenchymal	O
cell	O
populations	O
were	O
eliminated	O
by	O
subtracting	O
those	O
transcripts	O
also	O
expressed	O
in	O
at	O
least	O
one	O
of	O
three	O
independent	O
samples	O
of	O
undifferentiated	O
hESCs	O
.	O

Based	O
on	O
this	O
analysis	O
,	O
1,280	O
transcripts	O
were	O
selectively	O
expressed	O
in	O
hESMPC	O
-	O
H1.2	O
,	O
932	O
transcripts	O
in	O
hESMPC	O
-	O
H9.1	O
,	O
and	O
1,218	O
transcripts	O
in	O
primary	O
adult	O
MSCs	O
.	O

A	O
remarkable	O
overlap	O
of	O
579	O
transcripts	O
shared	O
among	O
the	O
three	O
mesenchymal	O
populations	O
was	O
observed	O
(	O
Figure	O
1D	O
)	O
.	O

Using	O
the	O
genes	O
that	O
were	O
selected	O
in	O
the	O
initial	O
filter	O
,	O
we	O
performed	O
a	O
statistical	O
analysis	O
on	O
the	O
expression	O
levels	O
to	O
determine	O
whether	O
the	O
genes	O
were	O
expressed	O
significantly	O
differently	O
in	O
the	O
two	O
cell	O
types	O
.	O

We	O
used	O
a	O
Bayesian	O
extension	O
to	O
the	O
standard	O
t	O
-	O
test	O
[	O
12	O
]	O
to	O
assess	O
this	O
difference	O
.	O

Of	O
the	O
579	O
genes	O
,	O
412	O
of	O
them	O
were	O
significantly	O
different	O
,	O
at	O
a	O
false	O
discovery	O
rate	O
cutoff	O
of	O
0.05	O
.	O

The	O
relative	O
fold	O
changes	O
were	O
also	O
extremely	O
large	O
in	O
many	O
of	O
the	O
cases	O
.	O

We	O
also	O
looked	O
at	O
the	O
variance	O
of	O
the	O
expression	O
levels	O
within	O
the	O
cell	O
types	O
.	O

For	O
the	O
MSCs	O
,	O
94	O
%	O
had	O
a	O
coefficient	O
of	O
variation	O
less	O
than	O
20	O
%	O
for	O
the	O
expression	O
(	O
log	O
transformed	O
)	O
;	O
for	O
the	O
ES	O
-	O
derived	O
cells	O
,	O
72	O
%	O
had	O
a	O
coefficient	O
of	O
variation	O
less	O
than	O
20	O
%	O
.	O

Numerous	O
known	O
MSC	O
markers	O
were	O
included	O
in	O
the	O
list	O
of	O
412	O
genes	O
,	O
such	O
as	O
the	O
mesenchymal	O
stem	O
cell	O
protein	O
DSC54	B
(	O
13.9-fold	O
increase	O
,	O
p	O
<	O
0.001	O
)	O
,	O
neuropilin	B
1	B
(	O
30.4-fold	O
increase	O
,	O
p	O
<	O
0.001	O
)	O
,	O
hepatocyte	B
growth	I
factor	I
(	O
48.1-fold	O
increase	O
,	O
p	O
<	O
0.001	O
)	O
,	O
forkhead	B
box	I
D1	I
(	O
14.8-fold	O
increase	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
notch	B
homolog	I
2	I
(	O
2.9-fold	O
increase	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Table	O
S2	O
lists	O
the	O
p	O
-	O
values	O
from	O
the	O
test	O
,	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
the	O
expression	O
levels	O
,	O
and	O
the	O
relative	O
fold	O
change	O
of	O
all	O
412	O
genes	O
between	O
the	O
two	O
types	O
.	O

Known	O
markers	O
of	O
MSCs	O
,	O
such	O
as	O
mesenchymal	O
stem	O
cell	O
protein	O
DSC54	B
,	O
were	O
all	O
included	O
within	O
the	O
579	O
shared	O
transcripts	O
.	O

These	O
findings	O
support	O
the	O
immunocytochemical	O
data	O
and	O
suggest	O
that	O
hESMPCs	O
and	O
primary	O
MSCs	O
are	O
highly	O
related	O
.	O

MSCs	O
are	O
characterized	O
functionally	O
by	O
their	O
ability	O
to	O
differentiate	O
into	O
mesenchymal	O
tissues	O
,	O
such	O
as	O
fat	O
,	O
cartilage	O
,	O
and	O
bone	O
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
hESMPCs	O
have	O
the	O
same	O
potential	O
(	O
Figure	O
2	O
)	O
.	O

Adipocytic	O
differentiation	O
of	O
hESMPCs	O
was	O
induced	O
under	O
conditions	O
described	O
previously	O
for	O
primary	O
adult	O
MSCs	O
[	O
5	O
]	O
.	O

Appearance	O
of	O
cells	O
harboring	O
fat	O
granules	O
was	O
observed	O
after	O
10–14	O
d	O
in	O
culture	O
.	O

After	O
3	O
wk	O
of	O
induction	O
,	O
more	O
than	O
70	O
%	O
of	O
the	O
cells	O
displayed	O
Oil	O
Red	O
O+	O
fat	O
granules	O
,	O
and	O
PPARγ	B
,	O
a	O
marker	O
of	O
adipocytic	O
differentiation	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

(	O
Figure	O
2A	O
)	O
.	O

Chondrocytic	O
differentiation	O
was	O
achieved	O
using	O
the	O
pellet	O
culture	O
system	O
[	O
5	O
]	O
.	O

After	O
28	O
d	O
in	O
culture	O
,	O
more	O
than	O
50	O
%	O
of	O
all	O
cells	O
exhibited	O
robust	O
staining	O
for	O
Alcian	O
Blue	O
,	O
a	O
marker	O
specific	O
for	O
extracellular	B
matrix	I
proteoglycans	I
.	O

Chondrocytic	O
differentiation	O
was	O
confirmed	O
by	O
the	O
gene	O
expression	O
of	O
collagen	B
II	I
and	O
aggrecan	B
,	O
two	O
components	O
of	O
extracellular	O
matrix	O
selectively	O
expressed	O
by	O
chondrocytes	O
,	O
using	O
RT	O
-	O
PCR	O
(	O
Figure	O
2B	O
)	O
.	O

Osteogenic	O
differentiation	O
was	O
induced	O
in	O
the	O
presence	O
of	O
β	B
-	I
glycerolphosphate	I
[	O
5	O
]	O
.	O

Osteogenesis	O
was	O
demonstrated	O
by	O
specific	O
staining	O
for	O
calcium	O
deposition	O
in	O
the	O
matrix	O
(	O
von	O
Kossa	O
,	O
Figure	O
2C	O
;	O
or	O
Alizarin	O
Red	O
,	O
Figure	O
S2A	O
)	O
and	O
increased	O
expression	O
of	O
bone	B
-	I
specific	I
alkaline	I
phosphatase	I
and	O
bone	B
sialoprotein	I
at	O
day	O
28	O
of	O
treatment	O
(	O
Figures	O
2C	O
and	O
S2B	O
)	O
.	O

At	O
day	O
28	O
,	O
Alizarin	O
Red	O
staining	O
was	O
detected	O
in	O
approximately	O
70	O
%	O
of	O
all	O
cells	O
.	O

Throughout	O
these	O
studies	O
,	O
human	O
adult	O
MSCs	O
and	O
foreskin	O
fibroblasts	O
were	O
used	O
as	O
positive	O
and	O
negative	O
controls	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
adipocytic	O
,	O
chondrocytic	O
,	O
and	O
osteogenic	O
differentiation	O
,	O
reports	O
suggested	O
that	O
adult	O
MSCs	O
can	O
form	O
skeletal	O
muscle	O
[	O
13	O
]	O
.	O

Although	O
generation	O
of	O
skeletal	O
muscle	O
cells	O
from	O
adult	O
MSCs	O
remains	O
controversial	O
,	O
we	O
tested	O
whether	O
hESMPCs	O
exhibit	O
this	O
potential	O
.	O

Under	O
the	O
conditions	O
previously	O
described	O
[	O
13	O
]	O
,	O
hESMPC	O
-	O
H1.1	O
and	O
-H9.1	O
did	O
not	O
yield	O
significant	O
numbers	O
of	O
MyoD+	B
cells	O
after	O
15–20	O
d	O
in	O
culture	O
.	O

However	O
,	O
when	O
confluent	O
cells	O
were	O
maintained	O
in	O
culture	O
in	O
the	O
presence	O
or	O
absence	O
of	O
5-AzaC	O
without	O
passage	O
for	O
more	O
than	O
21	O
d	O
,	O
expression	O
of	O
specific	O
skeletal	O
muscle	O
markers	O
such	O
as	O
MyoD	B
and	O
fast	B
-	I
switch	I
myosin	I
was	O
observed	O
(	O
Figure	O
3A	O
)	O
.	O

More	O
rapid	O
myogenic	O
differentiation	O
was	O
obtained	O
in	O
the	O
presence	O
of	O
24-h	O
-	O
conditioned	O
medium	O
from	O
the	O
murine	O
myoblastic	O
cell	O
line	O
C2C12	O
previously	O
induced	O
to	O
form	O
myotubes	O
[	O
14	O
]	O
.	O

Direct	O
coculture	O
of	O
hESMPCs	O
with	O
C2C12	O
cells	O
led	O
to	O
the	O
formation	O
of	O
hESMPC	O
-	O
derived	O
myotubes	O
,	O
as	O
visualized	O
by	O
expression	O
of	O
human	B
nuclear	I
antigen	I
(	O
Figure	O
3B	O
)	O
,	O
similar	O
to	O
those	O
formed	O
by	O
host	O
C2C12	O
cells	O
.	O

After	O
1	O
wk	O
of	O
coculture	O
,	O
myotubes	O
composed	O
of	O
human	O
nuclei	O
accounted	O
for	O
more	O
than	O
10	O
%	O
of	O
the	O
total	O
number	O
of	O
human	O
cells	O
present	O
,	O
and	O
each	O
human	O
myotube	O
was	O
composed	O
of	O
up	O
to	O
ten	O
human	O
nuclei	O
.	O

Human	O
cell	O
contribution	O
to	O
myotubes	O
in	O
coculture	O
was	O
confirmed	O
by	O
expression	O
of	O
human	O
muscle	O
-	O
specific	O
transcripts	O
such	O
as	O
MyoD	B
,	O
myosin	B
heavy	B
chain	I
IIa	I
,	O
and	O
myogenin	B
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
hESMPCs	O
can	O
give	O
rise	O
to	O
mesenchymal	O
derivatives	O
typically	O
obtained	O
from	O
primary	O
adult	O
MSCs	O
,	O
as	O
well	O
as	O
to	O
cells	O
expressing	O
markers	O
of	O
skeletal	O
muscle	O
.	O

One	O
concern	O
for	O
the	O
clinical	O
application	O
of	O
hESC	O
-	O
derived	O
progeny	O
in	O
regenerative	O
medicine	O
is	O
the	O
risk	O
of	O
teratoma	O
formation	O
due	O
to	O
the	O
presence	O
of	O
residual	O
undifferentiated	O
ES	O
cells	O
among	O
the	O
differentiated	O
progeny	O
.	O

We	O
did	O
not	O
detect	O
markers	O
of	O
undifferentiated	O
hESCs	O
,	O
such	O
as	O
Nanog	B
[	O
15	O
]	O
or	O
Oct-4	B
[	O
16	O
]	O
,	O
in	O
any	O
of	O
the	O
hESMPCs	O
by	O
RT	O
-	O
PCR	O
(	O
see	O
Figure	O
2D	O
)	O
and	O
immunocytochemistry	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
the	O
lack	O
of	O
any	O
undifferentiated	O
ES	O
cells	O
in	O
hESMPC	O
cultures	O
.	O

However	O
,	O
future	O
in	O
vivo	O
studies	O
are	O
required	O
to	O
rule	O
out	O
the	O
potential	O
of	O
these	O
cells	O
for	O
teratoma	O
formation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
the	O
derivation	O
of	O
neural	O
cells	O
[	O
1–3	O
]	O
,	O
hematopoietic	O
[	O
17	O
]	O
and	O
endothelial	O
lineages	O
[	O
18	O
]	O
,	O
and	O
cardiomyocytes	O
[	O
19	O
]	O
from	O
hESCs	O
.	O

This	O
study	O
presents	O
the	O
induction	O
of	O
paraxial	O
mesoderm	O
with	O
the	O
generation	O
of	O
multipotent	O
mesenchymal	O
precursors	O
.	O

We	O
calculate	O
that	O
under	O
these	O
conditions	O
a	O
single	O
undifferentiated	O
hESC	O
yields	O
an	O
average	O
of	O
one	O
CD73	B
+	O
cell	O
at	O
day	O
40	O
of	O
differentiation	O
,	O
suggesting	O
a	O
balance	O
between	O
cell	O
proliferation	O
and	O
cell	O
selection	O
.	O

There	O
were	O
no	O
obvious	O
differences	O
in	O
marker	O
and	O
gene	O
-	O
expression	O
profile	O
or	O
in	O
differentiation	O
behavior	O
among	O
the	O
five	O
hESMPC	O
lines	O
generated	O
.	O

However	O
,	O
some	O
of	O
the	O
lines	O
(	O
e.g.	O
,	O
hESMPC9.1	O
)	O
exhibited	O
a	O
tendency	O
of	O
spontaneous	O
osteogenic	O
differentiation	O
after	O
long	O
-	O
term	O
propagation	O
.	O

Directed	O
differentiation	O
of	O
hESCs	O
into	O
somatic	O
stem	O
-	O
cell	O
-	O
like	O
precursors	O
represents	O
a	O
substantial	O
advancement	O
in	O
harnessing	O
the	O
developmental	O
potential	O
of	O
hESCs	O
.	O

The	O
high	O
purity	O
,	O
unlimited	O
availability	O
,	O
and	O
multipotentiality	O
of	O
hESMPCs	O
will	O
provide	O
the	O
basis	O
for	O
future	O
therapeutic	O
efforts	O
using	O
these	O
cells	O
in	O
preclinical	O
animal	O
models	O
of	O
disease	O
.	O

Such	O
in	O
vivo	O
studies	O
will	O
also	O
be	O
required	O
to	O
properly	O
assess	O
the	O
safety	O
profile	O
of	O
these	O
cells	O
.	O

Furthermore	O
,	O
our	O
system	O
also	O
offers	O
a	O
novel	O
platform	O
to	O
study	O
basic	O
mechanisms	O
of	O
mesodermal	O
induction	O
and	O
differentiation	O
during	O
early	O
human	O
development	O
.	O

BackgroundMany	O
novel	O
studies	O
and	O
therapies	O
are	O
possible	O
with	O
the	O
use	O
of	O
human	O
embryonic	O
stem	O
cells	O
(	O
hES	O
cells	O
)	O
and	O
their	O
differentiated	O
cell	O
progeny	O
.	O

The	O
hES	O
cell	O
derived	O
CD34	B
hematopoietic	O
stem	O
cells	O
can	O
be	O
potentially	O
used	O
for	O
many	O
gene	O
therapy	O
applications	O
.	O

Here	O
we	O
evaluated	O
the	O
capacity	O
of	O
hES	O
cell	O
derived	O
CD34	B
cells	O
to	O
give	O
rise	O
to	O
normal	O
macrophages	O
as	O
a	O
first	O
step	O
towards	O
using	O
these	O
cells	O
in	O
viral	O
infection	O
studies	O
and	O
in	O
developing	O
novel	O
stem	O
cell	O
based	O
gene	O
therapy	O
strategies	O
for	O
AIDS.ResultsUndifferentiated	O
normal	O
and	O
lentiviral	O
vector	O
transduced	O
hES	O
cells	O
were	O
cultured	O
on	O
S17	O
mouse	O
bone	O
marrow	O
stromal	O
cell	O
layers	O
to	O
derive	O
CD34	B
hematopoietic	O
progenitor	O
cells	O
.	O

The	O
differentiated	O
CD34	B
cells	O
isolated	O
from	O
cystic	O
bodies	O
were	O
further	O
cultured	O
in	O
cytokine	O
media	O
to	O
derive	O
macrophages	O
.	O

Phenotypic	O
and	O
functional	O
analyses	O
were	O
carried	O
out	O
to	O
compare	O
these	O
with	O
that	O
of	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
macrophages	O
.	O

As	O
assessed	O
by	O
FACS	O
analysis	O
,	O
the	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
displayed	O
characteristic	O
cell	O
surface	O
markers	O
CD14	B
,	O
CD4	B
,	O
CCR5	B
,	O
CXCR4	B
,	O
and	O
HLA	B
-	I
DR	I
suggesting	O
a	O
normal	O
phenotype	O
.	O

Tests	O
evaluating	O
phagocytosis	O
,	O
upregulation	O
of	O
the	O
costimulatory	O
molecule	O
B7.1	B
,	O
and	O
cytokine	O
secretion	O
in	O
response	O
to	O
LPS	O
stimulation	O
showed	O
that	O
these	O
macrophages	O
are	O
also	O
functionally	O
normal	O
.	O

When	O
infected	O
with	O
HIV-1	O
,	O
the	O
differentiated	O
macrophages	O
supported	O
productive	O
viral	O
infection	O
.	O

Lentiviral	O
vector	O
transduced	O
hES	O
cells	O
expressing	O
the	O
transgene	O
GFP	B
were	O
evaluated	O
similarly	O
like	O
above	O
.	O

The	O
transgenic	O
hES	O
cells	O
also	O
gave	O
rise	O
to	O
macrophages	O
with	O
normal	O
phenotypic	O
and	O
functional	O
characteristics	O
indicating	O
no	O
vector	O
mediated	O
adverse	O
effects	O
during	O
differentiation	O
.	O

ConclusionPhenotypically	O
normal	O
and	O
functionally	O
competent	O
macrophages	O
could	O
be	O
derived	O
from	O
hES	O
-	O
CD34	B
cells	O
.	O

Since	O
these	O
cells	O
are	O
susceptible	O
to	O
HIV-1	O
infection	O
,	O
they	O
provide	O
a	O
uniform	O
source	O
of	O
macrophages	O
for	O
viral	O
infection	O
studies	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
is	O
also	O
now	O
feasible	O
to	O
transduce	O
hES	O
-	O
CD34	B
cells	O
with	O
anti	O
-	O
HIV	O
genes	O
such	O
as	O
inhibitory	O
siRNAs	B
and	O
test	O
their	O
antiviral	O
efficacy	O
in	O
down	O
stream	O
differentiated	O
cells	O
such	O
as	O
macrophages	O
which	O
are	O
among	O
the	O
primary	O
cells	O
that	O
need	O
to	O
be	O
protected	O
against	O
HIV-1	O
infection	O
.	O

Thus	O
,	O
the	O
potential	O
utility	O
of	O
hES	O
derived	O
CD34	B
hematopoietic	O
cells	O
for	O
HIV-1	O
gene	O
therapy	O
can	O
be	O
evaluated	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hES	O
cells	O
)	O
show	O
great	O
promise	O
for	O
many	O
novel	O
cellular	O
therapies	O
due	O
to	O
their	O
pluripotent	O
nature	O
[	O
1	O
]	O
.	O

These	O
cells	O
have	O
the	O
capacity	O
to	O
give	O
rise	O
to	O
mature	O
cells	O
and	O
tissues	O
that	O
arise	O
from	O
all	O
three	O
germ	O
layers	O
during	O
embryonic	O
development	O
[	O
2	O
-	O
4	O
]	O
.	O

Several	O
pluripotent	O
hES	O
cell	O
lines	O
have	O
so	O
far	O
been	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
human	O
blastocysts	O
and	O
can	O
be	O
cultured	O
indefinitely	O
in	O
an	O
undifferentiated	O
state	O
[	O
5	O
-	O
7	O
]	O
.	O

Thus	O
,	O
these	O
cells	O
provide	O
a	O
renewable	O
source	O
of	O
pluripotent	O
stem	O
cells	O
from	O
which	O
many	O
types	O
of	O
differentiated	O
cells	O
could	O
be	O
produced	O
for	O
experimental	O
and	O
therapeutic	O
purposes	O
.	O

Cell	O
differentiation	O
protocols	O
currently	O
exist	O
for	O
the	O
derivation	O
of	O
neurons	O
,	O
cardiomyocytes	O
,	O
endothelial	O
cells	O
,	O
hematopoietic	O
progenitor	O
cells	O
,	O
keratinocytes	O
,	O
osteoblasts	O
,	O
and	O
hepatocytes	O
to	O
name	O
a	O
few	O
[	O
2,3,8,9	O
]	O
.	O

In	O
addition	O
to	O
providing	O
for	O
potential	O
cellular	O
replacement	O
therapies	O
,	O
opportunities	O
exist	O
in	O
programming	O
hES	O
cells	O
to	O
correct	O
a	O
genetic	O
defect	O
and/or	O
to	O
express	O
a	O
therapeutic	O
transgene	O
of	O
interest	O
.	O

Using	O
such	O
approaches	O
,	O
many	O
possibilities	O
exist	O
for	O
treating	O
a	O
number	O
of	O
genetic	O
and	O
immune	O
system	O
disorders	O
[	O
1	O
]	O
.	O

Many	O
novel	O
applications	O
can	O
be	O
foreseen	O
for	O
hES	O
cells	O
in	O
infectious	O
disease	O
research	O
.	O

AIDS	O
is	O
a	O
potential	O
disease	O
that	O
can	O
benefit	O
from	O
exploiting	O
hES	O
cells	O
for	O
cell	O
replacement	O
therapy	O
as	O
they	O
have	O
the	O
capacity	O
to	O
differentiate	O
into	O
various	O
hematopoietic	O
cells	O
.	O

HIV	O
continues	O
to	O
be	O
a	O
major	O
global	O
public	O
health	O
problem	O
with	O
infections	O
increasing	O
at	O
an	O
alarming	O
rate	O
[	O
10,11	O
]	O
.	O

Given	O
the	O
present	O
lack	O
of	O
effective	O
vaccines	O
and	O
the	O
ineffectiveness	O
of	O
drug	O
based	O
therapies	O
for	O
a	O
complete	O
cure	O
,	O
new	O
and	O
innovative	O
approaches	O
are	O
essential	O
.	O

Gene	O
therapy	O
through	O
intracellular	O
immunization	O
offers	O
a	O
promising	O
alternative	O
approach	O
and	O
possible	O
supplement	O
to	O
current	O
HAART	O
therapy	O
[	O
12	O
-	O
14	O
]	O
.	O

HIV	O
mainly	O
targets	O
cells	O
of	O
the	O
hematopoietic	O
system	O
,	O
namely	O
,	O
T	O
cells	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
[	O
15	O
]	O
.	O

As	O
infection	O
progresses	O
,	O
the	O
immune	O
system	O
is	O
rendered	O
defenseless	O
against	O
other	O
invading	O
pathogens	O
and	O
succumbs	O
to	O
opportunistic	O
infections	O
.	O

There	O
is	O
a	O
great	O
deal	O
of	O
progress	O
in	O
the	O
area	O
of	O
stem	O
cell	O
gene	O
therapy	O
for	O
AIDS	O
[	O
12	O
]	O
.	O

A	O
primary	O
goal	O
of	O
many	O
ongoing	O
studies	O
is	O
to	O
introduce	O
an	O
effective	O
anti	O
-	O
HIV	O
gene	O
into	O
hematopoietic	O
stem	O
cells	O
[	O
16	O
-	O
18	O
]	O
.	O

As	O
these	O
cells	O
possess	O
the	O
ability	O
to	O
self	O
renew	O
,	O
they	O
have	O
the	O
potential	O
to	O
continually	O
produce	O
HIV	O
resistant	O
T	O
cells	O
and	O
macrophages	O
in	O
the	O
body	O
thus	O
providing	O
long	O
term	O
immune	O
reconstitution	O
.	O

These	O
approaches	O
use	O
CD34	B
hematopoietic	O
stem	O
cells	O
for	O
anti	O
-	O
HIV	O
gene	O
transduction	O
via	O
integrating	O
viral	O
vectors	O
such	O
as	O
lentiviral	O
vectors	O
[	O
16	O
-	O
18	O
]	O
.	O

Lentiviral	O
vectors	O
have	O
several	O
advantages	O
over	O
conventional	O
retroviral	O
vectors	O
since	O
higher	O
transduction	O
efficiencies	O
can	O
be	O
obtained	O
and	O
there	O
is	O
less	O
gene	O
silencing	O
.	O

The	O
CD34	B
cells	O
currently	O
used	O
for	O
many	O
therapies	O
are	O
primarily	O
obtained	O
from	O
bone	O
marrow	O
or	O
mobilized	O
peripheral	O
blood	O
[	O
1,19	O
]	O
.	O

Thus	O
,	O
CD34	B
progenitor	O
cells	O
are	O
an	O
essential	O
ingredient	O
for	O
HIV	O
gene	O
therapy	O
.	O

In	O
view	O
of	O
the	O
need	O
for	O
CD34	B
cells	O
for	O
HIV	O
gene	O
therapy	O
as	O
well	O
as	O
for	O
other	O
hematopoietic	O
disorders	O
,	O
if	O
one	O
can	O
produce	O
these	O
cells	O
in	O
unlimited	O
quantities	O
from	O
a	O
renewable	O
source	O
,	O
it	O
will	O
overcome	O
the	O
limitations	O
of	O
securing	O
large	O
numbers	O
of	O
CD34	B
cells	O
for	O
therapeutic	O
purposes	O
.	O

In	O
this	O
regard	O
,	O
progress	O
has	O
been	O
made	O
in	O
deriving	O
CD34	B
cells	O
from	O
hES	O
cells	O
(	O
hES	O
-	O
CD34	B
)	O
.	O

Different	O
methods	O
currently	O
exist	O
to	O
derive	O
CD34	B
cells	O
from	O
hES	O
cells	O
with	O
varying	O
efficiencies	O
[	O
20	O
-	O
27	O
]	O
.	O

Recent	O
reports	O
have	O
indicated	O
the	O
capacity	O
of	O
hES	O
cell	O
derived	O
CD34	B
cells	O
to	O
give	O
rise	O
to	O
lymphoid	O
and	O
myeloid	O
lineages	O
thus	O
paving	O
the	O
way	O
for	O
utilization	O
of	O
these	O
cells	O
for	O
hematopoietic	O
cell	O
therapy	O
[	O
20,27	O
-	O
29	O
]	O
.	O

For	O
the	O
effective	O
utilization	O
of	O
hES	O
-	O
CD34	B
cells	O
for	O
HIV	O
gene	O
therapy	O
,	O
a	O
number	O
of	O
parameters	O
need	O
to	O
be	O
examined	O
.	O

First	O
,	O
one	O
has	O
to	O
demonstrate	O
that	O
hES	O
-	O
CD34	B
cells	O
can	O
give	O
rise	O
to	O
macrophages	O
and	O
helper	O
T	O
cells	O
which	O
are	O
the	O
main	O
cells	O
that	O
need	O
to	O
be	O
protected	O
against	O
HIV	O
infection	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
hES	O
-	O
CD34	B
cells	O
can	O
give	O
rise	O
to	O
myelomonocytic	O
cells	O
[	O
21	O
]	O
.	O

However	O
,	O
thorough	O
phenotypic	O
or	O
functional	O
characterization	O
of	O
these	O
cells	O
is	O
lacking	O
.	O

It	O
is	O
also	O
not	O
clear	O
if	O
these	O
cells	O
are	O
susceptible	O
to	O
HIV	O
infection	O
.	O

Similarly	O
,	O
although	O
the	O
hES	O
-	O
CD34	B
cells	O
were	O
shown	O
to	O
have	O
lymphoid	O
progenitor	O
capacity	O
,	O
only	O
B	O
cell	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
differentiation	O
has	O
been	O
examined	O
so	O
far	O
[	O
21,28	O
]	O
.	O

The	O
capacity	O
to	O
generate	O
T	O
cells	O
remains	O
to	O
be	O
evaluated	O
.	O

With	O
this	O
background	O
,	O
as	O
a	O
first	O
step	O
,	O
our	O
primary	O
goal	O
in	O
these	O
studies	O
is	O
to	O
examine	O
the	O
capacity	O
of	O
hES	O
-	O
CD34	B
cells	O
to	O
give	O
rise	O
to	O
phenotypically	O
and	O
functionally	O
normal	O
macrophages	O
and	O
whether	O
such	O
cells	O
are	O
susceptible	O
to	O
productive	O
HIV	O
infection	O
.	O

Since	O
lentiviral	O
vectors	O
have	O
been	O
shown	O
to	O
successfully	O
transduce	O
hES	O
cells	O
[	O
30	O
-	O
33	O
]	O
,	O
we	O
further	O
investigated	O
the	O
ability	O
of	O
transduced	O
hES	O
cells	O
to	O
differentiate	O
into	O
transgenic	O
macrophages	O
that	O
can	O
support	O
HIV-1	O
infection	O
.	O

Demonstration	O
of	O
HIV-1	O
productive	O
infection	O
in	O
these	O
cells	O
will	O
permit	O
future	O
efficacy	O
evaluations	O
of	O
anti	O
-	O
HIV	O
genes	O
in	O
this	O
system	O
.	O

Here	O
we	O
show	O
that	O
normal	O
and	O
lentiviral	O
vector	O
transduced	O
hES	O
-	O
CD34	B
cells	O
can	O
give	O
rise	O
to	O
phenotypically	O
and	O
functionally	O
normal	O
macrophages	O
that	O
support	O
HIV	O
infection	O
thus	O
paving	O
the	O
way	O
for	O
many	O
novel	O
approaches	O
to	O
evaluate	O
their	O
potential	O
for	O
HIV	O
gene	O
therapy	O
.	O

Derivation	O
of	O
macrophages	O
from	O
hES	O
cellsUndifferentiated	O
hES	O
cell	O
colonies	O
grown	O
in	O
media	O
supplemented	O
with	O
4	O
ng	O
/	O
ml	O
bFGF	B
displayed	O
normal	O
morphology	O
of	O
pluripotent	O
human	O
embryonic	O
stem	O
cells	O
with	O
tight	O
and	O
discreet	O
borders	O
on	O
the	O
MEF	O
feeder	O
layers	O
(	O
Fig	O
1A	O
)	O
.	O

Similarly	O
,	O
lentiviral	O
vector	O
transduced	O
hES	O
cell	O
colonies	O
,	O
also	O
displayed	O
normal	O
morphology	O
and	O
growth	O
characteristics	O
(	O
Fig	O
1A	O
)	O
.	O

As	O
expected	O
,	O
the	O
vector	O
transduced	O
colonies	O
displayed	O
green	O
fluorescence	O
due	O
to	O
the	O
presence	O
of	O
the	O
GFP	B
reporter	O
gene	O
.	O

When	O
cultured	O
on	O
irradiated	O
S17	O
mouse	O
bone	O
marrow	O
stromal	O
cells	O
,	O
both	O
nontransduced	O
and	O
transduced	O
hES	O
cells	O
developed	O
into	O
embryonic	O
cystic	O
bodies	O
(	O
Fig	O
1A	O
)	O
.	O

FACS	O
analysis	O
of	O
single	O
cell	O
suspensions	O
of	O
the	O
cystic	O
bodies	O
showed	O
levels	O
of	O
CD34	B
cells	O
which	O
ranged	O
from	O
7–15	O
%	O
.	O

Figure	O
1B	O
displays	O
a	O
representative	O
FACS	O
profile	O
of	O
hES	O
-	O
CD34	B
cells	O
.	O

Purified	O
CD34	B
cells	O
were	O
later	O
cultured	O
in	O
semi	O
-	O
solid	O
methylcellulose	O
medium	O
to	O
derive	O
myeloid	O
colonies	O
.	O

Both	O
nontransduced	O
(	O
denoted	O
as	O
ES	O
in	O
figures	O
)	O
and	O
vector	O
transduced	O
(	O
denoted	O
as	O
GFP	B
ES	O
in	O
figures	O
)	O
hES	O
cell	O
derived	O
CD34	B
cells	O
gave	O
rise	O
to	O
normal	O
myelomonocytic	O
colonies	O
similar	O
to	O
human	O
fetal	O
liver	O
derived	O
CD34	B
cells	O
(	O
denoted	O
as	O
CD34	B
in	O
figures	O
)	O
(	O
Fig	O
1A	O
)	O
.	O

When	O
pooled	O
colonies	O
were	O
cultured	O
further	O
in	O
liquid	O
cytokine	O
media	O
for	O
12–15	O
days	O
for	O
differentiation	O
,	O
the	O
cells	O
developed	O
into	O
morphologically	O
distinct	O
macrophages	O
(	O
Fig	O
1A	O
)	O
.	O

When	O
compared	O
,	O
the	O
morphology	O
of	O
macrophages	O
derived	O
from	O
all	O
stem	O
cell	O
progenitor	O
populations	O
appeared	O
similar	O
.	O

These	O
results	O
were	O
found	O
to	O
be	O
consistent	O
in	O
replicative	O
experiments	O
.	O

The	O
transgene	O
GFP	B
expression	O
was	O
also	O
maintained	O
during	O
the	O
differentiation	O
of	O
hES	O
cells	O
into	O
mature	O
macrophages	O
.	O

GFP	B
expression	O
in	O
cystic	O
body	O
derived	O
CD34	B
cells	O
was	O
around	O
80	O
%	O
(	O
data	O
not	O
shown	O
)	O
with	O
similar	O
levels	O
seen	O
in	O
differentiated	O
macrophages	O
(	O
Fig	O
2	O
)	O
.Figure	O
1Derivation	O
of	O
macrophages	O
from	O
lentiviral	O
vector	O
transduced	O
and	O
normal	O
hES	O
cells	O
.	O

A	O
)	O
Transduced	O
and	O
non	O
-	O
transduced	O
H1	O
hES	O
cells	O
were	O
cultured	O
on	O
mouse	O
S17	O
bone	O
marrow	O
stromal	O
cell	O
layers	O
to	O
derive	O
cystic	O
bodies	O
.	O

Cystic	O
body	O
derived	O
CD34	B
cells	O
were	O
purified	O
by	O
positive	O
selection	O
with	O
antibody	O
conjugated	O
magnetic	O
beads	O
and	O
placed	O
in	O
methocult	O
media	O
to	O
obtain	O
myelomonocytic	O
colonies	O
.	O

Pooled	O
colonies	O
were	O
cultured	O
in	O
liquid	O
cytokine	O
media	O
supplemented	O
with	O
GM	B
-	I
CSF	I
and	O
M	B
-	I
CSF	I
to	O
promote	O
macrophage	O
growth	O
.	O

For	O
comparison	O
,	O
fetal	O
liver	O
derived	O
CD34	B
cells	O
were	O
cultured	O
similarly	O
to	O
derive	O
macrophages	O
.	O

Representative	O
ES	O
cell	O
colonies	O
,	O
cystic	O
bodies	O
,	O
methocult	O
colonies	O
,	O
and	O
derivative	O
macrophages	O
are	O
shown	O
with	O
GFP	B
expressing	O
cells	O
fluorescing	O
green	O
under	O
UV	O
illumination	O
.	O

B	O
)	O
Representative	O
FACS	O
profile	O
of	O
hES	O
cell	O
derived	O
CD34	B
cells	O
stained	O
with	O
PE	O
conjugated	O
antibodies	O
.	O

Percent	O
positive	O
CD34	B
cells	O
are	O
shown	O
with	O
isotype	O
control	O
shown	O
in	O
the	O
left	O
panel	O
.	O

Figure	O
2Phenotypic	O
FACS	O
analysis	O
of	O
hES	O
cell	O
derived	B
macrophages	O
.	O

A	O
)	O
Macrophages	O
derived	O
from	O
transduced	O
and	O
nontransduced	O
hES	O
CD34	B
and	O
fetal	O
liver	O
CD34	B
cells	O
were	O
stained	O
with	O
antibodies	O
to	O
CD14	B
,	O
HLA	B
-	I
DR	I
,	O
CD4	B
,	O
CCR5	B
,	O
and	O
CXCR4	B
and	O
the	O
expression	O
of	O
these	O
surface	O
markers	O
was	O
analyzed	O
by	O
FACS	O
.	O

B	O
)	O
Isotype	O
controls	O
for	O
PE	O
and	O
PE	O
-	O
CY5	O
antibodies	O
.	O

Percent	O
positive	O
cells	O
are	O
displayed	O
in	O
the	O
plots	O
for	O
each	O
respective	O
cell	O
surface	O
marker	O
staining	O
.	O

Dot	O
plots	O
are	O
representative	O
of	O
triplicate	O
experiments	O
.	O

hES	O
cell	O
derived	O
macrophages	O
display	O
a	O
normal	O
phenotypic	O
profileMacrophages	O
play	O
a	O
critical	O
role	O
in	O
immune	O
system	O
function	O
and	O
are	O
also	O
major	O
target	O
cells	O
for	O
many	O
viral	O
infections	O
including	O
HIV-1	O
.	O

Distinct	O
surface	O
phenotypic	O
markers	O
exist	O
on	O
these	O
cells	O
and	O
,	O
thus	O
far	O
,	O
there	O
has	O
been	O
no	O
thorough	O
evaluation	O
of	O
hES	O
cell	O
derived	O
macrophages	O
.	O

Therefore	O
we	O
analyzed	O
hES	O
cell	O
derived	O
macrophages	O
for	O
the	O
presence	O
of	O
characteristic	O
cell	O
surface	O
markers	O
and	O
compared	O
these	O
to	O
the	O
phenotypic	O
profile	O
displayed	O
on	O
fetal	O
CD34	B
cell	O
derived	O
macrophages	O
.	O

The	O
surface	O
markers	O
analyzed	O
were	O
CD14	B
,	O
a	O
monocyte	O
/	O
macrophage	O
specific	O
marker	O
,	O
HLA	B
-	I
DR	I
(	O
a	O
class	B
II	I
MHC	I
molecule	I
found	O
on	O
antigen	O
presenting	O
cells	O
)	O
,	O
CD4	B
,	O
the	O
major	O
receptor	O
for	O
HIV-1	O
infection	O
,	O
and	O
CCR5	B
and	O
CXCR4	B
,	O
chemokine	O
receptors	O
which	O
are	O
critical	O
coreceptors	O
essential	O
for	O
HIV-1	O
entry	O
.	O

EGFP	B
expression	O
was	O
also	O
analyzed	O
to	O
determine	O
the	O
levels	O
of	O
transduction	O
and	O
any	O
transgene	O
silencing	O
that	O
may	O
occur	O
during	O
differentiation	O
.	O

Fetal	O
liver	O
(	O
CD34	B
)	O
,	O
nontransduced	O
(	O
ES	O
)	O
,	O
and	O
vector	O
transduced	O
(	O
GFP	B
ES	O
)	O
hES	O
cell	O
derived	O
macrophages	O
were	O
all	O
positive	O
for	O
the	O
monocyte	O
/	O
macrophage	O
marker	O
CD14	B
(	O
99.3	O
%	O
,	O
88.7	O
%	O
,	O
and	O
99.2	O
%	O
,	O
respectively	O
)	O
(	O
Fig	O
2A	O
)	O
.	O

However	O
,	O
the	O
mean	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
was	O
found	O
to	O
be	O
lower	O
on	O
hES	O
cell	O
derived	O
macrophages	O
.	O

Surface	O
expression	O
of	O
HLA	B
-	I
DR	I
was	O
observed	O
at	O
similar	O
levels	O
between	O
macrophages	O
derived	O
from	O
fetal	O
liver	O
CD34	B
cells	O
(	O
99.6	O
%	O
)	O
,	O
nontransduced	O
hES	O
cells	O
(	O
92.8	O
%	O
)	O
,	O
and	O
transduced	O
hES	O
cells	O
(	O
98.2	O
%	O
)	O
(	O
Fig	O
2A	O
)	O
.	O

CD4	B
levels	O
were	O
comparable	O
for	O
all	O
stem	O
cell	O
derived	O
macrophages	O
(	O
99.2	O
%	O
,	O
83.3	O
%	O
,	O
and	O
88.7	O
%	O
,	O
respectively	O
)	O
(	O
Fig	O
2A	O
)	O
.	O

CCR5	B
and	O
CXCR4	B
cell	O
surface	O
expression	O
was	O
also	O
observed	O
for	O
fetal	O
liver	O
CD34	B
cell	O
(	O
99.6	O
%	O
and	O
99.3	O
%	O
)	O
,	O
nontransduced	O
hES	O
cell	O
(	O
91.9	O
%	O
and	O
92.6	O
%	O
)	O
,	O
and	O
transduced	O
hES	O
cell	O
(	O
98.9	O
%	O
and	O
99.3	O
%	O
)	O
derived	O
macrophages	O
(	O
Fig	O
2A	O
)	O
.	O

As	O
compared	O
to	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
macrophages	O
,	O
hES	O
cell	O
derived	O
macrophages	O
displayed	O
a	O
higher	O
level	O
of	O
expression	O
of	O
CXCR4	B
.	O

Isotype	O
controls	O
for	O
both	O
PE	O
and	O
PECY5	B
stains	O
are	O
shown	O
in	O
Fig	O
2B	O
.	O

The	O
above	O
phenotypic	O
data	O
are	O
representative	O
of	O
triplicate	O
experiments	O
.	O

Transgenic	O
hES	O
cell	O
derived	O
macrophages	O
are	O
functionally	O
normalThe	O
antigen	O
presenting	O
cell	O
surface	O
specific	O
marker	O
HLA	B
-	I
DR	I
(	O
MHC	B
II	I
)	O
on	O
normal	O
macrophages	O
is	O
critical	O
for	O
presenting	O
antigen	O
to	O
CD4	B
T	O
cells	O
.	O

A	O
second	O
co	O
-	O
stimulatory	O
molecule	O
,	O
B7.1	B
is	O
present	O
at	O
low	O
basal	O
levels	O
on	O
resting	O
macrophages	O
and	O
is	O
necessary	O
to	O
activate	O
T	O
cells	O
.	O

Its	O
expression	O
is	O
elevated	O
upon	O
activation	O
with	O
certain	O
stimuli	O
such	O
as	O
LPS	O
.	O

Our	O
results	O
of	O
LPS	B
stimulation	O
of	O
respective	O
macrophages	O
have	O
shown	O
upregulation	O
of	O
B7.1	B
with	O
values	O
for	O
fetal	O
liver	O
CD34	B
cell	O
(	O
CD34	O
)	O
(	O
27.9	O
%	O
to	O
75.4	O
%	O
)	O
nontransduced	O
(	O
ES	O
)	O
(	O
17.8	O
%	O
to	O
49.4	O
%	O
)	O
and	O
transduced	O
(	O
GFP	O
ES	O
)	O
(	O
35.6	O
%	O
to	O
65.7	O
%	O
)	O
hES	O
cell	O
derived	O
macrophages	O
(	O
Fig	O
3A	O
)	O
.	O

These	O
values	O
represent	O
a	O
significant	O
upregulation	O
of	O
B7.1	B
for	O
all	O
three	O
macrophage	O
populations	O
.	O

Figure	O
3Functional	O
analysis	O
of	O
hES	O
cell	O
derived	O
macrophages	O
for	O
B7.1	B
costimulatory	O
molecule	O
upregulation	O
and	O
phagocytosis	O
of	O
E.	O
coli	O
particles	O
:	O
A	O
)	O
Mature	O
macrophages	O
were	O
stimulated	O
with	O
LPS	B
to	O
determine	O
B7.1	B
upregulation	O
.	O

Twenty	O
-	O
four	O
hours	O
post	O
-	O
stimulation	O
,	O
macrophages	O
were	O
labeled	O
with	O
a	O
PE	O
-	O
CY5	O
conjugated	O
anti	O
-	O
B7.1	B
antibody	O
and	O
analyzed	O
by	O
FACS	O
.	O

B7.1	B
upregulation	O
data	O
are	O
representative	O
of	O
triplicate	O
experiments	O
.	O

Isotype	O
control	O
is	O
shown	O
in	O
the	O
left	O
panel	O
.	O

B	O
)	O
To	O
assess	O
phagocytic	O
function	O
,	O
E.	O
coli	O
Bioparticles	O
®	O
were	O
added	O
directly	O
to	O
the	O
cultured	O
macrophages	O
.	O

Twenty	O
four	O
hours	O
post	O
-	O
addition	O
,	O
cells	O
were	O
analyzed	O
by	O
FACS	O
.	O

Percent	O
positive	O
cells	O
are	O
displayed	O
in	O
the	O
plots	O
for	O
each	O
experiment	O
.	O

These	O
data	O
are	O
representative	O
of	O
triplicate	O
experiments	O
.	O

Another	O
important	O
function	O
of	O
macrophages	O
is	O
their	O
ability	O
to	O
phagocytose	O
foreign	O
material	O
and	O
present	O
antigenic	O
peptides	O
on	O
their	O
cell	O
surface	O
.	O

To	O
evaluate	O
phagocytic	O
function	O
,	O
fluorescently	O
labeled	O
E.	O
coli	O
Bioparticles	O
®	O
were	O
added	O
to	O
macrophage	O
cultures	O
followed	O
by	O
FACS	O
analysis	O
.	O

Nontransduced	O
(	O
94.6	O
%	O
)	O
as	O
well	O
as	O
lentiviral	O
vector	O
transduced	O
(	O
98.7	O
%	O
)	O
hES	O
cell	O
derived	O
macrophages	O
were	O
found	O
to	O
be	O
capable	O
of	O
phagocytosing	O
the	O
Bioparticles	O
®	O
in	O
comparison	O
to	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
macrophages	O
(	O
95.8	O
%	O
)	O
(	O
Fig	O
3B	O
)	O
.	O

These	O
values	O
are	O
representative	O
of	O
triplicate	O
experiments	O
.	O

Magi	O
-	O
CXCR4	B
cells	O
with	O
no	O
phagocytic	O
capacity	O
were	O
used	O
as	O
non	O
-	O
phagocytic	O
cell	O
controls	O
and	O
similarly	O
exposed	O
to	O
E.	O
coli	O
Bioparticles	O
®	O
(	O
Fig	O
3B	O
)	O
.	O

No	O
uptake	O
of	O
the	O
bacteria	O
could	O
be	O
seen	O
.	O

Thus	O
,	O
uptake	O
of	O
E.	O
coli	O
Bioparticles	O
®	O
by	O
macrophages	O
is	O
indicative	O
of	O
active	O
ingestion	O
.	O

Macrophages	O
,	O
as	O
effector	O
cells	O
,	O
play	O
a	O
key	O
role	O
in	O
the	O
inflammatory	O
response	O
.	O

Activated	O
macrophages	O
secrete	O
various	O
cytokines	O
,	O
two	O
of	O
the	O
major	O
ones	O
being	O
IL-1	B
and	O
TNF	B
-	I
α	I
.	O

To	O
determine	O
if	O
hES	O
cell	O
derived	O
macrophages	O
have	O
such	O
a	O
capacity	O
,	O
cells	O
were	O
stimulated	O
with	O
LPS	B
.	O

On	O
days	O
1	O
,	O
2	O
,	O
and	O
3	O
post	O
-	O
stimulation	O
,	O
culture	O
supernatants	O
were	O
analyzed	O
by	O
ELISA	O
to	O
detect	O
IL-1	B
and	O
TNF	B
-	I
α	I
.	O

As	O
seen	O
in	O
figure	O
4A	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
IL-1	B
secretion	O
between	O
the	O
three	O
sets	O
of	O
macrophages	O
.	O

Similarly	O
,	O
nontransduced	O
and	O
transduced	O
hES	O
cell	O
derived	O
macrophages	O
were	O
also	O
capable	O
of	O
TNF	B
-	I
α	I
secretion	O
upon	O
LPS	B
stimulation	O
.	O

However	O
,	O
levels	O
of	O
the	O
respective	O
cytokines	O
detected	O
were	O
slightly	O
lower	O
than	O
those	O
from	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
macrophages	O
(	O
Fig	O
4B	O
)	O
.	O

The	O
values	O
of	O
cytokine	O
secretion	O
levels	O
represent	O
triplicate	O
experiments	O
.	O

Figure	O
4Cytokine	O
IL-1	B
and	O
TNFα	B
secretion	O
by	O
stimulated	O
hES	O
cell	O
derived	O
macrophages	O
:	O
Macrophages	O
derived	O
from	O
transduced	O
and	O
nontransduced	O
hES	O
and	O
fetal	O
liver	O
CD34	B
cells	O
were	O
stimulated	O
with	O
5	O
μg	O
/	O
ml	O
LPS	B
.	O

On	O
days	O
1	O
,	O
2	O
,	O
and	O
3	O
post	O
-	O
stimulation	O
,	O
supernatants	O
were	O
collected	O
and	O
assayed	O
by	O
ELISA	O
for	O
(	O
A	O
)	O
IL-1	B
and	O
(	O
B	O
)	O
TNFα	B
.	O

Experiments	O
were	O
done	O
in	O
triplicate	O
.	O

hES	O
cell	O
derived	O
macrophages	O
support	O
productive	O
HIV-1	O
infectionThe	O
above	O
data	O
have	O
shown	O
that	O
hES	O
cell	O
derived	O
macrophages	O
are	O
very	O
similar	O
to	O
normal	O
human	O
macrophages	O
based	O
on	O
phenotypic	O
and	O
functional	O
analysis	O
.	O

In	O
addition	O
to	O
being	O
important	O
cells	O
of	O
the	O
immune	O
system	O
,	O
macrophages	O
are	O
among	O
the	O
major	O
target	O
cells	O
for	O
certain	O
viral	O
infections	O
,	O
particularly	O
for	O
HIV-1	O
.	O

We	O
wanted	O
to	O
determine	O
if	O
hES	O
cell	O
derived	O
macrophages	O
were	O
susceptible	O
to	O
HIV-1	O
infection	O
compared	O
to	O
standard	O
macrophages	O
.	O

In	O
these	O
studies	O
,	O
we	O
only	O
used	O
an	O
R5-tropic	O
strain	O
of	O
HIV-1	O
since	O
macrophages	O
are	O
natural	O
targets	O
for	O
this	O
virus	O
.	O

Our	O
results	O
from	O
challenge	O
studies	O
of	O
these	O
cells	O
clearly	O
indicated	O
the	O
capacity	O
of	O
hES	O
cell	O
derived	O
macrophages	O
in	O
supporting	O
a	O
productive	O
infection	O
.	O

Levels	O
of	O
virus	O
increased	O
up	O
to	O
15	O
days	O
similar	O
to	O
non	O
-	O
hES	O
derived	O
macrophages	O
showing	O
that	O
the	O
initial	O
viral	O
input	O
was	O
amplified	O
in	O
productive	O
viral	O
infection	O
.	O

However	O
,	O
the	O
levels	O
of	O
viral	O
yield	O
were	O
found	O
to	O
be	O
slightly	O
lower	O
for	O
the	O
ES	O
cell	O
derived	O
macrophages	O
.	O

In	O
the	O
case	O
of	O
GFP	B
-	O
ES	O
macrophages	O
,	O
there	O
was	O
a	O
decline	O
in	O
viral	O
titer	O
.	O

This	O
could	O
be	O
due	O
to	O
possible	O
lower	O
numbers	O
of	O
cells	O
present	O
in	O
the	O
initial	O
cultures	O
.	O

As	O
a	O
first	O
step	O
towards	O
the	O
use	O
of	O
hES	O
cells	O
for	O
hematopoietic	O
stem	O
cell	O
and	O
HIV	O
gene	O
therapies	O
,	O
we	O
have	O
shown	O
here	O
that	O
phenotypically	O
and	O
functionally	O
normal	O
macrophages	O
could	O
be	O
derived	O
from	O
hES	O
-	O
CD34	B
cells	O
.	O

Both	O
non	O
transduced	O
and	O
lentiviral	O
vector	O
transduced	O
hES	O
cells	O
were	O
found	O
to	O
be	O
capable	O
of	O
generating	O
CD34	B
cells	O
that	O
give	O
rise	O
to	O
macrophages	O
which	O
could	O
support	O
productive	O
HIV-1	O
infection	O
.	O

Current	O
sources	O
of	O
CD34	B
cells	O
consist	O
of	O
human	O
bone	O
marrow	O
,	O
cytokine	O
mobilized	O
peripheral	O
blood	O
,	O
fetal	O
liver	O
,	O
and	O
cord	O
blood	O
[	O
34	O
]	O
.	O

However	O
,	O
the	O
number	O
of	O
cells	O
that	O
can	O
be	O
obtained	O
for	O
manipulations	O
is	O
not	O
unlimited	O
.	O

Therefore	O
,	O
deriving	O
CD34	B
cells	O
for	O
therapeutic	O
and	O
investigative	O
purposes	O
from	O
hES	O
cells	O
with	O
unlimited	O
growth	O
potential	O
has	O
the	O
advantage	O
of	O
a	O
consistent	O
and	O
uniform	O
source	O
.	O

The	O
ability	O
to	O
obtain	O
phenotypically	O
normal	O
and	O
functionally	O
competent	O
macrophages	O
from	O
hES	O
cells	O
is	O
important	O
to	O
evaluate	O
their	O
potential	O
therapeutic	O
utilities	O
in	O
the	O
future	O
.	O

Additionally	O
,	O
testing	O
of	O
transgenic	O
hES	O
cells	O
derived	O
via	O
lentiviral	O
vector	O
gene	O
transduction	O
is	O
also	O
helpful	O
to	O
determine	O
the	O
stability	O
of	O
the	O
transgene	O
expression	O
and	O
their	O
capacity	O
for	O
differentiation	O
into	O
end	O
stage	O
mature	O
cells	O
such	O
as	O
macrophages	O
.	O

Based	O
on	O
these	O
considerations	O
,	O
both	O
non-	O
transduced	O
and	O
lentiviral	O
vector	O
transduced	O
hES	O
cells	O
were	O
evaluated	O
for	O
their	O
capacity	O
to	O
give	O
rise	O
to	O
CD34	B
progenitor	O
cells	O
.	O

In	O
colony	O
forming	O
assays	O
using	O
semisolid	O
methylcellulose	O
medium	O
,	O
the	O
morphology	O
of	O
myelomonocytic	O
colonies	O
derived	O
from	O
hES	O
CD34	B
cells	O
appeared	O
similar	O
to	O
that	O
of	O
fetal	O
liver	O
CD34	B
cells	O
.	O

When	O
subsequently	O
cultured	O
in	O
cytokine	O
media	O
that	O
promotes	O
macrophage	O
differentiation	O
,	O
morphologically	O
normal	O
macrophages	O
were	O
obtained	O
with	O
hES	O
-	O
CD34	B
cells	O
similar	O
to	O
that	O
of	O
fetal	O
liver	O
CD34	B
cells	O
.	O

At	O
higher	O
magnification	O
,	O
the	O
macrophages	O
displayed	O
flat	O
projecting	O
cellular	O
borders	O
with	O
fried	O
egg	O
appearance	O
with	O
distinct	O
refractory	O
lysosomal	O
granules	O
in	O
the	O
cytoplasm	O
(	O
data	O
not	O
shown	O
)	O
.	O

Lentiviral	O
vector	O
transduced	O
hES	O
cells	O
also	O
did	O
not	O
display	O
any	O
abnormal	O
growth	O
or	O
differentiation	O
characteristics	O
as	O
compared	O
to	O
nontransduced	O
hES	O
-	O
CD34	B
cells	O
indicating	O
no	O
adverse	O
effects	O
due	O
to	O
vector	O
integration	O
and	O
expression	O
.	O

Transduced	O
cells	O
gave	O
rise	O
to	O
cystic	O
bodies	O
with	O
similar	O
CD34	B
cell	O
content	O
and	O
profiles	O
upon	O
development	O
.	O

The	O
transduced	O
hES	O
-	O
CD34	B
cells	O
also	O
gave	O
rise	O
to	O
apparently	O
normal	O
macrophages	O
that	O
expressed	O
the	O
transgene	O
as	O
shown	O
by	O
GFP	B
expression	O
.	O

These	O
results	O
are	O
consistent	O
with	O
those	O
of	O
others	O
that	O
showed	O
normal	O
differentiation	O
of	O
hES	O
cells	O
to	O
other	O
cell	O
types	O
following	O
lentiviral	O
transduction	O
[	O
32	O
]	O
.	O

A	O
requirement	O
for	O
successful	O
cellular	O
and	O
HIV-1	O
gene	O
therapy	O
is	O
that	O
mature	O
end	O
stage	O
cells	O
derived	O
from	O
CD34	B
progenitor	O
cells	O
be	O
phenotypically	O
and	O
functionally	O
normal	O
to	O
maintain	O
and	O
restore	O
the	O
body	O
's	O
immunological	O
function	O
.	O

Accordingly	O
,	O
hES	O
cell	O
derived	O
macrophages	O
were	O
evaluated	O
to	O
determine	O
if	O
they	O
met	O
these	O
criteria	O
.	O

Macrophages	O
display	O
distinct	O
cell	O
surface	O
markers	O
upon	O
end	O
stage	O
differentiation	O
.	O

To	O
determine	O
whether	O
hES	O
cell	O
derived	O
macrophages	O
display	O
these	O
surface	O
markers	O
,	O
FACS	O
analysis	O
was	O
performed	O
to	O
detect	O
the	O
presence	O
of	O
CD14	B
,	O
HLA	B
-	I
DR	I
(	O
MHCII	B
)	O
,	O
CD4	B
,	O
CCR5	B
,	O
and	O
CXCR4	B
.	O

As	O
observed	O
in	O
Fig	O
2A	O
,	O
both	O
nontransduced	O
and	O
transduced	O
hES	O
cell	O
derived	O
macrophages	O
expressed	O
all	O
of	O
these	O
markers	O
with	O
some	O
differences	O
in	O
their	O
levels	O
of	O
expression	O
.	O

HLA	B
-	I
DR	I
,	O
CD4	B
,	O
and	O
CCR5	B
expression	O
profiles	O
were	O
comparable	O
between	O
all	O
cell	O
types	O
analyzed	O
.	O

Even	O
though	O
all	O
cell	O
types	O
analyzed	O
stained	O
positive	O
for	O
CD14	B
,	O
relative	O
expression	O
of	O
CD14	B
was	O
slightly	O
lower	O
on	O
hES	O
cell	O
derived	O
macrophages	O
compared	O
to	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
macrophages	O
.	O

On	O
the	O
contrary	O
,	O
the	O
levels	O
of	O
CXCR4	B
,	O
a	O
chemokine	O
receptor	O
involved	O
in	O
cellular	O
homing	O
,	O
were	O
found	O
to	O
be	O
higher	O
on	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
.	O

This	O
may	O
be	O
due	O
to	O
inherent	O
differences	O
in	O
the	O
cell	O
types	O
and/or	O
due	O
to	O
their	O
physiological	O
state	O
at	O
the	O
time	O
of	O
harvest	O
[	O
35	O
]	O
.	O

Additional	O
hES	O
cell	O
lines	O
need	O
to	O
be	O
evaluated	O
in	O
the	O
future	O
to	O
establish	O
if	O
these	O
differences	O
are	O
consistent	O
.	O

A	O
major	O
functional	O
role	O
of	O
macrophages	O
in	O
vivo	O
is	O
their	O
ability	O
to	O
serve	O
as	O
professional	O
antigen	O
presenting	O
cells	O
.	O

During	O
this	O
process	O
macrophages	O
present	O
antigen	O
peptide	O
fragments	O
complexed	O
with	O
both	O
classes	O
of	O
MHC	B
molecules	I
and	O
deliver	O
a	O
costimulatory	O
signal	O
through	O
the	O
expression	O
of	O
B7	B
molecules	B
.	O

Upon	O
stimulation	O
with	O
LPS	B
,	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
had	O
shown	O
upregulation	O
of	O
the	O
costimulatory	O
molecule	O
B7.1	B
similar	O
to	O
cells	O
derived	O
from	O
fetal	O
liver	O
.	O

Furthermore	O
,	O
the	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
also	O
showed	O
a	O
normal	O
capacity	O
to	O
ingest	O
foreign	O
particles	O
in	O
phagocytosis	O
assays	O
using	O
E.coli	O
Bioparticles	O
®	O
.	O

In	O
addition	O
to	O
antigen	O
presentation	O
and	O
phagocytosis	O
,	O
macrophages	O
also	O
play	O
a	O
critical	O
role	O
in	O
inflammation	O
and	O
secrete	O
cytokines	O
in	O
response	O
to	O
external	O
stimuli	O
.	O

When	O
exposed	O
to	O
LPS	B
,	O
the	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
secreted	O
two	O
important	O
cytokines	O
IL-1	B
and	O
TNF	B
-	I
α	I
similar	O
to	O
that	O
of	O
fetal	O
liver	O
derived	O
cells	O
.	O

The	O
above	O
data	O
has	O
established	O
that	O
phenotypically	O
and	O
functionally	O
normal	O
macrophages	O
could	O
be	O
derived	O
from	O
hES	O
-	O
CD34	B
cells	O
.	O

Macrophages	O
in	O
addition	O
to	O
playing	O
important	O
physiological	O
roles	O
are	O
also	O
major	O
cell	O
targets	O
for	O
certain	O
viral	O
infections	O
,	O
particularly	O
HIV-1	O
.	O

Here	O
we	O
evaluated	O
the	O
susceptibility	O
of	O
hES	O
-	O
CD34	B
cell	O
derived	O
macrophages	O
to	O
be	O
productively	O
infected	O
with	O
HIV-1	O
.	O

Similar	O
to	O
that	O
of	O
fetal	O
liver	O
CD34	B
cell	O
derived	O
cells	O
,	O
the	O
hES	O
-	O
CD34	B
macrophages	O
also	O
supported	O
HIV-1	O
infection	O
although	O
the	O
levels	O
of	O
viral	O
yield	O
differed	O
somewhat	O
.	O

However	O
this	O
should	O
not	O
be	O
a	O
major	O
concern	O
for	O
testing	O
anti	O
-	O
HIV	O
genes	O
in	O
these	O
cells	O
.	O

In	O
all	O
the	O
above	O
experiments	O
,	O
the	O
vector	O
transduced	O
transgenic	O
macrophages	O
also	O
behaved	O
similarly	O
to	O
that	O
of	O
nontransduced	O
cells	O
showing	O
that	O
they	O
were	O
also	O
physiologically	O
normal	O
.	O

The	O
lack	O
of	O
vector	O
toxicity	O
on	O
cellular	O
maturation	O
is	O
encouraging	O
for	O
future	O
work	O
with	O
transduced	O
hES	O
-	O
CD34	B
cells	O
to	O
derive	O
other	O
important	O
differentiated	O
cells	O
like	O
T	O
cells	O
and	O
dendritic	O
cells	O
relevant	O
for	O
HIV	O
studies	O
.	O

Although	O
there	O
are	O
numerous	O
studies	O
on	O
hES	O
cell	O
differentiation	O
into	O
many	O
important	O
end	O
stage	O
mature	O
cells	O
,	O
systematic	O
work	O
on	O
hES	O
cell	O
hematopoietic	O
differentiation	O
and	O
thorough	O
characterization	O
of	O
end	O
stage	O
mature	O
cells	O
that	O
participate	O
in	O
critical	O
immune	O
responses	O
has	O
just	O
begun	O
[	O
21,27	O
-	O
29	O
]	O
.	O

Our	O
current	O
results	O
established	O
that	O
physiologically	O
normal	O
macrophages	O
could	O
be	O
derived	O
from	O
hES	O
cells	O
and	O
that	O
these	O
cells	O
have	O
the	O
potential	O
for	O
use	O
in	O
cellular	O
and	O
gene	O
therapies	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
demonstration	O
that	O
hES	O
cell	O
derivatives	O
can	O
be	O
used	O
for	O
infectious	O
disease	O
research	O
.	O

Due	O
to	O
the	O
extensive	O
ability	O
for	O
hES	O
cells	O
to	O
self	O
-	O
renew	O
,	O
large	O
numbers	O
of	O
differentiated	O
cells	O
can	O
be	O
derived	O
so	O
that	O
infection	O
studies	O
and	O
evaluation	O
tests	O
can	O
be	O
carried	O
out	O
in	O
a	O
more	O
standardized	O
way	O
.	O

Our	O
results	O
showing	O
that	O
both	O
normal	O
and	O
transgenic	O
derivative	O
macrophages	O
support	O
HIV-1	O
infection	O
points	O
out	O
to	O
their	O
utility	O
for	O
testing	O
anti	O
-	O
HIV	O
constructs	O
transduced	O
into	O
hES	O
-	O
CD34	B
cells	O
and	O
pave	O
the	O
way	O
for	O
their	O
application	O
in	O
stem	O
cell	O
based	O
HIV	O
gene	O
therapy	O
.	O

So	O
far	O
a	O
number	O
of	O
studies	O
including	O
our	O
own	O
have	O
tested	O
many	O
gene	O
therapeutic	O
constructs	O
in	O
CD34	B
cells	O
from	O
conventional	O
sources	O
.	O

These	O
constructs	O
include	O
anti	B
-	I
HIV	I
ribozymes	I
,	O
RNA	O
decoys	O
,	O
transdominant	O
proteins	O
,	O
bacterial	O
toxins	O
,	O
anti	O
-	O
sense	O
nucleic	O
acids	O
,	O
and	O
most	O
recently	O
siRNAs	O
[	O
36	O
-	O
50	O
]	O
.	O

In	O
addition	O
,	O
a	O
number	O
of	O
cellular	O
molecules	O
that	O
aid	O
in	O
HIV-1	O
infection	O
such	O
as	O
cellular	O
receptors	O
and	O
coreceptors	O
CD4	B
,	O
CCR5	B
and	O
CXCR4	B
have	O
also	O
been	O
successfully	O
tested	O
in	O
CD34	B
cell	O
derived	O
macrophages	O
and	O
T	O
cells	O
[	O
16,18,38	O
]	O
.	O

Some	O
of	O
these	O
approaches	O
have	O
progressed	O
into	O
clinical	O
evaluations	O
as	O
well	O
[	O
14,51,52	O
]	O
.	O

Based	O
on	O
our	O
current	O
results	O
,	O
many	O
of	O
these	O
novel	O
anti	O
-	O
HIV	O
constructs	O
can	O
also	O
be	O
tested	O
in	O
hES	O
-	O
CD34	B
cells	O
for	O
their	O
potential	O
application	O
.	O

Although	O
there	O
are	O
advantages	O
of	O
using	O
hES	O
cell	O
derived	O
CD34	B
cells	O
for	O
potential	O
cellular	O
therapies	O
,	O
transplantation	O
of	O
these	O
cells	O
constitutes	O
an	O
allogenic	O
source	O
with	O
immune	O
rejection	O
as	O
a	O
major	O
issue	O
.	O

However	O
,	O
a	O
recent	O
study	O
using	O
human	O
leukocyte	O
reconstituted	O
mice	O
suggested	O
that	O
hESCs	O
and	O
their	O
derivative	O
cell	O
types	O
were	O
less	O
prone	O
to	O
invoking	O
an	O
allogeneic	O
response	O
[	O
53	O
]	O
.	O

Other	O
recent	O
studies	O
demonstrated	O
successful	O
engraftment	O
of	O
primary	O
and	O
secondary	O
recipients	O
with	O
hES	O
cell	O
derived	O
hematopoietic	O
cells	O
in	O
both	O
immunodeficient	O
mice	O
and	O
in	O
vivo	O
fetal	O
sheep	O
models	O
adding	O
further	O
support	O
that	O
any	O
obstacles	O
could	O
be	O
overcome	O
[	O
23,54,55	O
]	O
.	O

Moreover	O
,	O
multiple	O
novel	O
strategies	O
to	O
avoid	O
immune	O
-	O
mediated	O
rejection	O
of	O
hES	O
cell	O
-	O
derived	O
cells	O
have	O
been	O
proposed	O
[	O
56,57	O
]	O
.	O

It	O
is	O
not	O
too	O
far	O
in	O
the	O
future	O
that	O
even	O
autologous	O
hES	O
cells	O
may	O
be	O
derived	O
from	O
specific	O
individuals	O
for	O
deriving	O
CD34	B
cells	O
which	O
can	O
be	O
used	O
for	O
cell	O
replacement	O
therapy	O
.	O

Phenotypically	O
normal	O
and	O
functionally	O
competent	O
macrophages	O
could	O
be	O
derived	O
from	O
hES	O
-	O
CD34	O
cells	O
.	O

Since	O
these	O
cells	O
are	O
susceptible	O
to	O
HIV-1	O
infection	O
,	O
they	O
provide	O
a	O
uniform	O
source	O
of	O
macrophages	O
for	O
viral	O
infection	O
studies	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
is	O
also	O
now	O
feasible	O
to	O
transduce	O
hES	O
-	O
CD34	B
cells	O
with	O
anti	B
-	I
HIV	I
genes	I
such	O
as	O
inhibitory	O
siRNAs	B
and	O
test	O
their	O
antiviral	O
efficacy	O
in	O
down	O
stream	O
differentiated	O
cells	O
such	O
as	O
macrophages	O
which	O
are	O
among	O
the	O
primary	O
cells	O
that	O
need	O
to	O
be	O
protected	O
against	O
HIV-1	O
infection	O
.	O

Thus	O
,	O
the	O
potential	O
utility	O
of	O
hES	O
derived	O
CD34	B
hematopoietic	O
cells	O
for	O
HIV-1	O
gene	O
therapy	O
can	O
be	O
evaluated	O
.	O

Growth	O
,	O
propagation	O
and	O
lentiviral	O
transduction	O
of	O
hES	O
cellsThe	O
NIH	O
approved	O
human	O
ES	O
H1	O
cell	O
line	O
was	O
obtained	O
from	O
WiCell	O
(	O
Madison	O
,	O
Wisconsin	O
)	O
.	O

hES	O
cell	O
colonies	O
were	O
cultured	O
on	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	O
)	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
)	O
in	O
the	O
presence	O
of	O
DMEM	O
-	O
F12	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
supplemented	O
with	O
20	O
%	O
KNOCKOUT	O
serum	O
replacement	O
with	O
1	O
mM	O
L	O
-	O
glutamine	O
,	O
1	O
%	O
Nonessential	O
Amino	O
Acids	O
,	O
0.1	O
mM	O
β	O
-	O
mercaptoethanol	O
,	O
0.5	O
%	O
penicillin	O
/	O
streptomycin	O
,	O
and	O
4	O
ng	O
/	O
ml	O
human	B
basic	I
fibroblast	I
growth	I
factor	I
.	O

Culture	O
medium	O
was	O
replaced	O
daily	O
with	O
fresh	O
complete	O
DMEM	O
-	O
F12	O
.	O

Mature	O
colonies	O
were	O
subcultured	O
weekly	O
by	O
digesting	O
with	O
collagenase	B
IV	I
as	O
previously	O
described	O
[	O
5	O
]	O
.	O

A	O
VSV	O
-	O
G	O
pseudotyped	O
lentiviral	O
vector	O
(	O
SINF	O
-	O
EF1a	O
-	O
GFP	O
)	O
containing	O
a	O
GFP	B
reporter	O
gene	O
(	O
kindly	O
supplied	O
by	O
R.	O
Hawley	O
,	O
George	O
Washington	O
University	O
)	O
was	O
used	O
for	O
hES	O
cell	O
transductions	O
as	O
previously	O
described	O
(	O
30	O
,	O
58	O
)	O
.	O

Generation	O
of	O
the	O
pseudotyped	O
vector	O
in	O
293	O
T	O
cells	O
and	O
its	O
concentration	O
by	O
ultracentrifugation	O
were	O
described	O
previously	O
[	O
30,48	O
]	O
.	O

For	O
vector	O
transduction	O
,	O
the	O
undifferentiated	O
hES	O
cells	O
were	O
prepared	O
into	O
small	O
clumps	O
of	O
50–100	O
cells	O
with	O
enzyme	O
digestion	O
as	O
done	O
for	O
routine	O
passaging	O
of	O
cells	O
.	O

The	O
cell	O
clumps	O
were	O
incubated	O
with	O
the	O
vector	O
for	O
2	O
hrs	O
in	O
the	O
presence	O
of	O
polybrene	O
6	O
ug	O
/	O
ml	O
.	O

A	O
secondary	O
cycle	O
of	O
transduction	O
was	O
done	O
by	O
adding	O
fresh	O
vector	O
and	O
incubating	O
for	O
another	O
2	O
hrs	O
.	O

The	O
general	O
vector	O
titers	O
were	O
1	O
×	O
107	O
and	O
the	O
multiplicity	O
of	O
infection	O
was	O
10	O
.	O

The	O
transduction	O
efficiency	O
was	O
about	O
50	O
%	O
.	O

The	O
transduced	O
colonies	O
were	O
cultured	O
on	O
MEF	O
like	O
above	O
.	O

Derivation	O
and	O
purification	O
of	O
CD34	B
cells	O
from	O
hES	O
cellsUndifferentiated	O
hES	O
cells	O
were	O
cultured	O
on	O
S17	O
mouse	O
bone	O
marrow	O
stromal	O
cell	O
monolayers	O
to	O
derive	O
cystic	O
bodies	O
containing	O
CD34	B
+	O
hematopoietic	O
progenitor	O
stem	O
cells	O
.	O

hES	O
cell	O
cultures	O
were	O
treated	O
with	O
collagenase	B
IV	I
(	O
1	O
mg	O
/	O
ml	O
)	O
for	O
10	O
minutes	O
at	O
37	O
°	O
C	O
and	O
subsequently	O
detached	O
from	O
the	O
plate	O
by	O
gentle	O
scraping	O
of	O
the	O
colonies	O
.	O

The	O
hES	O
cell	O
clusters	O
were	O
then	O
transferred	O
to	O
irradiated	O
(	O
35	O
Gy	O
)	O
S17	O
cell	O
layers	O
and	O
cultured	O
with	O
RPMI	O
differentiation	O
medium	O
containing	O
15	O
%	O
FBS	O
(	O
HyClone	O
,	O
Logan	O
,	O
UT	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0.1	O
mM	O
β	O
-	O
mercaptoethanol	O
,	O
1	O
%	O
MEM	O
-	O
nonessential	O
amino	O
acids	O
,	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
.	O

Media	O
was	O
changed	O
every	O
2	O
to	O
3	O
days	O
during	O
14–17	O
days	O
of	O
culture	O
on	O
S17	O
cells	O
[	O
20	O
]	O
.After	O
allowing	O
adequate	O
time	O
for	O
differentiation	O
,	O
hES	O
cystic	O
bodies	O
were	O
harvested	O
and	O
processed	O
into	O
a	O
single	O
cell	O
suspension	O
by	O
collagenase	B
IV	I
treatment	O
followed	O
by	O
digestion	O
with	O
trypsin	B
/	O
EDTA	O
supplemented	O
with	O
2	O
%	O
chick	O
serum	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
for	O
20	O
minutes	O
at	O
37	O
°	O
C	O
.	O

Cells	O
were	O
washed	O
twice	O
with	O
PBS	O
and	O
filtered	O
through	O
a	O
70	O
uM	O
cell	O
strainer	O
to	O
obtain	O
a	O
single	O
cell	O
suspension	O
.	O

To	O
assess	O
the	O
levels	O
of	O
CD34	B
cells	O
in	O
the	O
bulk	O
cell	O
suspension	O
,	O
cells	O
were	O
labeled	O
with	O
PE	O
conjugated	O
anti	O
-	O
CD34	B
antibody	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
FACS	O
.	O

To	O
purify	O
the	O
CD34	B
cells	O
,	O
Direct	O
CD34	B
Progenitor	O
Cell	O
Isolation	O
Kit	O
(	O
Miltenyi	O
Biotech	O
,	O
Auburn	O
,	O
CA	O
)	O
was	O
used	O
following	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Isolated	O
CD34	B
hematopoietic	O
progenitor	O
stem	O
cells	O
were	O
then	O
analyzed	O
by	O
FACS	O
as	O
mentioned	O
above	O
to	O
determine	O
cell	O
purity	O
.	O

For	O
comparative	O
experiments	O
,	O
human	O
CD34	B
hematopoietic	O
progenitor	O
cells	O
were	O
also	O
purified	O
from	O
fetal	O
liver	O
tissue	O
as	O
described	O
above	O
.	O

Derivation	O
of	O
macrophages	O
from	O
hES	O
cell	O
derived	O
and	O
human	O
fetal	O
CD34	B
cellsCD34	O
cells	O
were	O
cultured	O
initially	O
in	O
semisolid	O
media	O
to	O
derive	O
myelomonocytic	O
colonies	O
followed	O
by	O
liquid	O
culture	O
in	O
cytokine	O
supplemented	O
media	O
as	O
described	O
below	O
.	O

Purified	O
CD34	B
+	O
progenitor	O
cells	O
(	O
~2.5	O
×	O
105	O
to	O
4.0	O
×	O
105	O
)	O
were	O
placed	O
directly	O
into	O
Methocult	O
semisolid	O
medium	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
Vancouver	O
,	O
BC	O
)	O
,	O
mixed	O
,	O
and	O
cultured	O
in	O
35	O
mm	O
plates	O
.	O

Myeloid	O
colonies	O
were	O
allowed	O
to	O
develop	O
for	O
12–15	O
days	O
.	O

Upon	O
differentiation	O
and	O
proliferation	O
,	O
myelomonocytic	O
colonies	O
were	O
harvested	O
by	O
the	O
addition	O
of	O
5	O
ml	O
DMEM	O
containing	O
10	O
%	O
FBS	O
,	O
10	O
ng	O
/	O
ml	O
each	O
GM	B
-	I
CSF	I
and	O
M	B
-	I
CSF	I
.	O

Cells	O
(	O
~106	O
)	O
were	O
placed	O
in	O
a	O
35	O
mm	O
well	O
and	O
allowed	O
to	O
adhere	O
for	O
48	O
hours	O
.	O

At	O
two	O
and	O
four	O
days	O
post	O
-	O
harvest	O
,	O
medium	O
was	O
replaced	O
with	O
fresh	O
complete	O
DMEM	O
supplemented	O
with	O
10	O
ng	O
/	O
ml	O
GM	B
-	I
CSF	I
and	O
M	B
-	I
CSF	I
.	O

By	O
4–5	O
days	O
,	O
cells	O
developed	O
into	O
mature	O
macrophages	O
which	O
were	O
used	O
for	O
subsequent	O
phenotypic	O
and	O
functional	O
characterization	O
.	O

Phenotypic	O
analysis	O
of	O
hES	O
cell	O
derived	O
macrophagesTo	O
determine	O
if	O
nontransduced	O
and	O
lentiviral	O
vector	O
transduced	O
hES	O
cell	O
derived	O
macrophages	O
display	O
normal	O
macrophage	O
surface	O
markers	O
,	O
FACS	O
analysis	O
was	O
performed	O
using	O
respective	O
fluorochrome	O
conjugated	O
antibodies	O
.	O

Fetal	O
liver	O
derived	O
CD34	B
+	B
cells	O
as	O
well	O
as	O
nontransduced	O
and	O
transduced	O
hES	O
cell	O
derived	O
macrophages	O
were	O
evaluated	O
in	O
parallel	O
.	O

Cells	O
were	O
scraped	O
from	O
their	O
wells	O
,	O
washed	O
two	O
times	O
with	O
PBS	O
,	O
and	O
stained	O
with	O
the	O
following	O
antibodies	O
:	O
PE	B
-	I
CD14	I
,	O
PE	B
-	I
HLA	I
-	I
DR	I
,	O
PECY5-CD4	B
,	O
PECY5-CCR5	B
,	O
PECY5-CXCR4	B
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
.	O

A	O
blocking	O
step	O
was	O
first	O
performed	O
by	O
incubating	O
the	O
cells	O
with	O
the	O
respective	O
isotype	O
control	O
for	O
30	O
minutes	O
at	O
4C	O
before	O
staining	O
with	O
the	O
respective	O
cell	O
surface	O
marker	O
antibodies	O
.	O

Isotype	O
control	O
staining	O
was	O
used	O
to	O
determine	O
background	O
levels	O
.	O

FACS	O
analysis	O
was	O
performed	O
on	O
a	O
Beckman	O
-	O
Coulter	O
EPICS	O
®	O
XL	O
-	O
MCL	O
flow	O
cytometer	O
with	O
data	O
analysis	O
using	O
EXPO32	O
ADC	O
software	O
(	O
Coulter	O
Corporation	O
,	O
Miami	O
,	O
FL	O
)	O
.	O

A	O
minimum	O
of	O
8,000	O
cells	O
were	O
analyzed	O
in	O
each	O
FACS	O
evaluation	O
.	O

Functional	O
analysis	O
of	O
hES	O
cell	O
derived	O
macrophagesPhysiological	O
roles	O
of	O
macrophages	O
include	O
phagocytic	O
and	O
immune	O
related	O
functions	O
.	O

To	O
determine	O
if	O
hES	O
cell	O
derived	O
macrophages	O
were	O
functionally	O
normal	O
,	O
a	O
stimulation	O
assay	O
to	O
determine	O
upregulation	O
of	O
the	O
costimulatory	B
molecule	I
B7.1	I
was	O
performed	O
.	O

Activated	O
macrophages	O
upregulate	O
the	O
expression	O
of	O
B7.1	B
upon	O
activation	O
with	O
various	O
stimuli	O
.	O

Accordingly	O
,	O
fetal	O
liver	O
CD34	B
,	O
nontransduced	O
hES	O
,	O
and	O
GFP	B
-	O
alone	O
transduced	O
hES	O
cell	O
derived	O
macrophages	O
were	O
stimulated	O
by	O
the	O
addition	O
of	O
LPS	B
(	O
5	O
ug	O
/	O
ml	O
)	O
to	O
the	O
cell	O
culture	O
medium	O
.	O

Twenty	O
-	O
four	O
hours	O
post	O
-	O
stimulation	O
,	O
cells	O
were	O
stained	O
with	O
an	O
anti	B
-	I
B7.1	I
antibody	I
labeled	O
with	O
PE	O
-	O
Cy5	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
FACS	O
.	O

To	O
assess	O
the	O
hES	O
cell	O
derived	O
macrophages	O
'	O
phagocytic	O
function	O
,	O
5	O
ug	O
/	O
ml	O
of	O
fluorescently	O
labeled	O
E.	O
coli	O
Bioparticles	O
®	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
were	O
added	O
directly	O
to	O
the	O
cell	O
culture	O
medium	O
.	O

Four	O
hours	O
later	O
,	O
macrophages	O
were	O
washed	O
six	O
times	O
with	O
PBS	O
and	O
fresh	O
medium	O
with	O
10	O
ng	O
/	O
ml	O
GM	B
-	I
CSF	I
and	O
M	B
-	I
CSF	I
was	O
added	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
cells	O
were	O
analyzed	O
by	O
FACS	O
for	O
the	O
presence	O
of	O
ingested	O
Bioparticles	O
®	O
which	O
can	O
be	O
detected	O
in	O
the	O
PE	O
(	O
FL2	O
)	O
channel	O
.	O

Lentiviral	O
vector	O
transduced	O
Magi	O
-	O
CXCR4	B
cells	O
,	O
a	O
HeLa	O
cell	O
derivative	O
with	O
no	O
phagocytic	O
capacity	O
,	O
were	O
used	O
as	O
non	O
-	O
phagocytic	O
cell	O
controls	O
and	O
similarly	O
exposed	O
to	O
E.	O
coli	O
Bioparticles	O
®	O
Human	O
ES	O
cell	O
derived	O
macrophages	O
were	O
also	O
analyzed	O
for	O
their	O
ability	O
to	O
secrete	O
two	O
major	O
cytokines	O
,	O
IL-1	B
and	O
TNF	B
-	I
α	I
,	O
upon	O
external	O
stimulation	O
.	O

Accordingly	O
,	O
macrophages	O
were	O
stimulated	O
with	O
5	O
ug	O
/	O
ml	O
of	O
LPS	O
during	O
culture	O
.	O

On	O
days	O
1	O
,	O
2	O
,	O
and	O
3	O
post	O
-	O
stimulation	O
,	O
cell	O
culture	O
supernatant	O
samples	O
were	O
collected	O
and	O
analyzed	O
by	O
a	O
Quantikine	O
®	O
ELISA	O
kit	O
(	O
R&D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
.	O

Non	O
-	O
stimulated	O
supernatants	O
were	O
also	O
analyzed	O
for	O
basal	O
levels	O
of	O
cytokine	O
secretion	O
.	O

HIV-1	O
infection	O
of	O
hES	O
cell	O
derived	O
macrophagesTo	O
determine	O
if	O
hES	O
cell	O
derived	O
macrophages	O
can	O
be	O
infected	O
with	O
HIV-1	O
and	O
support	O
viral	O
replication	O
,	O
cells	O
were	O
challenged	O
with	O
a	O
macrophage	O
R5-tropic	O
BaL-1	O
strain	O
of	O
HIV-1	O
.	O

An	O
m.o.i	O
.	O
of	O
0.01	O
in	O
the	O
presence	O
of	O
4	O
ug	O
/	O
ml	O
polybrene	O
was	O
used	O
.	O

At	O
different	O
days	O
post	O
-	O
infection	O
,	O
culture	O
supernatants	O
were	O
collected	O
and	O
assayed	O
for	O
p24	O
antigen	O
by	O
ELISA	O
.	O

To	O
quantify	O
viral	O
p24	O
levels	O
,	O
a	O
Coulter	O
-	O
p24	O
kit	O
(	O
Beckman	O
Coulter	O
,	O
Fullerton	O
,	O
CA	O
)	O
was	O
used	O
.	O

This	O
work	O
uncovers	O
novel	O
mechanisms	O
of	O
aging	O
within	O
stem	O
cell	O
niches	O
that	O
are	O
evolutionarily	O
conserved	O
between	O
mice	O
and	O
humans	O
and	O
affect	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
.	O

Specifically	O
,	O
we	O
have	O
examined	O
the	O
effects	O
of	O
aged	O
muscle	O
and	O
systemic	O
niches	O
on	O
key	O
molecular	O
identifiers	O
of	O
regenerative	O
potential	O
of	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
and	O
post	O
-	O
natal	O
muscle	O
stem	O
cells	O
(	O
satellite	O
cells	O
)	O
.	O

Our	O
results	O
reveal	O
that	O
aged	O
differentiated	O
niches	O
dominantly	O
inhibit	O
the	O
expression	O
of	O
Oct4	B
in	O
hESCs	O
and	O
Myf-5	B
in	O
activated	O
satellite	O
cells	O
,	O
and	O
reduce	O
proliferation	O
and	O
myogenic	O
differentiation	O
of	O
both	O
embryonic	O
and	O
tissue	O
-	O
specific	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
.	O

Therefore	O
,	O
despite	O
their	O
general	O
neoorganogenesis	O
potential	O
,	O
the	O
ability	O
of	O
hESCs	O
,	O
and	O
the	O
more	O
differentiated	O
myogenic	O
ASCs	O
to	O
contribute	O
to	O
tissue	O
repair	O
in	O
the	O
old	O
will	O
be	O
greatly	O
restricted	O
due	O
to	O
the	O
conserved	O
inhibitory	O
influence	O
of	O
aged	O
differentiated	O
niches	O
.	O

Significantly	O
,	O
this	O
work	O
establishes	O
that	O
hESC	O
-	O
derived	O
factors	O
enhance	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
,	O
importantly	O
,	O
aged	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
thus	O
,	O
suggesting	O
that	O
the	O
regenerative	O
outcome	O
of	O
stem	O
cell	O
-	O
based	O
replacement	O
therapies	O
will	O
be	O
determined	O
by	O
a	O
balance	O
between	O
negative	O
influences	O
of	O
aged	O
tissues	O
on	O
transplanted	O
cells	O
and	O
positive	O
effects	O
of	O
embryonic	O
cells	O
on	O
the	O
endogenous	O
regenerative	O
capacity	O
.	O

Comprehensively	O
,	O
this	O
work	O
points	O
toward	O
novel	O
venues	O
for	O
in	O
situ	O
restoration	O
of	O
tissue	O
repair	O
in	O
the	O
old	O
and	O
identifies	O
critical	O
determinants	O
of	O
successful	O
cell	O
-	O
replacement	O
therapies	O
for	O
aged	O
degenerating	O
organs	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
are	O
distinguished	O
by	O
their	O
ability	O
to	O
self	O
-	O
renew	O
and	O
to	O
differentiate	O
into	O
any	O
other	O
cell	O
type	O
via	O
asymmetric	O
cell	O
divisions	O
,	O
in	O
which	O
one	O
daughter	O
cell	O
maintains	O
'	O
stemness	O
'	O
while	O
the	O
other	O
daughter	O
cell	O
differentiates	O
into	O
a	O
particular	O
tissue	O
type	O
.	O

ESCs	O
,	O
including	O
those	O
of	O
human	O
origin	O
(	O
hESCs	O
)	O
,	O
are	O
derived	O
from	O
the	O
blastocyst	O
and	O
can	O
be	O
propagated	O
in	O
vitro	O
(	O
Evans	O
&	O
Kaufman	O
,	O
1981	O
;	O
Thomson	O
et	O
al.	O
,	O
1998	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

Their	O
tremendous	O
potential	O
for	O
organogenesis	O
has	O
created	O
a	O
great	O
interest	O
in	O
using	O
hESCs	O
for	O
replacing	O
tissues	O
and	O
organs	O
lost	O
to	O
disease	O
,	O
or	O
old	O
age	O
(	O
reviewed	O
in	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

As	O
such	O
,	O
the	O
use	O
of	O
hESCs	O
is	O
particularly	O
important	O
,	O
due	O
to	O
the	O
fact	O
that	O
adult	O
organ	O
stem	O
cells	O
are	O
often	O
limited	O
in	O
number	O
,	O
cell	O
-	O
fate	O
plasticity	O
,	O
expansion	O
capacity	O
,	O
telomere	O
length	O
,	O
and	O
lifespan	O
(	O
Mayhall	O
et	O
al.	O
,	O
2004	O
)	O
.	O

The	O
general	O
goal	O
behind	O
most	O
cell	O
-	O
replacement	O
approaches	O
is	O
to	O
expand	O
and	O
then	O
differentiate	O
hESCs	O
in	O
vitro	O
,	O
thus	O
producing	O
a	O
cell	O
type	O
of	O
interest	O
,	O
such	O
as	O
neuronal	O
,	O
blood	O
,	O
endothelial	O
,	O
pancreatic	O
,	O
bone	O
,	O
and	O
others	O
.	O

These	O
differentiated	O
cells	O
are	O
expected	O
to	O
replace	O
their	O
dysfunctional	O
counterparts	O
in	O
vivo	O
.	O

The	O
scope	O
of	O
disorders	O
that	O
can	O
be	O
potentially	O
treated	O
with	O
a	O
neoorganogenesis	O
approach	O
is	O
large	O
and	O
includes	O
many	O
that	O
are	O
currently	O
incurable	O
,	O
such	O
as	O
muscle	O
atrophy	O
,	O
diabetes	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
and	O
other	O
degenerative	O
diseases	O
that	O
often	O
accompany	O
human	O
aging	O
(	O
McDonald	O
et	O
al.	O
,	O
1999	O
;	O
Liu	O
et	O
al.	O
,	O
2000	O
;	O
Hori	O
et	O
al.	O
,	O
2002	O
;	O
Kim	O
et	O
al.	O
,	O
2002	O
;	O
Blyszczuk	O
et	O
al.	O
,	O
2003	O
)	O
.	O

While	O
many	O
studies	O
have	O
focused	O
on	O
the	O
derivation	O
,	O
propagation	O
,	O
and	O
in	O
vitro	O
differentiation	O
of	O
hESCs	O
(	O
reviewed	O
in	O
Hoffman	O
&	O
Carpenter	O
,	O
2005	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
,	O
relatively	O
few	O
have	O
examined	O
the	O
properties	O
of	O
these	O
cells	O
and	O
their	O
more	O
differentiated	O
progeny	O
in	O
the	O
aged	O
,	O
as	O
opposed	O
to	O
the	O
young	O
,	O
systemic	O
and	O
local	O
organ	O
environments	O
.	O

Recently	O
published	O
data	O
suggest	O
that	O
these	O
extrinsic	O
cues	O
become	O
altered	O
with	O
age	O
in	O
ways	O
that	O
preclude	O
activation	O
of	O
organ	O
stem	O
cells	O
(	O
such	O
as	O
satellite	O
cells	O
)	O
,	O
inhibit	O
repair	O
-	O
specific	O
molecular	O
signaling	O
(	O
such	O
as	O
delta	B
-	I
Notch	I
)	O
,	O
and	O
interfere	O
with	O
productive	O
tissue	O
repair	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Janzen	O
et	O
al.	O
,	O
2006	O
;	O
Krishnamurthy	O
et	O
al.	O
,	O
2006	O
;	O
Molofsky	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Furthermore	O
,	O
at	O
least	O
two	O
lines	O
of	O
evidence	O
suggest	O
that	O
stem	O
cell	O
-	O
based	O
tissue	O
-	O
replacement	O
therapies	O
might	O
be	O
hindered	O
in	O
the	O
elderly	O
,	O
because	O
all	O
cells	O
along	O
the	O
developmental	O
lineage	O
(	O
e.g.	O
,	O
stem	O
cells	O
,	O
more	O
differentiated	O
progenitor	O
cells	O
or	O
even	O
tissues	O
containing	O
a	O
pool	O
of	O
precursors	O
)	O
might	O
rapidly	O
'	O
age	O
'	O
and	O
fail	O
to	O
contribute	O
to	O
organ	O
repair	O
when	O
introduced	O
into	O
the	O
old	O
organism	O
in	O
vivo	O
.	O

First	O
,	O
in	O
heterochronic	O
tissue	O
-	O
transplantation	O
studies	O
,	O
the	O
age	O
of	O
the	O
host	O
environment	O
determined	O
the	O
regenerative	O
outcome	O
,	O
as	O
both	O
young	O
and	O
old	O
skeletal	O
muscle	O
explants	O
containing	O
differentiated	O
and	O
precursor	O
cells	O
effectively	O
regenerated	O
in	O
young	O
,	O
but	O
not	O
in	O
old	O
animals	O
(	O
Zacks	O
&	O
Sheff	O
,	O
1982	O
;	O
Carlson	O
&	O
Faulkner	O
,	O
1989	O
)	O
.	O

Second	O
,	O
using	O
parabiotically	O
paired	O
young	O
and	O
old	O
mice	O
,	O
the	O
regenerative	O
potential	O
of	O
muscle	O
and	O
liver	O
was	O
shown	O
to	O
be	O
influenced	O
by	O
the	O
age	O
of	O
the	O
systemic	O
environment	O
(	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
key	O
molecular	O
identifiers	O
of	O
stem	O
cell	O
properties	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
myogenic	O
capacity	O
would	O
be	O
influenced	O
by	O
the	O
age	O
of	O
extrinsic	O
milieu	O
,	O
regardless	O
of	O
whether	O
stem	O
cells	O
are	O
embryonic	O
or	O
the	O
more	O
differentiated	O
,	O
muscle	O
-	O
specific	O
satellite	O
cells	O
.	O

Satellite	O
cells	O
are	O
muscle	O
stem	O
cells	O
situated	O
in	O
direct	O
contact	O
with	O
myofibers	O
,	O
the	O
differentiated	O
muscle	O
cells	O
.	O

When	O
myofibers	O
are	O
damaged	O
,	O
quiescent	O
satellite	O
cells	O
are	O
activated	O
to	O
proliferate	O
and	O
then	O
differentiate	O
into	O
fusion	O
-	O
competent	O
myoblasts	O
that	O
continue	O
to	O
proliferate	O
and	O
can	O
form	O
primary	O
cultures	O
,	O
but	O
are	O
also	O
capable	O
of	O
producing	O
new	O
,	O
multinucleated	O
myofibers	O
or	O
myotubes	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
Morgan	O
et	O
al.	O
,	O
2002	O
;	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Activated	O
satellite	O
cells	O
express	O
myogenic	O
markers	O
,	O
such	O
as	O
Myf5	B
,	O
M	B
-	I
cadherin	I
,	O
and	O
Paired	B
box	I
gene	I
7	I
(	O
Pax7	B
)	O
;	O
fusion	O
-	O
competent	O
myoblasts	O
express	O
high	O
levels	O
of	O
desmin	B
,	O
and	O
de	O
novo	O
generated	O
myofibers	O
or	O
myotubes	O
express	O
embryonic	B
myosin	I
heavy	I
chain	I
(	O
eMyHC	B
)	O
and	O
continue	O
to	O
express	O
desmin	B
(	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

While	O
desmin	B
can	O
be	O
also	O
present	O
in	O
smooth	O
and	O
cardiac	O
muscle	O
cells	O
,	O
the	O
isolation	O
of	O
hind	O
limb	O
skeletal	O
muscle	O
with	O
subsequent	O
purification	O
of	O
myofibers	O
away	O
from	O
all	O
interstitial	O
cells	O
,	O
as	O
well	O
as	O
purification	O
of	O
associated	O
muscle	O
stem	O
cells	O
results	O
in	O
primary	O
cultures	O
that	O
are	O
uniformly	O
of	O
skeletal	O
muscle	O
lineage	O
.	O

Every	O
desmin+	B
cell	O
in	O
such	O
cultures	O
is	O
a	O
fusion	O
-	O
competent	O
myoblast	O
,	O
and	O
is	O
able	O
to	O
produce	O
multinucleated	O
myotubes	O
after	O
48	O
h	O
of	O
culture	O
in	O
differentiation	O
-	O
promoting	O
medium	O
[	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
with	O
2	O
%	O
horse	O
serum	O
]	O
.	O

Some	O
of	O
these	O
myogenic	O
cells	O
fuse	O
into	O
myotubes	O
,	O
even	O
in	O
the	O
mitogen	O
-	O
rich	O
medium	O
[	O
(	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
with	O
5–10	O
%	O
mouse	O
serum	O
or	O
DMEM	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
FBS	O
]	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
;	O
and	O
see	O
below	O
)	O
.	O

An	O
experimental	O
system	O
was	O
developed	O
that	O
(	O
i	O
)	O
provided	O
the	O
ability	O
to	O
study	O
the	O
regenerative	O
response	O
of	O
hESCs	O
and	O
of	O
muscle	O
stem	O
cells	O
in	O
various	O
heterochronic	O
environments	O
in	O
vitro	O
;	O
and	O
(	O
ii	O
)	O
allowed	O
examination	O
of	O
the	O
effects	O
of	O
hESCs	O
on	O
muscle	O
repair	O
,	O
in	O
vivo	O
,	O
after	O
transplantation	O
into	O
young	O
vs.	O
old	O
hosts	O
.	O

This	O
model	O
allowed	O
us	O
to	O
address	O
both	O
the	O
negative	O
effects	O
of	O
the	O
aged	O
niche	O
on	O
key	O
stem	O
cell	O
properties	O
and	O
the	O
positive	O
effects	O
of	O
hESCs	O
on	O
the	O
aged	O
muscle	O
-	O
specific	O
organ	O
progenitor	O
cells	O
in	O
vitro	O
,	O
and	O
on	O
the	O
regenerative	O
capacity	O
of	O
old	O
muscle	O
in	O
vivo	O
.	O

The	O
resulting	O
data	O
demonstrate	O
that	O
the	O
composition	O
of	O
conserved	O
extrinsic	O
cues	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
becomes	O
altered	O
with	O
age	O
in	O
ways	O
that	O
inhibit	O
both	O
hESCs	O
and	O
adult	O
stem	O
cell	O
regenerative	O
potential	O
.	O

Specifically	O
,	O
molecular	O
markers	O
of	O
stem	O
cell	O
functionality	O
,	O
e.g.	O
Oct4	B
(	O
in	O
hESCs	O
)	O
and	O
Myf5	B
(	O
in	O
muscle	O
stem	O
cells	O
)	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
capacity	O
for	O
myogenic	O
differentiation	O
are	O
all	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieu	O
,	O
and	O
by	O
the	O
old	O
differentiated	O
muscle	O
tissue	O
.	O

However	O
,	O
while	O
satellite	O
cells	O
are	O
unable	O
to	O
deter	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
and	O
local	O
niches	O
,	O
hESCs	O
are	O
capable	O
of	O
antagonizing	O
the	O
aged	O
environments	O
,	O
thereby	O
enhancing	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
old	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
a	O
complex	O
interplay	O
between	O
negative	O
regulation	O
of	O
hESCs	O
and	O
adult	O
muscle	O
stem	O
cells	O
by	O
the	O
aged	O
niche	O
,	O
and	O
positive	O
regulation	O
of	O
the	O
host	O
's	O
regenerative	O
responses	O
by	O
hESCs	O
will	O
likely	O
determine	O
the	O
success	O
of	O
hESC	O
-	O
based	O
cell	O
-	O
replacement	O
therapies	O
in	O
the	O
old	O
.	O

Regenerative	O
responses	O
of	O
adult	O
muscle	O
stem	O
cells	O
and	O
hESCs	O
are	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieuPrevious	O
work	O
established	O
that	O
the	O
upregulation	O
of	O
repair	O
-	O
specific	O
molecular	O
signaling	O
mechanisms	O
,	O
such	O
as	O
Notch	B
,	O
and	O
successful	O
engagement	O
of	O
resident	O
muscle	O
stem	O
cells	O
in	O
tissue	O
repair	O
are	O
largely	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
rather	O
than	O
by	O
the	O
cell	O
-	O
autonomous	O
age	O
of	O
muscle	O
cells	O
,	O
or	O
by	O
the	O
differences	O
in	O
their	O
numbers	O
(	O
Conboy	O
&	O
Rando	O
,	O
2005	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
these	O
experiments	O
also	O
hinted	O
at	O
a	O
small	O
but	O
persistent	O
inhibitory	O
effect	O
of	O
the	O
aged	O
systemic	O
milieu	O
on	O
the	O
performance	O
of	O
young	O
stem	O
cells	O
.	O

Exploring	O
this	O
further	O
,	O
we	O
found	O
that	O
young	O
serum	O
permits	O
satellite	O
cells	O
to	O
be	O
myogenic	O
,	O
while	O
old	O
serum	O
inhibits	O
the	O
satellite	O
cell	O
regenerative	O
potential	O
not	O
only	O
alone	O
,	O
but	O
also	O
when	O
mixed	O
with	O
young	O
serum	O
,	O
suggesting	O
a	O
dominant	O
over	O
-	O
riding	O
of	O
'	O
young	O
'	O
serum	O
factors	O
(	O
Fig.	O
1	O
)	O
.	O

Myofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
have	O
been	O
activated	O
by	O
injury	O
in	O
vivo	O
,	O
were	O
established	O
from	O
young	O
(	O
2–3	O
months	O
)	O
and	O
old	O
(	O
22–24	O
months	O
)	O
C57-BL	O
/	O
6	O
male	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

As	O
previously	O
shown	O
,	O
this	O
method	O
is	O
well	O
suited	O
for	O
the	O
assessment	O
of	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Isolated	O
myofiber	O
explants	O
with	O
associated	O
satellite	O
cells	O
were	O
cultured	O
overnight	O
in	O
the	O
presence	O
of	O
young	O
or	O
old	O
serum	O
(	O
alone	O
at	O
5	O
%	O
and	O
10	O
%	O
,	O
and	O
mixed	O
at	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
)	O
;	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

The	O
effects	O
of	O
heterochronic	O
systemic	O
milieu	O
on	O
myogenic	O
potential	O
were	O
examined	O
as	O
generation	O
of	O
proliferating	O
myoblasts	O
that	O
express	O
desmin	B
and	O
Myf5	B
,	O
and	O
that	O
spontaneously	O
form	O
multinucleated	O
nascent	O
myotubes	O
.	O

As	O
shown	O
in	O
Fig.	O
1A	O
and	O
quantified	O
in	O
Fig.	O
1B	O
,	O
the	O
age	O
of	O
sera	O
clearly	O
determined	O
satellite	O
cell	O
regenerative	O
potential	O
and	O
old	O
serum	O
strongly	O
inhibited	O
the	O
myogenic	O
potential	O
of	O
young	O
satellite	O
cells	O
either	O
when	O
present	O
alone	O
,	O
or	O
when	O
mixed	O
with	O
young	O
sera	O
.	O

Similar	O
data	O
was	O
obtained	O
by	O
using	O
another	O
myogenic	O
marker	O
,	O
Pax7	B
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Additionally	O
,	O
there	O
were	O
two	O
to	O
three	O
times	O
fewer	O
total	O
cells	O
generated	O
in	O
the	O
presence	O
of	O
aged	O
serum	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

1The	O
age	O
of	O
sera	O
determined	O
the	O
regenerative	O
potential	O
of	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Young	O
satellite	O
cells	O
were	O
cultured	O
either	O
in	O
5	O
%	O
or	O
10	O
%	O
young	O
(	O
Young	O
)	O
,	O
10	O
%	O
old	O
(	O
Old	O
)	O
,	O
or	O
in	O
a	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Cells	O
were	O
analyzed	O
by	O
immunofluorescence	O
microscopy	O
,	O
using	O
anti	O
-	O
BrdU	O
(	O
red	O
)	O
,	O
antidesmin	O
(	O
green	O
)	O
or	O
anti	O
-	O
Myf5	B
antibodies	O
(	O
green	O
,	O
small	O
panels	O
)	O
.	O

Similar	O
results	O
are	O
shown	O
for	O
Pax7	B
immunodetection	O
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labeled	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
were	O
quantified	O
[	O
300	O
young	O
myofibers	O
per	O
experiment	O
]	O
as	O
percentage	O
of	O
desmin+	B
/	O
Myf5+	B
/	O
BrdU+	O
de	O
novo	O
generated	O
cells	O
for	O
each	O
age	O
and	O
culture	O
condition	O
.	O

On	O
average	O
,	O
two	O
to	O
three	O
fewer	O
cells	O
were	O
generated	O
when	O
cultured	O
in	O
the	O
presence	O
of	O
old	O
.	O

Shown	O
are	O
identical	O
microscope	O
fields	O
at	O
×40	O
magnification	O
.	O

At	O
least	O
three	O
independent	O
experiments	O
produced	O
similar	O
results	O
.	O

(	O
*	O
)	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
sera	O
.	O

Importantly	O
,	O
it	O
was	O
not	O
simply	O
the	O
dilution	O
of	O
young	O
serum	O
factors	O
that	O
resulted	O
in	O
diminished	O
myogenic	O
capacity	O
when	O
young	O
and	O
old	O
sera	O
were	O
mixed	O
,	O
because	O
young	O
sera	O
promoted	O
robust	O
myogenesis	O
both	O
at	O
10	O
%	O
and	O
5	O
%	O
.	O

Thus	O
,	O
old	O
serum	O
factors	O
dominantly	O
inhibited	O
the	O
myogenic	O
capacity	O
of	O
young	O
satellite	O
cells	O
even	O
in	O
the	O
presence	O
of	O
young	O
serum	O
.	O

This	O
observation	O
suggests	O
that	O
satellite	O
cells	O
of	O
young	O
mice	O
engage	O
in	O
efficient	O
myogenic	O
responses	O
,	O
in	O
part	O
,	O
because	O
the	O
inhibitory	O
influence	O
of	O
old	O
circulatory	O
milieu	O
is	O
absent	O
.	O

These	O
data	O
reveal	O
that	O
the	O
regenerative	O
potential	O
of	O
young	O
muscle	O
stem	O
cells	O
is	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
prompting	O
us	O
to	O
investigate	O
whether	O
hESCs	O
would	O
similarly	O
succumb	O
to	O
inhibitory	O
factors	O
present	O
in	O
the	O
aged	O
circulation	O
.	O

To	O
determine	O
the	O
effects	O
of	O
aged	O
serum	O
on	O
stem	O
cell	O
self	O
-	O
renewal	O
/	O
pluripotency	O
,	O
we	O
analyzed	O
hESC	O
expression	O
of	O
Oct4	B
and	O
studied	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
by	O
assessing	O
BrdU	O
incorporation	O
(	O
Fig.	O
2	O
)	O
and	O
Ki67	B
expression	O
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Specifically	O
,	O
these	O
determinants	O
of	O
hESC	O
regenerative	O
potential	O
were	O
examined	O
in	O
the	O
presence	O
of	O
heterochronic	O
(	O
young	O
vs.	O
old	O
)	O
mouse	O
sera	O
added	O
to	O
typical	O
hESC	O
medium	O
,	O
e.g.	O
,	O
MEF	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
.	O

Oct4	B
is	O
expressed	O
by	O
self	O
-	O
renewing	O
,	O
pluripotent	O
ESCs	O
in	O
culture	O
,	O
by	O
the	O
totipotent	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
and	O
by	O
the	O
germ	O
cells	O
(	O
Nichols	O
et	O
al.	O
,	O
1998	O
;	O
Pesce	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Most	O
cells	O
in	O
control	O
cultures	O
or	O
young	O
conditions	O
expressed	O
high	O
levels	O
of	O
this	O
marker	O
of	O
'	O
stemness	O
'	O
,	O
and	O
maintained	O
their	O
normal	O
phenotype	O
and	O
morphology	O
throughout	O
the	O
various	O
co	O
-	O
culture	O
experiments	O
performed	O
in	O
this	O
study	O
(	O
see	O
below	O
)	O
.Fig	O
.	O

2The	O
regenerative	O
potential	O
of	O
embryonic	O
stem	O
cells	O
was	O
negatively	O
affected	O
by	O
aged	O
mouse	O
sera	O
.	O

(	O
A	O
)	O
hESCs	O
were	O
cultured	O
in	O
MCM	O
with	O
10	O
%	O
young	O
(	O
young	O
)	O
or	O
old	O
(	O
old	O
)	O
mouse	O
serum	O
,	O
or	O
in	O
three	O
control	O
media	O
:	O
MCM	O
without	O
mouse	O
sera	O
;	O
GM	O
(	O
myoblast	O
medium	O
of	O
Ham	O
's	O
F10	O
with	O
20	O
%	O
FBS	O
)	O
and	O
DMEM	O
/	O
FBS	O
(	O
hESC	O
differentiation	O
medium	O
of	O
DMEM	O
with	O
10	O
%	O
FBS	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
assays	O
were	O
performed	O
for	O
BrdU	O
(	O
red	O
)	O
,	O
Oct4	B
(	O
red	O
)	O
,	O
and	O
Ki67	B
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

A	O
high	O
rate	O
of	O
hESC	O
proliferation	O
and	O
Oct4	B
expression	O
is	O
displayed	O
in	O
all	O
control	O
media	O
and	O
in	O
the	O
presence	O
of	O
young	O
mouse	O
serum	O
.	O

In	O
contrast	O
,	O
hESC	O
proliferation	O
and	O
Oct4	B
expression	O
are	O
inhibited	O
in	O
the	O
presence	O
of	O
old	O
mouse	O
serum	O
,	O
either	O
alone	O
or	O
when	O
mixed	O
with	O
young	O
serum	O
.	O

MCM	O
with	O
mouse	O
sera	O
at	O
5	O
%	O
gave	O
results	O
similar	O
to	O
those	O
observed	O
with	O
10	O
%	O
young	O
mouse	O
sera	O
or	O
in	O
control	O
media	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
and	O
Oct4	B
+	O
cells	O
for	O
each	O
culture	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
young	O
serum	O
.	O

Importantly	O
,	O
at	O
10	O
%	O
aged	O
serum	O
dramatically	O
inhibited	O
the	O
self	O
-	O
renewal	O
and	O
proliferative	O
potential	O
of	O
hESCs	O
,	O
as	O
judged	O
by	O
highly	O
diminished	O
Oct4	B
expression	O
and	O
a	O
lack	O
of	O
BrdU	O
incorporation	O
.	O

Again	O
,	O
the	O
inhibitory	O
factors	O
in	O
the	O
aged	O
milieu	O
were	O
dominant	O
over	O
the	O
young	O
,	O
as	O
evidenced	O
by	O
a	O
decline	O
in	O
Oct4	B
expression	O
,	O
the	O
low	O
rate	O
of	O
BrdU	O
incorporation	O
,	O
and	O
Ki67	B
expression	O
in	O
young	O
and	O
old	O
mixed	O
environments	O
(	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
sera	O
in	O
MCM	O
)	O
.	O

Similar	O
to	O
the	O
data	O
shown	O
for	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
(	O
Fig.	O
1	O
)	O
,	O
it	O
was	O
not	O
simply	O
a	O
dilution	O
of	O
young	O
serum	O
factors	O
as	O
hESCs	O
robustly	O
proliferated	O
and	O
expressed	O
high	O
levels	O
of	O
Oct4	B
when	O
cultured	O
with	O
5	O
%	O
young	O
sera	O
in	O
MCM	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

Quantification	O
of	O
multiple	O
independent	O
experiments	O
has	O
demonstrated	O
that	O
hESC	O
expression	O
of	O
Oct4	B
and	O
BrdU	O
incorporation	O
have	O
been	O
reduced	O
by	O
two-	O
to	O
threefold	O
in	O
the	O
aged	O
milieu	O
(	O
Fig.	O
2B	O
)	O
.As	O
expected	O
,	O
hESCs	O
cultured	O
in	O
control	O
media	O
,	O
including	O
MCM	O
alone	O
that	O
does	O
not	O
contain	O
either	O
young	O
or	O
old	O
serum	O
,	O
also	O
displayed	O
a	O
high	O
rate	O
of	O
proliferation	O
and	O
Oct4	B
expression	O
(	O
Fig.	O
2	O
,	O
control	O
medium	O
)	O
.	O

Additionally	O
,	O
in	O
this	O
experimental	O
set	O
-	O
up	O
there	O
was	O
no	O
general	O
inhibitory	O
effect	O
of	O
sera	O
per	O
se	O
on	O
hESC	O
proliferation	O
and	O
Oct4	B
expression	O
,	O
as	O
10	O
%	O
young	O
mouse	O
sera	O
(	O
young	O
)	O
and	O
10–20	O
%	O
of	O
FBS	O
(	O
growth	O
medium	O
and	O
DMEM	O
/	O
FBS	O
)	O
allowed	O
for	O
a	O
high	O
rate	O
of	O
cell	O
proliferation	O
and	O
for	O
uniformly	O
high	O
Oct4	B
levels	O
(	O
Fig.	O
2	O
)	O
.When	O
instead	O
of	O
immediate	O
exposure	O
to	O
aged	O
mouse	O
serum	O
,	O
hESCs	O
were	O
first	O
cultured	O
overnight	O
in	O
MCM	O
,	O
these	O
cells	O
were	O
no	O
longer	O
susceptible	O
to	O
the	O
negative	O
effects	O
of	O
old	O
systemic	O
milieu	O
(	O
Fig.	O
3	O
)	O
,	O
suggesting	O
that	O
hESC	O
-	O
produced	O
factors	O
established	O
an	O
embryonic	O
microniche	O
that	O
may	O
provide	O
temporary	O
protection	O
from	O
the	O
aged	O
environment	O
.	O

It	O
appears	O
that	O
satellite	O
cells	O
do	O
not	O
have	O
such	O
anti	O
-	O
aging	O
ability	O
,	O
because	O
despite	O
an	O
initial	O
activation	O
in	O
entirely	O
young	O
environments	O
,	O
e.g.	O
,	O
after	O
muscle	O
injury	O
to	O
young	O
muscle	O
,	O
isolated	O
satellite	O
cells	O
remain	O
susceptible	O
to	O
inhibition	O
by	O
the	O
old	O
mouse	O
serum	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
.	O

Similarly	O
,	O
culturing	O
satellite	O
cells	O
isolated	O
from	O
noninjured	O
muscle	O
in	O
growth	O
-	O
promoting	O
medium	O
for	O
1–2	O
days	O
does	O
not	O
protect	O
against	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
milieu	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

3Embryonic	O
stem	O
cells	O
produce	O
youthful	O
microniche	O
in	O
culture	O
.	O

(	O
A	O
)	O
As	O
opposed	O
to	O
immediate	O
exposure	O
to	O
old	O
mouse	O
serum	O
after	O
passaging	O
(	O
10	O
%	O
old	O
)	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
feeder	O
-	O
free	O
conditions	O
,	O
e.g.	O
,	O
Matrigel	O
™	O
+	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
,	O
resulted	O
in	O
continuously	O
high	O
BrdU	O
incorporation	O
and	O
Oct4	B
expression	O
(	O
embryonic	O
microniche	O
+	O
10	O
%	O
old	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
of	O
BrdU	O
and	O
Oct4	B
(	O
both	O
in	O
red	O
)	O
was	O
performed	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
/	O
Oct4	B
+	O
for	O
each	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
'	O
old	O
+	O
MCM'.Fig	O
.	O

4Aged	O
muscle	O
niche	O
inhibits	O
the	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Immunodetection	O
of	O
a	O
mouse	O
-	O
specific	O
M	B
-	I
cadherin	I
(	O
green	O
)	O
or	O
desmin	B
(	O
red	O
;	O
both	O
human	O
and	O
mouse	O
proteins	O
are	O
detected	O
)	O
revealed	O
that	O
hESCs	O
underwent	O
muscle	O
lineage	O
differentiation	O
when	O
co	O
-	O
cultured	O
with	O
young	O
,	O
but	O
not	O
old	O
myofibers	O
.	O

The	O
myogenic	O
progeny	O
of	O
hESCs	O
appears	O
M	B
-	I
cadherin−	I
/	O
desmin+	B
(	O
white	O
arrow	O
in	O
young	O
)	O
,	O
as	O
opposed	O
to	O
M	B
-	I
cadherin−	I
/	O
desmin−	B
hESCs	O
that	O
lack	O
myogenic	O
commitment	O
(	O
white	O
arrow	O
in	O
old	O
)	O
.	O

M	B
-	I
cadherin+	I
/	O
desmin+	B
cells	O
are	O
the	O
myogenic	O
progeny	O
of	O
mouse	O
satellite	O
cells	O
(	O
yellow	O
arrows	O
)	O
.	O

To	O
assess	O
the	O
effects	O
of	O
secreted	O
factors	O
produced	O
by	O
young	O
vs.	O
old	O
myofibers	O
on	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
transient	O
,	O
2	O
h	O
BrdU	O
incorporation	O
was	O
examined	O
in	O
hESCs	O
cultured	O
for	O
48	O
h	O
with	O
supernatants	O
produced	O
by	O
heterochronic	O
myofiber	O
explants	O
(	O
See	O
Experimental	O
procedures	O
for	O
details	O
)	O
.	O

As	O
compared	O
to	O
young	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
young	O
myofiber	O
supernant	O
)	O
,	O
exposure	O
to	O
old	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
old	O
myofiber	O
supernant	O
)	O
inhibited	O
hESCs	O
proliferation	O
,	O
as	O
judged	O
by	O
BrdU	O
immunodetection	O
(	O
red	O
)	O
.	O

As	O
expected	O
,	O
the	O
rate	O
of	O
hESCs	O
proliferation	O
was	O
high	O
in	O
control	O
media	O
(	O
shown	O
in	O
Fig.	O
2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
in	O
all	O
experiments	O
.	O

Quantification	O
of	O
desmin+	B
/	O
BrdU+	O
hESCs	O
in	O
direct	O
myofiber	O
cocultures	O
,	O
or	O
with	O
muscle	O
supernatants	O
,	O
is	O
shown	O
in	O
(	O
B	O
)	O
.	O

*	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
.	O

(	O
C	O
)	O
Transwell	O
co	O
-	O
cultures	O
between	O
purified	O
young	O
satellite	O
cells	O
and	O
myofibers	O
isolated	O
from	O
uninjured	O
young	O
(	O
young	O
myofiber	O
)	O
and	O
old	O
(	O
old	O
myofiber	O
)	O
muscle	O
demonstrated	O
that	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
was	O
inhibited	O
by	O
the	O
aged	O
differentiated	O
muscle	O
.	O

Myogenic	O
potential	O
was	O
determined	O
by	O
the	O
ability	O
of	O
satellite	O
cells	O
to	O
generate	O
proliferating	O
desmin+	B
myoblasts	O
(	O
immunodetection	O
shown	O
in	O
green	O
)	O
and	O
by	O
rate	O
of	O
proliferation	O
(	O
2	O
h	O
BrdU	O
incorporation	O
;	O
immunodetection	O
shown	O
in	O
red	O
)	O
.	O

(	O
D	O
)	O
Satellite	O
cell	O
regenerative	O
potential	O
was	O
quantified	O
as	O
percentage	O
of	O
desmin+	B
/	O
BrdU+	O
cells	O
for	O
transwell	O
co	O
-	O
cultures	O
with	O
young	O
or	O
old	O
uninjured	O
myofibers	O
(	O
i.e.	O
,	O
RM	O
,	O
resting	O
muscle	O
)	O
.	O

n	O
=	O
3	O
;	O
*	O
indicates	O
P≤	O
0.05	O
as	O
compared	O
to	O
young	O
.	O

Comprehensively	O
,	O
these	O
data	O
establish	O
that	O
the	O
inhibition	O
of	O
stem	O
cell	O
regenerative	O
potential	O
by	O
the	O
aged	O
systemic	O
milieu	O
is	O
conserved	O
between	O
species	O
(	O
mouse	O
vs.	O
human	O
)	O
and	O
cell	O
types	O
(	O
adult	O
vs.	O
embryonic	O
stem	O
cells	O
)	O
.	O

As	O
summarized	O
in	O
Table	O
1	O
,	O
aged	O
mouse	O
sera	O
similarly	O
affected	O
the	O
expression	O
of	O
key	O
molecular	O
identifiers	O
of	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
,	O
e.g.	O
,	O
Oct4	B
in	O
hESCs	O
and	O
Myf5	B
in	O
mouse	O
ASCs	O
.	O

As	O
expected	O
,	O
adult	O
mouse	O
stem	O
cells	O
did	O
not	O
express	O
Oct4	B
,	O
and	O
hESCs	O
did	O
not	O
express	O
Myf5	B
in	O
these	O
experimental	O
conditions	O
(	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
aged	O
systemic	O
milieu	O
had	O
similar	O
inhibitory	O
effects	O
on	O
proliferation	O
of	O
hESCs	O
and	O
ASCs	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
regenerative	O
capacity	O
,	O
but	O
also	O
the	O
presence	O
and	O
expansion	O
of	O
stem	O
cells	O
will	O
be	O
significantly	O
restricted	O
in	O
aged	O
organs	O
.	O

Intriguingly	O
,	O
prolonged	O
culturing	O
of	O
hESCs	O
in	O
their	O
preferred	O
in	O
vitro	O
conditions	O
enables	O
generation	O
of	O
an	O
embryonic	O
microniche	O
that	O
antagonizes	O
the	O
inhibitory	O
influences	O
of	O
aged	O
circulatory	O
factors	O
.	O

Table	O
1Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
systemic	O
environmentRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Call	O
-	O
fate	O
identifier	O
ESC	O
(	O
percentage	O
of	O
Oct4	B
)	O
/	O
ASC	O
(	O
percentage	O
of	O
Myf5	B
)	O
10	O
%	O
young59.5	O
±	O
0.8	O
,	O
59.3	O
±	O
4.099.0	O
±	O
0.1	O
,	O
50.7	O
±	O
9.510	O
%	O
old32.7	O
±	O
2.1	O
,	O
27.3	O
±	O
3.517.6	O
±	O
3.2	O
,	O
18.1	O
±	O
5.95	O
%	O
young	O
+	O
5	O
%	O
old31.0	O

±	O
2.6	O
,	O
38.0	O
±	O
2.020.6	O
±	O
3.5	O
,	O
17.1	O
±	O
4.2Quantified	O
results	O
from	O
Figs	O
1	O
,	O
2	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
cell	O
-	O
fate	O
identifier	O
(	O
Oct4	B
or	O
Myf5	B
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
cultured	O
in	O
heterochronic	O
systemic	O
conditions	O
of	O
10	O
%	O
young	O
(	O
young	O
)	O
,	O
10	O
%	O
old	O
(	O
old	O
)	O
or	O
in	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Results	O
for	O
5	O
%	O
young	O
mouse	O
sera	O
are	O
very	O
similar	O
to	O
those	O
for	O
10	O
%	O
young	O
mouse	O
sera	O
and	O
are	O
shown	O
in	O
Fig.	O
1	O
(	O
ASCs	O
)	O
and	O
Supplementary	O
Fig.	O
S3	O
(	O
hESCs	O
)	O
.	O

The	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
ASCs	O
is	O
inhibited	O
by	O
aged	O
differentiated	O
muscleAfter	O
establishing	O
that	O
the	O
aged	O
systemic	O
niche	O
negatively	O
affects	O
the	O
regenerative	O
capacity	O
of	O
hESCs	O
and	O
of	O
ASCs	O
,	O
we	O
then	O
assessed	O
whether	O
myogenic	O
potential	O
and	O
the	O
rate	O
of	O
cell	O
proliferation	O
would	O
be	O
inhibited	O
in	O
hESCs	O
and	O
ASCs	O
by	O
the	O
aged	O
local	O
muscle	O
niche	O
.	O

Myofibers	O
with	O
associated	O
satellite	O
cells	O
were	O
isolated	O
from	O
young	O
and	O
old	O
injured	O
muscle	O
,	O
and	O
were	O
directly	O
co	O
-	O
cultured	O
with	O
hESCs	O
in	O
typical	O
hESC	O
differentiation	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
.	O

Similar	O
to	O
Fig.	O
1	O
,	O
the	O
myogenic	O
potential	O
in	O
these	O
co	O
-	O
cultures	O
was	O
assayed	O
by	O
the	O
expression	O
of	O
desmin	B
,	O
which	O
is	O
present	O
in	O
both	O
fusion	O
-	O
competent	O
myoblasts	O
and	O
newly	O
formed	O
myotubes	O
.	O

To	O
analyze	O
whether	O
hESCs	O
,	O
mouse	O
myogenic	O
progenitor	O
cells	O
or	O
both	O
could	O
express	O
desmin	B
in	O
direct	O
co	O
-	O
cultures	O
,	O
we	O
costained	O
these	O
cells	O
with	O
a	O
mouse	O
-	O
specific	O
antibody	O
to	O
a	O
myogenic	O
marker	O
,	O
M	B
-	I
cadherin	I
,	O
which	O
does	O
not	O
react	O
with	O
human	O
protein	O
,	O
and	O
a	O
desmin	B
-	O
specific	O
antibody	O
that	O
recognizes	O
both	O
mouse	O
and	O
human	O
proteins	O
.	O

As	O
shown	O
in	O
Fig.	O
4A	O
,	O
hESCs	O
underwent	O
myogenic	O
differentiation	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
(	O
M	B
-	I
cadherin−	I
/	O
desmin+	B
mononucleated	O
cells	O
,	O
white	O
arrow	O
in	O
young	O
)	O
.	O

These	O
myogenic	O
progeny	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
could	O
be	O
of	O
skeletal	O
,	O
smooth	O
or	O
cardiac	O
muscle	O
lineages	O
(	O
Debus	O
et	O
al.	O
,	O
1983	O
;	O
Fischman	O
&	O
Danto	O
,	O
1985	O
;	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
)	O
.	O

As	O
expected	O
,	O
the	O
young	O
mouse	O
muscle	O
progenitor	O
cells	O
(	O
M	B
-	I
cadherin+	I
/	O
desmin+	B
)	O
were	O
more	O
advanced	O
in	O
their	O
degree	O
of	O
myogenic	O
differentiation	O
,	O
which	O
was	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
as	O
judged	O
by	O
the	O
formation	O
of	O
large	O
,	O
multinucleated	O
de	O
novo	O
myotubes	O
(	O
yellow	O
arrow	O
in	O
young	O
)	O
.	O

In	O
addition	O
to	O
the	O
myogenically	O
differentiated	O
human	O
cells	O
,	O
co	O
-	O
cultures	O
with	O
young	O
myofiber	O
explants	O
also	O
contained	O
some	O
small	O
undifferentiated	O
hESC	O
colonies	O
,	O
as	O
determined	O
by	O
immunoreactivity	O
to	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
the	O
nuclear	B
mitotic	I
apparatus	I
protein	I
,	O
NuMA	B
and	O
Oct4	B
expression	O
(	O
Supplementary	O
Fig.	O
S4	O
)	O
.In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
the	O
aged	O
mouse	O
myofibers	O
,	O
only	O
mouse	O
cells	O
appeared	O
desmin+	B
(	O
Fig.	O
4A	O
,	O
yellow	O
arrow	O
in	O
old	O
)	O
.	O

These	O
aged	O
myogenic	O
cells	O
were	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
based	O
on	O
spontaneous	O
generation	O
of	O
multinucleated	O
myotubes	O
(	O
see	O
Fig.	O
5B	O
)	O
and	O
based	O
on	O
induced	O
differentiation	O
into	O
myotubes	O
in	O
DMEM	O
+	O
2	O
%	O
horse	O
serum	O
(	O
not	O
shown	O
)	O
.	O

Importantly	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
failed	O
in	O
the	O
aged	O
co	O
-	O
cultures	O
(	O
Fig.	O
4A	O
,	O
white	O
arrow	O
in	O
old	O
)	O
.	O

Furthermore	O
,	O
colonies	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
aged	O
myofibers	O
typically	O
differentiated	O
into	O
cells	O
with	O
fibroblast	O
morphology	O
,	O
which	O
lacked	O
Oct4	B
expression	O
(	O
not	O
shown	O
)	O
.	O

Spontaneous	O
production	O
of	O
desmin+	B
myogenic	O
cells	O
in	O
control	O
hESC	O
cultures	O
without	O
myofibers	O
,	O
or	O
with	O
young	O
/	O
old	O
mouse	O
sera	O
was	O
less	O
than	O
0.1	O
%	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

5In	O
vitro	O
co	O
-	O
culture	O
with	O
hESCs	O
enhanced	O
myogenesis	O
of	O
mouse	O
cells	O
.	O

(	O
A	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
5	O
×	O
106	O
primary	O
mouse	O
myoblasts	O
.	O

hESCs	O
expressing	O
Oct4	B
(	O
immunodetection	O
shown	O
in	O
red	O
)	O
dramatically	O
enhanced	O
myotube	O
formation	O
of	O
co	O
-	O
cultured	O
mouse	O
myoblasts	O
(	O
immunodetection	O
of	O
eMyHC	B
is	O
shown	O
in	O
green	O
)	O
,	O
as	O
compared	O
to	O
co	O
-	O
cultures	O
between	O
mouse	O
myoblasts	O
and	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
Mb	O
+	O
hMSCs	O
)	O
or	O
myoblasts	O
alone	O
(	O
Mb	O
alone	O
)	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
throughout	O
this	O
figure	O
.	O

(	O
B	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
young	O
or	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Co	O
-	O
culture	O
with	O
hESCs	O
(	O
myofiber	O
+	O
hESC	O
)	O
,	O
but	O
not	O
hMSCs	O
(	O
myofiber	O
+	O
hMSC	O
)	O
or	O
control	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
,	O
greatly	O
enhanced	O
the	O
myogenic	O
potential	O
of	O
both	O
young	O
and	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
based	O
on	O
immunodetection	O
of	O
percentage	O
of	O
desmin+	B
de	O
novo	O
generated	O
myoblasts	O
and	O
multinucleated	O
myotubes	O
.	O

These	O
experiments	O
were	O
carried	O
out	O
in	O
GM	O
.	O

Shown	O
are	O
myogenic	O
responses	O
of	O
mouse	O
cells	O
only	O
,	O
judged	O
by	O
lack	O
of	O
immunoreactivity	O
to	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
antigens	O
,	O
such	O
as	O
NuMA	B
and	O
Oct4	B
;	O
and	O
presence	O
of	O
mouse	O
-	O
specific	O
immunoreactivity	O
,	O
e.g.	O
,	O
M	B
-	I
cadherin	I
(	O
not	O
shown	O
)	O
.	O

Both	O
young	O
and	O
old	O
myofiber	O
associated	O
satellite	O
cells	O
exhibited	O
considerable	O
myogenic	O
improvement	O
over	O
control	O
conditions	O
.	O

n	O
=	O
3.In	O
concert	O
with	O
the	O
conservation	O
of	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
niche	O
,	O
the	O
negative	O
influence	O
of	O
local	O
muscle	O
niche	O
was	O
also	O
found	O
to	O
be	O
conserved	O
in	O
its	O
inhibition	O
of	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
.	O

Specifically	O
,	O
the	O
myogenic	O
capacity	O
(	O
generation	O
of	O
desmin+	B
myoblasts	O
)	O
was	O
inhibited	O
in	O
young	O
satellite	O
cells	O
co	O
-	O
cultured	O
in	O
a	O
transwell	O
system	O
with	O
aged	O
myofibers	O
(	O
Fig.	O
4B	O
)	O
.	O

In	O
addition	O
,	O
hESC	O
and	O
ASC	O
proliferation	O
(	O
BrdU	O
incorporation	O
)	O
was	O
also	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
(	O
Fig.	O
4A	O
,	O
C	O
)	O
.	O

These	O
data	O
suggest	O
that	O
not	O
only	O
systemic	O
but	O
also	O
local	O
organ	O
niches	O
would	O
inhibit	O
key	O
stem	O
cell	O
properties	O
,	O
e.g.	O
,	O
myogenic	O
capacity	O
and	O
the	O
rate	O
of	O
proliferation	O
in	O
the	O
aged	O
organism	O
.	O

The	O
conserved	O
inhibitory	O
influences	O
of	O
the	O
differentiated	O
muscle	O
niche	O
on	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
local	O
organ	O
nicheRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Myogenic	O
differentiation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
desmin	B
)	O
Young	O
myofiber60.2	O
±	O
2.5	O
,	O
40.5	O
±	O
2.67.4	O
±	O
0.9	O
,	O
47.6	O
±	O
5.0Old	O
myofiber30.1	O
±	O
4.3	O
,	O
21.5	O
±	O
4.11.3	O
±	O
0.7	O
,	O
19.7	O
±	O
4.7Quantified	O
results	O
from	O
Fig.	O
4	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
myogenic	O
differentiation	O
(	O
desmin	B
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
,	O
in	O
the	O
presence	O
of	O
young	O
vs.	O
old	O
differentiated	O
muscle	O
environments	O
(	O
young	O
myofiber	O
or	O
old	O
myofiber	O
)	O
.	O

hESCs	O
indirectly	O
enhance	O
and	O
rejuvenate	O
the	O
regeneration	O
of	O
skeletal	O
muscleWhile	O
hESC	O
properties	O
were	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
,	O
the	O
myogenic	O
potential	O
of	O
aged	O
satellite	O
cells	O
seemed	O
to	O
be	O
enhanced	O
by	O
co	O
-	O
cultures	O
with	O
hESCs	O
(	O
Fig.	O
4A	O
)	O
.	O

Therefore	O
,	O
we	O
further	O
explored	O
the	O
enhancing	O
and	O
rejuvenating	O
effects	O
of	O
hESCs	O
on	O
myogenic	O
potential	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
using	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSCs	O
)	O
as	O
a	O
negative	O
control	O
.	O

First	O
,	O
we	O
examined	O
the	O
effects	O
of	O
hESCs	O
on	O
myotube	O
generation	O
by	O
co	O
-	O
culture	O
with	O
primary	O
myoblasts	O
freshly	O
derived	O
from	O
activated	O
-	O
by	O
-	O
injury	O
satellite	O
cells	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
5A	O
(	O
Mb	O
+	O
hESC	O
)	O
,	O
primary	O
myoblasts	O
underwent	O
very	O
rapid	O
and	O
robust	O
nascent	O
myotube	O
formation	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Namely	O
,	O
remarkably	O
large	O
fused	O
myotubes	O
containing	O
approximately	O
50–70	O
nuclei	O
formed	O
around	O
hESCs	O
colonies	O
(	O
Fig.	O
5A	O
)	O
.	O

In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hMSCs	O
,	O
myotube	O
formation	O
was	O
no	O
greater	O
than	O
in	O
myoblast	O
cultures	O
alone	O
(	O
Fig.	O
5A	O
,	O
Mb	O
+	O
hMSC	O
and	O
Mb	O
alone	O
)	O
.	O

Encouraged	O
by	O
these	O
data	O
,	O
we	O
analyzed	O
the	O
myogenic	O
potential	O
of	O
young	O
and	O
old	O
satellite	O
cells	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h.	O
As	O
shown	O
in	O
Fig.	O
5B	O
,	O
hESCs	O
conferred	O
a	O
much	O
-	O
enhanced	O
myogenic	O
capacity	O
on	O
both	O
young	O
and	O
,	O
importantly	O
,	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
(	O
rapid	O
formation	O
of	O
desmin+	B
myogenic	O
cells	O
,	O
many	O
of	O
which	O
formed	O
de	O
novo	O
multinucleated	O
myotubes	O
)	O
.	O

Control	O
co	O
-	O
cultures	O
of	O
these	O
satellite	O
cells	O
with	O
hMSCs	O
displayed	O
no	O
enhanced	O
myogenicity	O
.	O

In	O
summary	O
,	O
while	O
the	O
myogenic	O
potential	O
(	O
production	O
of	O
desmin+	B
fusion	O
-	O
competent	O
cells	O
)	O
was	O
more	O
pronounced	O
in	O
young	O
vs.	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
under	O
all	O
experimental	O
conditions	O
,	O
a	O
finding	O
that	O
is	O
consistent	O
with	O
previous	O
data	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
a	O
clear	O
increase	O
in	O
myogenic	O
potential	O
of	O
old	O
satellite	O
cells	O
was	O
noted	O
in	O
co	O
-	O
cultures	O
with	O
hESCs	O
,	O
as	O
compared	O
to	O
control	O
cultures	O
devoid	O
of	O
hESCs	O
(	O
Fig.	O
4A	O
,	O
B	O
)	O
.Interestingly	O
,	O
in	O
addition	O
to	O
the	O
rejuvenating	O
effects	O
of	O
direct	O
co	O
-	O
cultures	O
shown	O
in	O
Fig.	O
5	O
,	O
soluble	O
factors	O
present	O
in	O
hESC	O
-	O
conditioned	O
culture	O
supernatants	O
were	O
also	O
able	O
to	O
enhance	O
myogenesis	O
of	O
aged	O
satellite	O
cells	O
(	O
Supplementary	O
Fig.	O
S5	O
)	O
.	O

Thus	O
,	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
an	O
established	O
embryonic	O
microniche	O
antagonizes	O
the	O
inhibitory	O
effects	O
of	O
the	O
aged	O
environment	O
on	O
stem	O
cell	O
responses	O
(	O
Fig.	O
3	O
)	O
,	O
the	O
hESC	O
-	O
produced	O
factors	O
enhanced	O
myogenic	O
capacity	O
of	O
even	O
old	O
mouse	O
satellite	O
cells	O
.	O

Establishing	O
that	O
hESC	O
-	O
produced	O
factors	O
enhance	O
adult	O
myogenesis	O
and	O
rejuvenate	O
the	O
regenerative	O
capacity	O
of	O
even	O
aged	O
satellite	O
cells	O
in	O
vitro	O
prompted	O
us	O
to	O
examine	O
whether	O
the	O
regeneration	O
of	O
old	O
injured	O
muscle	O
will	O
be	O
improved	O
by	O
hESC	O
transplantation	O
in	O
vivo	O
.	O

Additionally	O
,	O
based	O
on	O
the	O
data	O
shown	O
above	O
,	O
we	O
speculated	O
that	O
even	O
if	O
the	O
host	O
's	O
repair	O
capacity	O
is	O
improved	O
,	O
hESCs	O
themselves	O
will	O
not	O
be	O
efficiently	O
maintained	O
or	O
expanded	O
in	O
the	O
context	O
of	O
old	O
systemic	O
and	O
local	O
organ	O
environments	O
,	O
and	O
will	O
not	O
directly	O
contribute	O
to	O
the	O
repair	O
of	O
aged	O
skeletal	O
muscle	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
injected	O
5	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
into	O
the	O
tibialis	O
anterior	O
(	O
TA	O
)	O
and	O
gastrocnemius	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
at	O
24	O
h	O
after	O
cardiotoxin	O
-	O
induced	O
injury	O
,	O
when	O
activation	O
/	O
proliferation	O
of	O
endogenous	O
satellite	O
cells	O
normally	O
begins	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

To	O
avoid	O
immune	O
response	O
against	O
hESC	O
antigens	O
,	O
mice	O
were	O
immunosuppressed	O
using	O
FK506	O
(	O
Ito	O
&	O
Tanaka	O
,	O
1997	O
;	O
Dumont	O
,	O
2000	O
)	O
.	O

Muscle	O
was	O
isolated	O
5	O
days	O
post	O
-	O
injury	O
,	O
when	O
nascent	O
differentiated	O
myofibers	O
normally	O
replace	O
the	O
damaged	O
tissue	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
and	O
10	O
µm	O
cryosections	O
were	O
analyzed	O
for	O
the	O
success	O
in	O
tissue	O
repair	O
using	O
hematoxylin	O
and	O
eosin	O
(	O
H&E	O
)	O
histochemistry	O
and	O
eMyHC	B
immunodetection	O
.	O

H&E	O
analysis	O
reveals	O
newly	O
formed	O
myofibers	O
,	O
based	O
on	O
their	O
smaller	O
size	O
and	O
centrally	O
located	O
nuclei	O
.	O

Additionally	O
,	O
de	O
novo	O
myofibers	O
in	O
the	O
damaged	O
area	O
appear	O
positive	O
for	O
eMyHC	B
,	O
while	O
undamaged	O
myofibers	O
remain	O
negative	O
.	O

As	O
shown	O
in	O
Fig.	O
6A	O
and	O
quantified	O
in	O
6B	O
,	O
injection	O
of	O
hESCs	O
significantly	O
enhanced	O
regeneration	O
of	O
skeletal	O
muscle	O
.	O

Remarkably	O
,	O
this	O
positive	O
embryonic	O
effect	O
was	O
especially	O
pronounced	O
in	O
old	O
tissue	O
.	O

Fig.	O

6Skeletal	O
muscle	O
regeneration	O
following	O
hESC	O
transplantation	O
is	O
a	O
balance	O
between	O
the	O
inhibitory	O
influence	O
of	O
aged	O
niches	O
and	O
the	O
rejuvenating	O
effects	O
of	O
hESCs	O
.	O

Young	O
and	O
old	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
were	O
injured	O
by	O
cardiotoxin	O
injection	O
.	O

hESCs	O
or	O
hMSCs	O
were	O
transplanted	O
at	O
the	O
site	O
of	O
injury	O
and	O
were	O
analyzed	O
by	O
cryosectioning	O
at	O
Day	O
5	O
after	O
injury	O
(	O
as	O
described	O
in	O
Experimental	O
procedures	O
)	O
.	O

(	O
A	O
)	O
Newly	O
regenerated	O
myofibers	O
were	O
detected	O
using	O
eMyHC	B
-	O
specific	O
antibody	O
(	O
green	O
)	O
and	O
staining	O
with	O
H&E.	O
In	O
H&E	O
staining	O
,	O
newly	O
regenerated	O
areas	O
contain	O
smaller	O
,	O
immature	O
myofibers	O
with	O
centrally	O
located	O
nuclei	O
.	O

Uninjured	O
myofibers	O
are	O
much	O
larger	O
,	O
by	O
comparison	O
,	O
with	O
peripherally	O
restricted	O
nuclei	O
.	O

Poorly	O
regenerated	O
areas	O
lack	O
new	O
myofibers	O
and	O
contain	O
areas	O
of	O
fibrosis	O
and	O
inflammation	O
.	O

eMyHC	B
immunodetection	O
is	O
specific	O
for	O
regenerating	O
areas	O
of	O
muscle	O
only	O
.	O

Both	O
assays	O
showed	O
dramatic	O
enhancement	O
of	O
muscle	O
regeneration	O
in	O
'	O
old	O
+	O
hESC	O
'	O
vs.	O
'	O
old	O
+	O
hMSC	O
'	O
.	O

Regeneration	O
improvement	O
was	O
also	O
seen	O
in	O
young	O
+	O
hESC	O
,	O
as	O
compared	O
to	O
young	O
+	O
hMSC	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
muscle	O
regeneration	O
was	O
performed	O
by	O
analyzing	O
the	O
density	O
of	O
newly	O
formed	O
myofibers	O
per	O
mm2	O
of	O
injury	O
site	O
,	O
which	O
is	O
the	O
volume	O
that	O
typically	O
covers	O
the	O
whole	O
injured	O
area	O
.	O

Multiple	O
,	O
10	O
µm	O
H&E	O
sections	O
were	O
examined	O
through	O
the	O
entire	O
volume	O
of	O
injury	O
in	O
multiple	O
,	O
independently	O
injured	O
muscles	O
.	O

n	O
=	O
20	O
;	O

*	O
indicates	O
P	O
<	O
0.001	O
(	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
young	O
+	O
hMSC	O
and	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
'	O
old	O
+	O
hESC	O
'	O
.	O

(	O
C	O
)	O
H&E	O
and	O
immunofluoresence	O
staining	O
for	O
Oct4	B
,	O
and	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
NuMA	B
,	O
revealed	O
the	O
failure	O
of	O
hESCs	O
to	O
expand	O
or	O
persist	O
in	O
old	O
,	O
but	O
the	O
presence	O
of	O
hESCs	O
in	O
young	O
muscle	O
at	O
5	O
days	O
post	O
-	O
transplantation	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

Importantly	O
,	O
such	O
enhanced	O
and	O
rejuvenated	O
muscle	O
repair	O
stems	O
from	O
an	O
indirect	O
induction	O
,	O
as	O
hESCs	O
themselves	O
(	O
or	O
control	O
hMSCs	O
)	O
did	O
not	O
physically	O
contribute	O
to	O
the	O
mouse	O
myofibers	O
,	O
as	O
judged	O
by	O
near	O
absence	O
(	O
less	O
than	O
0.1	O
%	O
)	O
of	O
human	O
-	O
specific	O
NuMA+	B
nuclei	O
in	O
de	O
novo	O
desmin+	B
myofibers	O
,	O
analyzed	O
through	O
multiple	O
injury	O
sites	O
.	O

An	O
example	O
of	O
one	O
regenerated	O
myofiber	O
from	O
young	O
muscle	O
injected	O
with	O
hESCs	O
,	O
with	O
NuMA+	B
nucleus	O
in	O
a	O
field	O
of	O
NuMA−	B
/	O
desmin+	B
mouse	O
myofibers	O
,	O
is	O
shown	O
in	O
Supplementary	O
Fig.	O
S6	O
.	O

No	O
such	O
NuMA+	B
/	O
desmin+	B
myofibers	O
were	O
detected	O
in	O
aged	O
regenerated	O
muscle	O
(	O
not	O
shown	O
)	O
.In	O
agreement	O
with	O
the	O
in	O
vitro	O
data	O
,	O
establishing	O
that	O
aged	O
systemic	O
and	O
local	O
niches	O
inhibit	O
hESC	O
proliferation	O
and	O
Oct4	B
expression	O
(	O
Figs	O
2	O
and	O
4	O
and	O
Supplementary	O
Fig.	O
S2	O
)	O
,	O
hESCs	O
failed	O
to	O
expand	O
or	O
even	O
persist	O
in	O
old	O
muscle	O
,	O
as	O
judged	O
by	O
the	O
absence	O
of	O
NuMA+	B
/	O
Oct4	B
+	O
hESC	O
-	O
derived	O
cells	O
in	O
the	O
aged	O
tissue	O
.	O

In	O
contrast	O
,	O
colonies	O
of	O
Numa+	B
/	O
Oct4	B
+	O
hESC	O
-	O
derived	O
cells	O
that	O
did	O
not	O
undergo	O
myogenic	O
differentiation	O
were	O
easily	O
detected	O
in	O
young	O
regenerating	O
muscle	O
(	O
Fig.	O
6C	O
)	O
.	O

This	O
finding	O
validates	O
several	O
technical	O
aspects	O
of	O
these	O
experiments	O
,	O
and	O
confirms	O
the	O
contrasting	O
effects	O
of	O
young	O
and	O
old	O
systemic	O
and	O
local	O
organ	O
niches	O
on	O
hESC	O
self	O
-	O
renewal	O
.	O

These	O
data	O
further	O
confirm	O
and	O
extrapolate	O
our	O
findings	O
and	O
demonstrate	O
that	O
when	O
exposed	O
to	O
both	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
,	O
hESCs	O
fail	O
to	O
persist	O
and	O
do	O
not	O
contribute	O
to	O
tissue	O
repair	O
directly	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
embryonic	O
cells	O
indirectly	O
but	O
significantly	O
improve	O
the	O
repair	O
of	O
aged	O
injured	O
muscle	O
in	O
vivo	O
.	O

The	O
data	O
presented	O
here	O
establish	O
for	O
the	O
first	O
time	O
that	O
both	O
the	O
local	O
environment	O
of	O
old	O
differentiated	O
organ	O
,	O
e.g.	O
,	O
skeletal	O
muscle	O
and	O
the	O
systemic	O
milieu	O
dramatically	O
affect	O
the	O
regenerative	O
potential	O
of	O
both	O
hESCs	O
and	O
mouse	O
post	O
-	O
natal	O
myogenic	O
progenitor	O
cells	O
.	O

Not	O
only	O
are	O
the	O
factors	O
promoting	O
myogenic	O
differentiation	O
and	O
proliferation	O
of	O
hESCs	O
likely	O
to	O
become	O
depleted	O
with	O
age	O
,	O
but	O
the	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
are	O
likely	O
to	O
contain	O
dominant	O
inhibitors	O
of	O
ASC	O
and	O
hESC	O
regenerative	O
potential	O
(	O
Figs	O
1	O
,	O
2	O
,	O
and	O
4	O
,	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
)	O
.	O

Importantly	O
,	O
the	O
similar	O
inhibitory	O
effects	O
of	O
old	O
mouse	O
serum	O
and	O
old	O
myofibers	O
on	O
satellite	O
cell	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
and	O
hESC	O
(	O
Figs	O
2	O
and	O
4A	O
)	O
proliferation	O
and	O
regenerative	O
capacity	O
suggest	O
the	O
conservation	O
of	O
elements	O
in	O
age	O
-	O
specific	O
extrinsic	O
regulatory	O
mechanisms	O
between	O
evolutionarily	O
distinct	O
species	O
and	O
stem	O
cell	O
types	O
.	O

Additionally	O
,	O
a	O
similarity	O
in	O
the	O
inhibitory	O
properties	O
between	O
systemic	O
and	O
local	O
organ	O
niches	O
is	O
also	O
of	O
interest	O
and	O
may	O
indicate	O
that	O
molecules	O
produced	O
by	O
old	O
tissues	O
have	O
circulatory	O
/	O
endocrine	O
activity	O
;	O
and/or	O
that	O
age	O
-	O
specific	O
systemic	O
inhibitory	O
components	O
become	O
deposited	O
in	O
the	O
old	O
tissues	O
.	O

Humans	O
display	O
broad	O
genetic	O
polymorphisms	O
and	O
behavioral	O
variations	O
,	O
which	O
makes	O
the	O
identification	O
of	O
age	O
-	O
specific	O
molecular	O
changes	O
complicated	O
.	O

In	O
contrast	O
,	O
laboratory	O
mice	O
are	O
genetically	O
and	O
environmentally	O
controlled	O
.	O

Establishing	O
that	O
age	O
-	O
specific	O
signals	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
are	O
evolutionarily	O
conserved	O
and	O
soluble	O
enables	O
the	O
formation	O
of	O
rational	O
approaches	O
for	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
inhibitors	O
involved	O
,	O
and	O
for	O
revealing	O
the	O
precise	O
timing	O
of	O
their	O
first	O
appearance	O
in	O
serum	O
and	O
differentiated	O
tissues	O
with	O
advancing	O
age	O
.	O

Significantly	O
,	O
these	O
experiments	O
have	O
also	O
revealed	O
that	O
not	O
only	O
are	O
hESCs	O
able	O
to	O
protect	O
themselves	O
against	O
the	O
negative	O
influences	O
of	O
aged	O
mouse	O
sera	O
(	O
Fig.	O
3	O
)	O
,	O
but	O
these	O
cells	O
also	O
produce	O
factors	O
that	O
dramatically	O
enhance	O
the	O
myogenic	O
capacity	O
of	O
primary	O
myoblasts	O
and	O
young	O
and	O
old	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
,	O
and	O
also	O
significantly	O
improve	O
repair	O
of	O
young	O
and	O
old	O
injured	O
muscle	O
in	O
vivo	O
(	O
Fig.	O
6	O
)	O
.	O

Identification	O
of	O
these	O
embryonic	O
factors	O
would	O
allow	O
us	O
to	O
potentially	O
enrich	O
the	O
arsenal	O
of	O
therapeutic	O
tools	O
for	O
combating	O
age	O
-	O
specific	O
degenerative	O
disorders	O
.	O

The	O
interactions	O
between	O
hESCs	O
and	O
heterochronic	O
differentiated	O
niches	O
,	O
initially	O
identified	O
in	O
vitro	O
,	O
have	O
been	O
confirmed	O
by	O
in	O
vivo	O
experiments	O
.	O

Namely	O
,	O
while	O
the	O
regenerative	O
capacity	O
,	O
or	O
presence	O
,	O
of	O
hESCs	O
is	O
greatly	O
restricted	O
in	O
aged	O
,	O
as	O
compared	O
to	O
young	O
skeletal	O
muscle	O
(	O
where	O
transplanted	O
cells	O
experience	O
both	O
old	O
systemic	O
and	O
local	O
environments	O
)	O
,	O
embryonic	O
cells	O
indirectly	O
enhance	O
and	O
rejuvenate	O
muscle	O
repair	O
when	O
introduced	O
at	O
the	O
time	O
of	O
muscle	O
stem	O
cell	O
activation	O
in	O
the	O
host	O
,	O
e.g.	O
,	O
at	O
Day	O
1	O
after	O
the	O
injury	O
(	O
Fig.	O
6	O
)	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
the	O
percentage	O
of	O
hESCs	O
direct	O
contribution	O
to	O
desmin+	B
myofibers	O
in	O
young	O
muscle	O
will	O
be	O
increased	O
by	O
transplanting	O
these	O
cells	O
at	O
a	O
different	O
time	O
-	O
point	O
after	O
muscle	O
injury	O
,	O
e.g.	O
,	O
at	O
Days	O
3–5	O
(	O
as	O
in	O
co	O
-	O
cultures	O
with	O
myofibers	O
pre	O
-	O
injured	O
for	O
3	O
days	O
,	O
Fig.	O
4A	O
)	O
.	O

In	O
any	O
case	O
,	O
the	O
virtual	O
lack	O
of	O
hESC	O
and	O
hMSC	O
direct	O
contribution	O
to	O
the	O
newly	O
regenerated	O
skeletal	O
muscle	O
,	O
when	O
small	O
numbers	O
of	O
these	O
cells	O
were	O
injected	O
into	O
injured	O
tissue	O
,	O
is	O
completely	O
consistent	O
with	O
the	O
body	O
of	O
previous	O
data	O
demonstrating	O
that	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
conduct	O
rapid	O
and	O
robust	O
muscle	O
repair	O
and	O
greatly	O
outnumber	O
injected	O
human	O
cells	O
(	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
;	O
that	O
compared	O
to	O
muscle	O
-	O
specific	O
satellite	O
cells	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
in	O
vitro	O
remains	O
very	O
small	O
(	O
Fig.	O
5	O
,	O
Table	O
2	O
)	O
,	O
and	O
that	O
control	O
hMSCs	O
are	O
not	O
normally	O
myogenic	O
unless	O
these	O
cells	O
overexpress	O
exogenous	O
constitutively	O
active	O
domain	O
of	O
Notch	B
(	O
Dezawa	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
the	O
failure	O
of	O
hESCs	O
to	O
strive	O
in	O
old	O
skeletal	O
muscle	O
might	O
represent	O
a	O
therapeutically	O
desirable	O
outcome	O
.	O

For	O
example	O
,	O
while	O
in	O
young	O
tissue	O
hESC	O
derivatives	O
putatively	O
would	O
go	O
on	O
to	O
produce	O
teratomas	O
,	O
it	O
is	O
unlikely	O
that	O
teratoma	O
formation	O
would	O
occur	O
after	O
hESC	O
transplantation	O
into	O
aged	O
skeletal	O
muscle	O
.	O

Thus	O
,	O
the	O
indirect	O
beneficial	O
effects	O
of	O
hESCs	O
on	O
tissue	O
repair	O
are	O
unlikely	O
to	O
be	O
compromised	O
by	O
the	O
oncogenic	O
properties	O
of	O
these	O
embryonic	O
cells	O
in	O
the	O
context	O
of	O
old	O
skeletal	O
muscle	O
.	O

Comprehensively	O
,	O
the	O
results	O
of	O
this	O
work	O
increase	O
our	O
understanding	O
of	O
aging	O
as	O
a	O
process	O
,	O
reveal	O
evolutionary	O
conserved	O
age	O
-	O
specific	O
interactions	O
between	O
stem	O
cells	O
and	O
their	O
differentiated	O
niches	O
,	O
and	O
suggest	O
novel	O
therapeutic	O
approaches	O
for	O
improving	O
the	O
regenerative	O
responses	O
of	O
endogenous	O
or	O
transplanted	O
stem	O
cells	O
in	O
old	O
individuals	O
.	O

Animal	O
strainsYoung	O
(	O
2–3	O
months	O
)	O
,	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
pathogen	O
-	O
free	O
breeding	O
colonies	O
at	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
.	O

Aged	O
22–24	O
months	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
the	O
National	O
Institute	O
on	O
Aging	O
(	O
NIH	O
)	O
.	O

Animals	O
were	O
maintained	O
in	O
the	O
North	O
-	O
West	O
Animal	O
Facility	O
of	O
the	O
University	O
of	O
California	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
,	O
and	O
handled	O
in	O
accordance	O
with	O
the	O
Administrative	O
Panel	O
on	O
Laboratory	O
Animal	O
Care	O
at	O
UC	O
Berkeley	O
.	O

Muscle	O
injury	O
and	O
isolationMyofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
were	O
activated	O
by	O
in	O
vivo	O
injury	O
,	O
were	O
set	O
up	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Briefly	O
,	O
mice	O
were	O
injured	O
by	O
direct	O
injection	O
with	O
5	O
ng	O
cardiotoxin	O
(	O
CTX-1	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
into	O
the	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
using	O
a	O
28-gauge	O
needle	O
.	O

After	O
1–5	O
days	O
post	O
-	O
injection	O
,	O
injured	O
or	O
uninjured	O
muscle	O
tissue	O
was	O
dissected	O
out	O
.	O

Once	O
isolated	O
,	O
whole	O
muscle	O
was	O
prepared	O
for	O
cryosectioning	O
(	O
see	O
below	O
)	O
or	O
myofiber	O
fragments	O
were	O
obtained	O
from	O
hind	O
limb	O
muscles	O
by	O
enzymatic	O
digestion	O
(	O
see	O
below	O
)	O
,	O
trituration	O
,	O
and	O
multiple	O
sedimentation	O
and	O
washing	O
procedures	O
.	O

Additionally	O
,	O
blood	O
was	O
collected	O
from	O
mice	O
for	O
the	O
isolation	O
of	O
sera	O
.	O

Briefly	O
,	O
blood	O
cells	O
were	O
coagulated	O
at	O
37	O
°	O
C	O
for	O
15	O
'	O
and	O
then	O
were	O
centrifuged	O
repeatedly	O
at	O
5900	O
g	O
,	O
4	O
°	O
C	O
in	O
a	O
microfuge	O
for	O
3	O
'	O
to	O
isolate	O
sera	O
.	O

Mixtures	O
of	O
young	O
and	O
old	O
sera	O
were	O
made	O
1	O
:	O
1	O
.	O

For	O
example	O
,	O
in	O
5%+	O
5	O
%	O
conditions	O
,	O
50	O
µL	O
of	O
young	O
and	O
50	O
µL	O
old	O
serum	O
were	O
added	O
to	O
900	O
µL	O
of	O
culture	O
medium	O
(	O
Opti	O
-	O
MEM	O
or	O
MCM	O
,	O
see	O
co	O
-	O
culture	O
procedures	O
below	O
)	O
.	O

Myofiber	O
explant	O
culturesExplant	O
and	O
primary	O
cell	O
cultures	O
were	O
generated	O
from	O
C57-BL	O
/	O
6	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

Dissected	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
underwent	O
enzymatic	O
digestion	O
at	O
37	O
°	O
C	O
in	O
DMEM	O
(	O
Invitrogen	O
)	O
/	O
Pen	O
-	O
Strep	O
(	O
Invitrogen	O
)	O
/	O
0.2	O
%	O
Collagenase	B
Type	I
IIA	I
(	O
Sigma	O
)	O
solution	O
.	O

Isolated	O
fibers	O
were	O
resuspended	O
in	O
GM	O
(	O
Ham	O
's	O
F10	O
nutrient	O
mixture	O
(	O
Mediatech	O
,	O
Inc.	O
,	O
Herndon	O
,	O
VA	O
,	O
USA	O
)	O
,	O
20	O
%	O
FBS	O
(	O
Mediatech	O
)	O
,	O
5	O
ng	O
mL−1	O
bFGF	B
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
and	O
1	O
%	O
Pen	O
-	O
Strep	O
,	O
and	O
cultured	O
on	O
ECM	O
-	O
coated	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
plates	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
)	O
.	O

Cultures	O
of	O
primary	O
myoblasts	O
were	O
derived	O
from	O
isolated	O
fibers	O
,	O
through	O
repeated	O
passaging	O
,	O
and	O
were	O
maintained	O
in	O
GM	O
.	O

Myoblast	O
differentiation	O
medium	O
[	O
DMEM	O
,	O
supplemented	O
with	O
2	O
%	O
horse	O
serum	O
(	O
Mediatech	O
)	O
]	O
was	O
used	O
to	O
promote	O
rapid	O
formation	O
of	O
myotubes	O
from	O
cultured	O
myoblasts	O
(	O
Morgan	O
&	O
Partridge	O
,	O
2003	O
)	O
.	O

Human	O
embryonic	O
and	O
mesenchymal	O
stem	O
cell	O
cultureThe	O
federally	O
approved	O
hESC	O
line	O
,	O
H7	O
(	O
NIH	O
no.	O
WA07	O
,	O
obtained	O
from	O
WiCell	O
Research	O
Institue	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
,	O
was	O
used	O
in	O
accordance	O
with	O
the	O
UC	O
Berkeley	O
and	O
UC	O
San	O
Francisco	O
Committee	O
on	O
Human	O
Research	O
guidelines	O
,	O
and	O
in	O
accordance	O
with	O
NIH	O
guidelines	O
.	O

To	O
propagate	O
hESCs	O
,	O
routine	O
culturing	O
and	O
maintenance	O
was	O
performed	O
using	O
standard	O
in	O
vitro	O
conditions	O
for	O
both	O
feeder	O
-	O
dependent	O
and	O
feeder	O
-	O
free	O
cultures	O
(	O
Geron	O
Corporation	O
,	O
2002	O
)	O
.	O

Briefly	O
,	O
hESCs	O
grown	O
on	O
MEFs	O
were	O
cultured	O
in	O
standard	O
hESC	O
medium	O
[	O
Knockout	O
™	O
DMEM	O
,	O
20	O
%	O
KSR	O
,	O
1	O
%	O
NEAA	O
,	O
1	O
mm	O
l	O
-	O
glutamine	O
(	O
Invitrogen	O
)	O
,	O
0.1	O
mmβ	O
-	O
mercaptoethanol	O
(	O
Sigma	O
)	O
]	O
and	O
were	O
supplemented	O
with	O
4	O
ng	O
mL−1	O
hbFGF	B
(	O
Invitrogen	O
)	O
.	O

Feeder	O
-	O
free	O
hESC	O
cultures	O
were	O
maintained	O
in	O
MEF	O
-	O
conditioned	O
hESC	O
medium	O
(	O
MCM	O
)	O
,	O
4	O
ng	O
mL−1	O
hbFGF	B
.	O

Differentiation	O
medium	O
for	O
hESCs	O
(	O
DMEM	O
/	O
FBS	O
)	O
was	O
made	O
by	O
replacing	O
KSR	O
with	O
20	O
%	O
FBS	O
(	O
Hyclone	O
,	O
Logan	O
,	O
UH	O
,	O
USA	O
)	O
.	O

hMSCs	O
were	O
maintained	O
in	O
mesenchymal	O
stem	O
cell	O
GM	O
,	O
MSC	O
-	O
GM	O
™	O
and	O
were	O
cultured	O
according	O
to	O
supplier	O
recommendations	O
(	O
Cambrex	O
Walkersville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
typically	O
seeded	O
onto	O
chambered	O
slides	O
coated	O
with	O
a	O
3	O
%	O
GFR	O
Matrigel	O
™	O
(	O
BD	O
Biosciences	O
)	O
substrate	O
in	O
PBS	O
.	O

Cells	O
were	O
typically	O
incubated	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
under	O
the	O
various	O
experimental	O
conditions	O
employed	O
,	O
then	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
analyzed	O
24–48	O
h	O
after	O
experimental	O
treatments	O
,	O
during	O
which	O
no	O
apoptosis	O
-	O
related	O
differences	O
in	O
cell	O
numbers	O
were	O
observed	O
.	O

Heterochronic	O
co	O
-	O
culture	O
systemsHeterochronic	O
systemic	O
cultures	O
were	O
established	O
by	O
culturing	O
myofiber	O
explants	O
(	O
in	O
GM	O
)	O
or	O
hESCs	O
(	O
in	O
MCM	O
)	O
in	O
the	O
presence	O
of	O
young	O
,	O
old	O
or	O
young	O
+	O
old	O
sera	O
for	O
48	O
h	O
(	O
Figs	O
1	O
and	O
2	O
and	O
Supplementary	O
Figs	O
S1–3	O
)	O
.	O

In	O
such	O
cultures	O
,	O
hESCs	O
were	O
passaged	O
immediately	O
prior	O
to	O
sera	O
exposure	O
.	O

In	O
contrast	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
was	O
done	O
for	O
embryonic	O
microniche	O
experiments	O
(	O
Fig.	O
3	O
)	O
.	O

For	O
heterochronic	O
local	O
organ	O
niche	O
cultures	O
,	O
hESCs	O
were	O
co	O
-	O
cultured	O
directly	O
with	O
myofiber	O
explants	O
for	O
48	O
h	O
in	O
GM	O
,	O
or	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
supernatants	O
derived	O
from	O
cultured	O
myofiber	O
explants	O
for	O
48	O
h	O
(	O
Figs	O
4A	O
and	O
5	O
)	O
.	O

Specifically	O
,	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
identical	O
volume	O
,	O
e.g.	O
,	O
100	O
µL	O
,	O
of	O
young	O
or	O
old	O
myofiber	O
fragments	O
with	O
their	O
associated	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
experiments	O
shown	O
in	O
Supplementary	O
Fig.	O
S5	O
,	O
culture	O
-	O
conditioned	O
supernatant	O
produced	O
by	O
hESCs	O
grown	O
in	O
MCM	O
was	O
used	O
as	O
a	O
medium	O
in	O
which	O
1	O
×	O
105	O
of	O
myofiber	O
-	O
associated	O
young	O
or	O
old	O
satellite	O
cells	O
were	O
cultured	O
for	O
48	O
h.	O
In	O
direct	O
co	O
-	O
cultures	O
,	O
mouse	O
vs.	O
human	O
cells	O
were	O
distinguished	O
by	O
immunodetection	O
with	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
and	O
mouse	O
-	O
specific	O
antibodies	O
(	O
Supplementary	O
Fig.	O
S4	O
and	O
see	O
below	O
)	O
.	O

To	O
prepare	O
muscle	O
supernatants	O
,	O
explants	O
were	O
cultured	O
for	O
24	O
h	O
in	O
GM	O
and	O
cellular	O
debris	O
was	O
removed	O
from	O
conditioned	O
media	O
by	O
multiple	O
rounds	O
of	O
centrifugation	O
.	O

The	O
absence	O
of	O
cells	O
was	O
confirmed	O
by	O
microscopic	O
examination	O
.	O

To	O
mimic	O
the	O
local	O
organ	O
niche	O
for	O
satellite	O
cell	O
assays	O
(	O
Fig.	O
4B	O
)	O
,	O
1.0	O
µm	O
transwell	O
(	O
Corning	O
,	O
NY	O
,	O
USA	O
)	O
co	O
-	O
cultures	O
of	O
uninjured	O
explants	O
with	O
activated	O
satellite	O
cells	O
were	O
established	O
.	O

Activated	O
-	O
by	O
-	O
injury	O
(	O
24	O
h	O
post	O
-	O
injury	O
)	O
satellite	O
cells	O
were	O
seeded	O
onto	O
ECM	O
-	O
coated	O
12-well	O
plates	O
in	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
)	O
and	O
5	O
%	O
FBS	O
.	O

Transwells	O
were	O
placed	O
over	O
satellite	O
cells	O
and	O
contained	O
isolated	O
myofiber	O
explants	O
from	O
uninjured	O
young	O
or	O
old	O
muscle	O
(	O
i.e.	O
,	O
resting	O
muscle	O
)	O
.	O

Satellite	O
cells	O
were	O
cultured	O
for	O
72–96	O
h	O
in	O
the	O
presence	O
of	O
myofiber	O
explants	O
and	O
were	O
fixed	O
for	O
immunodetection	O
,	O
as	O
described	O
above	O
.	O

Cell	O
transplantationhESCs	O
were	O
grown	O
on	O
MEFs	O
and	O
expanded	O
in	O
6-well	O
plates	O
.	O

Cells	O
were	O
treated	O
with	O
1	O
mg	O
mL−1	O
Collagenase	B
Type	I
IV	I
(	O
Invitrogen	O
)	O
for	O
5–10	O
min	O
,	O
were	O
washed	O
and	O
then	O
incubated	O
with	O
0.5	O
mg	O
mL−1	O
Dispase	B
(	O
Invitrogen	O
)	O
to	O
lift	O
only	O
human	O
cell	O
colonies	O
.	O

Isolated	O
hESCs	O
were	O
washed	O
several	O
times	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Similarly	O
,	O
hMSCs	O
were	O
expanded	O
in	O
6-well	O
plates	O
,	O
lifted	O
with	O
Trypsin	B
/	O
EDTA	O
(	O
Invitrogen	O
)	O
,	O
washed	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Approximately	O
5	O
×	O
105	O
hESCs	O
or	O
hMSCs	O
were	O
injected	O
into	O
24	O
h	O
post	O
-	O
injured	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
,	O
using	O
a	O
21-gauge	O
needle	O
.	O

Immunosuppression	O
of	O
animals	O
was	O
achieved	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
mg	O
kg−1	O
FK506	O
(	O
Sigma	O
)	O
at	O
48	O
h	O
prior	O
to	O
cell	O
transplantation	O
,	O
and	O
on	O
each	O
day	O
following	O
transplantation	O
.	O

Immunodetection	O
and	O
histological	O
analysisTo	O
assay	O
the	O
affects	O
of	O
heterochronic	O
local	O
and	O
systemic	O
environments	O
on	O
stem	O
cell	O
regenerative	O
potential	O
,	O
hESC	O
,	O
hMSC	O
,	O
and	O
myofiber	O
-	O
derived	O
precursor	O
cell	O
cultures	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
,	O
and	O
were	O
analyzed	O
by	O
indirect	O
immunofluorescence	O
.	O

Combinations	O
of	O
antibodies	O
were	O
used	O
to	O
co	O
-	O
stain	O
cultures	O
and	O
histosections	O
,	O
in	O
order	O
to	O
determine	O
the	O
percentages	O
of	O
cells	O
that	O
proliferated	O
or	O
differentiated	O
and	O
to	O
distinguish	O
hESCs	O
from	O
mouse	O
cells	O
.	O

Antibodies	O
to	O
the	O
myogenic	O
transcription	O
factors	O
,	O
Myf5	B
/	O
Pax7	B
,	O
the	O
intermediate	O
filament	O
protein	O
,	O
desmin	B
,	O
and	O
the	O
marker	O
of	O
newly	O
formed	O
myotubes	O
,	O
eMyHC	B
,	O
were	O
used	O
to	O
reveal	O
commitment	O
to	O
myogenic	O
differentiation	O
.	O

Cell	O
commitment	O
to	O
this	O
differentiation	O
program	O
was	O
assessed	O
by	O
the	O
efficiency	O
of	O
myotube	O
formation	O
,	O
estimated	O
by	O
the	O
number	O
of	O
nuclei	O
per	O
myotube	O
.	O

Ki67	B
,	O
a	O
cell	O
cycle	O
related	O
nuclear	O
protein	O
consistently	O
absent	O
in	O
quiescent	O
cells	O
,	O
was	O
used	O
as	O
a	O
marker	O
for	O
proliferation	O
.	O

Whereas	O
Ki67	B
appears	O
in	O
all	O
active	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
BrdU	O
staining	O
allowed	O
exclusive	O
detection	O
of	O
cells	O
in	O
S	O
-	O
phase	O
,	O
thereby	O
enabling	O
accurate	O
quantification	O
of	O
DNA	O
synthesis	O
.	O

In	O
select	O
cultures	O
,	O
10	O
µm	O
BrdU	O
was	O
added	O
for	O
2	O
h	O
prior	O
to	O
fixation	O
.	O

BrdU	O
-	O
specific	O
immunostaining	O
required	O
nuclear	O
permeabilization	O
with	O
treatment	O
of	O
4N	O
HCl	O
.	O

hESCs	O
were	O
distinguished	O
from	O
mouse	O
cells	O
by	O
using	O
a	O
species	O
-	O
specific	O
antibody	O
to	O
the	O
cell	O
-	O
surface	O
marker	O
M	B
-	I
cadherin	I
for	O
murine	O
and	O
the	O
nuclear	O
marker	O
NuMA	B
for	O
human	O
cells	O
.	O

Antibodies	O
to	O
Oct4	B
were	O
used	O
as	O
a	O
marker	O
of	O
hESC	O
self	O
-	O
renewal	O
/	O
pluripotency	O
.	O

Following	O
permeabilization	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
+	O
0.25	O
%	O
Triton	O
X-100	O
,	O
cells	O
were	O
incubated	O
with	O
primary	O
antibodies	O
(	O
concentration	O
determined	O
as	O
per	O
manufacturer	O
's	O
recommendations	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
washed	O
several	O
times	O
,	O
and	O
then	O
incubated	O
with	O
fluorophore	O
-	O
conjugated	O
,	O
species	O
-	O
specific	O
secondary	O
antibodies	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
+	O
1	O
%	O
FBS	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

For	O
histological	O
analysis	O
,	O
dissected	O
muscle	O
was	O
treated	O
in	O
a	O
25	O
%	O
sucrose	O
/	O
PBS	O
solution	O
,	O
frozen	O
in	O
OCT	O
compound	O
(	O
Tissue	O
Tek	O
)	O
and	O
cryosectioned	O
at	O
10	O
µm	O
.	O

Immunostaining	O
was	O
performed	O
in	O
the	O
manner	O
described	O
above	O
,	O
or	O
H&E	O
staining	O
of	O
cryosections	O
was	O
performed	O
.	O

Nuclei	O
were	O
visualized	O
by	O
Hoechst	O
staining	O
for	O
all	O
immunostains	O
.	O

Samples	O
were	O
analyzed	O
at	O
room	O
temperature	O
by	O
using	O
a	O
Zeiss	O
Axioscope	O
40	O
fluorescent	O
microscope	O
,	O
and	O
imaged	O
with	O
an	O
Axiocan	O
MRc	O
camera	O
and	O
AxioVision	O
software	O
.	O

All	O
images	O
depict	O
identical	O
microscope	O
fields	O
at	O
×20	O
magnification	O
,	O
unless	O
otherwise	O
noted	O
.	O

ReagentsAntibodies	O
to	O
Oct4	B
(	O
ab18976	O
)	O
,	O
BrdU	B
(	O
BU1	O
/	O
75	O
(	O
ICR1	O
)	O
,	O
and	O
Ki67	B
(	O
ab15580	O
)	O
were	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
M	B
-	I
cadherin	I
(	O
clone	O
12G4	O
)	O
was	O
acquired	O
from	O
Upstate	O
Biotechnology	O
(	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
)	O
,	O
and	O
NuMA	B
antibody	O
(	O
Catalog	O
number	O
NA09L	O
)	O
from	O
EMD	O
Biosciences	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
developmental	O
eMyHC	B
(	O
clone	O
RNMy2	O
/	O
9D2	O
)	O
was	O
acquired	O
from	O
Vector	O
Laboratories	O
(	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Myf5	B
(	O
GTX77876	O
)	O
and	O
Pax7	B
(	O
GTX77888	O
)	O
antibodies	O
were	O
obtained	O
from	O
GeneTex	O
(	O
San	O
Antonio	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Desmin	B
antibodies	O
(	O
clone	O
DE	O
-	O
U-10	O
and	O
Catalog	O
number	O
D8281	O
)	O
,	O
BrdU	O
labeling	O
reagent	O
and	O
FK506	B
(	O
Catalog	O
number	O
F4679	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

Fluorophore	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Alexa	O
Fluor	O
)	O
were	O
obtained	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
.	O

Statistical	O
analysesA	O
minimum	O
of	O
three	O
replicates	O
were	O
undertaken	O
for	O
each	O
experimental	O
condition	O
.	O

Quantified	O
data	O
are	O
presented	O
as	O
means	O
±	O
SE	O
.	O

Significance	O
testing	O
was	O
performed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
anova	O
)	O
to	O
compare	O
data	O
from	O
different	O
experimental	O
groups	O
.	O

P	O
values	O
of	O
<	O
0.05	O
were	O
considered	O
as	O
statistically	O
significant	O
.	O

Mapping	O
sites	O
within	O
the	O
genome	O
that	O
are	O
hypersensitive	O
to	O
digestion	O
with	O
DNaseI	B
is	O
an	O
important	O
method	O
for	O
identifying	O
DNA	O
elements	O
that	O
regulate	O
transcription	O
.	O

The	O
standard	O
approach	O
to	O
locating	O
these	O
DNaseI	B
-	O
hypersensitive	O
sites	O
(	O
DHSs	O
)	O
has	O
been	O
to	O
use	O
Southern	O
blotting	O
techniques	O
,	O
although	O
we	O
,	O
and	O
others	O
,	O
have	O
recently	O
published	O
alternative	O
methods	O
using	O
a	O
range	O
of	O
technologies	O
including	O
high	O
-	O
throughput	O
sequencing	O
and	O
genomic	O
array	O
tiling	O
paths	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
a	O
novel	O
protocol	O
to	O
use	O
real	O
-	O
time	O
PCR	O
to	O
map	O
DHS	O
.	O

Advantages	O
of	O
the	O
technique	O
reported	O
here	O
include	O
the	O
small	O
cell	O
numbers	O
required	O
for	O
each	O
analysis	O
,	O
rapid	O
,	O
relatively	O
low	O
-	O
cost	O
experiments	O
with	O
minimal	O
need	O
for	O
specialist	O
equipment	O
.	O

Presented	O
examples	O
include	O
comparative	O
DHS	O
mapping	O
of	O
known	O
TAL1	B
/	B
SCL	I
regulatory	O
elements	O
between	O
human	O
embryonic	O
stem	O
cells	O
and	O
K562	O
cells	O
.	O

Mapping	O
the	O
location	O
of	O
DNaseI	B
-	O
hypersensitive	O
sites	O
(	O
DHSs	O
)	O
remains	O
central	O
to	O
developing	O
our	O
understanding	O
of	O
transcriptional	O
regulation	O
.	O

Elements	O
with	O
a	O
range	O
of	O
transcriptional	O
regulatory	O
functions	O
have	O
been	O
identified	O
initially	O
as	O
DHSs	O
.	O

These	O
include	O
transcriptional	O
enhancers	O
(	O
1,2	O
)	O
and	O
repressors	O
(	O
3,4	O
)	O
as	O
well	O
as	O
chromatin	O
insulators	O
and	O
barrier	O
elements	O
(	O
5,6	O
)	O
.	O

A	O
number	O
of	O
techniques	O
have	O
been	O
published	O
recently	O
that	O
permit	O
the	O
mapping	O
of	O
DHSs	O
without	O
the	O
need	O
for	O
Southern	O
blotting	O
(	O
7–13	O
)	O
.	O

These	O
include	O
high	O
-	O
throughput	O
sequencing	O
of	O
cloned	O
DNA	O
libraries	O
derived	O
from	O
DNaseI	B
-	O
digested	O
chromatin	O
(	O
8,9	O
)	O
,	O
and	O
a	O
number	O
of	O
different	O
approaches	O
that	O
use	O
genomic	O
tiling	O
path	O
arrays	O
to	O
map	O
DHSs	O
(	O
7,11,13	O
)	O
.	O

While	O
these	O
approaches	O
have	O
the	O
advantage	O
of	O
covering	O
large	O
genomic	O
regions	O
with	O
a	O
limited	O
number	O
of	O
experiments	O
,	O
they	O
are	O
inherently	O
costly	O
and	O
less	O
applicable	O
to	O
the	O
rapid	O
DHS	O
mapping	O
of	O
specific	O
genomic	O
sites	O
in	O
a	O
range	O
of	O
cell	O
types	O
.	O

An	O
alternative	O
approach	O
that	O
does	O
permit	O
the	O
targeted	O
semi	O
-	O
quantitative	O
DHS	O
mapping	O
of	O
specific	O
loci	O
has	O
used	O
quantitative	O
real	O
-	O
time	O
PCR	O
to	O
map	O
sites	O
from	O
digested	O
DNA	O
(	O
10	O
)	O
.	O

This	O
technique	O
depends	O
on	O
the	O
quantification	O
of	O
relative	O
loss	O
of	O
PCR	O
signal	O
observed	O
when	O
PCR	O
primers	O
amplify	O
across	O
regions	O
of	O
digested	O
DNA	O
compared	O
with	O
amplification	O
of	O
undigested	O
DNA	O
.	O

This	O
approach	O
has	O
been	O
reported	O
as	O
showing	O
good	O
sensitivity	O
,	O
but	O
a	O
limitation	O
is	O
the	O
large	O
number	O
of	O
PCR	O
reactions	O
required	O
to	O
quantify	O
the	O
calculated	O
loss	O
of	O
signal	O
with	O
significant	O
certainty	O
.	O

In	O
this	O
article	O
,	O
we	O
present	O
an	O
alternative	O
method	O
to	O
identify	O
DHS	O
using	O
real	O
-	O
time	O
PCR	O
by	O
adapting	O
the	O
protocol	O
we	O
have	O
used	O
to	O
map	O
DHS	O
using	O
genomic	O
tiling	O
path	O
arrays	O
(	O
11	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
the	O
high	O
sensitivity	O
and	O
specificity	O
of	O
the	O
basic	O
protocol	O
with	O
regard	O
to	O
identifying	O
DHS	O
across	O
large	O
genomic	O
regions	O
(	O
11	O
)	O
.	O

Here	O
,	O
we	O
detail	O
the	O
laboratory	O
protocol	O
that	O
permits	O
the	O
rapid	O
comparative	O
mapping	O
of	O
known	O
and	O
candidate	O
DHS	O
between	O
different	O
cell	O
types	O
using	O
real	O
-	O
time	O
PCR	O
.	O

As	O
examples	O
,	O
we	O
include	O
comparative	O
DHS	O
mapping	O
of	O
regulatory	O
elements	O
located	O
across	O
the	O
extended	O
TAL1	B
(	O
T	B
-	I
cell	I
acute	I
lymphocytic	I
leukaemia-1	I
,	O
also	O
known	O
as	O
SCL	B
(	O
stem	B
cell	I
leukaemia	I
)	O
)	O
locus	O
in	O
human	O
embryonic	O
stem	O
(	O
hES	O
)	O
cells	O
and	O
the	O
leukaemia	O
cell	O
line	O
K562	O
.	O

Generating	O
a	O
library	O
of	O
DHSsThe	O
basic	O
protocol	O
is	O
outlined	O
in	O
Figure	O
1	O
.	O

Nuclei	O
are	O
extracted	O
from	O
living	O
cells	O
,	O
then	O
digested	O
on	O
ice	O
for	O
1	O
h	O
with	O
a	O
range	O
of	O
DNaseI	B
concentrations	O
,	O
as	O
detailed	O
in	O
the	O
'	O
Materials	O
and	O
methods	O
'	O
sections	O
.	O

Following	O
RNaseA	B
and	O
proteinaseK	B
treatment	O
,	O
the	O
DNA	O
is	O
extracted	O
and	O
run	O
on	O
a	O
1	O
%	O
agarose	O
gel	O
to	O
check	O
for	O
the	O
size	O
of	O
digested	O
DNA	O
.	O

The	O
gel	O
in	O
Figure	O
1A	O
shows	O
the	O
DNA	O
from	O
mouse	O
thymocyte	O
nuclei	O
digested	O
with	O
0	O
,	O
40	O
and	O
120	O
units	O
of	O
DNaseI.	B
Maximal	O
enrichment	O
at	O
DHS	O
is	O
usually	O
observed	O
with	O
samples	O
that	O
are	O
not	O
over	O
-	O
digested	O
.	O

In	O
the	O
experiment	O
shown	O
,	O
maximal	O
enrichment	O
at	O
a	O
known	O
control	O
DHS	O
was	O
seen	O
with	O
40	O
units	O
DNaseI	B
(	O
real	O
-	O
time	O
PCR	O
quantification	O
shown	O
in	O
Figure	O
2B	O
)	O
.	O

The	O
DNA	O
is	O
then	O
blunt	O
-	O
ended	O
using	O
T4	B
polymerase	I
(	O
Figure	O
1B	O
)	O
and	O
ligated	O
with	O
an	O
asymmetric	O
double	O
-	O
stranded	O
linker	O
.	O

After	O
extraction	O
,	O
DNA	O
is	O
amplified	O
using	O
a	O
biotinylated	O
linker	O
-	O
specific	O
primer	O
and	O
35	O
thermal	O
polymerase	B
cycles	O
,	O
as	O
detailed	O
in	O
'	O
Materials	O
and	O
methods	O
'	O
section	O
.	O

As	O
the	O
linker	O
will	O
ligate	O
to	O
both	O
ends	O
of	O
digested	O
DNA	O
,	O
the	O
amplification	O
will	O
represent	O
a	O
mix	O
of	O
primer	O
extension	O
and	O
PCR	O
,	O
depending	O
on	O
the	O
length	O
of	O
DNA	O
amplified	O
.	O

As	O
has	O
been	O
previously	O
reasoned	O
(	O
13	O
)	O
,	O
one	O
double	O
strand	O
of	O
DNA	O
in	O
a	O
region	O
of	O
DNaseI	B
hypersensitivity	O
is	O
more	O
likely	O
to	O
be	O
digested	O
twice	O
within	O
a	O
short	O
distance	O
than	O
non	O
-	O
hypersensitive	O
DNA	O
.	O

This	O
will	O
lead	O
to	O
the	O
preferential	O
amplification	O
of	O
DNA	O
from	O
regions	O
of	O
DHS	O
.	O

The	O
amplified	O
DNA	O
is	O
then	O
extracted	O
using	O
para	O
-	O
magnetic	O
streptavidin	O
beads	O
,	O
which	O
provides	O
a	O
DNA	O
library	O
representative	O
of	O
whole	O
-	O
genome	O
DHS	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
the	O
DNA	O
recovered	O
from	O
the	O
beads	O
confirms	O
that	O
the	O
vast	O
majority	O
of	O
these	O
products	O
are	O
between	O
300	O
and	O
500	O
base	O
pairs	O
in	O
length	O
(	O
Figure	O
1B	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
quantification	O
of	O
DNA	O
within	O
the	O
DHS	O
libraryFigure	O
2	O
documents	O
the	O
quantification	O
of	O
specific	O
DNA	O
sites	O
from	O
different	O
mouse	O
-	O
cell	O
-	O
derived	O
DNA	O
libraries	O
.	O

Figure	O
2A	O
shows	O
the	O
quantification	O
of	O
material	O
from	O
two	O
primer	O
sets	O
,	O
which	O
are	O
within	O
(	O
primer	O
pair	O
A	O
)	O
and	O
3′	O
(	O
primer	O
pair	O
B	O
)	O
to	O
the	O
mouse	O
Stil	B
promoter	O
.	O

The	O
left	O
-	O
hand	O
panels	O
of	O
Figure	O
2A	O
show	O
the	O
Sybr	O
-	O
green	O
real	O
-	O
time	O
fluorescence	O
profiles	O
using	O
serial	O
5-fold	O
dilutions	O
of	O
quantified	O
mouse	O
genomic	O
DNA	O
standards	O
with	O
primers	O
A	O
and	O
B.	O
A	O
calculated	O
standard	O
curve	O
then	O
permits	O
the	O
quantification	O
of	O
DNA	O
from	O
this	O
sequence	O
in	O
library	O
samples	O
.	O

The	O
right	O
-	O
hand	O
panels	O
of	O
Figure	O
2A	O
show	O
the	O
quantification	O
of	O
samples	O
from	O
0	O
and	O
40	O
units	O
DNaseI	B
-	O
treated	O
material	O
using	O
primers	O
A	O
and	O
B.	O
While	O
there	O
is	O
no	O
difference	O
in	O
amplification	O
between	O
the	O
samples	O
using	O
primer	O
pair	O
B	O
,	O
with	O
primer	O
pair	O
A	O
,	O
the	O
40	O
units	O
DNaseI	B
sample	O
amplifies	O
∼5.5	O
PCR	O
cycles	O
before	O
the	O
0	O
units	O
sample	O
.	O

This	O
equates	O
to	O
greater	O
than	O
40-fold	O
enrichment	O
at	O
the	O
Stil	B
promoter	O
compared	O
with	O
no	O
observed	O
enrichment	O
downstream	O
of	O
the	O
promoter	O
.	O

Figure	O
2B	O
shows	O
the	O
quantifiable	O
differences	O
in	O
enrichment	O
at	O
the	O
porphobilinogen	B
deaminase	I
(	O
Hmbs	B
)	O
promoter	O
between	O
primary	O
mouse	O
thymocytes	O
and	O
the	O
mouse	O
T	O
-	O
cell	O
line	O
BW5147	O
.	O

This	O
representative	O
primary	O
mouse	O
cell	O
experiment	O
was	O
performed	O
with	O
the	O
DNA	O
shown	O
in	O
Figure	O
1A	O
,	O
which	O
confirms	O
that	O
with	O
these	O
cells	O
,	O
maximal	O
enrichment	O
is	O
observed	O
from	O
DNA	O
that	O
is	O
not	O
over	O
-	O
digested	O
.	O

The	O
comparison	O
of	O
the	O
thymocytes	O
with	O
the	O
BW5147	O
cells	O
illustrates	O
another	O
common	O
finding	O
that	O
,	O
in	O
our	O
experience	O
of	O
primary	O
cell	O
experiments	O
,	O
maximal	O
enrichment	O
is	O
often	O
obtained	O
using	O
lower	O
amounts	O
of	O
DNaseI	B
compared	O
with	O
cell	O
lines	O
.	O

Comparison	O
of	O
real	O
-	O
time	O
PCR	O
DHS	O
with	O
Southern	O
blottingAs	O
the	O
protocol	O
generates	O
template	O
by	O
primer	O
extending	O
away	O
from	O
a	O
DNaseI	B
-	O
digestion	O
site	O
,	O
as	O
well	O
as	O
PCR	O
amplification	O
between	O
DNaseI	B
-	O
digestion	O
sites	O
,	O
there	O
is	O
the	O
potential	O
for	O
the	O
genomic	O
size	O
of	O
the	O
real	O
-	O
time	O
DHS	O
to	O
be	O
larger	O
than	O
sites	O
revealed	O
by	O
Southern	O
blotting	O
.	O

There	O
is	O
also	O
potential	O
for	O
signal	O
to	O
be	O
lost	O
at	O
the	O
most	O
'	O
open	O
'	O
stretch	O
of	O
DNA	O
,	O
due	O
to	O
over	O
-	O
digestion	O
with	O
DNaseI.	B
These	O
issues	O
are	O
addressed	O
in	O
Figure	O
3	O
.	O

The	O
upper	O
panel	O
shows	O
a	O
Southern	O
blot	O
of	O
the	O
human	O
STIL	B
(	O
SCL	B
/	O
TAL1	B
interrupting	O
locus	O
)	O
promoter	O
in	O
K562	O
cells	O
.	O

The	O
BglII	B
restricted	O
fragment	O
is	O
probed	O
from	O
the	O
3′	O
end	O
,	O
as	O
shown	O
in	O
the	O
upper	O
panel	O
.	O

This	O
reveals	O
a	O
central	O
DHS	O
∼500	O
bp	O
wide	O
,	O
with	O
a	O
suggestion	O
of	O
weaker	O
hypersensitivity	O
for	O
a	O
few	O
hundred	O
base	O
pairs	O
5′	O
and	O
3′	O
to	O
the	O
central	O
region	O
.	O

The	O
lower	O
panel	O
shows	O
real	O
-	O
time	O
PCR	O
data	O
from	O
K562	O
material	O
using	O
10	O
primer	O
sets	O
,	O
each	O
generating	O
an	O
amplicon	O
∼120	O
bp	O
long	O
.	O

This	O
permits	O
the	O
quantification	O
of	O
enrichments	O
over	O
1200	O
bp	O
,	O
centred	O
around	O
the	O
STIL	B
transcription	O
start	O
site	O
.	O

The	O
lower	O
panel	O
represents	O
the	O
mean	O
±	O
SD	O
enrichment	O
from	O
three	O
independent	O
biological	O
replicates	O
from	O
K562	O
cells	O
.	O

The	O
black	O
bar	O
denotes	O
the	O
location	O
of	O
the	O
'	O
core	O
'	O
hypersensitive	O
site	O
as	O
defined	O
by	O
Southern	O
blotting	O
.	O

There	O
is	O
good	O
correlation	O
between	O
the	O
location	O
of	O
the	O
DHS	O
between	O
the	O
two	O
techniques	O
.	O

The	O
5′	O
extension	O
of	O
enrichment	O
seen	O
in	O
the	O
lower	O
panel	O
appears	O
to	O
reflect	O
the	O
weaker	O
5′	O
extension	O
seen	O
in	O
the	O
Southern	O
blot	O
in	O
the	O
upper	O
panel	O
.	O

A	O
dip	O
in	O
enrichment	O
is	O
observed	O
in	O
the	O
lower	O
panel	O
over	O
the	O
previously	O
mapped	O
transcription	O
-	O
factor	O
-	O
binding	O
sites	O
(	O
14	O
)	O
,	O
which	O
may	O
represent	O
over	O
-	O
digestion	O
of	O
the	O
most	O
accessible	O
core	O
region	O
of	O
the	O
DHS	O
.	O

Quantification	O
of	O
DHS	O
across	O
the	O
TAL1	B
locus	O
in	O
hES	O
and	O
K562	O
cellsAs	O
examples	O
of	O
relative	O
enrichments	O
at	O
different	O
regulatory	O
elements	O
,	O
we	O
present	O
a	O
comparison	O
of	O
enrichments	O
across	O
the	O
extended	O
TAL1	B
locus	O
from	O
human	O
embryonic	O
stem	O
(	O
hES	O
)	O
cells	O
and	O
K562	O
cells	O
in	O
Figure	O
4B	O
.	O

Relative	O
quantification	O
of	O
mRNA	O
expression	O
using	O
real	O
-	O
time	O
PCR	O
shows	O
that	O
both	O
of	O
these	O
cell	O
types	O
express	O
STIL	B
,	O
but	O
only	O
K562	O
cells	O
express	O
TAL1	B
(	O
Figure	O
4A	O
)	O
.	O

TAL1	B
expression	O
is	O
critical	O
to	O
the	O
establishment	O
of	O
haematopoiesis	O
in	O
a	O
developing	O
embryo	O
(	O
15	O
)	O
.	O

Post	O
embryogenesis	O
,	O
TAL1	B
expression	O
is	O
maintained	O
in	O
the	O
non	O
-	O
lymphoid	O
haematopoietic	O
system	O
,	O
although	O
in	O
addition	O
,	O
expression	O
is	O
observed	O
in	O
a	O
range	O
of	O
non	O
-	O
haematopoietic	O
tissues	O
,	O
including	O
endothelium	O
and	O
brain	O
(	O
16–18	O
)	O
.	O

Over	O
the	O
past	O
10	O
years	O
,	O
we	O
and	O
others	O
have	O
dissected	O
the	O
regulatory	O
elements	O
that	O
direct	O
the	O
expression	O
of	O
TAL1	B
to	O
different	O
tissues	O
(	O
11,19–31	O
)	O
.	O

These	O
include	O
the	O
3′	O
haematopoietic	B
stem	I
cell	I
enhancer	I
(	O
+	O
19	O
)	O
(	O
24,30	O
)	O
,	O
the	O
5′	O
endothelial	B
-	I
haematopoietic	I
enhancer	I
(	O
−4	O
)	O
(	O
31	O
)	O
,	O
the	O
3′	O
erythroid	B
enhancer	I
(	O
+	O
40	O
in	O
mouse	O
,	O
+	O
50	O
in	O
human	O
)	O
(	O
28	O
)	O
,	O
and	O
a	O
number	O
of	O
neuronal	O
elements	O
(	O
25,26	O
)	O
.	O

The	O
location	O
of	O
the	O
STIL	B
promoter	O
has	O
been	O
previously	O
mapped	O
(	O
14	O
)	O
,	O
although	O
no	O
other	O
STIL	B
regulatory	O
elements	O
have	O
yet	O
been	O
identified	O
.	O

Figure	O
4B	O
shows	O
the	O
mean	O
±	O
SD	O
ratio	O
(	O
DNaseI	B
-	O
treated	O
enrichment	O
/	O
DNaseI	B
-	O
untreated	O
enrichment	O
)	O
of	O
quantitative	O
enrichments	O
from	O
two	O
independent	O
hES	O
cell	O
biological	O
replicates	O
and	O
two	O
independent	O
K562	O
biological	O
replicates	O
,	O
using	O
primer	O
sets	O
from	O
different	O
locations	O
as	O
indicated	O
in	O
the	O
figure	O
.	O

Primers	O
indicated	O
in	O
red	O
correspond	O
to	O
known	O
regulatory	O
elements	O
.	O

The	O
hES	O
cell	O
cultures	O
were	O
maintained	O
as	O
detailed	O
in	O
methods	O
.	O

Both	O
cell	O
types	O
show	O
significant	O
enrichment	O
at	O
the	O
STIL	B
promoter	O
.	O

Four	O
control	O
regions	O
were	O
selected	O
:	O
−16	O
kb	O
,	O
upstream	O
of	O
TAL1	B
;	O
+	O
5	O
and	O
+	O
22	O
kb	O
,	O
within	O
the	O
TAL1	B
locus	O
;	O
+	O
70	O
kb	O
,	O
downstream	O
of	O
TAL1	B
.	O

These	O
sequences	O
were	O
chosen	O
as	O
control	O
regions	O
as	O
they	O
show	O
limited	O
homology	O
between	O
a	O
number	O
of	O
species	O
(	O
26	O
)	O
and	O
were	O
considered	O
highly	O
unlikely	O
to	O
represent	O
regulatory	O
elements	O
.	O

All	O
four	O
regions	O
showed	O
no	O
enrichments	O
between	O
DNaseI	B
-	O
treated	O
and	O
-untreated	O
samples	O
in	O
either	O
the	O
hES	O
cells	O
or	O
K562	O
cells	O
.	O

The	O
most	O
striking	O
differences	O
between	O
hES	O
cells	O
and	O
K562	O
cells	O
were	O
found	O
at	O
the	O
TAL1	B
regulatory	O
elements	O
.	O

With	O
K562	O
cells	O
,	O
there	O
is	O
prominent	O
enrichment	O
at	O
the	O
TAL1	B
promoter	O
1a	O
,	O
and	O
the	O
−4	O
,	O
+	O
19	O
and	O
+	O
50	O
enhancers	O
.	O

These	O
cells	O
express	O
high	O
levels	O
of	O
TAL1	B
transcripts	O
,	O
and	O
were	O
originally	O
derived	O
from	O
a	O
patient	O
with	O
blastic	O
transformation	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

K562	O
cells	O
are	O
relatively	O
undifferentiated	O
,	O
although	O
they	O
have	O
a	O
partial	O
erythroid	O
phenotype	O
.	O

This	O
potentially	O
explains	O
the	O
marked	O
enrichment	O
seen	O
at	O
the	O
+	B
19	I
stem	I
cell	I
enhancer	I
and	O
the	O
+	B
50	I
erythroid	I
enhancer	I
.	O

This	O
is	O
similar	O
to	O
data	O
obtained	O
from	O
primary	O
mouse	O
erythroid	O
cells	O
(	O
day	O
14.5	O
foetal	O
liver	O
)	O
,	O
which	O
show	O
the	O
highest	O
enrichments	O
at	O
the	O
mouse	B
+	I
40	I
enhancer	I
(	O
homologous	O
to	O
the	O
human	O
+	O
50	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
,	O
the	O
hES	O
cells	O
show	O
markedly	O
reduced	O
enrichment	O
at	O
the	O
TAL1	B
regulatory	O
elements	O
when	O
compared	O
with	O
K562	O
cells	O
.	O

Although	O
there	O
is	O
enrichment	O
at	O
the	O
+	O
50	O
enhancer	O
,	O
there	O
is	O
minimal	O
enrichment	O
at	O
the	O
−4	O
,	O
promoter	O
1A	O
and	O
+	O
19	O
elements	O
.	O

Reduced	O
/	O
absent	O
accessibility	O
of	O
regulatory	O
elements	O
to	O
DNaseI	B
digestion	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
expression	O
of	O
TAL1	B
in	O
hES	O
cells	O
(	O
Figure	O
4A	O
)	O
.	O

As	O
ES	O
cells	O
differentiate	O
to	O
form	O
embryoid	O
bodies	O
,	O
expression	O
of	O
TAL1	B
is	O
rapidly	O
switched	O
on	O
,	O
appearing	O
from	O
day	O
3	O
of	O
mouse	O
ES	O
cell	O
differentiation	O
(	O
32	O
)	O
.	O

The	O
relative	O
accessibility	O
of	O
the	O
+	O
50	O
enhancer	O
may	O
reflect	O
a	O
poised	O
chromatin	O
state	O
in	O
hES	O
cells	O
,	O
which	O
permits	O
a	O
rapid	O
response	O
to	O
the	O
changing	O
transcription	O
factor	O
environment	O
that	O
accompanies	O
differentiation	O
.	O

The	O
development	O
of	O
techniques	O
that	O
permit	O
the	O
rapid	O
comparative	O
mapping	O
of	O
DHS	O
between	O
different	O
cell	O
types	O
will	O
greatly	O
facilitate	O
the	O
study	O
of	O
transcriptional	O
regulation	O
in	O
both	O
normal	O
and	O
diseased	O
cells	O
.	O

Recently	O
published	O
high	O
-	O
throughput	O
techniques	O
that	O
map	O
DHS	O
sites	O
using	O
high	O
-	O
throughput	O
sequencing	O
(	O
8,9	O
)	O
and	O
genomic	O
array	O
tiling	O
paths	O
(	O
7,11,13	O
)	O
have	O
clear	O
advantages	O
of	O
scale	O
over	O
more	O
targeted	O
approaches	O
.	O

Major	O
disadvantages	O
of	O
these	O
approaches	O
include	O
cost	O
and	O
lack	O
of	O
focus	O
.	O

This	O
makes	O
them	O
less	O
suitable	O
for	O
many	O
laboratories	O
that	O
want	O
to	O
assess	O
the	O
chromatin	O
accessibility	O
of	O
a	O
number	O
of	O
defined	O
or	O
presumed	O
regulatory	O
elements	O
in	O
a	O
range	O
of	O
cell	O
types	O
.	O

A	O
real	O
-	O
time	O
-	O
PCR	O
-	O
based	O
approach	O
to	O
DHS	O
mapping	O
has	O
,	O
therefore	O
,	O
a	O
number	O
of	O
potential	O
advantages	O
for	O
researchers	O
interested	O
in	O
specific	O
regulatory	O
questions	O
at	O
defined	O
loci	O
.	O

Real	O
-	O
time	O
PCR	O
is	O
relatively	O
inexpensive	O
compared	O
with	O
the	O
large	O
-	O
scale	O
techniques	O
,	O
and	O
permits	O
a	O
rapid	O
,	O
focused	O
DHS	O
analysis	O
of	O
defined	O
regions	O
of	O
DNA	O
from	O
multiple	O
cell	O
types	O
.	O

It	O
also	O
provides	O
flexibility	O
,	O
as	O
any	O
genomic	O
region	O
can	O
be	O
analysed	O
from	O
the	O
DNA	O
library	O
derived	O
from	O
the	O
DNaseI	B
-	O
treated	O
samples	O
by	O
designing	O
further	O
real	O
-	O
time	O
PCR	O
primer	O
sets	O
.	O

We	O
have	O
previously	O
shown	O
that	O
our	O
basic	O
technique	O
for	O
amplifying	O
a	O
library	O
of	O
DHS	O
generates	O
a	O
template	O
representative	O
of	O
known	O
DHS	O
with	O
excellent	O
sensitivity	O
and	O
specificity	O
(	O
11	O
)	O
.	O

Although	O
the	O
experiments	O
presented	O
in	O
this	O
paper	O
were	O
each	O
performed	O
using	O
5	O
million	O
cells	O
/	O
digestion	O
condition	O
,	O
we	O
have	O
obtained	O
reproducible	O
data	O
using	O
5-fold	O
fewer	O
cells	O
as	O
starting	O
material	O
.	O

We	O
feel	O
our	O
technique	O
can	O
deliver	O
acceptable	O
specificity	O
and	O
sensitivity	O
for	O
DHS	O
mapping	O
with	O
small	O
numbers	O
of	O
cells	O
,	O
and	O
will	O
therefore	O
be	O
of	O
use	O
to	O
those	O
researchers	O
working	O
with	O
limited	O
numbers	O
of	O
primary	O
cells	O
.	O

An	O
alternative	O
approach	O
using	O
real	O
-	O
time	O
PCR	O
to	O
define	O
DHS	O
has	O
been	O
previously	O
published	O
(	O
10	O
)	O
.	O

The	O
two	O
approaches	O
differ	O
in	O
that	O
Dorscher	O
et	O
al.	O
quantify	O
the	O
DHS	O
through	O
the	O
loss	O
of	O
PCR	O
signal	O
obtained	O
from	O
DHS	O
when	O
DNA	O
is	O
digested	O
,	O
whereas	O
our	O
approach	O
uses	O
real	O
-	O
time	O
PCR	O
to	O
quantify	O
a	O
gain	O
of	O
signal	O
observed	O
from	O
DHS	O
.	O

Dorscher	O
et	O
al.	O
report	O
excellent	O
sensitivity	O
using	O
their	O
approach	O
to	O
map	O
DHS	O
.	O

However	O
,	O
the	O
technique	O
depends	O
on	O
large	O
numbers	O
of	O
comparative	O
quantitative	O
real	O
-	O
time	O
PCR	O
reactions	O
across	O
a	O
region	O
in	O
both	O
digested	O
and	O
undigested	O
material	O
,	O
in	O
order	O
to	O
quantify	O
the	O
loss	O
of	O
enrichment	O
.	O

One	O
advantage	O
of	O
our	O
technique	O
published	O
here	O
is	O
that	O
data	O
can	O
be	O
obtained	O
using	O
far	O
fewer	O
quantitative	O
PCR	O
reactions	O
.	O

The	O
technique	O
is	O
highly	O
reproducible	O
,	O
with	O
relatively	O
little	O
variation	O
in	O
quantifiable	O
enrichments	O
observed	O
between	O
different	O
biological	O
replicates	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
tissue	O
specificity	O
,	O
with	O
variable	O
enrichment	O
at	O
known	O
regulatory	O
elements	O
between	O
different	O
cell	O
types	O
.	O

The	O
technique	O
published	O
here	O
permits	O
the	O
rapid	O
comparative	O
analysis	O
of	O
DHS	O
between	O
different	O
cell	O
types	O
from	O
relatively	O
small	O
numbers	O
of	O
cells	O
.	O

It	O
will	O
have	O
potential	O
use	O
for	O
researchers	O
across	O
a	O
broad	O
spectrum	O
of	O
biology	O
for	O
the	O
study	O
of	O
transcriptional	O
regulation	O
in	O
both	O
healthy	O
and	O
diseased	O
tissues	O
.	O

Cell	O
cultureCell	O
lines	O
were	O
maintained	O
in	O
culture	O
as	O
previously	O
described	O
(	O
11	O
)	O
.	O

Care	O
was	O
taken	O
to	O
ensure	O
maximum	O
viability	O
of	O
cells	O
when	O
taken	O
for	O
experiments	O
.	O

The	O
primary	O
thymocytes	O
used	O
for	O
Figure	O
2	O
were	O
prepared	O
by	O
gentle	O
physical	O
disassociation	O
of	O
a	O
whole	O
thymus	O
gland	O
into	O
PBS	O
supplemented	O
with	O
2	O
%	O
FCS	O
.	O

Cells	O
were	O
filtered	O
to	O
ensure	O
that	O
a	O
single	O
-	O
cell	O
suspension	O
was	O
taken	O
forward	O
for	O
nuclei	O
isolation	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hES	O
)	O
were	O
grown	O
in	O
chemically	O
defined	O
media	O
in	O
the	O
presence	O
of	O
Activin	B
and	O
FGF2	B
,	O
as	O
detailed	O
previously	O
(	O
33	O
)	O
.	O

In	O
these	O
conditions	O
,	O
hES	O
cells	O
remain	O
homogenously	O
undifferentiated	O
.	O

Nuclei	O
preparationUp	O
to	O
3	O
×	O
107	O
cells	O
were	O
washed	O
in	O
ice	O
-	O
cold	O
PBS	O
and	O
resuspended	O
in	O
2	O
ml	O
of	O
ice	O
-	O
cold	O
cell	O
lysis	O
buffer	O
[	O
300	O
mM	O
sucrose	O
,	O
10	O
mM	O
Tris	O
pH	O
7.4	O
,	O
15	O
mM	O
NaCl	O
,	O
5	O
mM	O
MgCl	O
,	O
0.1	O
mM	O
EGTA	O
,	O
60	O
mM	O
KCl	O
,	O
0.2	O
%	O
NP-40	O
,	O
0.5	O
mM	O
DTT	O
,	O
0.5	O
μM	O
spermidine	O
,	O
1	O
×	O
protease	B
inhibitor	O
(	O
complete	O
,	O
Roche	O
)	O
]	O
.	O

After	O
5	O
min	O
,	O
the	O
lysed	O
cells	O
were	O
spun	O
at	O
500	O
g	O
for	O
5	O
min	O
at	O
4	O
°	O
C	O
with	O
brakes	O
off	O
.	O

After	O
careful	O
removal	O
of	O
supernatant	O
,	O
the	O
nuclei	O
were	O
gently	O
resuspended	O
in	O
200	O
μl	O
of	O
ice	O
-	O
cold	O
reaction	O
buffer	O
(	O
20	O
μl	O
10	O
×	O
DNaseI	B
buffer	O
,	O
4	O
μl	O
glycerol	O
,	O
176	O
μl	O
water	O
)	O
using	O
pipette	O
tips	O
with	O
cut	O
off	O
ends	O
.	O

The	O
nuclei	O
were	O
spun	O
again	O
at	O
500	O
g	O
for	O
5	O
min	O
at	O
4	O
°	O
C	O
and	O
,	O
following	O
supernatant	O
removal	O
,	O
were	O
resuspended	O
in	O
30	O
μl	O
of	O
reaction	O
buffer	O
per	O
DNaseI	B
condition	O
.	O

For	O
example	O
,	O
if	O
2	O
×	O
107	O
cells	O
were	O
taken	O
to	O
look	O
at	O
four	O
different	O
conditions	O
(	O
e.g.	O
0	O
,	O
20	O
,	O
60	O
,	O
120	O
units	O
DNaseI	B
)	O
,	O
the	O
nuclei	O
were	O
resuspended	O
in	O
120	O
μl	O
of	O
reaction	O
buffer	O
.	O

Separate	O
30	O
μl	O
aliquots	O
were	O
then	O
taken	O
and	O
gently	O
mixed	O
with	O
70	O
μl	O
of	O
DNaseI	B
mix	O
(	O
see	O
Table	O
1	O
)	O
on	O
ice	O
.	O

This	O
made	O
a	O
final	O
digestion	O
volume	O
of	O
100	O
μl	O
for	O
each	O
sample	O
,	O
which	O
was	O
left	O
to	O
incubate	O
for	O
1	O
h	O
on	O
ice	O
in	O
the	O
cold	O
room	O
.	O

After	O
1	O
h	O
,	O
700	O
μl	O
of	O
nuclei	O
lysis	O
buffer	O
(	O
100	O
mM	O
tris	O
HCL	O
pH	O
8	O
,	O
5	O
mM	O
EDTA	O
pH	O
8	O
,	O
200	O
mM	O
NaCl	O
,	O
0.2	O
%	O
SDS	O
)	O
was	O
added	O
to	O
each	O
sample	O
with	O
50	O
μg	O
proteinase	B
K.	I
Following	O
gentle	O
mixing	O
with	O
inversion	O
,	O
the	O
lysed	O
samples	O
were	O
incubated	O
at	O
55	O
°	O
C	O
for	O
1	O
h.	O
RNaseA	B
(	O
10	O
μg	O
(	O
Ambion	O
)	O
)	O
was	O
then	O
added	O
to	O
each	O
sample	O
and	O
further	O
incubated	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
.	O

DNA	O
was	O
then	O
extracted	O
using	O
standard	O
phenol	O
–	O
chloroform	O
techniques	O
.	O

Care	O
was	O
taken	O
to	O
use	O
cut	O
-	O
off	O
tips	O
and	O
very	O
gentle	O
pipetting	O
to	O
reduce	O
non	O
-	O
specific	O
DNA	O
sheering	O
.	O

Following	O
precipitation	O
,	O
DNA	O
was	O
resuspended	O
in	O
200	O
μl	O
of	O
0.1	O
TE	O
and	O
quantified	O
using	O
spectophotometry	O
.	O

Samples	O
(	O
1	O
μg	O
)	O
were	O
analysed	O
using	O
gel	O
-	O
electrophoresis	O
,	O
as	O
shown	O
in	O
Figure	O
1A	O
.	O

DNA	O
library	O
preparationFollowing	O
quantification	O
,	O
7.5	O
μg	O
of	O
DNA	O
was	O
taken	O
for	O
each	O
sample	O
condition	O
.	O

This	O
was	O
blunt	O
-	O
ended	O
using	O
T4	B
polymerase	I
(	O
10	O
μl	O
10	O
×	O
buffer	O
,	O
0.5	O
μl	O
25	O
mM	O
dNTP	O
,	O
3	O
μl	O
BSA	O
,	O
1	O
μl	O
T4	B
polymerase	I
(	O
3	O
U	O
/	O
μl	O
NE	O
Biolabs	O
)	O
,	O
85.5	O
μl	O
of	O
water	O
/	O
DNA	O
in	O
0.1	O
TE	O
)	O
.	O

The	O
samples	O
were	O
mixed	O
gently	O
on	O
ice	O
,	O
then	O
put	O
at	O
12	O
°	O
C	O
for	O
16	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
with	O
excess	O
EDTA	O
(	O
4	O
μl	O
0.5	O
M	O
)	O
followed	O
by	O
75	O
°	O
C	O
for	O
10	O
min	O
.	O

The	O
DNA	O
was	O
further	O
extracted	O
using	O
phenol	O
–	O
chloroform	O
and	O
precipitated	O
with	O
ethanol	O
.	O

Glycogen	O
carrier	O
(	O
5	O
μg	O
)	O
was	O
used	O
at	O
this	O
stage	O
,	O
and	O
the	O
pellet	O
resuspended	O
in	O
80	O
μl	O
water	O
.	O

The	O
blunt	O
-	O
ended	O
DNA	O
was	O
then	O
ligated	O
to	O
the	O
LP21–25	O
linker	O
.	O

A	O
stock	O
of	O
linker	O
was	O
prepared	O
by	O
mixing	O
80	O
μl	O
LP21	O
(	O
100	O
μM	O
:	O
GAATTCAGATCTCCCGGGTCA	O
)	O
with	O
80	O
μl	O
LP25	O
(	O
100	O
μM	O
:	O
GCGGTGACCCGGGAGATCTG	O
AATTC	O
)	O
and	O
240	O
μl	O
water	O
.	O

The	O
mix	O
was	O
then	O
placed	O
on	O
a	O
95	O
°	O
C	O
hot	O
block	O
and	O
the	O
power	O
supply	O
turned	O
off	O
.	O

When	O
the	O
block	O
had	O
cooled	O
to	O
room	O
temperature	O
,	O
the	O
LP21–25	O
linker	O
was	O
aliquoted	O
and	O
frozen	O
.	O

The	O
80	O
μl	O
DNA	O
sample	O
was	O
split	O
into	O
two	O
samples	O
for	O
ligation	O
(	O
5	O
μl	O
10	O
×	O
buffer	O
,	O
3	O
μl	O
LP21–25	O
linker	O
,	O
3	O
μl	O
ligase	O
(	O
NE	O
biolabs	O
400	O
U	O
/	O
μl	O
and	O
39	O
μl	O
DNA	O
)	O
.	O

This	O
was	O
mixed	O
well	O
with	O
a	O
pipette	O
and	O
left	O
at	O
16	O
°	O
C	O
overnight	O
.	O

Following	O
ligation	O
,	O
the	O
DNA	O
was	O
precipitated	O
with	O
ethanol	O
,	O
and	O
resuspended	O
in	O
42	O
μl	O
water	O
.	O

The	O
sample	O
was	O
amplified	O
using	O
Vent	B
exo	I
-	I
polymerase	I
and	O
a	O
biotinylated	O
LP25	O
primer	O
.	O

The	O
mix	O
(	O
5	O
μl	O
ThermoPol	O
10	O
×	O
buffer	O
,	O
0.5	O
μl	O
B	O
-	O
LP25	O
(	O
200	O
μM	O
)	O
,	O
2	O
μl	O
Vent	O
exo-	O
(	O
NE	O
Biolabs	O
2	O
U	O
/	O
μl	O
)	O
,	O
1	O
μl	O
dNTP	O
(	O
25	O
mM	O
)	O
and	O
41.5	O
μl	O
DNA	O
)	O
was	O
amplified	O
with	O
the	O
following	O
thermal	O
cycle	O
:	O
(	O
95	O
°	O
C	O
3	O
min	O
,	O
95	O
°	O
C	O
30	O
s	O
,	O
61	O
°	O
C	O
30	O
s	O
,	O
72	O
°	O
C	O
30	O
s	O
)	O
×	O
35	O
cycles	O
.	O

Following	O
amplification	O
,	O
the	O
biotinylated	O
products	O
were	O
extracted	O
using	O
Dynal	O
streptavidin	O
beads	O
.	O

For	O
each	O
sample	O
,	O
30	O
μl	O
of	O
beads	O
(	O
Dyabeads	O
M-270	O
;	O
Dynal	O
biotech	O
)	O
were	O
washed	O
twice	O
in	O
2	O
×	O
binding	O
buffer	O
(	O
10	O
mM	O
Tris	O
HCL	O
pH7.5	O
,	O
1	O
mM	O
EDTA	O
,	O
2	O
M	O
NaCl	O
)	O
using	O
a	O
magnet	O
,	O
and	O
then	O
resuspended	O
in	O
50	O
μl	O
of	O
2	O
×	O
binding	O
buffer	O
/	O
sample	O
.	O

Each	O
post	O
amplification	O
sample	O
(	O
50	O
μl	O
)	O
was	O
then	O
mixed	O
with	O
50	O
μl	O
of	O
resuspended	O
beads	O
and	O
incubated	O
at	O
room	O
temperature	O
on	O
a	O
rotator	O
for	O
1	O
h.	O
After	O
binding	O
,	O
the	O
samples	O
were	O
washed	O
twice	O
with	O
2	O
×	O
binding	O
buffer	O
,	O
then	O
once	O
with	O
1	O
×	O
TE	O
.	O

After	O
the	O
last	O
wash	O
,	O
each	O
sample	O
was	O
resuspended	O
in	O
30	O
μl	O
0.1	O
TE	O
.	O

The	O
paired	O
samples	O
that	O
were	O
split	O
before	O
ligation	O
were	O
then	O
pooled	O
,	O
making	O
a	O
60	O
μl	O
final	O
aliquot	O
.	O

This	O
was	O
heated	O
at	O
95	O
°	O
C	O
for	O
10	O
min	O
to	O
free	O
the	O
DNA	O
from	O
the	O
beads	O
,	O
and	O
then	O
stored	O
at	O
4	O
°	O
C	O
.	O

Real	O
-	O
time	O
PCR	O
quantificationWe	O
have	O
used	O
Stratagene	O
Brilliant	O
SYBR	O
Green	O
QPCR	O
Master	O
Mix	O
as	O
our	O
standard	O
kit	O
for	O
quantification	O
of	O
genomic	O
controls	O
and	O
samples	O
.	O

We	O
have	O
used	O
a	O
range	O
of	O
primer	O
sets	O
.	O

The	O
HMBS	O
primers	O
are	O
:	O
human	O
—	O
Forward	O
;	O
ATGCTGCCTATTTCAAGGTTGT	O
,	O
Reverse	O
;	O
GAATT	O
GGAACATTGCGACAGT	O
,	O
and	O
mouse	O
—	O
Forward	O
;	O
CGGAGTCATGTCCGGTAAC	O
,	O
Reverse	O
;	O
CGACCAA	O
TAGACGACGAGAA	O
.	O

Primers	O
from	O
the	O
TAL1	B
locus	O
(	O
human	O
and	O
mouse	O
)	O
are	O
available	O
on	O
request	O
.	O

Amplification	O
conditions	O
and	O
PCR	O
mixes	O
were	O
as	O
recommended	O
by	O
Stratagene	O
.	O

Genomic	O
standard	O
curves	O
were	O
calculated	O
for	O
each	O
primer	O
using	O
serial	O
5-fold	O
dilutions	O
from	O
50	O
ng	O
genomic	O
DNA	O
/	O
PCR	O
reaction	O
.	O

For	O
each	O
sample	O
PCR	O
,	O
a	O
45	O
μl	O
stock	O
was	O
made	O
using	O
1.3	O
μl	O
of	O
sample	O
DNA	O
+	O
43.7	O
μl	O
water	O
.	O

This	O
stock	O
was	O
used	O
as	O
5	O
μl	O
per	O
real	O
-	O
time	O
PCR	O
reaction	O
,	O
and	O
following	O
amplification	O
,	O
quantified	O
relative	O
to	O
the	O
genomic	O
DNA	O
standard	O
curve	O
,	O
for	O
each	O
primer	O
set	O
.	O

The	O
quantifications	O
shown	O
in	O
Figure	O
3	O
represent	O
the	O
absolute	O
quantification	O
of	O
DNA	O
at	O
each	O
primer	O
set	O
for	O
the	O
5	O
μl	O
PCR	O
sample	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
TAL1	B
and	O
STIL	B
in	O
Figure	O
4A	O
were	O
normalised	O
relative	O
to	O
β	B
-	I
actin	I
and	O
plotted	O
relative	O
to	O
mRNA	O
expression	O
from	O
normal	O
human	O
donor	O
CD34	B
+	O
cells	O
,	O
as	O
described	O
previously	O
(	O
11	O
)	O
.	O

BackgroundMuch	O
of	O
our	O
current	O
knowledge	O
of	O
the	O
molecular	O
expression	O
profile	O
of	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
is	O
based	O
on	O
transcriptional	O
approaches	O
.	O

These	O
analyses	O
are	O
only	O
partly	O
predictive	O
of	O
protein	O
expression	O
however	O
,	O
and	O
do	O
not	O
shed	O
light	O
on	O
post	O
-	O
translational	O
regulation	O
,	O
leaving	O
a	O
large	O
gap	O
in	O
our	O
knowledge	O
of	O
the	O
biology	O
of	O
pluripotent	O
stem	O
cells	O
.	O

ResultsHere	O
we	O
describe	O
the	O
use	O
of	O
two	O
large	O
-	O
scale	O
western	O
blot	O
assays	O
to	O
identify	O
over	O
600	O
proteins	O
expressed	O
in	O
undifferentiated	O
hESCs	O
,	O
and	O
highlight	O
over	O
40	O
examples	O
of	O
multiple	O
gel	O
mobility	O
variants	O
,	O
which	O
are	O
suspected	O
protein	O
isoforms	O
and/or	O
post	O
-	O
translational	O
modifications	O
.	O

Twenty	O
-	O
two	O
phosphorylation	O
events	O
in	O
cell	O
signaling	O
molecules	O
,	O
as	O
well	O
as	O
potential	O
new	O
markers	O
of	O
undifferentiated	O
hESCs	O
were	O
also	O
identified	O
.	O

We	O
confirmed	O
the	O
expression	O
of	O
a	O
subset	O
of	O
the	O
identified	O
proteins	O
by	O
immunofluorescence	O
and	O
correlated	O
the	O
expression	O
of	O
transcript	O
and	O
protein	O
for	O
key	O
molecules	O
in	O
active	O
signaling	O
pathways	O
in	O
hESCs	O
.	O

These	O
analyses	O
also	O
indicated	O
that	O
hESCs	O
exhibit	O
several	O
features	O
of	O
polarized	O
epithelia	O
,	O
including	O
expression	O
of	O
tight	O
junction	O
proteins	O
.	O

ConclusionOur	O
approach	O
complements	O
proteomic	O
and	O
transcriptional	O
analysis	O
to	O
provide	O
unique	O
information	O
on	O
human	O
pluripotent	O
stem	O
cells	O
,	O
and	O
is	O
a	O
framework	O
for	O
the	O
continued	O
analyses	O
of	O
self	O
-	O
renewal	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
pluripotent	O
cells	O
isolated	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
[	O
1	O
]	O
.	O

They	O
can	O
be	O
maintained	O
for	O
prolonged	O
periods	O
in	O
culture	O
and	O
differentiate	O
to	O
representatives	O
of	O
the	O
three	O
germ	O
layers	O
as	O
well	O
as	O
trophoblasts	O
and	O
germ	O
cells	O
.	O

This	O
differentiation	O
potential	O
may	O
be	O
used	O
to	O
model	O
certain	O
aspects	O
of	O
human	O
embryogenesis	O
,	O
including	O
the	O
development	O
and	O
differentiation	O
of	O
pluripotent	O
and	O
other	O
stem	O
cell	O
types	O
during	O
the	O
processes	O
of	O
gastrulation	O
,	O
neurogenesis	O
and	O
organogenesis	O
.	O

Thus	O
,	O
hESCs	O
provide	O
a	O
unique	O
and	O
powerful	O
system	O
to	O
study	O
otherwise	O
intractable	O
aspects	O
of	O
human	O
development	O
.	O

Furthermore	O
,	O
these	O
approaches	O
have	O
the	O
potential	O
to	O
provide	O
differentiated	O
cell	O
types	O
for	O
cell	O
replacement	O
therapies	O
of	O
degenerative	O
disorders	O
such	O
as	O
Parkinson	O
's	O
disease	O
and	O
Type	O
I	O
diabetes	O
[	O
2,3	O
]	O
.	O

Before	O
these	O
cell	O
therapy	O
applications	O
are	O
developed	O
,	O
an	O
understanding	O
of	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
that	O
drive	O
self	O
-	O
renewal	O
and	O
differentiation	O
is	O
required	O
.	O

Fundamental	O
to	O
this	O
understanding	O
is	O
the	O
elucidation	O
of	O
the	O
transcriptome	O
and	O
proteome	O
of	O
hESCs	O
,	O
using	O
approaches	O
that	O
lay	O
a	O
framework	O
for	O
functional	O
analyses	O
of	O
the	O
unique	O
properties	O
of	O
these	O
cells	O
.	O

Large	O
-	O
scale	O
gene	O
expression	O
analyses	O
such	O
as	O
microarray	O
,	O
massive	O
parallel	O
signature	O
sequencing	O
(	O
MPSS	O
)	O
,	O
expressed	O
sequenced	O
tag	O
(	O
EST	O
)	O
enumeration	O
,	O
and	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
have	O
been	O
used	O
to	O
compare	O
multiple	O
hESC	O
lines	O
[	O
4	O
-	O
7	O
]	O
;	O
hESCs	O
to	O
germ	O
cell	O
tumors	O
[	O
8	O
]	O
;	O
or	O
to	O
differentiated	O
derivatives	O
in	O
embryoid	O
bodies	O
[	O
9	O
-	O
11	O
]	O
or	O
neural	O
populations	O
[	O
12	O
]	O
.	O

These	O
approaches	O
have	O
highlighted	O
an	O
expanded	O
set	O
of	O
transcripts	O
that	O
mark	O
the	O
pluripotent	O
state	O
[	O
4,13,14	O
]	O
,	O
cross	O
-	O
species	O
commonalities	O
in	O
the	O
molecular	O
profile	O
of	O
ESCs	O
[	O
6,12,15	O
]	O
,	O
prominent	O
receptors	O
expressed	O
by	O
hESCs	O
[	O
8	O
]	O
and	O
pathways	O
that	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
pluripotency	O
[	O
16,17	O
]	O
.	O

Nevertheless	O
,	O
cataloguing	O
the	O
cellular	O
transcriptome	O
is	O
only	O
predictive	O
of	O
protein	O
expression	O
and	O
typically	O
does	O
not	O
shed	O
light	O
on	O
post	O
-	O
transcriptional	O
regulation	O
.	O

For	O
example	O
,	O
while	O
tens	O
of	O
thousands	O
of	O
transcripts	O
can	O
be	O
followed	O
simultaneously	O
with	O
SAGE	O
,	O
microarrays	O
and	O
MPSS	O
,	O
these	O
methods	O
do	O
not	O
routinely	O
detect	O
differences	O
in	O
transcript	O
splice	O
variants	O
,	O
or	O
polyadenylation	O
status	O
.	O

These	O
differences	O
may	O
have	O
profound	O
effects	O
on	O
translation	O
,	O
as	O
well	O
as	O
the	O
isoform	O
and	O
function	O
of	O
the	O
protein	O
produced	O
.	O

Finally	O
,	O
numerous	O
post	O
-	O
translational	O
modifications	O
are	O
known	O
to	O
regulate	O
protein	O
function	O
,	O
including	O
enzymatic	O
cleavage	O
,	O
covalent	O
coupling	O
to	O
other	O
molecules	O
,	O
glycosylation	O
,	O
phosphorylation	O
and	O
ubiquitination	O
.	O

These	O
issues	O
all	O
highlight	O
potential	O
shortfalls	O
in	O
our	O
understanding	O
of	O
the	O
hESC	O
proteome	O
.	O

Several	O
practical	O
approaches	O
for	O
proteomic	O
analyses	O
are	O
currently	O
available	O
,	O
the	O
most	O
established	O
of	O
which	O
is	O
the	O
2-dimensional	O
(	O
2D	O
)	O
separation	O
of	O
proteins	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
.	O

HPLC	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
HPLC	O
-	O
MS	O
/	O
MS	O
)	O
based	O
technology	O
is	O
rapidly	O
evolving	O
and	O
has	O
recently	O
been	O
used	O
to	O
detect	O
protein	O
expression	O
in	O
multiple	O
cell	O
types	O
.	O

An	O
alternate	O
approach	O
is	O
the	O
recent	O
large	O
-	O
scale	O
adaptation	O
of	O
standard	O
western	O
blotting	O
[	O
18	O
]	O
.	O

In	O
this	O
procedure	O
,	O
a	O
large	O
well	O
is	O
used	O
to	O
separate	O
the	O
sample	O
by	O
PAGE	O
and	O
lanes	O
are	O
created	O
on	O
the	O
membrane	O
containing	O
immobilized	O
protein	O
with	O
the	O
use	O
of	O
a	O
manifold	O
.	O

Compatible	O
combinations	O
of	O
primary	O
antibodies	O
are	O
predetermined	O
,	O
with	O
the	O
criterion	O
of	O
being	O
able	O
to	O
identify	O
proteins	O
that	O
do	O
not	O
co	O
-	O
migrate	O
.	O

Different	O
combinations	O
of	O
primary	O
antibodies	O
are	O
added	O
to	O
each	O
well	O
,	O
with	O
appropriate	O
dilutions	O
of	O
each	O
primary	O
antibody	O
so	O
that	O
expressed	O
proteins	O
are	O
detected	O
in	O
a	O
single	O
condition	O
.	O

The	O
scalability	O
of	O
the	O
system	O
depends	O
on	O
defining	O
suitable	O
combinations	O
of	O
primary	O
antibodies	O
,	O
with	O
up	O
to	O
1000	O
antibodies	O
in	O
200	O
lanes	O
being	O
used	O
in	O
the	O
largest	O
screens	O
thus	O
far	O
.	O

Detection	O
software	O
is	O
used	O
to	O
identify	O
proteins	O
based	O
on	O
their	O
expected	O
and	O
observed	O
gel	O
mobility	O
.	O

Unlike	O
2D	O
PAGE	O
and	O
HPLC	O
-	O
MS	O
/	O
MS	O
,	O
large	O
-	O
scale	O
western	O
blotting	O
only	O
identifies	O
proteins	O
for	O
which	O
antibodies	O
are	O
already	O
available	O
.	O

While	O
this	O
is	O
not	O
an	O
appropriate	O
screen	O
for	O
identifying	O
uncharacterized	O
proteins	O
,	O
it	O
greatly	O
simplifies	O
the	O
verification	O
and	O
functional	O
analyses	O
of	O
proteins	O
that	O
are	O
detected	O
.	O

In	O
addition	O
,	O
this	O
approach	O
is	O
highly	O
flexible	O
,	O
and	O
if	O
desired	O
can	O
be	O
focused	O
to	O
particular	O
sets	O
of	O
proteins	O
or	O
protein	O
function	O
,	O
such	O
as	O
cell	O
signaling	O
molecules	O
.	O

Importantly	O
,	O
the	O
foundation	O
of	O
this	O
approach	O
is	O
the	O
large	O
amount	O
of	O
data	O
on	O
individual	O
antibodies	O
,	O
which	O
are	O
already	O
available	O
and	O
characterized	O
in	O
the	O
literature	O
.	O

More	O
recently	O
,	O
two	O
research	O
groups	O
have	O
conducted	O
proteomic	O
analyses	O
of	O
hESCs	O
using	O
MS	O
[	O
19	O
-	O
22	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
two	O
large	O
-	O
scale	O
western	O
blot	O
systems	O
to	O
examine	O
the	O
expression	O
of	O
>	O
1000	O
proteins	O
in	O
hESCs	O
and	O
detected	O
>	O
600	O
proteins	O
that	O
were	O
grouped	O
into	O
18	O
functional	O
classes	O
.	O

In	O
addition	O
,	O
we	O
identified	O
42	O
examples	O
of	O
multiple	O
bands	O
for	O
a	O
single	O
protein	O
,	O
likely	O
to	O
be	O
protein	O
isoforms	O
and/or	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
22	O
phosphorylation	O
events	O
in	O
cell	O
signaling	O
molecules	O
.	O

We	O
correlated	O
the	O
expression	O
of	O
members	O
of	O
key	O
active	O
pathways	O
in	O
our	O
transcriptional	O
and	O
proteomic	O
databases	O
and	O
confirmed	O
the	O
validity	O
of	O
this	O
approach	O
.	O

Using	O
these	O
approaches	O
we	O
identified	O
new	O
markers	O
for	O
undifferentiated	O
hESCs	O
and	O
highlighted	O
unrecognized	O
epithelial	O
characteristics	O
of	O
hESCs	O
.	O

Our	O
data	O
confirm	O
the	O
importance	O
of	O
proteomic	O
analyses	O
in	O
complementing	O
transcriptional	O
profiling	O
and	O
provide	O
a	O
framework	O
for	O
continued	O
analyses	O
of	O
the	O
molecular	O
and	O
cellular	O
biology	O
of	O
pluirpotent	O
hESCs	O
.	O

PowerBlot	O
analysis	O
of	O
hESCsWe	O
first	O
employed	O
a	O
large	O
-	O
scale	O
western	O
blot	O
screen	O
,	O
the	O
PowerBlot	O
system	O
,	O
to	O
profile	O
protein	O
expression	O
in	O
undifferentiated	O
hESCs	O
.	O

This	O
system	O
used	O
934	O
antibodies	O
toward	O
proteins	O
representing	O
22	O
diverse	O
classes	O
of	O
function	O
,	O
such	O
as	O
transcription	O
factors	O
,	O
the	O
MAP	B
kinase	I
(	O
MAPK	B
)	O
pathway	O
,	O
and	O
apoptosis	O
,	O
among	O
others	O
.	O

To	O
expand	O
a	O
large	O
-	O
scale	O
culture	O
of	O
BG01	O
cells	O
for	O
this	O
assay	O
,	O
a	O
collagenase-	B
and	O
trypsin-	B
based	O
passaging	O
method	O
was	O
used	O
[	O
23	O
]	O
.	O

While	O
these	O
conditions	O
have	O
been	O
associated	O
with	O
the	O
accumulation	O
of	O
trisomies	O
of	O
chromosomes	O
12	O
,	O
17	O
and	O
X	O
[	O
24	O
]	O
,	O
the	O
ease	O
of	O
use	O
of	O
these	O
cultures	O
and	O
similarity	O
in	O
gene	O
expression	O
and	O
differentiation	O
potential	O
to	O
karyotypically	O
normal	O
BG01	O
hESCs	O
[	O
11,24,25	O
]	O
make	O
them	O
suitable	O
for	O
such	O
large	O
scale	O
applications	O
.	O

For	O
the	O
PowerBlot	O
screen	O
,	O
whole	O
cell	O
lysate	O
from	O
BG01	O
hESCs	O
was	O
separated	O
on	O
five	O
4–15	O
%	O
gradient	O
gels	O
.	O

Each	O
blot	O
contained	O
size	O
markers	O
and	O
39	O
lanes	O
.	O

Each	O
lane	O
was	O
screened	O
with	O
1–8	O
antibodies	O
in	O
combinations	O
that	O
had	O
been	O
predetermined	O
to	O
enable	O
accurate	O
identification	O
of	O
well	O
-	O
separated	O
proteins	O
(	O
Fig.	O
1A	O
–	O
E	O
)	O
.	O

The	O
gels	O
and	O
blots	O
were	O
performed	O
in	O
duplicate	O
and	O
expressed	O
proteins	O
were	O
identified	O
by	O
their	O
predicted	O
size	O
and	O
verified	O
by	O
visual	O
inspection	O
.	O

Figure	O
1PowerBlot	O
analysis	O
of	O
undifferentiated	O
BG01	O
hESCs	O
.	O

This	O
large	O
-	O
scale	O
western	O
blot	O
consisted	O
of	O
five	O
gels	O
run	O
in	O
duplicate	O
and	O
probed	O
with	O
934	O
antibodies	O
.	O

(	O
A	O
-	O
E	O
)	O
One	O
set	O
of	O
blots	O
is	O
shown	O
at	O
a	O
contrast	O
that	O
highlights	O
most	O
bands	O
.	O

(	O
F	O
)	O
A	O
representative	O
lane	O
(	O
gel	O
C	O
,	O
lane	O
24	O
)	O
aligned	O
with	O
protein	O
markers	O
used	O
for	O
band	O
identification	O
.	O

(	O
G	O
)	O
Scatter	O
-	O
plot	O
of	O
the	O
normalized	O
average	O
intensity	O
(	O
i.u	O
.	O
)	O
values	O
for	O
each	O
protein	O
indicating	O
a	O
linear	O
relationship	O
between	O
duplicate	O
blots	O
.	O

Datasets	O
for	O
this	O
analysis	O
are	O
in	O
Additional	O
Tables	O
1	O
and	O
2.A	O
total	O
of	O
545	O
antibodies	O
detected	O
bands	O
of	O
appropriate	O
size	O
,	O
which	O
could	O
be	O
compressed	O
to	O
529	O
proteins	O
with	O
unique	O
SwissProt	O
identification	O
numbers	O
(	O
Fig.	O
1A	O
–	O
E	O
and	O
Additional	O
File	O
1	O
)	O
.	O

An	O
enlargement	O
of	O
a	O
representative	O
lane	O
(	O
lane	O
24	O
of	O
Blot	O
C	O
)	O
alongside	O
protein	O
markers	O
is	O
shown	O
in	O
Fig.	O
1F	O
.	O

Thirteen	O
proteins	O
including	O
AKT	B
,	O
caveolin1	B
and	O
ERK1	B
were	O
detected	O
in	O
multiple	O
lanes	O
using	O
the	O
same	O
or	O
different	O
antibodies	O
.	O

Information	O
on	O
the	O
antibody	O
catalogue	O
number	O
and	O
dilution	O
,	O
band	O
intensity	O
for	O
each	O
repeat	O
and	O
the	O
averaged	O
value	O
,	O
description	O
of	O
protein	O
function	O
,	O
and	O
Entrez	O
gene	O
and	O
SwissProt	O
database	O
identification	O
numbers	O
is	O
shown	O
in	O
Additional	O
File	O
1	O
.	O

Three	O
hundred	O
and	O
eighty	O
three	O
antibodies	O
did	O
not	O
detect	O
bands	O
in	O
this	O
screen	O
,	O
indicating	O
lack	O
of	O
expression	O
,	O
or	O
possibly	O
technical	O
issues	O
with	O
detection	O
under	O
standard	O
conditions	O
(	O
Additional	O
File	O
1	O
)	O
.The	O
size	O
of	O
the	O
detected	O
proteins	O
ranged	O
from	O
15	O
kD	O
(	O
GS15	B
)	O
to	O
280	O
kD	O
(	O
ABP-280	B
)	O
.	O

The	O
average	O
intensity	O
of	O
the	O
detected	O
proteins	O
ranged	O
from	O
195	O
to	O
117926	O
normalized	O
intensity	O
units	O
(	O
i.u	O
.	O
)	O
,	O
with	O
an	O
average	O
of	O
5367	O
i.u	O
.	O

The	O
proteins	O
with	O
the	O
highest	O
band	O
intensity	O
were	O
the	O
B2	B
Bradykinin	I
Receptor	I
(	O
117926	O
i.u	O
.	O
)	O
,	O
Karyopherin	B
α	I
(	O
80698	O
i.u	O
.	O
)	O
,	O
and	O
BiP	B
(	O
74922	O
i.u	O
.	O
)	O
,	O
whilst	O
the	O
proteins	O
with	O
the	O
lowest	O
intensity	O
that	O
could	O
be	O
verified	O
by	O
visual	O
inspection	O
were	O
Inhibitor	B
2	I
(	O
247	O
i.u	O
.	O
)	O
,	O
Caspase	B
8	I
(	O
201	O
i.u	O
.	O
)	O
,	O
and	O
OXA1Hs	B
(	O
195	O
i.u	O
.	O
)	O
.	O

Finally	O
,	O
the	O
consistency	O
of	O
this	O
assay	O
was	O
demonstrated	O
by	O
plotting	O
the	O
normalized	O
average	O
intensity	O
values	O
for	O
each	O
protein	O
,	O
which	O
revealed	O
a	O
linear	O
relationship	O
between	O
the	O
duplicate	O
samples	O
(	O
Fig.	O
1	O
G	O
)	O
.	O

Kinexus	O
analysis	O
of	O
hESCsA	O
more	O
focused	O
screen	O
was	O
used	O
to	O
profile	O
expression	O
of	O
protein	B
kinases	I
,	O
phosphatases	B
and	O
phosphorylated	O
sites	O
in	O
cell	O
signaling	O
molecules	O
in	O
hESCs	O
.	O

The	O
Kinexus	O
assays	O
contained	O
140	O
antibodies	O
to	O
these	O
related	O
classes	O
of	O
proteins	O
and	O
phospho	O
-	O
sites	O
.	O

Karyotypically	O
normal	O
BG03	O
hESCs	O
grown	O
on	O
a	O
fibronectin	B
matrix	O
in	O
MEF	O
-	O
CM	O
[	O
26	O
]	O
were	O
used	O
for	O
this	O
analysis	O
,	O
and	O
whole	O
cell	O
lysate	O
was	O
separated	O
on	O
four	O
12.5	O
%	O
gels	O
for	O
western	O
blotting	O
.	O

Eighty	O
five	O
immunoreactive	O
bands	O
were	O
identified	O
,	O
representing	O
38	O
protein	B
kinases	I
and	O
16	O
phosphatases	B
,	O
their	O
isoforms	O
,	O
and	O
22	O
phosphorylated	O
sites	O
in	O
signaling	O
molecules	O
(	O
Fig.	O
2A	O
–	O
D	O
,	O
Additional	O
File	O
1	O
)	O
.	O

Sixty	O
-	O
four	O
antibodies	O
did	O
not	O
detect	O
their	O
corresponding	O
antigen	O
(	O
Additional	O
File	O
1	O
)	O
.Figure	O
2Kinexus	O
blots	O
of	O
undifferentiated	O
BG03	O
cells	O
.	O

Four	O
blots	O
were	O
used	O
to	O
probe	O
BG03	O
lysate	O
with	O
(	O
A	O
,	O
B	O
)	O
76	O
antibodies	O
for	O
protein	B
kinases	I
,	O
(	O
C	O
)	O
27	O
antibodies	O
for	O
phosphatases	B
and	O
(	O
D	O
)	O
37	O
antibodies	O
for	O
phosphoylated	O
sites	O
in	O
cell	O
signaling	O
molecules	O
.	O

Identified	O
bands	O
are	O
indicated	O
(	O
*	O
)	O
.	O

Datasets	O
for	O
this	O
analysis	O
are	O
in	O
Additional	O
Tables	O
1	O
and	O
2	O
.	O

Functional	O
classification	O
of	O
proteins	O
expressed	O
in	O
hESCsThe	O
PowerBlot	O
and	O
Kinexus	O
assays	O
identified	O
a	O
diverse	O
range	O
of	O
proteins	O
expressed	O
in	O
hESCs	O
.	O

To	O
further	O
annotate	O
these	O
data	O
,	O
the	O
detected	O
proteins	O
were	O
ordered	O
into	O
18	O
subgroups	O
based	O
on	O
protein	O
function	O
(	O
Additional	O
File	O
2	O
)	O
.	O

For	O
example	O
,	O
16	O
factors	O
with	O
known	O
or	O
implied	O
roles	O
in	O
the	O
regulation	O
of	O
self	O
-	O
renewal	O
or	O
pluripotency	O
of	O
mESCs	O
or	O
hESCs	O
,	O
such	O
as	O
Oct4	B
[	O
27	O
]	O
,	O
STAT3	B
[	O
28	O
]	O
,	O
members	O
of	O
the	O
FGF	B
[	O
29	O
]	O
,	O
PI3	B
kinase	I
[	O
30	O
]	O
,	O
Src	B
[	O
31	O
]	O
or	O
MAPK	B
pathways	O
[	O
32	O
]	O
,	O
and	O
phosphorylated	O
isoforms	O
of	O
GSK3	B
,	O
STAT3	B
and	O
p38	B
MAPK	I
,	O
were	O
grouped	O
under	O
""""	O
Pluripotency	O
""""	O
(	O
Fig.	O
3A	O
and	O
Additional	O
File	O
2	O
)	O
.	O

Another	O
functional	O
group	O
(	O
Cell	O
surface	O
)	O
consisted	O
of	O
20	O
transmembrane	O
or	O
cell	B
surface	I
proteins	I
(	O
Additional	O
File	O
2	O
)	O
.	O

This	O
included	O
several	O
receptors	O
for	O
peptides	O
and	O
growth	O
factors	O
,	O
such	O
as	O
neurotensin	B
receptor	I
3	I
,	O
the	O
B2	B
bradykinin	I
,	O
endothelin	B
1	I
,	O
and	O
thrombin	B
receptors	O
,	O
and	O
the	O
glial	B
derived	I
neurotrophic	I
factor	I
receptor	I
α	I
(	O
Fig.	O
3B	O
)	O
.	O

These	O
molecules	O
may	O
be	O
useful	O
as	O
targets	O
for	O
cell	O
sorting	O
experiments	O
,	O
and	O
expression	O
of	O
these	O
receptors	O
could	O
identify	O
bioactive	O
peptides	O
or	O
growth	O
factors	O
that	O
may	O
influence	O
hESC	O
self	O
-	O
renewal	O
or	O
differentiation	O
.	O

Figure	O
3Functional	O
classification	O
and	O
mobility	O
variants	O
of	O
proteins	O
detected	O
in	O
hESCs	O
.	O

(	O
A	O
)	O
Proteins	O
with	O
known	O
or	O
suggested	O
roles	O
in	O
self	O
-	O
renewal	O
are	O
shown	O
,	O
including	O
Oct4	B
,	O
STAT3	B
,	O
Smad2	B
/	I
3	I
and	O
FGF2	B
(	O
Additional	O
Table	O
2	O
,	O
""""	O
Pluripotency	O
""""	O
)	O
.	O

Isoforms	O
of	O
FGF2	B
,	O
and	O
phospho	B
-	I
GSK3	I
are	O
indicated	O
(	O
*	O
)	O
.	O

(	O
B	O
)	O
Cell	O
surface	O
proteins	O
are	O
shown	O
,	O
including	O
Connexin	B
43	I
,	O
E	B
-	I
Cad	I
and	O
GDNFRα	B
(	O
Additional	O
Table	O
2	O
,	O
""""	O
Cell	O
Surface	O
""""	O
)	O
.	O

Other	O
functional	O
classes	O
of	O
proteins	O
are	O
indicated	O
in	O
Additional	O
Table	O
2	O
.	O

(	O
C	O
)	O
A	O
total	O
of	O
42	O
proteins	O
,	O
including	O
FGF2	B
,	O
HSP70	B
and	O
ERK1	B
,	O
were	O
found	O
to	O
have	O
multiple	O
bands	O
in	O
either	O
the	O
PowerBlot	O
or	O
Kinexus	O
blots	O
.	O

These	O
bands	O
migrated	O
closely	O
but	O
were	O
sufficiently	O
separated	O
from	O
other	O
detected	O
proteins	O
.	O

Bands	O
predicted	O
to	O
be	O
isoforms	O
of	O
the	O
indicated	O
protein	O
are	O
highlighted	O
in	O
some	O
panels	O
(	O
*	O
)	O
.Other	O
functional	O
classification	O
of	O
the	O
proteins	O
detected	O
by	O
the	O
PowerBlot	O
screen	O
included	O
:	O
transcription	O
factors	O
(	O
71	O
proteins	O
)	O
,	O
nucleus	O
and	O
nuclear	O
transport	O
(	O
144	O
)	O
,	O
cytoskeleton	O
(	O
75	O
)	O
,	O
cell	O
adhesion	O
(	O
45	O
)	O
,	O
MAP	B
kinase	I
pathway	O
(	O
24	O
)	O
,	O
protein	B
kinase	I
A	I
(	O
13	O
)	O
,	O
protein	B
kinase	I
C	I
(	O
20	O
)	O
,	O
tyrosine	B
kinases	I
(	O
15	O
)	O
,	O
adaptors	O
and	O
tyrosine	O
kinase	O
substrates	O
(	O
51	O
)	O
,	O
protein	B
phosphatases	I
(	O
17	O
)	O
,	O
GTPases	B
and	O
regulators	O
(	O
42	O
)	O
,	O
calcium	O
signaling	O
(	O
23	O
)	O
,	O
cell	O
cycle	O
(	O
87	O
)	O
,	O
apoptosis	O
(	O
61	O
)	O
,	O
membrane	O
research	O
(	O
62	O
)	O
,	O
and	O
other	O
functions	O
(	O
51	O
)	O
(	O
Additional	O
File	O
1	O
)	O
.	O

Some	O
proteins	O
were	O
included	O
in	O
multiple	O
functional	O
categories	O
due	O
to	O
overlapping	O
properties	O
,	O
such	O
as	O
AIM-1	B
,	O
which	O
was	O
included	O
in	O
the	O
cell	O
cycle	O
as	O
well	O
as	O
in	O
the	O
nucleus	O
/	O
nuclear	O
transport	O
categories	O
.	O

The	O
Kinexus	O
expression	O
data	O
was	O
organized	O
separately	O
into	O
cell	O
signaling	O
-	O
related	O
functional	O
groups	O
(	O
Additional	O
File	O
1	O
)	O
.	O

In	O
addition	O
,	O
35	O
proteins	O
were	O
detected	O
by	O
both	O
the	O
PowerBlot	O
and	O
Kinexus	O
systems	O
(	O
Table	O
1	O
)	O
.Table	O
1Proteins	O
detected	O
by	O
both	O
PowerBlot	O
and	O
Kinexus	O
systemsProtein	O
nameSwiss	O
NrProtein	O
nameSwiss	O
NrBMXP51813MEK2P36506CaM	B
Kinase	B
KinaseQ64572MKP2Q62767Casein	I
Kinase	B
I	I
epsilonP49674p38	I
alpha	B
/	O
SAPK2aQ16539Casein	B
Kinase	B
II	I
alpha	I
/	O
CK2aP19139PaxillinP49024Cdk1	O
/	O
Cdc2P06493PKA	B
CP17612Cdk5Q00535PKC	B
betaP05771Cdk7P50613PKC	B
deltaQ05655DAP	B
KinaseP53355PP2A	B
Catalytic	O
alphaP05323DAP3P51398PP5	O
/	B
PPTP53042ERK1Q63538PTP1BP18031ERK2P27703PTP1C	I
/	B
SHP1P29350FAKQ00944PTP1D	I
/	B
SHP2Q06124GSK-3	I
betaP18266RbP13405I	B
kappa	B
B	I
alphaP25963RskQ15418IKK	I
betaO14920Stat1A46159JAK1P23458Stat3P52631JNK1P45983VHRP51452MEK1Q02750	B
Detection	O
of	O
protein	O
isoforms	O
or	O
post	O
-	O
translational	O
variantsUnlike	O
many	O
cDNA	O
-	O
based	O
gene	O
expression	O
assays	O
,	O
western	O
blotting	O
has	O
the	O
capacity	O
to	O
detect	O
multiple	O
protein	O
isoforms	O
due	O
to	O
translation	O
of	O
different	O
mRNA	O
splice	O
variants	O
,	O
as	O
well	O
as	O
post	O
-	O
translational	O
modifications	O
such	O
as	O
enzymatic	O
cleavage	O
,	O
glycosylation	O
,	O
or	O
phosphorylation	O
.	O

Examination	O
of	O
the	O
blots	O
described	O
here	O
identified	O
42	O
examples	O
of	O
multiple	O
banding	O
for	O
a	O
single	O
target	O
antigen	O
(	O
Fig.	O
3C	O
)	O
.	O

These	O
candidates	O
exhibited	O
closely	O
migrating	O
multiple	O
bands	O
,	O
which	O
were	O
close	O
to	O
their	O
predicted	O
size	O
but	O
were	O
sufficiently	O
separated	O
from	O
other	O
proteins	O
.	O

For	O
example	O
,	O
four	O
closely	O
migrating	O
bands	O
were	O
observed	O
for	O
FGF2	B
(	O
Fig.	O
3C	O
,	O
top	O
panel	O
)	O
,	O
which	O
may	O
represent	O
known	O
glycosylation	O
variants	O
of	O
this	O
growth	O
factor	O
[	O
33	O
]	O
.	O

Other	O
known	O
examples	O
of	O
post	O
-	O
translational	O
modifications	O
included	O
those	O
of	O
HSP70	B
,	O
IKKgamma	B
and	O
ERK1	B
.	O

Verification	O
of	O
protein	O
expression	O
by	O
immunocytochemistryThe	O
PowerBlot	O
and	O
Kinexus	O
assays	O
identified	O
proteins	O
based	O
on	O
their	O
expected	O
and	O
observed	O
molecular	O
weight	O
,	O
using	O
combinations	O
of	O
antibodies	O
that	O
had	O
been	O
predetermined	O
to	O
detect	O
proteins	O
of	O
sufficiently	O
different	O
sizes	O
.	O

Proteins	O
known	O
to	O
be	O
expressed	O
by	O
hESCs	O
and	O
also	O
identified	O
by	O
these	O
assays	O
,	O
included	O
Oct4	B
,	O
E	B
-	I
CAD	I
,	O
Connexin	B
43	I
and	O
Hsp70	B
.	O

To	O
verify	O
expression	O
using	O
a	O
complementary	O
approach	O
,	O
we	O
performed	O
immunoflurorescent	O
staining	O
for	O
10	O
proteins	O
not	O
previously	O
reported	O
to	O
be	O
expressed	O
in	O
hESCs	O
by	O
immunocytochemistry	O
,	O
using	O
karyotypically	O
normal	O
BG01	O
cultures	O
(	O
Fig.	O
4A	O
–	O
K	O
)	O
.	O

These	O
included	O
ABP-280	B
,	O
a	O
homodimeric	O
actin	O
-	O
binding	O
protein	O
often	O
associated	O
with	O
membrane	O
glycoproteins	O
;	O
CtBP1	B
and	O
CtBP2	B
,	O
two	O
C	O
terminal	O
binding	O
proteins	O
that	O
are	O
a	O
class	O
of	O
transcription	O
corepressors	O
;	O
GS-28	B
,	O
a	O
golgi	O
protein	O
;	O
HDJ-2	B
,	O
a	O
member	O
of	O
the	O
DnaJ	O
-	O
related	O
Hsp40	B
(	O
heat	B
shock	I
protein	I
40	I
)	O
subfamily	O
;	O
L	B
-	I
Caldesmon	I
,	O
a	O
cytoplasmic	O
actin	O
-	O
binding	O
protein	O
;	O
Rabaptin	B
,	O
a	O
GTP	O
-	O
binding	O
protein	O
;	O
phosphorylated	B
-	I
p130	I
Cas	I
,	O
a	O
docking	O
protein	O
with	O
an	O
amino	O
-	O
terminal	O
SH3	O
domain	O
that	O
may	O
function	O
as	O
a	O
molecular	O
switch	O
that	O
regulates	O
CAS	O
(	O
Crk	B
-	I
associated	I
substrate	I
)	O
tyrosine	O
phosphorylation	O
;	O
Ras	B
-	I
GAP	I
and	O
phosphorylated	B
Ras	I
-	I
GAP	I
(	O
p	O
-	O
Y460	O
)	O
,	O
a	O
protein	O
that	O
down	O
-	O
regulates	O
the	O
signal	O
transducer	O
p21ras	B
;	O
and	O
ShcC	B
,	O
a	O
protein	O
with	O
an	O
N	O
-	O
terminal	O
phosphotyrosine	O
-	O
binding	O
domain	O
.	O

These	O
proteins	O
were	O
all	O
expressed	O
by	O
hESCs	B
,	O
with	O
the	O
expected	O
subcellular	O
localization	O
(	O
Fig.	O
4A	O
–	O
K	O
)	O
.	O

Oct4	B
was	O
used	O
as	O
a	O
positive	O
control	O
(	O
Fig.	O
4L	O
)	O
.	O

These	O
results	O
suggested	O
that	O
most	O
of	O
the	O
bands	O
in	O
the	O
PowerBlot	O
and	O
Kinexus	O
assays	O
were	O
likely	O
to	O
be	O
correctly	O
identified	O
.	O

Figure	O
4Verification	O
of	O
protein	O
expression	O
using	O
immunocytochemistry	O
.	O

(	O
A	O
-	O
K	O
)	O
Ten	O
proteins	O
that	O
were	O
detected	O
in	O
undifferentiated	O
hESCs	O
by	O
western	O
blotting	O
were	O
also	O
detected	O
by	O
immunofluorescence	O
of	O
BG01	O
cells	O
grown	O
in	O
MEF	O
-	O
CM	O
.	O

Ras	B
-	I
GAP	I
(	O
pY460	O
)	O
is	O
a	O
phosphorylated	O
form	O
of	O
Ras	B
-	I
GAP	I
.	O

The	O
same	O
antibodies	O
were	O
used	O
in	O
this	O
analysis	O
as	O
in	O
the	O
PowerBlot	O
assay	O
,	O
except	O
phospho	B
-	I
p130	I
Cas	I
(	O
Tyr165	O
)	O
.	O

(	O
L	O
)	O
Oct4	B
was	O
used	O
as	O
a	O
positive	O
control	O
.	O

(	O
M	O
-	O
R	O
)	O
Oct4	B
,	O
TNIK	B
and	O
p130	B
Cas	I
as	O
markers	O
of	O
undifferentiated	O
hESCs	O
.	O

BG01	O
cultures	O
were	O
partially	O
differentiated	O
by	O
exposure	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
for	O
3	O
days	O
.	O

(	O
M	O
)	O
Oct4	B
was	O
expressed	O
uniformly	O
in	O
undifferentiated	O
cells	O
,	O
(	O
P	O
)	O
but	O
was	O
downregulated	O
in	O
morphologically	O
differentiated	O
areas	O
after	O
3	O
days	O
in	O
serum	O
(	O
arrowhead	O
)	O
.	O

(	O
N	O
)	O
TNIK	B
expression	O
was	O
localized	O
to	O
the	O
cytoplasm	O
,	O
and	O
(	O
N	O
,	O
Q	O
)	O
expression	O
appeared	O
to	O
be	O
restricted	O
to	O
morphologically	O
undifferentiated	O
cells	O
(	O
arrowhead	O
)	O
.	O

(	O
O	O
)	O
p130	B
Cas	I
was	O
detected	O
in	O
a	O
membrane	O
/	O
peripheral	O
-	O
cytoplasmic	O
pattern	O
in	O
undifferentiated	O
cells	O
,	O
(	O
R	O
)	O
but	O
this	O
distribution	O
was	O
substantially	O
altered	O
in	O
differentiating	O
cells	O
with	O
a	O
flattened	O
morphology	O
,	O
which	O
exhibited	O
a	O
general	O
cytoplasmic	O
,	O
or	O
perinuclear	O
profile	O
.	O

Scale	O
bar	O
for	O
A	O
-	O
L	O
:	O
(	O
A	O
,	O
L	O
)	O
200	O
μm	O
;	O
(	O
C	O
,	O
D	O
,	O
F	O
,	O
H	O
,	O
I	O
,	O
J	O
,	O
K	O
)	O
100	O
μm	O
;	O
(	O
B	O
,	O
E	O
,	O
G	O
)	O
50	O
μm	O
.	O

Scale	O
bar	O
for	O
M	O
-	O
R	O
:	O
(	O
M	O
,	O
N	O
,	O
P	O
,	O
Q	O
)	O
:	O
100	O
μm	O
;	O
(	O
O	O
,	O
R	O
)	O
:	O
50	O
μm	O
.	O

Preliminary	O
analyses	O
also	O
indicated	O
that	O
expression	O
of	O
some	O
of	O
these	O
proteins	O
was	O
downregulated	O
in	O
differentiated	O
cells	O
,	O
including	O
p130	B
Cas	I
and	O
the	O
Traf2-	B
and	B
Nck	I
-	I
interacting	I
kinase	I
(	O
TNIK	B
)	O
.	O

TNIK	B
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
inhibition	O
of	O
cell	O
spreading	O
via	O
disruption	O
of	O
F	B
-	I
actin	I
[	O
34,35	O
]	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
examine	O
the	O
expression	O
of	O
TNIK	B
and	O
p130	B
Cas	I
during	O
early	O
differentiation	O
of	O
hESCs	O
.	O

BG01	O
cultures	O
were	O
partially	O
differentiated	O
by	O
growth	O
in	O
serum	O
containing	O
media	O
for	O
3	O
days	O
.	O

This	O
condition	O
generated	O
heterogeneous	O
populations	O
containing	O
Oct4	B
+	O
cells	O
with	O
characteristic	O
hESC	O
morphology	O
and	O
less	O
tightly	O
packed	O
,	O
and	O
morphologically	O
differentiated	O
areas	O
,	O
lacking	O
expression	O
of	O
Oct4	B
(	O
Fig	O
4	O
M	O
,	O
P	O
)	O
.	O

TNIK	B
was	O
expressed	O
highly	O
in	O
undifferentiated	O
hESCs	O
,	O
and	O
in	O
the	O
undifferentiated	O
areas	O
at	O
day	O
3	O
,	O
but	O
was	O
downregulated	O
in	O
areas	O
undergoing	O
morphological	O
differentiation	O
(	O
Fig	O
4N	O
,	O
Q	O
)	O
.	O

This	O
may	O
indicate	O
that	O
TNIK	B
is	O
active	O
in	O
hESCs	O
and	O
degraded	O
rapidly	O
upon	O
differentiation	O
.	O

p130	B
Cas	I
was	O
detected	O
in	O
a	O
membrane	O
/	O
peripheral	O
-	O
cytoplasmic	O
pattern	O
in	O
hESCs	O
(	O
Fig	O
4O	O
)	O
.	O

The	O
distribution	O
of	O
p130Cas	B
was	O
substantially	O
altered	O
in	O
differentiating	O
cells	O
with	O
a	O
flattened	O
morphology	O
,	O
exhibiting	O
a	O
general	O
cytoplasmic	O
,	O
or	O
perinuclear	O
profile	O
(	O
Fig	O
4R	O
)	O
.	O

This	O
could	O
indicate	O
an	O
alteration	O
in	O
the	O
function	O
of	O
p130	B
Cas	I
as	O
pluripotent	O
cells	O
differentiate	O
.	O

These	O
analyses	O
suggested	O
that	O
the	O
change	O
in	O
expression	O
or	O
distribution	O
of	O
these	O
proteins	O
could	O
be	O
used	O
as	O
markers	O
for	O
undifferentiated	O
hESCs	O
.	O

Comparison	O
of	O
proteomic	O
and	O
transcriptional	O
profiles	O
of	O
hESCsWe	O
have	O
previously	O
employed	O
the	O
Illumina	O
Bead	O
Array	O
system	O
for	O
the	O
large	O
-	O
scale	O
profiling	O
of	O
gene	O
expression	O
in	O
hESCs	O
using	O
24,000	O
transcript	O
probes	O
[	O
11	O
]	O
.	O

To	O
compare	O
proteomic	O
and	O
transcriptional	O
analyses	O
of	O
hESCs	O
,	O
the	O
levels	O
of	O
>	O
600	O
proteins	O
detected	O
using	O
large	O
scale	O
blotting	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
transcripts	O
detected	O
with	O
the	O
Illumina	O
platform	O
(	O
Additional	O
File	O
3	O
)	O
.	O

In	O
general	O
,	O
a	O
close	O
match	O
between	O
the	O
expression	O
level	O
of	O
transcript	O
and	O
protein	O
was	O
observed	O
:	O
transcripts	O
for	O
nearly	O
all	O
the	O
detected	O
proteins	O
were	O
also	O
identified	O
in	O
the	O
Illumina	O
analysis	O
,	O
and	O
most	O
proteins	O
expressed	O
at	O
high	O
levels	O
also	O
exhibited	O
high	O
mRNA	O
levels	O
.	O

We	O
reasoned	O
that	O
a	O
focused	O
comparison	O
of	O
specific	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
proteomic	O
and	O
transcriptional	O
data	O
was	O
likely	O
to	O
be	O
much	O
more	O
informative	O
than	O
a	O
global	O
interrogation	O
of	O
hESCs	O
.	O

Several	O
major	O
signal	O
pathways	O
that	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
self	O
-	O
renewal	O
were	O
examined	O
to	O
test	O
this	O
approach	O
.	O

These	O
included	O
the	O
FGF	B
,	O
TGFβ	B
,	O
GSK3β	B
/	O
Wnt	B
/	O
β	B
-	I
catenin	I
and	O
Jak	B
/	O
Stat	B
pathways	O
[	O
17,29,36	O
-	O
39	O
]	O
,	O
as	O
well	O
as	O
the	O
more	O
recently	O
suggested	O
MAPK	B
/	O
ERK	B
and	O
Gap	B
junction	I
pathways	O
[	O
32,40	O
]	O
.	O

Correlating	O
transcriptional	O
and	O
proteomic	O
data	O
provided	O
direct	O
confirmation	O
that	O
these	O
pathways	O
were	O
present	O
and	O
likely	O
functional	O
in	O
hESCs	O
(	O
Table	O
2	O
)	O
.	O

For	O
example	O
,	O
FGF2	B
protein	O
was	O
expressed	O
highly	O
in	O
hESCs	O
and	O
expression	O
of	O
key	O
members	O
of	O
the	O
TGFβ	B
,	O
Wnt	B
,	O
Jak	B
/	O
Stat	B
and	O
Gap	B
junction	I
pathways	O
,	O
namely	O
Stat1	B
,	O
SMADs	B
,	O
GSK3β	B
,	O
β	B
-	I
catenin	I
and	O
Connexin	B
43	I
,	O
were	O
detected	O
in	O
both	O
transcriptional	O
and	O
proteomic	O
databases	O
.	O

Table	O
2Signal	O
pathways	O
that	O
may	O
be	O
active	O
in	O
hESCsNameProteinmRNATGF	O
βStat1++++++PAI-1	B
/	O
SERPINE1+++-Smad2	B
/	B
3++++Jun+++Smad4	I
/	O
DPC4+++Endoglin+-WntCtBP2+++++++PP2A	B
Catalytic	B
alpha	I
/	O
PPP2CA+++++++EBP50	B
/	O
SLC9A3R1++++++beta	B
-	B
Catenin	I
/	O
Ctnnb1++++Cyclin	B
D3	B
/	O
CCND3++++GSK-3	B
beta++++Jun+++Casein	B
Kinase	B
II	I
alpha	I
/	O
CSNK2A1++++Jak	B
-	O
StatStat1++++++Crk++++Stat3	O
/	B
2+++++Stat6+++++PTP1B+++++JAK1++-Glucocorticoid	I
R	O
/	O
NR3C1++-Thrombin	B
Receptor	B
/	O
PAR1	B
/	O
F2R+++SHPS-1	B
/	O
PTPNS1++++MCM5+++++Smad2	B
/	B
3++++Tyk2++++Jun+++Bcl	I
-	B
x	I
/	O
BCL2L1++++Smad4	B
/	O
DPC4+++Stat5A++GPCRB2	B
Bradykinin	B
Receptor	I
/	O
BDKRB2++++-Neurotensin	B
Receptor	B
3	I
/	O
SORT1+++-Endopeptidase	B
3.4.24.16/NLN++++IP3R-3++++SHC++++Gap	B
JunctionCdk1	O
/	O
Cdc2++++++GRB2++++++MEK1	B
/	O
MAP2K1++++++PKA	B
C++-PKA	B
RI	B
alpha++-PKC	I
alpha++-C	B
-	B
Raf	I
/	O
RAF1++++ZO-1	B
/	O
TJP1+++++Connexin-43	B
/	O
GJA1++++IGFPKC	B
iota++++++MEK1	B
/	O
MAP2K1++++++Rsk	B
/	O
RPS6KA1+++++GRB2++++++MEK2	B
/	O
MAP2K2++++++PI3Kinase	B
/	O
PIK3R1+++++pan	B
ERK	O
/	O
MAPK1+++++Crk++++eIF-4E+++++ShcC+++-PAI-1	B
/	O
SERPINE1+++-C	B
-	B
Raf++++SHC+++++PKC	I
beta	B
/	O
PRKCB1++++NCK++++PKB	B
alpha	B
/	O
Akt+++GSK-3	O
beta++++Ercc-1++++Fatty	B
Acid	B
Synthase	I
/	O
FASN+++++Jun+++RAFT1	B
/	O
FRAP++++PTP1D	B
/	O
SHP2	B
/	O
PTPN11++++SCAMP1++++Bcl	B
-	B
x	I
/	O
BCL2L1++++p70s6k	B
/	O
RPS6KB1	B
+	O
-PI3-Kinase	O
p170	B
/	O
PIK3C2A++PTP1B	B
/	O
PTPN1+++Dok1	B
/	O
p62dok+++PI3-Kinase	B
p110	B
alpha	I
/	O
PIK3CA+-ERBBEphA4	B
/	O
Sek++++-ShcC	B
/	O
SHC3+++-c	B
-	B
erb	I
-	I
B2	I
/	O
ERBB2++++C	B
-	B
Raf	I
/	O
RAF1++++SHC	B
/	O
SHC1+++++GDNFI	B
kappa	B
B	I
epsilon	O
/	O
NFKBIE++++++GRB2++++++MEK2++++++NCK+++++C	B
-	B
Raf++++Ras	I
-	B
GAP	I
/	O
RASA1++++SHC+++++GDNFR	B
-	B
alpha	I
/	O
Gfra1++-Jun+++IKK	B
beta++++pan	B
-	O
JNK	O
/	O
SAPK1	B
/	O
MAPK10+++NBS1	B
/	O
ARTN++Dok1	B
/	O
p62dok+++Tight	B
JunctionPTEN++++++PP2A	O
Catalytic	B
alpha+++++++PKC	I
iota++++++Sec8	B
/	O
SEC8L1+++++beta	B
-	B
Catenin	I
/	O
CTNNB1++++CDC42+++++AF6	B
/	O
MLLT4+++++PKC	B
alpha++-Yes++++Rho	B
/	O
ARHA+++++ZO-1	B
/	O
TJP1+++++CASK+++Symplekin	B
/	O
SYMPK++-Ras	B
/	O
NRAS++++Casein	B
Kinase	B
II	I
alpha	I
/	O
CSNK2A1++++VAP33	B
/	O
VAPA+++alpha	B
-	B
Catenin	I
/	O
Ctnna1+++MAPKpan	B
ERK++++++MEK1++++++Rsk++++++ERK2++++++MEK2	O
/	O
Map2k2++++++MST3	B
/	O
STK25++++++ERK1+++++CDC42+++++C	B
-	B
Raf++++p38	I
alpha	B
/	O
SAPK2a++-G3BP+++++TFII	B
-	B
I	I
/	O
GTF2IRD1++++MST1	B
/	O
STK4++++MKP2	B
/	O
Dusp4++++Ras++++Phospho	B
-	O
p38MAPK	B
(	O
T180	O
/	O
Y182	O
)	O
+++pan	O
-	O
JNK	O
/	O
SAPK1+++Inhibitor2	B
/	O
PPP1R2++++ABP-280++++++14	B
-	B
3	I
-	I
3	I
epsilon	I
/	O
YWHAE++++MAPKAPK-5+++TAO1+*PBK+++MKK3b	B
/	O
Map2k3++Protein	B
expression	O
level	O
:	O
>	O
10,000	O
:	O
+	O
+	O
+	O
+	O
;	O
5,000–10,000	O
:	O
+	O
+	O
+	O
;	O
1,000–5,000:++	O
;	O
100–1,000	O
:	O
+	O
mRNA	O
gene	O
expression	O
level	O
:	O
>	O
5,000:++++	O
;	O
1,000–5,000	O
:	O
+	O
+	O
+	O
;	O
100–1,000	O
:	O
+	O
+	O
;	O
30–100	O
:	O
+	O

*	O
:	O
not	O
included	O
in	O
the	O
gene	O
expression	O
arrayThis	O
independent	O
confirmation	O
of	O
known	O
networks	O
led	O
us	O
to	O
examine	O
other	O
pathways	O
that	O
showed	O
a	O
similar	O
correlation	O
but	O
have	O
not	O
been	O
identified	O
as	O
key	O
regulators	O
of	O
either	O
self	O
-	O
renewal	O
or	O
differentiation	O
,	O
or	O
suggest	O
unappreciated	O
characteristics	O
of	O
hESCs	O
.	O

Four	O
signaling	O
pathways	O
(	O
IGF	B
,	O
ERBB2	B
,	O
GPCR	B
,	O
and	O
GDNF	B
)	O
and	O
the	O
tight	O
junction	O
complex	O
were	O
highlighted	O
by	O
this	O
analysis	O
(	O
Table	O
2	O
)	O
,	O
and	O
expression	O
of	O
key	O
proteins	O
in	O
these	O
pathways	O
was	O
confirmed	O
.	O

A	O
detailed	O
study	O
demonstrating	O
the	O
importance	O
of	O
the	O
IGF	B
and	O
ERBB2	B
pathways	O
in	O
hESC	O
self	O
-	O
renewal	O
has	O
been	O
performed	O
and	O
enabled	O
the	O
development	O
of	O
a	O
defined	O
medium	O
for	O
hESC	O
maintenance	O
(	O
TCS	O
and	O
AJR	O
,	O
submitted	O
)	O
.	O

Tight	O
junctions	O
are	O
apical	O
cell	O
-	O
cell	O
junctions	O
found	O
in	O
epithelia	O
that	O
establish	O
a	O
barrier	O
to	O
the	O
extracellular	O
environment	O
and	O
a	O
border	O
for	O
apical	O
-	O
basolateral	O
polarity	O
.	O

While	O
hESCs	O
grow	O
in	O
colonies	O
that	O
are	O
highly	O
reminiscent	O
of	O
epithelia	O
,	O
and	O
have	O
been	O
shown	O
to	O
be	O
coupled	O
by	O
gap	O
junctions	O
[	O
40	O
]	O
,	O
the	O
formation	O
of	O
tight	O
junction	O
complexes	O
has	O
not	O
been	O
described	O
.	O

hESCs	O
expressed	O
the	O
ZO1	B
and	O
occludin	B
tight	O
junction	O
proteins	O
along	O
cell	O
borders	O
as	O
expected	O
in	O
polarized	O
epithelia	O
.	O

The	O
distribution	O
of	O
ZO1	B
expression	O
changed	O
dramatically	O
as	O
hESCs	O
proliferated	O
in	O
culture	O
.	O

When	O
tight	O
junction	O
complexes	O
were	O
disrupted	O
by	O
disaggreagation	O
to	O
single	O
cells	O
,	O
only	O
a	O
subset	O
of	O
cells	O
showed	O
ZO1	B
staining	O
4	O
days	O
after	O
plating	O
(	O
Fig.	O
5	O
)	O
.	O

Continued	O
proliferation	O
to	O
a	O
confluent	O
monolayer	O
on	O
day	O
7	O
was	O
accompanied	O
by	O
widespread	O
expression	O
of	O
ZO1	B
,	O
suggesting	O
the	O
formation	O
of	O
a	O
general	O
tight	O
junction	O
barrier	O
.	O

These	O
cultures	O
were	O
undifferentiated	O
and	O
retained	O
uniform	O
expression	O
of	O
Oct4	B
protein	O
(	O
not	O
shown	O
)	O
.	O

ERBB2	B
and	O
3	O
are	O
members	O
of	O
the	O
epidermal	O
growth	O
factor	O
(	O
EGF	B
)	O
-receptor	O
family	O
,	O
which	O
regulate	O
epithelial	O
proliferation	O
via	O
EGF	B
-	O
family	O
ligands	O
.	O

ERBB2	B
and	O
3	O
transcripts	O
are	O
expressed	O
by	O
hESCs	O
[	O
8	O
]	O
,	O
are	O
known	O
to	O
function	O
as	O
a	O
heterodimer	O
[	O
41	O
]	O
,	O
and	O
transmit	O
a	O
strong	O
proliferative	O
signal	O
for	O
hESCs	O
by	O
Heregulin	B
1β	I
(	O
an	O
EGF	B
-	O
family	O
ligand	O
)	O
(	O
TCS	O
and	O
AJR	O
,	O
submitted	O
)	O
.	O

Immunofluorescence	O
revealed	O
general	O
cell	O
surface	O
expression	O
of	O
ERBB2	B
on	O
hESCs	O
.	O

Conversely	O
,	O
ERBB3	B
was	O
highly	O
localized	O
to	O
a	O
concentrated	O
area	O
,	O
and	O
observed	O
in	O
cells	O
that	O
also	O
expressed	O
ZO1	B
.	O

Epithelial	O
cells	O
are	O
known	O
to	O
localize	O
ERBB	B
receptors	I
to	O
the	O
basolateral	O
side	O
of	O
tight	O
junctions	O
,	O
which	O
serves	O
to	O
functionally	O
separate	O
receptors	O
from	O
ligands	O
[	O
42,43	O
]	O
.	O

This	O
is	O
a	O
basic	O
epithelial	O
wound	O
healing	O
mechanism	O
,	O
whereby	O
disruption	O
of	O
the	O
tight	O
junction	O
barrier	O
by	O
injury	O
immediately	O
exposes	O
receptors	O
to	O
extracelluar	O
ligands	O
[	O
43	O
]	O
.	O

These	O
staining	O
patterns	O
are	O
also	O
suggestive	O
of	O
basolateral	O
sorting	O
of	O
ERBB3	B
in	O
hESCs	O
.	O

The	O
pathways	O
and	O
complexes	O
identified	O
by	O
these	O
analyses	O
lay	O
a	O
framework	O
for	O
future	O
functional	O
analyses	O
of	O
signaling	O
networks	O
in	O
hESCs	O
.	O

Figure	O
5Tight	O
junction	O
proteins	O
and	O
ERBB2	B
/	I
3	I
expression	O
in	O
hESCs	O
.	O

BG01	O
hESCs	O
were	O
disaggregated	O
to	O
single	O
cells	O
using	O
accutase	B
[	O
52	O
]	O
and	O
cultured	O
in	O
defined	O
conditions	O
.	O

(	O
A	O
)	O
ZO1	B
expression	O
four	O
and	O
(	O
B	O
)	O
seven	O
days	O
after	O
plating	O
,	O
indicating	O
progressive	O
tight	O
junction	O
formation	O
.	O

(	O
C	O
)	O
Occludin	B
expression	O
5	O
days	O
after	O
plating	O
.	O

(	O
D	O
)	O
General	O
cell	O
surface	O
expression	O
of	O
ERBB2	B
,	O
in	O
the	O
same	O
field	O
of	O
view	O
as	O
(	O
A	O
)	O
.	O

(	O
E	O
)	O
Localized	O
expression	O
of	O
ERBB3	B
,	O
in	O
the	O
same	O
field	O
of	O
view	O
as	O
(	O
B	O
)	O
.	O

(	O
F	O
)	O
Higher	O
magnification	O
of	O
ERBB3	B
localization	O
in	O
ZO1	B
expressing	O
BG01	O
cells	O
,	O
5	O
days	O
after	O
plating	O
.	O

Nuclei	O
were	O
stained	O
with	O
DAPI	O
.	O

Attempts	O
to	O
harness	O
the	O
potential	O
of	O
hESCs	O
for	O
models	O
of	O
human	O
embryogenesis	O
and	O
cell	O
therapy	O
applications	O
will	O
be	O
greatly	O
enhanced	O
by	O
a	O
detailed	O
understanding	O
of	O
their	O
molecular	O
characteristics	O
.	O

This	O
includes	O
definition	O
of	O
the	O
transcripts	O
,	O
splice	O
variants	O
,	O
and	O
protein	O
isoforms	O
expressed	O
by	O
these	O
cells	O
.	O

Post	O
-	O
translational	O
modifications	O
such	O
as	O
phosphorylation	O
and	O
glycosylation	O
,	O
and	O
the	O
receptors	O
and	O
signaling	O
pathways	O
active	O
in	O
the	O
pluripotent	O
state	O
,	O
or	O
during	O
early	O
differentiation	O
,	O
also	O
need	O
to	O
be	O
determined	O
.	O

This	O
should	O
also	O
be	O
complemented	O
by	O
an	O
understanding	O
of	O
epigenetic	O
characteristics	O
of	O
pluripotency	O
,	O
including	O
methylation	O
,	O
imprinting	O
and	O
chromatin	O
conformation	O
.	O

Such	O
a	O
comprehensive	O
definition	O
of	O
the	O
molecular	O
state	O
of	O
hESCs	O
will	O
enable	O
more	O
accurate	O
prediction	O
and	O
testing	O
of	O
the	O
conditions	O
used	O
for	O
growth	O
and	O
differentiation	O
of	O
hESCs	O
,	O
by	O
precise	O
genetic	O
modification	O
or	O
application	O
of	O
specific	O
growth	O
factor	O
cocktails	O
and	O
reagents	O
.	O

For	O
example	O
,	O
a	O
scalable	O
,	O
fully	O
defined	O
and	O
GMP	O
-	O
certified	O
culture	O
system	O
will	O
need	O
to	O
be	O
developed	O
for	O
the	O
eventual	O
development	O
of	O
hESC	O
-	O
based	O
cellular	O
therapies	O
.	O

Progress	O
has	O
been	O
made	O
in	O
defining	O
growth	O
factor	O
conditions	O
that	O
support	O
self	O
-	O
renewal	O
[	O
44	O
-	O
46	O
]	O
,	O
and	O
hESC	O
lines	O
have	O
been	O
isolated	O
in	O
the	O
absence	O
of	O
mouse	O
embryonic	O
fibroblasts	O
and	O
in	O
animal	O
protein	O
free	O
culture	O
conditions	O
[	O
47,48	O
]	O
.	O

A	O
more	O
refined	O
understanding	O
of	O
the	O
biology	O
of	O
hESCs	O
has	O
contributed	O
the	O
development	O
of	O
a	O
defined	O
medium	O
utilizing	O
ligands	O
for	O
IGF1R	B
and	O
ERBB2	B
/	I
3	I
receptors	O
to	O
promote	O
in	O
self	O
-	O
renewal	O
(	O
TCS	O
and	O
AJR	O
,	O
submitted	O
)	O
.	O

We	O
and	O
others	O
have	O
performed	O
transcriptional	O
analyses	O
of	O
hESCs	O
,	O
using	O
cDNA	O
and	O
oligonucleotide	O
microarrays	O
,	O
SAGE	O
,	O
MPSS	O
and	O
EST	O
enumeration	O
.	O

These	O
techniques	O
have	O
enabled	O
the	O
collation	O
and	O
comparison	O
of	O
transcriptional	O
profiles	O
from	O
multiple	O
hESC	O
lines	O
and	O
their	O
differentiated	O
derivatives	O
and	O
have	O
highlighted	O
an	O
expanded	O
set	O
of	O
hESC	O
specific	O
markers	O
and	O
signaling	O
pathways	O
that	O
may	O
regulate	O
self	O
-	O
renewal	O
or	O
differentiation	O
.	O

Using	O
pathway	O
analysis	O
we	O
were	O
also	O
able	O
to	O
identify	O
key	O
pathways	O
that	O
are	O
active	O
in	O
ESCs	O
(	O
reviewed	O
in	O
[	O
16	O
]	O
)	O
.	O

While	O
these	O
efforts	O
have	O
been	O
highly	O
valuable	O
in	O
defining	O
the	O
transcriptional	O
profile	O
of	O
undifferentiated	O
hESCs	O
,	O
they	O
are	O
only	O
predictive	O
of	O
translation	O
and	O
do	O
not	O
shed	O
light	O
on	O
post	O
-	O
translational	O
events	O
in	O
this	O
unique	O
cell	O
type	O
.	O

These	O
processes	O
may	O
also	O
be	O
highly	O
regulated	O
,	O
which	O
could	O
contribute	O
significantly	O
to	O
the	O
overall	O
conversion	O
of	O
genetic	O
information	O
to	O
actual	O
protein	O
function	O
.	O

We	O
report	O
here	O
a	O
proteomic	O
analysis	O
of	O
pluripotent	O
hESCs	O
by	O
using	O
two	O
large	O
-	O
scale	O
western	O
blotting	O
systems	O
and	O
highlight	O
post	O
-	O
translational	O
events	O
in	O
undifferentiated	O
hESCs	O
.	O

The	O
expression	O
of	O
545	O
bands	O
was	O
detected	O
,	O
potentially	O
representing	O
529	O
proteins	O
,	O
or	O
their	O
migratory	O
isoforms	O
.	O

In	O
addition	O
,	O
one	O
hundred	O
and	O
forty	O
phospho	O
-	O
specific	O
antibodies	O
were	O
used	O
to	O
identify	O
85	O
different	O
phosphorylated	O
sites	O
,	O
on	O
76	O
proteins	O
in	O
these	O
cells	O
.	O

The	O
detected	O
proteins	O
were	O
annotated	O
into	O
functional	O
classes	O
representing	O
diverse	O
cellular	O
processes	O
.	O

For	O
example	O
,	O
multiple	O
proteins	O
were	O
detected	O
that	O
have	O
been	O
suggested	O
to	O
regulate	O
the	O
pluirpotent	O
state	O
in	O
mouse	O
ESCs	O
or	O
hESCs	O
.	O

Defining	O
the	O
interplay	O
of	O
these	O
multiple	O
signaling	O
pathways	O
will	O
be	O
critical	O
in	O
understanding	O
the	O
self	O
-	O
renewal	O
versus	O
differentiation	O
decisions	O
of	O
hESCs	O
.	O

Therefore	O
,	O
our	O
data	O
provide	O
a	O
powerful	O
framework	O
for	O
the	O
functional	O
analysis	O
of	O
specific	O
proteins	O
,	O
protein	O
classes	O
,	O
or	O
molecular	O
pathways	O
.	O

In	O
particular	O
,	O
the	O
availability	O
of	O
antibodies	O
for	O
candidate	O
proteins	O
is	O
a	O
major	O
benefit	O
of	O
this	O
approach	O
compared	O
to	O
2D	O
-	O
gel	O
or	O
HPLC	O
-	O
MS	O
/	O
MS	O
based	O
proteomics	O
.	O

Although	O
these	O
western	O
blotting	O
approaches	O
are	O
currently	O
more	O
limited	O
in	O
scope	O
than	O
most	O
large	O
-	O
scale	O
cDNA	O
based	O
assays	O
,	O
detecting	O
up	O
to	O
1000	O
proteins	O
compared	O
to	O
tens	O
of	O
thousands	O
of	O
transcripts	O
,	O
they	O
have	O
the	O
potential	O
to	O
highlight	O
translational	O
events	O
and	O
post	O
-	O
translational	O
modifications	O
.	O

By	O
comparison	O
,	O
SAGE	O
and	O
MPSS	O
are	O
limited	O
to	O
detecting	O
short	O
sequence	O
""""	O
tags	O
""""	O
adjacent	O
to	O
the	O
poly	O
-	O
A	O
tail	O
of	O
transcripts	O
,	O
and	O
may	O
not	O
distinguish	O
splice	O
variants	O
with	O
the	O
same	O
3	O
'	O
exon	O
.	O

We	O
detected	O
42	O
proteins	O
with	O
multiple	O
closely	O
migrating	O
bands	O
(	O
Fig.	O
3C	O
)	O
,	O
suggestive	O
of	O
closely	O
related	O
isoforms	O
or	O
post	O
-	O
translational	O
modifications	O
such	O
as	O
phosphorylation	O
.	O

These	O
focused	O
proteomic	O
approaches	O
are	O
therefore	O
likely	O
to	O
be	O
highly	O
complimentary	O
to	O
transcriptional	O
analyses	O
in	O
investigating	O
the	O
functional	O
expression	O
of	O
the	O
genome	O
in	O
hESCs	O
and	O
during	O
cellular	O
differentiation	O
.	O

One	O
potential	O
issue	O
with	O
this	O
approach	O
is	O
that	O
multiple	O
antibodies	O
are	O
included	O
in	O
each	O
lane	O
,	O
which	O
could	O
possibly	O
lead	O
to	O
misidentification	O
of	O
bands	O
.	O

To	O
demonstrate	O
that	O
identified	O
proteins	O
were	O
expressed	O
in	O
hESCs	O
,	O
the	O
same	O
antibodies	O
used	O
in	O
the	O
PowerBlot	O
assay	O
were	O
used	O
to	O
confirm	O
expression	O
of	O
10	O
representative	O
proteins	O
by	O
immunofluorescence	O
(	O
Fig.	O
4	O
)	O
.	O

Furthermore	O
,	O
13	O
proteins	O
were	O
detected	O
with	O
multiple	O
different	O
antibodies	O
,	O
and	O
35	O
proteins	O
(	O
Table	O
1	O
)	O
were	O
detected	O
in	O
both	O
the	O
PowerBlot	O
and	O
Kinexus	O
assays	O
.	O

This	O
provided	O
internal	O
,	O
or	O
independent	O
,	O
confirmation	O
of	O
expression	O
of	O
these	O
proteins	O
.	O

Other	O
studies	O
have	O
also	O
demonstrated	O
the	O
expression	O
of	O
several	O
of	O
the	O
proteins	O
we	O
detected	O
in	O
hESCs	O
.	O

These	O
include	O
Oct4	B
,	O
a	O
key	O
marker	O
of	O
the	O
pluripotent	O
state	O
,	O
Connexin	B
43	I
and	O
GSK3β	B
,	O
confirming	O
the	O
reliability	O
of	O
large	O
-	O
scale	O
western	O
blotting	O
.	O

Finally	O
,	O
several	O
proteins	O
detected	O
by	O
our	O
assays	O
were	O
also	O
detected	O
in	O
hESCs	O
by	O
MS	O
approaches	O
including	O
Karyopherin	B
α	I
[	O
19	O
]	O
.	O

Additionally	O
,	O
the	O
PowerBlot	O
assay	O
was	O
performed	O
in	O
duplicate	O
,	O
and	O
was	O
shown	O
to	O
be	O
highly	O
reproducible	O
.	O

This	O
suggested	O
that	O
this	O
approach	O
should	O
be	O
informative	O
when	O
comparing	O
hESCs	O
to	O
their	O
differentiated	O
derivatives	O
.	O

Two	O
candidate	O
proteins	O
,	O
TNIK	B
and	O
p130	B
Cas	I
,	O
were	O
downregulated	O
,	O
or	O
exhibited	O
altered	O
localization	O
upon	O
spontaneous	O
differentiation	O
of	O
hESCs	O
,	O
respectively	O
.	O

This	O
indicated	O
that	O
they	O
were	O
novel	O
markers	O
of	O
undifferentiated	O
cells	O
and	O
molecules	O
that	O
could	O
be	O
functionally	O
involved	O
with	O
self	O
-	O
renewal	O
.	O

It	O
is	O
impossible	O
in	O
an	O
initial	O
manuscript	O
to	O
analyze	O
and	O
rigorously	O
test	O
all	O
the	O
predictions	O
that	O
could	O
be	O
made	O
from	O
comparing	O
transcriptional	O
and	O
proteomic	O
data	O
sets	O
.	O

However	O
,	O
we	O
did	O
examine	O
key	O
features	O
to	O
illustrate	O
the	O
power	O
of	O
this	O
methodology	O
.	O

Potential	O
new	O
markers	O
for	O
hESCs	O
were	O
identified	O
,	O
the	O
expression	O
and	O
activation	O
of	O
proteins	O
in	O
key	O
self	O
-	O
renewal	O
pathways	O
were	O
confirmed	O
,	O
and	O
a	O
diverse	O
range	O
of	O
proteins	O
were	O
detected	O
and	O
expression	O
correlated	O
with	O
transcriptional	O
analyses	O
.	O

In	O
addition	O
,	O
we	O
highlighted	O
several	O
candidate	O
signaling	O
pathways	O
that	O
may	O
be	O
relevant	O
to	O
self	O
-	O
renewal	O
.	O

Examination	O
of	O
tight	B
junction	I
protein	I
expression	O
indicated	O
that	O
undifferentiated	O
hESCs	O
could	O
form	O
polarized	O
epithelia	O
,	O
which	O
has	O
also	O
been	O
recently	O
suggested	O
by	O
ultrastructural	O
analyses	O
[	O
49	O
]	O
.	O

Discrete	O
localization	O
of	O
ERBB3	B
may	O
also	O
suggest	O
basolateral	O
separation	O
of	O
this	O
receptor	O
from	O
soluble	O
ligand	O
.	O

These	O
analyses	O
highlight	O
that	O
predictions	O
from	O
a	O
combination	O
of	O
transcriptional	O
and	O
proteomic	O
approaches	O
will	O
serve	O
to	O
focus	O
the	O
investigation	O
of	O
hESCs	O
in	O
the	O
future	O
.	O

In	O
summary	O
,	O
we	O
generated	O
a	O
focused	O
proteome	O
of	O
hESCs	O
using	O
large	O
-	O
scale	O
western	O
blotting	O
and	O
sorted	O
the	O
detected	O
proteins	O
according	O
to	O
function	O
and	O
signaling	O
pathways	O
.	O

This	O
characterization	O
provides	O
important	O
basic	O
information	O
on	O
expressed	O
proteins	O
,	O
their	O
isoforms	O
and	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
tools	O
for	O
the	O
continued	O
investigation	O
of	O
the	O
underlying	O
molecular	O
characteristics	O
of	O
hESCs	O
.	O

Importantly	O
,	O
we	O
provide	O
a	O
list	O
of	O
tools	O
,	O
in	O
the	O
form	O
of	O
commercially	O
available	O
antibodies	O
,	O
which	O
can	O
be	O
used	O
to	O
interrogate	O
the	O
function	O
of	O
these	O
molecules	O
in	O
self	O
-	O
renewal	O
or	O
differentiation	O
.	O

Culture	O
of	O
human	O
embryonic	O
stem	O
cellsFor	O
the	O
PowerBlot	O
analysis	O
,	O
enzymatically	O
passaged	O
BG01	O
hESCs	O
were	O
grown	O
as	O
described	O
previously	O
[	O
23	O
]	O
.	O

These	O
conditions	O
were	O
necessary	O
to	O
scale	O
up	O
the	O
culture	O
to	O
generate	O
the	O
milligram	O
amounts	O
of	O
protein	O
lysate	O
required	O
for	O
this	O
analysis	O
.	O

These	O
conditions	O
maintain	O
cell	O
populations	O
that	O
express	O
the	O
appropriate	O
markers	O
of	O
pluripotency	O
and	O
can	O
differentiate	O
to	O
representatives	O
of	O
all	O
three	O
germ	O
layers	O
,	O
but	O
may	O
lead	O
to	O
eventual	O
accumulation	O
of	O
trisomies	O
for	O
chromosomes	O
12	O
,	O
17	O
or	O
X	O
[	O
26	O
]	O
.	O

For	O
the	O
Kinexus	O
assays	O
,	O
BG03	O
hESCs	O
were	O
maintained	O
in	O
MEF	O
-	O
conditioned	O
medium	O
(	O
MEF	O
-	O
CM	O
)	O
without	O
the	O
accumulation	O
of	O
karyotypic	O
abnormalities	O
as	O
described	O
previously	O
[	O
14,26	O
]	O
.hESCs	O
were	O
also	O
maintained	O
in	O
a	O
defined	O
medium	O
as	O
indicated	O
.	O

These	O
conditions	O
are	O
described	O
in	O
detail	O
elsewhere	O
(	O
TCS	O
,	O
AJR	O
,	O
submitted	O
)	O
.	O

Briefly	O
,	O
the	O
media	O
consisted	O
of	O
DMEM	O
/	O
F12	O
(	O
Invitrogen	O
)	O
,	O
2	O
%	O
fatty	O
acid	O
-	O
free	O
Cohn	O
's	O
fraction	O
V	O
BSA	O
(	O
Serologicals	O
)	O
,	O
1	O
×	O
nonessential	O
amino	O
acids	O
,	O
50	O
U	O
/	O
ml	O
penicillin	O
/	O
streptomycin	O
,	O
50	O
μg	O
/	O
ml	O
ascorbic	O
acid	O
,	O
10	O
μg	O
/	O
ml	O
bovine	O
transferrin	B
,	O
0.1	O
mM	O
β	O
-	O
mecaptoethanol	O
(	O
all	O
from	O
Invitrogen	O
)	O
,	O
1	O
×	O
Trace	O
Elements	O
A	O
,	O
B	O
&	O
C	O
(	O
Mediatech	O
)	O
,	O
10	O
ng	O
/	O
ml	O
hergulin1β	B
(	O
Peprotech	O
)	O
,	O
10	O
ng	O
/	O
ml	O
activinA	B
(	O
R&D	O
Systems	O
)	O
,	O
200	O
ng	O
/	O
ml	O
LR3-IGF1	B
(	O
JRH	O
Biosciences	O
)	O
,	O
and	O
8	O
ng	O
/	O
ml	O
FGF2	B
(	O
R&D	O
Systems	O
)	O
.	O

Cultures	O
were	O
passaged	O
using	O
Collagenase	B
IV	I
and	O
plated	O
on	O
growth	O
factor	O
depleted	O
Matrigel	O
(	O
BD	O
Biosciences	O
)	O
diluted	O
1:200	O
.	O

These	O
cultures	O
were	O
karyotypically	O
normal	O
.	O

To	O
partially	O
differentiate	O
hESC	O
cultures	O
for	O
immunostaining	O
analysis	O
,	O
karyotypically	O
normal	O
BG01	O
cells	O
were	O
plated	O
on	O
matrigel	O
and	O
grown	O
for	O
three	O
days	O
in	O
DMEM	O
/	O
F12	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
HyClone	O
)	O
,	O
1	O
×	O
nonessential	O
amino	O
acids	O
,	O
20	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
U	O
/	O
ml	O
penicillin	O
/	O
streptomycin	O
,	O
and	O
0.1	O
mM	O
β	O
-	O
mecaptoethanol	O
.	O

PowerBlot	O
assaysBG01	O
hESC	O
lysate	O
was	O
prepared	O
in	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7.4	O
,	O
1	O
mM	O
sodium	O
orthovanadate	O
and	O
1	O
%	O
SDS	O
,	O
and	O
the	O
PowerBlot	O
assays	O
were	O
performed	O
by	O
BD	O
Biosciences	O
(	O
BD	O
Biosciences	O
)	O
.	O

Briefly	O
,	O
200	O
μg	O
of	O
protein	O
lysate	O
was	O
loaded	O
in	O
a	O
single	O
,	O
gel	O
-	O
wide	O
well	O
,	O
on	O
a	O
SDS-4–15	O
%	O
gradient	O
polyacrylamide	O
gel	O
.	O

The	O
full	O
PowerBlot	O
screen	O
consisted	O
of	O
five	O
gels	O
,	O
which	O
were	O
blotted	O
and	O
probed	O
with	O
934	O
antibodies	O
,	O
and	O
was	O
performed	O
in	O
duplicate	O
with	O
the	O
same	O
cell	O
lysate	O
.	O

The	O
gel	O
dimensions	O
were	O
130	O
×	O
100	O
×	O
0.5	O
mm	O
,	O
and	O
proteins	O
were	O
separated	O
at	O
150	O
volts	O
for	O
1.5	O
hours	O
,	O
and	O
transferred	O
to	O
an	O
Immobilon	O
-	O
P	O
membrane	O
(	O
Millipore	O
)	O
.	O

The	O
membranes	O
were	O
blocked	O
and	O
clamped	O
in	O
a	O
manifold	O
that	O
created	O
40	O
lanes	O
across	O
each	O
membrane	O
.	O

A	O
mix	O
of	O
1	O
to	O
8	O
mouse	O
monoclonal	O
primary	O
antibodies	O
was	O
added	O
to	O
each	O
lane	O
,	O
in	O
dilutions	O
and	O
combinations	O
that	O
had	O
been	O
predetermined	O
to	O
enable	O
accurate	O
identification	O
of	O
well	O
-	O
separated	O
proteins	O
.	O

The	O
predicted	O
sizes	O
of	O
detectable	O
proteins	O
in	O
the	O
blots	O
ranged	O
from	O
10–540	O
kD	O
,	O
and	O
the	O
dilutions	O
of	O
the	O
primary	O
antibodies	O
ranged	O
from	O
1:250	O
to	O
1:15,000.The	O
blots	O
were	O
removed	O
from	O
the	O
manifolds	O
,	O
washed	O
and	O
incubated	O
with	O
goat	O
anti	O
-	O
mouse	O
secondary	O
antibody	O
conjugated	O
to	O
the	O
Alexa680	O
fluorophore	O
(	O
Molecular	O
Probes	O
)	O
.	O

The	O
membranes	O
were	O
scanned	O
using	O
the	O
Odyssey	O
Imaging	O
System	O
(	O
LI	O
-	O
COR	O
)	O
.	O

Molecular	O
weight	O
standards	O
were	O
generated	O
by	O
adding	O
a	O
cocktail	O
of	O
antibodies	O
to	O
P190	B
(	O
190	O
kD	O
)	O
,	O
Adaptin	B
beta	I
(	O
106	O
kD	O
)	O
,	O
STAT-3	B
(	O
92	O
kD	O
)	O
,	O
PTP1D	B
(	O
72	O
kD	O
)	O
,	O
Mek-2	B
(	O
46	O
kD	O
)	O
,	O
RACK-1	B
(	O
36	O
kD	O
)	O
,	O
GRB-2	B
(	O
24	O
kD	O
)	O
and	O
Rap2	B
(	O
21	O
kD	O
)	O
to	O
lane	O
40	O
of	O
gels	O
A	O
-	O
D.	O
Molecular	O
standards	O
for	O
gel	O
E	O
were	O
generated	O
by	O
adding	O
a	O
cocktail	O
of	O
antibodies	O
to	O
Exportin-1	B
/	B
CRM1	I
(	O
112	O
kD	O
)	O
,	O
MCM	B
(	O
83	O
kD	O
)	O
,	O
Nucleoporin	B
p62	I
(	O
62	O
kD	O
)	O
,	O
α	B
-	I
tubulin	I
(	O
55	O
kD	O
)	O
,	O
Actin	B
(	O
42	O
kD	O
)	O
,	O
KNP-1	B
/	B
HES1	I
(	O
28	O
kD	O
)	O
and	O
NTF2	B
(	O
15	O
kD	O
)	O
to	O
lane	O
16	O
,	O
and	O
antibodies	O
to	O
p190	B
(	O
190	O
kD	O
)	O
,	O
Hip1R	B
(	O
120	O
kD	O
)	O
,	O
Transportin	B
(	O
101	O
kD	O
)	O
,	O
Calreticulin	B
(	O
60	O
kD	O
)	O
,	O
Arp3	B
(	O
50	O
kD	O
)	O
,	O
eIF-6	B
(	O
27	O
kD	O
)	O
and	O
Rap2	B
(	O
21	O
kD	O
)	O
to	O
lane	O
17.Bands	O
were	O
detected	O
and	O
raw	O
signal	O
intensity	O
captured	O
automatically	O
using	O
the	O
PDQuest	O
software	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

To	O
normalize	O
the	O
signal	O
intensities	O
,	O
the	O
total	O
raw	O
quantity	O
of	O
each	O
band	O
was	O
divided	O
by	O
the	O
average	O
intensity	O
value	O
of	O
the	O
molecular	O
standards	O
in	O
that	O
image	O
and	O
the	O
normalized	O
values	O
for	O
the	O
duplicate	O
samples	O
were	O
averaged	O
and	O
expressed	O
as	O
normalized	O
intensity	O
units	O
(	O
i.u	O
.	O
)	O
.	O

These	O
values	O
represent	O
the	O
relative	O
signal	O
intensity	O
observed	O
for	O
each	O
identified	O
protein	O
band	O
,	O
rather	O
than	O
relative	O
expression	O
levels	O
of	O
different	O
proteins	O
,	O
due	O
to	O
differences	O
in	O
the	O
efficiencies	O
of	O
antibody	O
binding	O
and	O
dilution	O
of	O
the	O
primary	O
antibodies	O
used	O
.	O

Proteins	O
were	O
identified	O
based	O
on	O
the	O
similarity	O
of	O
expected	O
and	O
observed	O
band	O
migration	O
profiles	O
and	O
bands	O
that	O
could	O
not	O
be	O
identified	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

All	O
identified	O
proteins	O
were	O
verified	O
by	O
visual	O
inspection	O
,	O
and	O
proteins	O
exhibiting	O
a	O
low	O
signal	O
intensity	O
,	O
with	O
an	O
averaged	O
signal	O
of	O
<	O
1000	O
i.u	O
.	O
,	O
were	O
verified	O
by	O
visual	O
inspection	O
using	O
contrast	O
enhancement	O
in	O
Adobe	O
Photoshop	O
.	O

Bands	O
with	O
>	O
800	O
i.u	O
.	O
could	O
typically	O
be	O
observed	O
without	O
additional	O
image	O
enhancement	O
.	O

Microsoft	O
Excel	O
files	O
were	O
generated	O
that	O
contained	O
information	O
on	O
:	O
gel	O
number	O
,	O
lane	O
number	O
,	O
antibody	O
catalogue	O
number	O
(	O
BD	O
Biosciences	O
)	O
,	O
protein	O
name	O
,	O
expected	O
size	O
,	O
observed	O
size	O
,	O
repeat	O
1	O
i.u	O
.	O

value	O
,	O
repeat	O
2	O
i.u	O
.	O

value	O
,	O
averaged	O
i.u	O
.	O

value	O
,	O
antibody	O
dilution	O
,	O
outline	O
of	O
protein	O
function	O
,	O
Entrez	O
gene	O
and	O
SwissProt	O
identification	O
numbers	O
.	O

These	O
tables	O
were	O
used	O
to	O
list	O
expressed	O
proteins	O
(	O
Additional	O
File	O
1	O
)	O
.	O

Kinexus	O
assaysPreparation	O
of	O
the	O
BG03	O
cell	O
lysate	O
and	O
western	O
blotting	O
was	O
performed	O
according	O
to	O
published	O
protocols	O
[	O
50	O
]	O
.	O

Briefly	O
,	O
cell	O
lysate	O
was	O
prepared	O
in	O
20	O
mM	O
MOPS	O
pH	O
7.0	O
,	O
2	O
mM	O
EGTA	O
,	O
5	O
mM	O
EDTA	O
,	O
30	O
mM	O
sodium	O
fluoride	O
,	O
40	O
mM	O
β	O
-	O
glycerolphosphate	O
pH	O
7.2	O
,	O
20	O
mM	O
sodium	O
pyrophosphate	O
,	O
1	O
mM	O
sodium	O
orthovanadate	O
,	O
1	O
mM	O
PMSF	O
,	O
3	O
mM	O
benzamidine	O
,	O
5	O
μM	O
pepstatin	O
,	O
10	O
μM	O
leupeptin	O
,	O
0.5	O
%	O
nonidet	O
P-40	O
,	O
with	O
the	O
final	O
pH	O
adjusted	O
to	O
7.2	O
.	O

The	O
Kinexus	O
assays	O
for	O
protein	B
kinases	I
(	O
KPKS-1.2A	O
and	O
B	O
[	O
76	O
antibodies	O
]	O
)	O
,	O
phosphatases	B
(	O
KPPS-1.2	O
[	O
27	O
antibodies	O
]	O
)	O
and	O
phosporylated	O
sites	O
in	O
cell	O
signaling	O
molecules	O
(	O
KPSS-3.1	O
[	O
37	O
antibodies	O
]	O
)	O
were	O
performed	O
by	O
Kinexus	O
.	O

The	O
Bio	O
-	O
Rad	O
Mini	O
-	O
PROTEAN	O
3	O
electrophoresis	O
system	O
was	O
used	O
to	O
separate	O
proteins	O
by	O
SDS	O
-	O
PAGE	O
.	O

For	O
each	O
assay	O
,	O
250	O
μg	O
of	O
cell	O
lysate	O
was	O
loaded	O
in	O
a	O
single	O
well	O
spanning	O
the	O
width	O
of	O
the	O
stacking	O
gel	O
,	O
then	O
separated	O
through	O
a	O
12.5	O
%	O
SDS	O
-	O
Polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
PVDF	O
membrane	O
.	O

A	O
20-lane	O
manifold	O
was	O
placed	O
over	O
the	O
membrane	O
and	O
a	O
different	O
mixture	O
of	O
up	O
to	O
3	O
primary	O
antibodies	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
combinations	O
of	O
primary	O
antibodies	O
had	O
been	O
predetermined	O
to	O
detect	O
well	O
-	O
separated	O
proteins	O
,	O
avoiding	O
crossreaction	O
to	O
different	O
proteins	O
that	O
co	O
-	O
migrate	O
.	O

The	O
primary	O
antibodies	O
were	O
rabbit	O
and	O
goat	O
polyclonal	O
,	O
and	O
mouse	O
monoclonal	O
antibodies	O
,	O
diluted	O
1:1000	O
.	O

After	O
incubation	O
with	O
the	O
primary	O
antibodies	O
,	O
the	O
membranes	O
were	O
removed	O
from	O
the	O
manifolds	O
,	O
washed	O
and	O
incubated	O
with	O
a	O
mix	O
of	O
the	O
appropriate	O
secondary	O
antibodies	O
.	O

The	O
secondary	O
antibodies	O
were	O
donkey	O
anti	O
-	O
rabbit	O
(	O
at	O
1:5000	O
)	O
,	O
sheep	O
anti	O
-	O
mouse	O
(	O
at	O
1:10,000	O
)	O
and	O
bovine	O
anti	O
-	O
goat	O
(	O
at	O
1:10,000	O
)	O
,	O
all	O
conjugated	O
with	O
horse	B
radish	I
peroxidase	I
.	O

The	O
membranes	O
were	O
washed	O
and	O
immunoreactive	O
bands	O
detected	O
by	O
enhanced	O
chemiluminescence	O
(	O
Amersham	O
-	O
Pharmacia	O
)	O
using	O
a	O
FluorS	O
Max	O
Multi	O
-	O
imager	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Prestained	O
size	O
markers	O
(	O
201.5	O
,	O
156.8	O
,	O
106	O
,	O
79.7	O
,	O
48.4	O
,	O
37.8	O
,	O
23.3	O
,	O
and	O
18.2	O
kD	O
)	O
and	O
predetermined	O
human	O
-	O
specific	O
protein	O
migration	O
profiles	O
were	O
used	O
to	O
accurately	O
identify	O
proteins	O
using	O
the	O
Kinexus	O
immuno	O
-	O
reactivity	O
identification	O
system	O
(	O
IRIS	O
)	O
software	O
.	O

Detected	O
proteins	O
were	O
verified	O
by	O
visual	O
inspection	O
.	O

ImmunocytochemistryImmunocytochemistry	O
and	O
staining	O
procedures	O
were	O
as	O
described	O
previously	O
[	O
51	O
]	O
.	O

Briefly	O
,	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
for	O
half	O
an	O
hour	O
,	O
blocked	O
in	O
blocking	O
buffer	O
(	O
5	O
%	O
goat	O
serum	O
,	O
1	O
%	O
BSA	O
,	O
0.1	O
%	O
Triton	O
X-100	O
)	O
for	O
1	O
hour	O
followed	O
by	O
incubation	O
with	O
the	O
primary	O
antibody	O
at	O
4	O
°	O
C	O
overnight	O
.	O

Appropriately	O
coupled	O
secondary	O
antibodies	O
(	O
Molecular	O
Probes	O
)	O
were	O
used	O
for	O
single	O
and	O
double	O
labeling	O
.	O

All	O
secondary	O
antibodies	O
were	O
tested	O
for	O
cross	O
reactivity	O
and	O
non	O
-	O
specific	O
immunoreactivity	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
:	O
ABP-280	B
(	O
1:250	O
,	O
BD	O
Biosciences	O
610798	O
)	O
,	O
CtBP1	B
(	O
1:1000	O
,	O
BD	O
Biosciences	O
612042	O
)	O
,	O
CtBP2	B
(	O
1:1000	O
,	O
BD	O
Biosciences	O
612044	O
)	O
,	O
GS-28	B
(	O
1:2000	O
,	O
BD	O
Biosciences	O
611184	O
)	O
,	O
HDJ-2	B
(	O
1:100	O
,	O
BD	O
Biosciences	O
611872	O
)	O
,	O
L	B
-	I
Caldesmon	I
(	O
1:2000	O
,	O
BD	O
Biosciences	O
610660	O
)	O
,	O
Rabaptin-5	B
(	O
1:500	O
,	O
BD	O
Biosciences	O
611080	O
)	O
,	O
phospho	B
-	I
p130	I
Cas	I
(	O
Tyr165	O
)	O
(	O
1:50	O
,	O
Cell	O
Signaling	O
Technology	O
4015	O
)	O
,	O
phospho	B
-	I
Ras	I
-	I
GAP	I
(	O
pY460	O
)	O
(	O
1:250	O
,	O
BD	O
Biosciences	O
612736	O
)	O
,	O
Ras	B
-	I
GAP	I
(	O
1:250	O
,	O
BD	O
Biosciences	O
610043	O
)	O
,	O
Shc	B
-	I
C	I
(	O
1:1000	O
,	O
BD	O
Biosciences	O
610642	O
)	O
,	O
Oct-4	B
(	O
Santa	O
Cruz	O
biotechnology	O
,	O
1:200	O
SC-8628	O
)	O
,	O
TNIK	B
(	O
1:100	O
,	O
BD	O
Biosciences	O
,	O
612250	O
)	O
,	O
p130	B
Cas	I
(	O
1:100	O
,	O
BD	O
Biosciences	O
,	O
610272	O
)	O
,	O
ERBB2	B
(	O
1:100	O
,	O
Lab	O
Vision	O
,	O
9G6.10	O
)	O
,	O
ERBB3	B
(	O
1:100	O
,	O
R&D	O
Systems	O
,	O
MAB348	O
)	O
,	O
ZO1	B
(	O
1:100	O
,	O
Invitrogen	O
,	O
61–7300	O
)	O
,	O
or	O
Occludin	B
(	O
1:100	O
,	O
Invitrogen	O
,	O
71–1500	O
)	O
.	O

Hoechst	O
(	O
Invitrogen	O
)	O
or	O
DAPI	O
(	O
Sigma	O
)	O
were	O
used	O
to	O
identify	O
nuclei	O
,	O
and	O
Triton	O
X-100	O
was	O
omitted	O
when	O
staining	O
for	O
extracellular	O
antigens	O
(	O
ZO1	B
,	O
occludin	B
,	O
ERBB2	B
/	I
3	I
)	O
.	O

Images	O
were	O
captured	O
on	O
an	O
Olympus	O
or	O
Nikon	O
fluorescence	O
microscope	O
.	O

lllumina	O
data	O
and	O
comparison	O
to	O
proteomic	O
databaseExpression	O
levels	O
of	O
proteins	O
detected	O
by	O
the	O
PowerBlot	O
assay	O
were	O
compared	O
to	O
our	O
previous	O
published	O
database	O
of	O
multiple	O
hESC	O
lines	O
examined	O
using	O
the	O
Illumina	O
bead	O
array	O
platform	O
(	O
Liu	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Averaged	O
transcript	O
expression	O
signals	O
from	O
the	O
BG01	O
,	O
BG02	O
and	O
BG03	O
cell	O
lines	O
were	O
converted	O
to	O
a	O
+	O
/-	O

format	O
,	O
based	O
on	O
the	O
following	O
criteria	O

:	O
A	O
mean	O
transcript	O
detection	O
level	O
of	O
>	O
5,000	O
was	O
designated	O
as	O
+	O
+	O
+	O
+	O
;	O

1,000–5,000	O
as	O
+	O
+	O
+	O
;	O
100–1,000	O
as	O
+	O
+	O
;	O
30–100	O
as	O
+	O
;	O
and	O
signals	O
<	O
30	O
was	O
represented	O
as	O
-	O
.	O

In	O
parallel	O
,	O
the	O
protein	O
expression	O
levels	O
were	O
converted	O
to	O
a	O
+	O
/-	O

format	O
based	O
on	O
these	O
criteria	O
:	O
i.u	O
.	O

>	O
10,000	O
as	O
+	O
+	O
+	O
+	O
;	O
5,000–10,000	O
as	O
+	O
+	O
+	O
;	O
1,000–5,000	O
as	O
+	O
+	O
;	O
100–1,000	O
as	O
+	O
.	O

In	O
addition	O
,	O
genes	O
were	O
categorized	O
into	O
the	O
same	O
functional	O
/	O
signaling	O
pathways	O
as	O
per	O
the	O
western	O
blot	O
database	O
.	O

BackgroundHuman	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
offer	O
a	O
virtually	O
unlimited	O
source	O
of	O
neural	O
cells	O
for	O
structural	O
repair	O
in	O
neurological	O
disorders	O
,	O
such	O
as	O
stroke	O
.	O

Neural	O
cells	O
can	O
be	O
derived	O
from	O
hESCs	O
either	O
by	O
direct	O
enrichment	O
,	O
or	O
by	O
isolating	O
specific	O
growth	O
factor	O
-	O
responsive	O
and	O
expandable	O
populations	O
of	O
human	O
neural	O
stem	O
cells	O
(	O
hNSCs	O
)	O
.	O

Studies	O
have	O
indicated	O
that	O
the	O
direct	O
enrichment	O
method	O
generates	O
a	O
heterogeneous	O
population	O
of	O
cells	O
that	O
may	O
contain	O
residual	O
undifferentiated	O
stem	O
cells	O
that	O
could	O
lead	O
to	O
tumor	O
formation	O
in	O
vivo	O
.	O

Methods	O
/	O
Principal	O
FindingsWe	O
isolated	O
an	O
expandable	O
and	O
homogenous	O
population	O
of	O
hNSCs	O
(	O
named	O
SD56	O
)	O
from	O
hESCs	O
using	O
a	O
defined	O
media	O
supplemented	O
with	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
,	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
and	O
leukemia	B
inhibitory	I
growth	I
factor	I
(	O
LIF	B
)	O
.	O

These	O
hNSCs	O
grew	O
as	O
an	O
adherent	O
monolayer	O
culture	O
.	O

They	O
were	O
fully	O
neuralized	O
and	O
uniformly	O
expressed	O
molecular	O
features	O
of	O
NSCs	O
,	O
including	O
nestin	B
,	O
vimentin	B
and	O
radial	O
glial	O
markers	O
.	O

These	O
hNSCs	O
did	O
not	O
express	O
the	O
pluripotency	O
markers	O
Oct4	B
or	O
Nanog	B
,	O
nor	O
did	O
they	O
express	O
markers	O
for	O
the	O
mesoderm	O
or	O
endoderm	O
lineages	O
.	O

The	O
self	O
-	O
renewal	O
property	O
of	O
the	O
hNSCs	O
was	O
characterized	O
by	O
a	O
predominant	O
symmetrical	O
mode	O
of	O
cell	O
division	O
.	O

The	O
SD56	O
hNSCs	O
differentiated	O
into	O
neurons	O
,	O
astrocytes	O
and	O
oligodendrocytes	O
throughout	O
multiple	O
passages	O
in	O
vitro	O
,	O
as	O
well	O
as	O
after	O
transplantation	O
.	O

Together	O
,	O
these	O
criteria	O
confirm	O
the	O
definitive	O
NSC	O
identity	O
of	O
the	O
SD56	O
cell	O
line	O
.	O

Importantly	O
,	O
they	O
exhibited	O
no	O
chromosome	O
abnormalities	O
and	O
did	O
not	O
form	O
tumors	O
after	O
implantation	O
into	O
rat	O
ischemic	O
brains	O
and	O
into	O
naïve	O
nude	O
rat	O
brains	O
and	O
flanks	O
.	O

Furthermore	O
,	O
hNSCs	O
isolated	O
under	O
these	O
conditions	O
migrated	O
toward	O
the	O
ischemia	O
-	O
injured	O
adult	O
brain	O
parenchyma	O
and	O
improved	O
the	O
independent	O
use	O
of	O
the	O
stroke	O
-	O
impaired	O
forelimb	O
two	O
months	O
post	O
-	O
transplantation	O
.	O

Conclusions	O
/	O
SignificanceThe	O
SD56	O
human	O
neural	O
stem	O
cells	O
derived	O
under	O
the	O
reported	O
conditions	O
are	O
stable	O
,	O
do	O
not	O
form	O
tumors	O
in	O
vivo	O
and	O
enable	O
functional	O
recovery	O
after	O
stroke	O
.	O

These	O
properties	O
indicate	O
that	O
this	O
hNSC	O
line	O
may	O
offer	O
a	O
renewable	O
,	O
homogenous	O
source	O
of	O
neural	O
cells	O
that	O
will	O
be	O
valuable	O
for	O
basic	O
and	O
translational	O
research	O
.	O

To	O
date	O
there	O
have	O
been	O
no	O
effective	O
treatments	O
for	O
improving	O
residual	O
structural	O
and	O
functional	O
deficits	O
resulting	O
from	O
stroke	O
.	O

Current	O
therapeutic	O
approaches	O
,	O
such	O
as	O
the	O
use	O
of	O
thrombolytics	O
,	O
benefit	O
only	O
1	O
to	O
4	O
%	O
of	O
patients	O
[	O
1	O
]	O
.	O

Consequently	O
,	O
the	O
majority	O
of	O
stroke	O
patients	O
experience	O
progression	O
of	O
ischemia	O
associated	O
with	O
debilitating	O
neurological	O
deficits	O
.	O

Recent	O
evidence	O
has	O
suggested	O
that	O
the	O
transplantation	O
of	O
cells	O
derived	O
from	O
cord	O
blood	O
,	O
bone	O
marrow	O
or	O
brain	O
tissue	O
(	O
fetal	O
and	O
adult	O
)	O
enhances	O
sensorimotor	O
function	O
in	O
experimental	O
models	O
of	O
stroke	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

However	O
,	O
the	O
normal	O
human	O
-	O
derived	O
somatic	O
stem	O
cells	O
used	O
in	O
these	O
studies	O
have	O
a	O
limited	O
capacity	O
to	O
differentiate	O
into	O
the	O
diverse	O
neural	O
cell	O
types	O
optimal	O
for	O
structural	O
and	O
physiological	O
tissue	O
repair	O
and	O
are	O
not	O
amenable	O
for	O
large	O
-	O
scale	O
cell	O
production	O
.	O

Unlike	O
other	O
sources	O
of	O
stem	O
cells	O
,	O
hESC	O
lines	O
possess	O
a	O
nearly	O
unlimited	O
self	O
-	O
renewal	O
capacity	O
and	O
the	O
developmental	O
potential	O
to	O
differentiate	O
into	O
virtually	O
any	O
cell	O
type	O
of	O
the	O
organism	O
.	O

As	O
such	O
,	O
they	O
constitute	O
an	O
ideal	O
source	O
of	O
cells	O
for	O
regenerative	O
medicine	O
.	O

The	O
successful	O
derivation	O
of	O
hESC	O
lines	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
preimplantation	O
embryos	O
and	O
their	O
long	O
-	O
term	O
maintenance	O
in	O
vitro	O
over	O
multiple	O
passages	O
has	O
been	O
demonstrated	O
[	O
4	O
]	O
and	O
standardized	O
.	O

Differentiation	O
and	O
enrichment	O
processes	O
that	O
direct	O
hESCs	O
towards	O
a	O
neural	O
lineage	O
have	O
also	O
been	O
achieved	O
.	O

To	O
promote	O
neuralization	O
,	O
ESCs	O
were	O
cultured	O
in	O
a	O
defined	O
media	O
supplemented	O
with	O
morphogens	O
or	O
growth	O
factors	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
or	O
cultured	O
under	O
conditions	O
that	O
promote	O
""""	O
rosettes	O
""""	O
,	O
structures	O
morphologically	O
similar	O
to	O
the	O
developing	O
neural	O
tube	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

This	O
neuralization	O
process	O
has	O
proven	O
invaluable	O
in	O
understanding	O
the	O
specification	O
of	O
hESC	O
-	O
derived	O
neural	O
tissue	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

However	O
,	O
the	O
enriched	O
neural	O
progeny	O
derived	O
displayed	O
overgrowth	O
and	O
limited	O
migration	O
after	O
grafting	O
into	O
normal	O
newborn	O
mice	O
[	O
13	O
]	O
and	O
lesioned	O
adult	O
rat	O
striatum	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

The	O
inner	O
cores	O
of	O
these	O
grafts	O
contained	O
tumorigenic	O
precursor	O
cells	O
(	O
reviewed	O
in	O
[	O
17	O
]	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
neural	O
cells	O
generated	O
by	O
acute	O
exposure	O
to	O
growth	O
factors	O
and/or	O
morphogens	O
may	O
still	O
be	O
heterogeneous	O
and	O
potentially	O
tumorigenic	O
.	O

We	O
report	O
an	O
alternative	O
method	O
for	O
the	O
isolation	O
and	O
the	O
perpetuation	O
of	O
a	O
multipotent	O
hNSC	O
line	O
from	O
the	O
hESCs	O
with	O
a	O
primitive	O
mode	O
of	O
self	O
-	O
renewal	O
.	O

We	O
also	O
demonstrate	O
their	O
long	O
-	O
term	O
expansion	O
,	O
non	O
-	O
tumorigenic	O
properties	O
and	O
functional	O
engraftability	O
in	O
an	O
experimental	O
model	O
of	O
stroke	O
.	O

1	O
.	O

In	O
vitro	O
isolation	O
,	O
growth	O
and	O
differentiation	O
of	O
hESC	O
-	O
derived	O
hNSCsThe	O
hESCs	O
were	O
maintained	O
and	O
expanded	O
on	O
mouse	O
feeder	O
layer	O
in	O
media	O
supplemented	O
with	O
bFGF	B
(	O
Figure	O
1A	O
)	O
.	O

After	O
cell	O
dissociation	O
,	O
a	O
portion	O
of	O
the	O
hESCs	O
was	O
cultured	O
in	O
serum	O
free	O
medium	O
containing	O
EGF	B
,	O
bFGF	B
and	O
LIF	B
.	O

These	O
factors	O
are	O
known	O
to	O
stimulate	O
the	O
proliferation	O
of	O
human	O
fetal	O
-	O
derived	O
NSCs	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

After	O
3	O
days	O
in	O
vitro	O
(	O
DIV	O
)	O
,	O
there	O
was	O
selective	O
survival	O
and	O
growth	O
of	O
cells	O
that	O
aggregated	O
in	O
clusters	O
or	O
spheres	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
primary	O
spheres	O
were	O
harvested	O
and	O
replated	O
in	O
fresh	O
media	O
.	O

During	O
the	O
following	O
week	O
,	O
the	O
spheres	O
attached	O
to	O
the	O
flask	O
and	O
a	O
fibroblast	O
-	O
like	O
cell	O
population	O
began	O
to	O
migrate	O
out	O
(	O
Figure	O
1C	O
)	O
.	O

Secondary	O
spheres	O
(	O
2	O
°	O
spheres	O
)	O
were	O
generated	O
from	O
these	O
cultures	O
and	O
lifted	O
off	O
by	O
the	O
end	O
of	O
the	O
week	O
leaving	O
a	O
hollow	O
in	O
the	O
middle	O
of	O
the	O
attached	O
cells	O
(	O
Figure	O
1D	O
)	O
.	O

The	O
floating	O
2	O
°	O
spheres	O
were	O
collected	O
and	O
replated	O
in	O
fresh	O
growth	O
medium	O
for	O
2	O
weeks	O
.	O

The	O
cultures	O
were	O
then	O
passaged	O
by	O
collagenase	B
cell	O
dissociation	O
every	O
7	O
DIV	O
for	O
an	O
additional	O
4	O
passages	O
(	O
Figure	O
S1	O
)	O
.	O

At	O
the	O
5th	O
and	O
6th	O
passages	O
,	O
spheres	O
were	O
dissociated	O
into	O
a	O
single	O
-	O
cell	O
suspension	O
using	O
trypsin	B
-	O
EDTA	O
.	O

At	O
this	O
stage	O
there	O
was	O
a	O
change	O
in	O
the	O
hNSCs	O
'	O
adherent	O
properties	O
,	O
and	O
the	O
cells	O
began	O
to	O
grow	O
as	O
a	O
monolayer	O
with	O
multiple	O
foci	O
of	O
cells	O
throughout	O
the	O
culture	O
(	O
Figure	O
1F	O
)	O
.	O

The	O
adherent	O
hNSC	O
culture	O
stained	O
uniformly	O
for	O
nestin	B
(	O
Figure	O
1	O
K	O
)	O
,	O
vimentin	B
(	O
Figure	O
1L	O
)	O
and	O
with	O
the	O
radial	O
glial	O
marker	O
3CB2	B
(	O
Figure	O
1	O
M	O
)	O
indicating	O
their	O
homogeneity	O
and	O
NSC	O
identity	O
.	O

Under	O
these	O
culture	O
conditions	O
,	O
it	O
is	O
noteworthy	O
that	O
we	O
did	O
not	O
observe	O
the	O
formation	O
of	O
rosettes	O
which	O
has	O
been	O
previously	O
reported	O
to	O
occur	O
under	O
certain	O
conditions	O
during	O
neuralization	O
of	O
hESCs	O
[	O
8	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

RT	O
-	O
PCR	O
analysis	O
confirmed	O
that	O
these	O
hNSCs	O
did	O
not	O
express	O
the	O
pluripotency	O
transcripts	O
Oct-4	B
and	O
Nanog	B
(	O
Figure	O
1I	O
)	O
.	O

Furthermore	O
,	O
the	O
hNSCs	O
did	O
not	O
express	O
transcripts	O
for	O
brachyury	B
and	O
foxa2	B
,	O
marker	O
genes	O
for	O
mesoderm	O
and	O
endoderm	O
respectively	O
(	O
negative	O
result	O
,	O
data	O
not	O
shown	O
)	O
.10.1371	O
/	O
journal.pone.0001644.g001Figure	O
1Isolation	O
and	O
purification	O
of	O
hNSCs	O
from	O
the	O
hESCs	O
.	O

The	O
hESCs	O
were	O
grown	O
on	O
a	O
mouse	O
feeder	O
layer	O
(	O
A	O
)	O
.	O

Primary	O
neurospheres	O
(	O
B	O
)	O
were	O
isolated	O
and	O
replated	O
to	O
eliminate	O
other	O
non	O
-	O
neural	O
cells	O
.	O

The	O
selectively	O
harvested	O
secondary	O
neurospheres	O
(	O
arrow	O
in	O
C	O
)	O
,	O
left	O
behind	O
hollow	O
cores	O
in	O
the	O
surface	O
area	O
(	O
star	O
in	O
D	O
)	O
where	O
they	O
attached	O
earlier	O
.	O

They	O
were	O
perpetuated	O
for	O
an	O
additional	O
5	O
passages	O
(	O
E	O
)	O
.	O

These	O
2	O
°	O
spheres	O
were	O
then	O
passaged	O
using	O
a	O
single	O
cell	O
dissociation	O
protocol	O
(	O
F	O
)	O
.	O

Arrow	O
in	O
F	O
shows	O
an	O
example	O
of	O
a	O
focus	O
of	O
proliferating	O
cells	O
.	O

(	O
G	O
,	O
H	O
)	O
The	O
hNSCs	O
were	O
passaged	O
every	O
5–7	O
days	O
,	O
as	O
described	O
in	O
the	O
Methods	O
section	O
.	O

Starting	O
from	O
an	O
initial	O
population	O
of	O
1	O
million	O
cells	O
,	O
the	O
cumulative	O
cell	O
number	O
was	O
calculated	O
at	O
each	O
passage	O
as	O
the	O
fold	O
of	O
increase	O
×	O
the	O
total	O
cell	O
number	O
and	O
plotted	O
as	O
logarithm	O
with	O
base	O
2	O
in	O
function	O
of	O
time	O
(	O
G	O
)	O
.	O

The	O
cell	O
perpetuation	O
(	O
G	O
)	O
and	O
population	O
doubling	O
(	O
H	O
)	O
analysis	O
demonstrated	O
the	O
continuous	O
and	O
stable	O
growth	O
of	O
the	O
hNSCs	O
.	O

(	O
I	O
)	O
RT	O
-	O
PCR	O
analysis	O
showing	O
the	O
down	O
regulation	O
of	O
the	O
pluripotency	O
transcripts	O
Oct4	B
and	O
Nanog	B
in	O
secondary	O
neurospheres	O
and	O
in	O
expanded	O
hNSCs	O
at	O
passage	O
8	O
(	O
P8	O
)	O
.	O

(	O
J	O
)	O
Cytogenetic	O
evaluation	O
of	O
the	O
SD56	O
hNSCs	O
line	O
at	O
passage	O
12	O
by	O
standard	O
G	O
-	O
banding	O
was	O
performed	O
.	O

Twenty	O
metaphase	O
cells	O
were	O
analyzed	O
and	O
showed	O
a	O
normal	O
female	O
chromosome	O
complement	O
(	O
46,XX	O
)	O
.	O

Isolated	O
and	O
expanded	O
hNSCs	O
expressed	O
the	O
neural	O
precursor	O
cell	O
markers	O
nestin	B
(	O
K	O
)	O
,	O
Vimentin	B
(	O
L	O
)	O
and	O
the	O
radial	O
glial	O
cell	O
marker	O
3CB2	B
(	O
M	O
)	O
in	O
virtually	O
all	O
the	O
progeny	O
.	O

(	O
N	O
-	O
P	O
)	O
Clonal	O
self	O
-	O
renewal	O
ability	O
of	O
the	O
isolated	O
hNSCs	O
through	O
symmetrical	O
cell	O
division	O
.	O

Single	O
(	O
N	O
)	O
,	O
two	O
-	O
cell	O
stage	O
(	O
O	O
)	O
and	O
four	O
-	O
cell	O
stage	O
(	O
P	O
)	O
of	O
a	O
hNSC	O
proliferating	O
over	O
a	O
3-day	O
culture	O
period	O
.	O

Note	O
the	O
symmetrical	O
segregation	O
of	O
BrdU	O
and	O
nestin	B
in	O
the	O
progeny	O
.	O

Bars	O
:	O
(	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
)	O
200	O
µm	O
;	O
(	O
E	O
,	O
F	O
)	O
100	O
µm	O
;	O
(	O
K	O
–	O
M	O
)	O
20	O
µm	O
;	O
(	O
N	O
–	O
P	O
)	O
10	O
µm	O
.	O

To	O
ascertain	O
self	O
-	O
renewal	O
ability	O
under	O
clonal	O
conditions	O
,	O
a	O
single	O
cell	O
suspension	O
was	O
plated	O
at	O
clonal	O
density	O
(	O
1–2	O
cell	O
/	O
10	O
µl	O
)	O
.	O

To	O
determine	O
if	O
the	O
hNSCs	O
divide	O
symmetrically	O
,	O
we	O
pulsed	O
cultures	O
with	O
the	O
thymidine	O
analog	O
,	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
,	O
after	O
plating	O
and	O
looked	O
for	O
the	O
expression	O
of	O
nestin	B
in	O
the	O
progeny	O
.	O

Cultures	O
were	O
fixed	O
after	O
1	O
,	O
2	O
or	O
3	O
DIV	O
(	O
Figure	O
1N	O
–	O
P	O
)	O
.	O

After	O
2	O
days	O
,	O
plated	O
single	O
cells	O
first	O
underwent	O
a	O
symmetric	O
cell	O
division	O
and	O
gave	O
rise	O
to	O
daughter	O
cells	O
that	O
were	O
both	O
positive	O
for	O
BrdU	O
and	O
nestin	B
.	O

The	O
clone	O
of	O
cells	O
continued	O
to	O
grow	O
over	O
the	O
3	O
DIV	O
and	O
all	O
the	O
progeny	O
expressed	O
nestin	B
.	O

BrdU	O
labeling	O
demonstrated	O
that	O
it	O
was	O
rare	O
for	O
only	O
one	O
daughter	O
cell	O
to	O
inherit	O
the	O
BrdU	O
and	O
thus	O
had	O
undergone	O
asymmetric	O
segregation	O
of	O
the	O
chromatids	O
(	O
Figure	O
S2	O
)	O
.	O

G	O
-	O
band	O
karyotyping	O
of	O
these	O
hNSCs	O
confirmed	O
the	O
normal	O
,	O
non	O
-	O
transformed	O
nature	O
of	O
cells	O
after	O
12	O
passages	O
(	O
Figure	O
1J	O
)	O
.	O

We	O
named	O
the	O
derived	O
hNSCs	O
SD56	O
(	O
intermittently	O
referred	O
to	O
as	O
SD56	O
hNSCs	O
or	O
hNSCs	O
)	O
.Under	O
these	O
defined	O
growth	O
conditions	O
,	O
the	O
hNSCs	O
showed	O
stable	O
growth	O
with	O
a	O
2.7±0.2	O
fold	O
increase	O
every	O
5	O
to	O
7	O
days	O
(	O
Figure	O
1	O
G	O
)	O
.	O

The	O
population	O
doubling	O
at	O
each	O
passage	O
averaged	O
at	O
1.4±0.1	O
(	O
Figure	O
1H	O
)	O
.	O

The	O
viability	O
of	O
hNSCs	O
at	O
each	O
passage	O
was	O
consistent	O
at	O
the	O
approximate	O
value	O
of	O
98	O
%	O
.	O

The	O
projected	O
cumulative	O
cell	O
numbers	O
demonstrated	O
that	O
trillions	O
of	O
cells	O
could	O
be	O
generated	O
over	O
a	O
period	O
of	O
5	O
months	O
(	O
Figure	O
1	O
G	O
)	O
.	O

We	O
expanded	O
the	O
isolated	O
hNSCs	O
lines	O
for	O
over	O
20	O
passages	O
with	O
a	O
stable	O
phenotype	O
.	O

An	O
initial	O
cell	O
bank	O
of	O
75	O
vials	O
containing	O
2	O
to	O
5	O
million	O
cells	O
each	O
was	O
generated	O
and	O
cryopreserved	O
.	O

Upon	O
removal	O
of	O
the	O
mitogenic	O
factors	O
and	O
plating	O
on	O
a	O
coverslip	O
pre	O
-	O
coated	O
with	O
poly	O
-	O
L	O
-	O
ornithine	O
(	O
PLO	O
)	O
substrate	O
,	O
the	O
hNSCs	O
spontaneously	O
differentiated	O
into	O
neurons	O
,	O
astrocytes	O
and	O
oligodendrocytes	O
,	O
a	O
property	O
that	O
is	O
consistent	O
with	O
normal	O
multipotent	O
hNSCs	O
(	O
Figure	O
2	O
)	O
.	O

After	O
2	O
DIV	O
,	O
hNSCs	O
expressed	O
transcripts	O
for	O
the	O
neural	O
-	O
specific	O
genes	O
nestin	B
,	O
Notch1	B
and	O
neural	B
cell	I
adhesion	I
molecule	I
(	O
N	B
-	I
CAM	I
)	O
(	O
Figure	O
2A	O
)	O
and	O
for	O
the	O
lineage	O
specific	O
markers	O
β	B
-	I
tubulin	I
class	I
III	I
,	O
medium	B
-	I
size	I
neurofilament	I
(	O
NF	B
-	I
M	I
)	O
and	O
microtubule	B
-	I
associated	I
protein	I
2	I
(	O
MAP-2	B
)	O
for	O
neurons	O
,	O
GFAP	B
for	O
astrocytes	O
and	O
myelin	B
basic	I
protein	I
(	O
MBP	B
)	O
for	O
oligodendrocytes	O
(	O
Figure	O
2A	O
)	O
.	O

Transcripts	O
for	O
the	O
GABAergic	O
cell	O
marker	O
glutamic	B
acid	I
decarboxylase	I
(	O
GAD	B
)	O
were	O
expressed	O
,	O
but	O
transcripts	O
for	O
the	O
tyrosine	B
hydroxylase	I
(	O
TH	B
)	O
,	O
a	O
marker	O
for	O
dopaminergic	O
neurons	O
,	O
were	O
undetectable	O
.	O

Immunocytochemical	O
analysis	O
(	O
Figure	O
2B	O
–	O
F	O
)	O
of	O
10	O
day	O
-	O
old	O
cultures	O
demonstrated	O
that	O
the	O
proportion	O
of	O
nestin+	B
cells	O
was	O
36.6±2.7	O
%	O
,	O
62.5±2.8	O
%	O
expressed	O
the	O
neuronal	O
marker	O
TuJ1	B
,	O
1.9±0.3	O
%	O
expressed	O
the	O
astrocytic	O
marker	O
GFAP	B
and	O
7.1±0.4	O
%	O
were	O
oligodendrocytes	O
and	O
expressed	O
galactocerebrocide	B
(	O
GC	B
)	O
(	O
Figure	O
2F	O
)	O
.	O

A	O
subset	O
(	O
9.8±1.6	O
%	O
)	O
of	O
the	O
GFAP+	B
astrocytes	O
co	O
-	O
expressed	O
nestin.10.1371	B
/	O
journal.pone.0001644.g002Figure	O
2hESC	O
-	O
derived	O
hNSCs	O
spontaneously	O
differentiated	O
into	O
the	O
3	O
principal	O
central	O
nervous	O
system	O
cell	O
types	O
.	O

Dissociated	O
hNSCs	O
were	O
washed	O
free	O
of	O
growth	O
factors	O
and	O
plated	O
on	O
poly	O
-	O
L	O
-	O
onithine	O
coated	O
glass	O
coverslips	O
.	O

Differentiated	O
cultures	O
were	O
either	O
harvested	O
after	O
2	O
DIV	O
for	O
total	O
RNA	O
extraction	O
and	O
RT	O
-	O
PCR	O
analysis	O
or	O
fixed	O
after	O
10	O
DIV	O
and	O
processed	O
for	O
indirect	O
immunocytochemistry	O
.	O

(	O
A	O
)	O
Differentiated	O
hNSCs	O
expressed	O
the	O
neural	O
-	O
specific	O
transcripts	O
nestin	B
and	O
Notch1	B
as	O
well	O
as	O
transcripts	O
:	O
for	O
neurons	O
(	O
β	B
-	I
tubulin	I
class	I
III	I
,	O
MAP-2	B
,	O
NCAM	B
and	O
medium	B
-	I
size	I
neurofilament	I
,	O
NF	B
-	I
M	I
)	O
,	O
for	O
astrocytes	O
(	O
GFAP	B
)	O
and	O
for	O
oligodendrocytes	O
(	O
MBP	B
)	O
.	O

The	O
hNSCs	O
expressed	O
transcripts	O
for	O
GAD	B
,	O
but	O
not	O
for	O
TH	B
.	O

B	O
,	O
C	O
&	O
D	O
,	O
morphology	O
of	O
NSC	O
-	O
derived	O
progeny	O
differentiated	O
into	O
GFAP+	B
astrocytes	O
(	O
B	O
)	O
,	O
GC	B
-	O
expressing	O
oligodendrocytes	O
(	O
C	O
)	O
and	O
TuJ1	B
+	O
neurons	O
(	O
D	O
)	O
,	O
DAPI	O
(	O
blue	O
)	O
show	O
life	O
cell	O
nuclei	O
.	O

(	O
E	O
)	O
Photo	O
showing	O
cultures	O
double	O
-	O
immunostained	O
for	O
TuJ1	B
(	O
green	O
)	O
and	O
nestin	B
(	O
red	O
)	O
(	O
DAPI	O
,	O
blue	O
)	O
.	O

(	O
F	O
)	O
Quantitative	O
analysis	O
of	O
immunostained	O
10	O
day	O
-	O
old	O
cultures	O
for	O
the	O
3	O
neural	O
cell	O
types	O
.	O

Results	O
are	O
mean±s.e.m	O
.	O
of	O
three	O
independent	O
experiments	O
,	O
each	O
performed	O
in	O
duplicate	O
.	O

Bars	O
:	O
(	O
c	O
)	O
20	O
µm	O
;	O
(	O
d	O
,	O
e	O
)	O
10	O
µm	O
.	O
2	O
.	O

The	O
isolated	O
hNSCs	O
are	O
normal	O
and	O
do	O
not	O
form	O
tumors	O
in	O
normal	O
nude	O
ratsThe	O
self	O
-	O
renewal	O
and	O
pluripotent	O
abilities	O
of	O
the	O
hESCs	O
are	O
also	O
associated	O
with	O
tumorigenic	O
properties	O
.	O

Therefore	O
,	O
the	O
first	O
critical	O
step	O
toward	O
developing	O
therapeutic	O
hNSCs	O
is	O
to	O
verify	O
that	O
they	O
are	O
non	O
-	O
tumorigenic	O
.	O

The	O
monolayer	O
culture	O
of	O
SD56	O
hNSCs	O
clearly	O
demonstrated	O
contact	O
inhibition	O
of	O
growth	O
,	O
a	O
normal	O
karyotype	O
and	O
did	O
not	O
express	O
the	O
pluripotency	O
transcripts	O
Oct-4	B
and	O
Nanog	B
.	O

Removal	O
of	O
mitogenic	O
factors	O
and	O
continued	O
culture	O
on	O
plastic	O
resulted	O
in	O
cell	O
senescence	O
that	O
is	O
characteristic	O
of	O
non	O
-	O
transformed	O
cells	O
.	O

To	O
determine	O
whether	O
SD56	O
hNSCs	O
form	O
tumors	O
in	O
vivo	O
,	O
we	O
transplanted	O
them	O
at	O
high	O
density	O
(	O
see	O
Methods	O
)	O
into	O
the	O
forebrain	O
and	O
subcutaneously	O
into	O
the	O
flank	O
of	O
nude	O
rats	O
.	O

The	O
animals	O
were	O
kept	O
for	O
a	O
two	O
-	O
month	O
post	O
-	O
transplant	O
survival	O
period	O
.	O

To	O
label	O
mitotically	O
active	O
cells	O
in	O
vivo	O
during	O
S	O
-	O
phase	O
,	O
the	O
rats	O
were	O
injected	O
IP	O
with	O
BrdU	O
(	O
50	O
mg	O
/	O
kg	O
)	O
every	O
8	O
hours	O
during	O
the	O
last	O
24	O
hours	O
before	O
euthanasia	O
.	O

The	O
transit	O
amplifying	O
endogenous	O
precursors	O
located	O
in	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
were	O
labeled	O
(	O
Figure	O
S3	O
)	O
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
detect	O
grafted	O
SD56	O
hNSCs	O
co	O
-	O
localizing	O
the	O
human	O
-	O
specific	O
nuclear	O
marker	O
hNuc	B
and	O
BrdU	O
(	O
Figure	O
S3	O
)	O
.	O

No	O
surviving	O
SD56	O
hNSCs	O
were	O
detected	O
in	O
the	O
flank	O
of	O
the	O
transplanted	O
animals	O
suggesting	O
that	O
the	O
grafted	O
cells	O
are	O
not	O
tumorigenic	O
.	O

3	O
.	O

Transplanted	O
cells	O
survived	O
,	O
migrated	O
toward	O
and	O
engrafted	O
into	O
the	O
stroke	O
-	O
damaged	O
host	O
tissueTo	O
investigate	O
the	O
survival	O
and	O
functional	O
engraftment	O
in	O
an	O
injury	O
environment	O
,	O
hNSCs	O
(	O
4	O
×	O
105	O
)	O
were	O
transplanted	O
into	O
the	O
ischemic	O
boundary	O
zone	O
in	O
the	O
rat	O
striatum	O
one	O
week	O
after	O
the	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
was	O
performed	O
.	O

Animals	O
were	O
euthanized	O
two	O
months	O
later	O
and	O
the	O
brains	O
processed	O
for	O
histo	O
-	O
pathology	O
and	O
immunocytochemistry	O
.	O

Grafted	O
SD56	O
hNSCs	O
,	O
identified	O
with	O
hNuc	B
,	O
demonstrated	O
a	O
37.0±15.8	O
%	O
survival	O
rate	O
and	O
a	O
remarkable	O
dispersion	O
toward	O
the	O
stroke	O
-	O
damaged	O
tissue	O
with	O
no	O
sign	O
of	O
overgrowth	O
or	O
tumorigenesis	O
.	O

The	O
majority	O
of	O
grafted	O
cells	O
(	O
61.2±4.7	O
%	O
)	O
migrated	O
at	O
least	O
200	O
µm	O
away	O
from	O
the	O
injection	O
site	O
and	O
penetrated	O
an	O
average	O
distance	O
of	O
806.4±49.3	O
µm	O
into	O
the	O
stroke	O
-	O
damaged	O
tissue	O
(	O
Figure	O
3A	O
–	O
C	O
)	O
.	O

Immunostaining	O
with	O
the	O
blood	O
vessel	O
marker	O
,	O
GluT1	B
,	O
revealed	O
dilated	O
vessels	O
in	O
the	O
infarcted	O
striatum	O
and	O
a	O
close	O
association	O
between	O
vessels	O
and	O
the	O
grafted	O
hNSCs	O
(	O
Figure	O
3B	O
,	O
3C	O
)	O
.	O

The	O
grafted	O
cells	O
rarely	O
expressed	O
the	O
proliferation	O
marker	O
Ki67	B
(	O
Figure	O
3D	O
)	O
,	O
29.8±4.4	O
%	O
expressed	O
nestin	B
(	O
Figure	O
3E	O
)	O
,	O
6.5±0.9	O
%	O
expressed	O
doublecortin	B
(	O
DCX	B
)	O
and	O
60.8±8.1	O
%	O
were	O
TuJ1	B
+	O
(	O
Figure	O
3F	O
,	O
G	O
)	O
.	O

Grafted	O
cells	O
rarely	O
co	O
-	O
expressed	O
the	O
astroglial	O
marker	O
GFAP	B
(	O
Figure	O
3H	O
)	O
or	O
differentiated	O
into	O
CNPase	B
-	O
expressing	O
oligodendrocytes	O
(	O
Figure	O
3I	O
)	O
.	O

Immunostaining	O
for	O
GAD	B
demonstrated	O
that	O
25.1±2.3	O
%	O
of	O
grafted	O
hNSCs	O
differentiated	O
into	O
GABAergic	O
neurons	O
while	O
less	O
than	O
2	O
%	O
were	O
positive	O
for	O
glutamate	B
(	O
Figure	O
3J	O
,	O
K	O
)	O
.10.1371	O
/	O
journal.pone.0001644.g003Figure	O
3Dispersion	O
,	O
engraftment	O
and	O
differentiation	O
of	O
the	O
hNSCs	O
in	O
stroke	O
-	O
lesioned	O
animals.	O
(	O
A	O
)	O

Schematic	O
drawing	O
of	O
a	O
frontal	O
section	O
through	O
the	O
striatum	O
illustrating	O
the	O
dispersion	O
of	O
grafted	O
hNSCs	O
in	O
the	O
focal	O
ischemia	O
-	O
lesioned	O
parenchyma	O
(	O
shaded	O
area	O
)	O
.	O

(	O
B	O
,	O
C	O
)	O
Photos	O
show	O
frontal	O
sections	O
through	O
the	O
graft	O
in	O
the	O
striatum	O
immunostained	O
with	O
the	O
human	O
specific	O
antibodies	O
:	O
anti	O
-	O
hNuc	B
(	O
green	O
in	O
B	O
&	O
C	O
)	O
and	O
anti	O
-	O
GluT1	B
(	O
red	O
,	O
B	O
&	O
C	O
)	O
showing	O
blood	O
vessels	O
and	O
dispersed	O
hNSCs	O
in	O
the	O
graft	O
zone	O
.	O

C	O
:	O
higher	O
magnification	O
of	O
the	O
inset	O
in	O
B.	O
(	O
D	O
–	O
I	O
)	O
Photos	O
taken	O
from	O
frontal	O
sections	O
through	O
the	O
graft	O
in	O
the	O
striatum	O
double	O
immunoprocessed	O
for	O
cell	O
proliferation	O
and	O
neural	O
lineage	O
markers	O
.	O

(	O
D	O
)	O
Note	O
the	O
endogenous	O
Ki67	B
+	O
cells	O
(	O
red	O
cells	O
,	O
arrow	O
)	O
in	O
the	O
stroke	O
damaged	O
area	O
and	O
the	O
hNuc+	B
(	O
green	O
)	O
/	O
Ki67-	B
grafted	O
hNSCs	O
(	O
arrowheads	O
)	O
.	O

(	O
E	O
)	O
Examples	O
of	O
grafted	O
SD56	O
hNSCs	O
showing	O
co	O
-	O
expression	O
of	O
hNuc	B
(	O
green	O
)	O
and	O
nestin	B
(	O
red	O
)	O
.	O

(	O
F	O
)	O
Confocal	O
3D	O
reconstructed	O
orthogonal	O
images	O
of	O
the	O
hNuc+	B
(	O
green	O
)	O
/	O
DCX+	B
(	O
red	O
)	O
NSCs	O
(	O
arrowheads	O
)	O
viewed	O
in	O
the	O
x	O
-	O
z	O
plan	O
on	O
the	O
top	O
and	O
y	O
-	O
z	O
plan	O
on	O
the	O
right	O
.	O

(	O
G	O
)	O
Examples	O
show	O
the	O
majority	O
of	O
grafted	O
NSC	O
progeny	O
co	O
-	O
expressing	O
hNuc	B
(	O
red	O
)	O
and	O
the	O
neuronal	O
marker	O
TuJ1	B
(	O
green	O
)	O
.	O

Grafted	O
NSCs	O
rarely	O
differentiate	O
into	O
GFAP+	B
astrocytes	O
(	O
H	O
)	O
.	O

In	O
I	O
,	O
rare	O
example	O
of	O
grafted	O
NSC	O
progeny	O
becoming	O
an	O
oligodendrocyte	O
identified	O
by	O
the	O
expression	O
of	O
CNPase	B
(	O
green	O
)	O
.	O

Grafted	O
NSCs	O
expressed	O
the	O
GABAergic	O
marker	O
GAD65	B
/	I
67	I
(	O
J	O
)	O
and	O
rarely	O
expressed	O
glutamate	B
(	O
K	O
)	O
.	O

(	O
Abbreviations	O
:	O
Cx	O
:	O
cortex	O
,	O
Str	O
:	O
striatum	O
)	O
.	O

Bars	O
:	O
(	O
B	O
,	O
C	O
)	O
100	O
µm	O
;	O
(	O
D	O
,	O
F	O
)	O
20	O
µm	O
;	O
(	O
E	O
,	O
G	O
–	O
K	O
)	O
10	O
µm	O
.	O
4	O
.	O

Transplanted	O
cells	O
improve	O
sensorimotor	O
function	O
of	O
the	O
stroke	O
-	O
disabled	O
forelimbWe	O
asked	O
whether	O
transplanted	O
SD56	O
hNSCs	O
could	O
enhance	O
the	O
recovery	O
of	O
sensorimotor	O
function	O
that	O
is	O
compromised	O
in	O
the	O
stroke	O
-	O
injured	O
rats	O
.	O

We	O
used	O
the	O
cylinder	O
test	O
to	O
measure	O
the	O
sensorimotor	O
asymmetry	O
in	O
forelimb	O
use	O
during	O
spontaneous	O
exploration	O
[	O
22	O
]	O
.	O

To	O
establish	O
the	O
baseline	O
of	O
the	O
stroke	O
-	O
induced	O
sensorimotor	O
deficit	O
,	O
spontaneous	O
behavior	O
of	O
rats	O
in	O
a	O
transparent	O
cylinder	O
was	O
videotaped	O
one	O
week	O
after	O
stroke	O
(	O
pre	O
-	O
transplant	O
,	O
Figure	O
4	O
)	O
.	O

Tests	O
were	O
then	O
conducted	O
4	O
and	O
8	O
weeks	O
after	O
vehicle	O
and	O
SD56	O
hNSCs	O
transplantation	O
.	O

Stable	O
asymmetry	O
in	O
forelimb	O
use	O
was	O
observed	O
7	O
days	O
post	O
-	O
stroke	O
(	O
pre	O
-	O
transplant	O
,	O
Figure	O
4	O
)	O
.	O

Ischemic	O
rats	O
used	O
their	O
impaired	O
forelimbs	O
(	O
contralateral	O
to	O
lesion	O
)	O
during	O
lateral	O
exploration	O
less	O
than	O
they	O
did	O
before	O
stroke	O
.	O

Transplantation	O
of	O
SD56	O
hNSCs	O
significantly	O
enhanced	O
the	O
independent	O
use	O
of	O
the	O
impaired	O
contralateral	O
forelimb	O
4	O
weeks	O
post	O
transplantation	O
(	O
P<0.05	O
vs	O
pre	O
-	O
transplant	O
)	O
.	O

Eight	O
weeks	O
after	O
transplantation	O
the	O
improvement	O
in	O
the	O
use	O
of	O
the	O
impaired	O
forelimb	O
was	O
stable	O
and	O
significant	O
when	O
compared	O
to	O
the	O
pre	O
-	O
transplant	O
group	O
and	O
significantly	O
improved	O
in	O
comparison	O
to	O
vehicle	O
treated	O
group	O
at	O
8	O
weeks	O
(	O
Figure	O
4	O
)	O
.	O

In	O
the	O
vehicle	O
treated	O
group	O
,	O
the	O
independent	O
use	O
of	O
the	O
contralateral	O
forelimb	O
remained	O
impaired	O
4	O
and	O
8	O
weeks	O
post	O
-	O
injection	O
.	O

In	O
an	O
independent	O
study	O
and	O
using	O
the	O
same	O
MCAO	O
rat	O
animal	O
model	O
,	O
we	O
found	O
that	O
transplantation	O
of	O
dermal	O
fibroblasts	O
did	O
not	O
improve	O
the	O
stroke	O
-	O
induced	O
motor	O
deficits	O
(	O
unpublished	O
data	O
)	O
.10.1371	O
/	O
journal.pone.0001644.g004Figure	O
4Transplantation	O
of	O
NSCs	O
improves	O
sensorimotor	O
function	O
of	O
the	O
stroke	O
-	O
disabled	O
forelimb	O
.	O

Forelimb	O
use	O
during	O
spontaneous	O
lateral	O
exploration	O
was	O
measured	O
in	O
the	O
cylinder	O
test	O
(	O
see	O
Method	O
and	O
Results	O
sections	O
for	O
details	O
)	O
.	O

Groups	O
of	O
vehicle	O
injected	O
(	O
n	O
=	O
7	O
)	O
and	O
hNSCs	O
(	O
n	O
=	O
10	O
)	O
transplanted	O
are	O
represented	O
.	O

The	O
animals	O
were	O
tested	O
as	O
described	O
in	O
Method	O
section	O
.	O

Note	O
the	O
significant	O
increase	O
in	O
the	O
independent	O
use	O
of	O
the	O
impaired	O
contralateral	O
forelimb	O
at	O
4	O
and	O
8	O
weeks	O
post	O
transplantation	O
(	O
P<0.05	O
vs	O
pre	O
-	O
transplant	O
group	O
)	O
.	O

The	O
contralateral	O
forelimb	O
remained	O
impaired	O
in	O
the	O
vehicle	O
treated	O
group	O
at	O
4	O
and	O
8	O
weeks	O
post	O
-	O
injection	O
.	O

Bars	O
represent	O
percentages±s.e.m	O
.	O

of	O
steps	O
taken	O
by	O
the	O
ipsilateral	O
,	O
contralateral	O
and	O
both	O
forelimbs	O
simultaneously	O
.	O

*	O
P<0.05	O
vs	O
pre	O
-	O
transplant	O
group	O
;	O
#	O
P<0.05	O
vs	O
vehicle	O
groups	O
.	O

Our	O
results	O
indicate	O
that	O
a	O
self	O
-	O
renewable	O
and	O
homogenous	O
population	O
of	O
hNSCs	O
,	O
SD56	O
,	O
was	O
derived	O
from	O
hESCs	O
using	O
defined	O
media	O
supplemented	O
with	O
a	O
specific	O
combination	O
of	O
growth	O
factors	O
.	O

The	O
SD56	O
hNSCs	O
grew	O
as	O
an	O
adherent	O
monolayer	O
culture	O
,	O
uniformly	O
expressed	O
molecular	O
features	O
of	O
hNSCs	O
including	O
nestin	B
,	O
vimentin	B
and	O
the	O
radial	O
glial	O
marker	O
3CB2	B
,	O
and	O
did	O
not	O
express	O
the	O
pluripotency	O
markers	O
Oct4	B
or	O
Nanog	B
.	O

The	O
self	O
-	O
renewal	O
property	O
of	O
the	O
hNSCs	O
was	O
characterized	O
by	O
a	O
predominant	O
symmetrical	O
mode	O
of	O
cell	O
division	O
.	O

They	O
exhibited	O
no	O
chromosomal	O
abnormalities	O
and	O
demonstrated	O
non	O
-	O
tumorigenic	O
properties	O
after	O
implantation	O
into	O
ischemic	O
brains	O
and	O
into	O
naïve	O
nude	O
rat	O
brains	O
and	O
flanks	O
.	O

Furthermore	O
,	O
the	O
transplanted	O
SD56	O
hNSCs	O
migrated	O
toward	O
the	O
stroke	O
-	O
damaged	O
adult	O
brain	O
parenchyma	O
,	O
engrafted	O
and	O
improved	O
the	O
independent	O
use	O
of	O
the	O
stroke	O
-	O
impaired	O
forelimb	O
.	O

Maintenance	O
of	O
stem	O
cells	O
requires	O
symmetrical	O
and	O
asymmetrical	O
cell	O
divisions	O
to	O
both	O
expand	O
and	O
to	O
give	O
rise	O
to	O
specialized	O
progeny	O
of	O
a	O
specific	O
tissue	O
(	O
reviewed	O
in	O
[	O
23	O
]	O
)	O
.	O

In	O
vivo	O
,	O
a	O
complex	O
cellular	O
micro	O
-	O
environment	O
or	O
niche	O
ensures	O
the	O
self	O
-	O
maintenance	O
property	O
of	O
NSCs	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O

In	O
vitro	O
,	O
defined	O
growth	O
factors	O
and	O
extracellular	O
matrices	O
support	O
stem	O
cell	O
self	O
-	O
renewal	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

The	O
embryonic	O
stem	O
cells	O
can	O
propagate	O
in	O
a	O
predominantly	O
proliferative	O
symmetrical	O
mode	O
,	O
leading	O
to	O
homogeneous	O
cell	O
cultures	O
growing	O
relatively	O
quickly	O
with	O
minimal	O
cell	O
differentiation	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
.	O

Tissue	O
specific	O
stem	O
cells	O
,	O
however	O
,	O
self	O
-	O
renew	O
in	O
a	O
predominant	O
asymmetric	O
mode	O
to	O
maintain	O
them	O
selves	O
and	O
compensate	O
for	O
the	O
loss	O
of	O
differentiated	O
cells	O
due	O
to	O
disease	O
or	O
injury	O
.	O

Thus	O
,	O
NSCs	O
isolated	O
from	O
developing	O
or	O
adult	O
brain	O
grow	O
as	O
a	O
mixture	O
of	O
undifferentiated	O
and	O
differentiated	O
cells	O
due	O
the	O
predominant	O
asymmetrical	O
mode	O
of	O
cell	O
division	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
,	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
,	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
.	O

A	O
recent	O
study	O
has	O
reported	O
that	O
a	O
murine	O
ESC	O
-	O
derived	O
NSC	O
line	O
(	O
LC1	O
)	O
is	O
propagated	O
as	O
an	O
adherent	O
homogenous	O
culture	O
with	O
a	O
dominant	O
mode	O
of	O
symmetrical	O
self	O
-	O
renewal	O
[	O
21	O
]	O
.	O

A	O
combination	O
of	O
EGF	B
and	O
FGF2	B
was	O
sufficient	O
to	O
propagate	O
these	O
NSCs	O
as	O
an	O
adherent	O
monolayer	O
.	O

However	O
,	O
the	O
SD56	O
hNSC	O
line	O
described	O
here	O
required	O
the	O
combination	O
of	O
EGF	B
,	O
bFGF	B
and	O
LIF	B
for	O
self	O
-	O
maintenance	O
.	O

Although	O
there	O
are	O
morphological	O
and	O
molecular	O
similarities	O
between	O
our	O
hNSCs	O
and	O
the	O
NSCs	O
previously	O
described	O
[	O
21	O
]	O
,	O
the	O
methods	O
of	O
isolation	O
and	O
growth	O
are	O
different	O
.	O

In	O
addition	O
to	O
the	O
different	O
combination	O
of	O
growth	O
factors	O
used	O
,	O
the	O
hNSC	O
line	O
we	O
have	O
isolated	O
did	O
not	O
go	O
through	O
the	O
rosette	O
-	O
structure	O
stage	O
.	O

The	O
in	O
vitro	O
analysis	O
of	O
BrdU	O
incorporation	O
and	O
nestin	O
expression	O
indicated	O
that	O
our	O
hNSCs	O
divide	O
predominantly	O
symmetrically	O
.	O

This	O
type	O
of	O
growth	O
pattern	O
is	O
characteristic	O
of	O
primitive	O
normal	O
stem	O
cells	O
undergoing	O
mostly	O
symmetric	O
cell	O
division	O
to	O
increase	O
the	O
stem	O
cell	O
pool	O
at	O
the	O
early	O
stage	O
of	O
development	O
or	O
during	O
tissue	O
regeneration	O
after	O
injury	O
[	O
23	O
]	O
.	O

RT	O
-	O
PCR	O
and	O
immunocytochemistry	O
analysis	O
demonstrated	O
that	O
these	O
undifferentiated	O
SD56	O
cells	O
did	O
not	O
express	O
any	O
pluripotency	O
,	O
endodermal	O
or	O
mesodermal	O
markers	O
.	O

Furthermore	O
,	O
the	O
SD56	O
hNSCs	O
described	O
here	O
exhibited	O
the	O
multipotential	O
characteristic	O
to	O
differentiate	O
into	O
neurons	O
,	O
astrocytes	O
and	O
oligodendrocytes	O
both	O
in	O
vitro	O
and	O
upon	O
transplantation	O
.	O

Together	O
these	O
findings	O
suggest	O
that	O
the	O
hNSC	O
line	O
we	O
isolated	O
are	O
appropriately	O
programmed	O
and	O
share	O
similar	O
characteristics	O
with	O
the	O
definitive	O
NSCs	O
of	O
the	O
developing	O
brain	O
.	O

The	O
SD56	O
hNSCs	O
demonstrated	O
a	O
remarkable	O
ability	O
to	O
migrate	O
toward	O
the	O
stroke	O
-	O
damaged	O
parenchyma	O
of	O
the	O
adult	O
rat	O
brain	O
.	O

This	O
directed	O
migration	O
by	O
the	O
majority	O
of	O
the	O
grafted	O
cells	O
could	O
be	O
due	O
to	O
their	O
uniform	O
cellular	O
composition	O
,	O
which	O
results	O
in	O
an	O
equal	O
response	O
to	O
the	O
host	O
microenvironment	O
.	O

In	O
previous	O
studies	O
,	O
subpopulations	O
of	O
transplanted	O
hESCs	O
that	O
were	O
enriched	O
in	O
neural	O
cells	O
migrated	O
in	O
host	O
microenvironments	O
conducive	O
to	O
cell	O
migration	O
,	O
such	O
as	O
the	O
developing	O
brain	O
or	O
in	O
structures	O
such	O
as	O
the	O
rostral	O
migratory	O
stream	O
[	O
13	O
]	O
,	O
[	O
20	O
]	O
.	O

In	O
the	O
adult	O
lesioned	O
brain	O
,	O
the	O
grafted	O
hESC	O
-	O
derived	O
neural	O
cells	O
proliferated	O
and	O
formed	O
rosettes	O
[	O
14	O
]	O
,	O
teratomas	O
[	O
12	O
]	O
,	O
[	O
15	O
]	O
or	O
a	O
cellular	O
mass	O
that	O
induced	O
a	O
gliotic	O
host	O
response	O
whereby	O
local	O
astrocytes	O
demarcated	O
the	O
grafts	O
[	O
16	O
]	O
.	O

Enriched	O
neural	O
cultures	O
derived	O
from	O
mouse	O
[	O
42	O
]	O
and	O
monkey	O
ESCs	O
[	O
43	O
]	O
have	O
produced	O
behavioral	O
improvements	O
when	O
transplanted	O
into	O
animal	O
models	O
of	O
stroke	O
and	O
brain	O
injury	O
.	O

However	O
,	O
in	O
these	O
cases	O
,	O
the	O
transplanted	O
non	O
-	O
human	O
ESCs	O
also	O
formed	O
a	O
mass	O
with	O
signs	O
of	O
overgrowth	O
in	O
the	O
core	O
,	O
as	O
well	O
as	O
deformations	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

ESCs	O
plated	O
at	O
low	O
density	O
acquire	O
neural	O
identity	O
within	O
few	O
hours	O
after	O
plating	O
[	O
47	O
]	O
.	O

Interestingly	O
,	O
nearly	O
all	O
viable	O
cells	O
expressed	O
nestin	B
,	O
the	O
early	O
neural	O
fate	O
marker	O
Sox1	B
,	O
and	O
the	O
pluripotency	O
marker	O
Oct4	B
.	O

Together	O
,	O
these	O
studies	O
are	O
seminal	O
and	O
suggest	O
that	O
complete	O
neuralization	O
may	O
not	O
be	O
achieved	O
through	O
certain	O
enrichment	O
processes	O
,	O
consequently	O
the	O
neural	O
cells	O
could	O
revert	O
to	O
a	O
pluripotent	O
stage	O
[	O
17	O
]	O
.	O

The	O
dispersion	O
of	O
the	O
grafted	O
hNSCs	O
within	O
host	O
parenchyma	O
may	O
allow	O
for	O
more	O
graft	O
-	O
host	O
interactions	O
that	O
could	O
stabilize	O
differentiation	O
,	O
inhibit	O
growth	O
and	O
prevent	O
gliotic	O
host	O
response	O
.	O

In	O
the	O
present	O
study	O
,	O
SD56	O
hNSC	O
-	O
transplanted	O
animals	O
demonstrated	O
a	O
stable	O
improvement	O
in	O
the	O
sensorimotor	O
function	O
when	O
evaluated	O
for	O
spontaneous	O
exploratory	O
activity	O
in	O
the	O
cylinder	O
test	O
that	O
detects	O
long	O
-	O
lasting	O
deficits	O
in	O
forelimb	O
use	O
in	O
the	O
experimental	O
models	O
of	O
stroke	O
[	O
22	O
]	O
.	O

The	O
transplantation	O
of	O
hNSCs	O
significantly	O
enhanced	O
the	O
independent	O
use	O
of	O
the	O
impaired	O
contralateral	O
forelimb	O
8	O
weeks	O
post	O
transplantation	O
.	O

This	O
is	O
the	O
first	O
report	O
demonstrating	O
that	O
the	O
transplantation	O
of	O
hNSCs	O
derived	O
from	O
hESCs	O
can	O
improve	O
neurologic	O
behavior	O
after	O
experimental	O
stroke	O
.	O

Together	O
,	O
these	O
findings	O
are	O
encouraging	O
and	O
suggest	O
that	O
these	O
cells	O
are	O
promising	O
for	O
future	O
development	O
.	O

In	O
addition	O
to	O
their	O
therapeutic	O
application	O
,	O
the	O
hNSCs	O
isolated	O
under	O
the	O
reported	O
conditions	O
offer	O
a	O
means	O
to	O
interrogate	O
host	O
environments	O
and	O
unravel	O
mechanistic	O
features	O
of	O
self	O
-	O
renewal	O
,	O
non	O
-	O
tumorigenicity	O
and	O
functional	O
engraftability	O
in	O
animal	O
models	O
of	O
neurological	O
disorders	O
.	O

hESC	O
and	O
NSC	O
CulturesThe	O
hESC	O
line	O
H9	O
(	O
WiCell	O
Research	O
Institute	O
)	O
was	O
propagated	O
every	O
5	O
to	O
7	O
days	O
on	O
irradiated	O
mouse	O
embryonic	O
fibroblasts	O
.	O

The	O
cell	O
culture	O
media	O
consisted	O
of	O
a	O
1∶1	O
mixture	O
of	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
and	O
F12	O
nutrient	O
,	O
20	O
%	O
serum	O
replacement	O
(	O
Invitrogen	O
)	O
,	O
0.1	O
mM	O
β	O
-	O
mercaptoethanol	O
,	O
2	O
µg	O
/	O
ml	O
heparin	B
and	O
4	O
ng	O
/	O
ml	O
bFGF	B
(	O
R&D	O
Systems	O
)	O
.	O

To	O
generate	O
the	O
NSCs	O
,	O
dissociated	O
hESCs	O
were	O
cultured	O
in	O
a	O
chemically	O
defined	O
medium	O
composed	O
of	O
DMEM	O
/	O
F12	O
(	O
1∶1	O
)	O
including	O
glucose	O
(	O
0.6	O
%	O
)	O
,	O
glutamine	O
(	O
2	O
mM	O
)	O
,	O
sodium	O
bicarbonate	O
(	O
3	O
mM	O
)	O
,	O
and	O
HEPES	O
buffer	O
(	O
5	O
mM	O
)	O
[	O
all	O
from	O
Sigma	O
except	O
glutamine	O
(	O
Invitrogen	O
)	O
]	O
.	O

A	O
defined	O
hormone	O
mix	O
and	O
salt	O
mixture	O
(	O
Sigma	O
)	O
,	O
including	O
insulin	B
(	O
25	O
mg	O
/	O
ml	O
)	O
,	O
transferrin	B
(	O
100	O
mg	O
/	O
ml	O
)	O
,	O
progesterone	O
(	O
20	O
nM	O
)	O
,	O
putrescine	O
(	O
60	O
mM	O
)	O
,	O
and	O
selenium	O
chloride	O
(	O
30	O
nM	O
)	O
was	O
used	O
in	O
place	O
of	O
serum	O
.	O

The	O
medium	O
was	O
supplemented	O
with	O
EGF	B
(	O
20	O
ng	O
/	O
ml	O
)	O
,	O
bFGF	B
(	O
10	O
ng	O
/	O
ml	O
)	O
and	O
LIF	B
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

Dissociated	O
hNSCs	O
were	O
plated	O
at	O
a	O
density	O
of	O
100,000	O
cell	O
/	O
ml	O
in	O
Corning	O
T75	O
(	O
Invitrogen	O
)	O
culture	O
flasks	O
in	O
the	O
defined	O
media	O
together	O
with	O
the	O
growth	O
factors	O
.	O

After	O
5–7	O
DIV	O
,	O
the	O
adherent	O
culture	O
was	O
incubated	O
in	O
0.025%trypsin	O
/	O
0.01	O
%	O
EDTA	O
(	O
w	O
/	O
v	O
)	O
for	O
1	O
min	O
followed	O
by	O
the	O
addition	O
of	O
trypsin	B
inhibitor	O
(	O
Invitrogen	O
)	O
then	O
gently	O
triturated	O
to	O
achieve	O
single	O
cell	O
suspension	O
.	O

The	O
cells	O
were	O
then	O
washed	O
twice	O
with	O
fresh	O
medium	O
and	O
reseeded	O
in	O
fresh	O
growth	O
factor	O
-	O
containing	O
media	O
at	O
100,000	O
cells	O
/	O
ml	O
.	O

This	O
procedure	O
was	O
performed	O
for	O
21	O
passages	O
and	O
the	O
fold	O
of	O
increase	O
and	O
population	O
doubling	O
were	O
calculated	O
at	O
each	O
passage	O
.	O

For	O
clonal	O
analysis	O
,	O
single	O
spheres	O
or	O
confluent	O
hNSC	O
cultures	O
were	O
single	O
cell	O
dissociated	O
and	O
serially	O
diluted	O
to	O
yield	O
1–2	O
cell	O
/	O
10	O
µl	O
.	O

A	O
10-µl	O
-	O
cell	O
suspension	O
was	O
then	O
added	O
to	O
each	O
of	O
96	O
or	O
24	O
well	O
plates	O
containing	O
200–300	O
µl	O
of	O
growth	O
media	O
.	O

Wells	O
containing	O
one	O
viable	O
cell	O
were	O
marked	O
the	O
next	O
day	O
and	O
re	O
-	O
scored	O
5	O
to	O
7	O
days	O
later	O
for	O
cell	O
proliferation	O
.	O

The	O
differentiation	O
of	O
the	O
hNSCs	O
was	O
performed	O
as	O
previously	O
described	O
[	O
48	O
]	O
.	O

Dissociated	O
hNSCs	O
were	O
plated	O
at	O
a	O
density	O
of	O
106	O
cells	O
/	O
ml	O
in	O
control	O
(	O
media	O
/	O
hormone	O
mix	O
)	O
medium	O
devoid	O
of	O
any	O
growth	O
factors	O
and	O
supplemented	O
with	O
1	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
on	O
poly	O
-	O
L	O
-	O
ornithine	O
-	O
coated	O
(	O
15	O
mg	O
/	O
ml	O
;	O
Sigma	O
)	O
glass	O
coverslips	O
in	O
24-well	O
Nunclon	O
culture	O
dishes	O
with	O
0.5	O
ml	O
/	O
well	O
.	O

After	O
2	O
,	O
7–15	O
DIV	O
cultures	O
were	O
fixed	O
and	O
processed	O
for	O
immunocytochemistry	O
or	O
used	O
for	O
RT	O
-	O
PCR	O
analysis	O
.	O

Karyotype	O
analysisLong	O
-	O
term	O
cultures	O
of	O
hNSCs	O
were	O
incubated	O
at	O
37	O
°	O
C	O
and	O
harvested	O
for	O
metaphase	O
chromosomes	O
when	O
the	O
cultures	O
were	O
75	O
%	O
confluent	O
.	O

Metaphase	O
chromosomes	O
were	O
obtained	O
by	O
standard	O
chromosome	O
harvest	O
methods	O
by	O
exposure	O
to	O
Colcemid	O
at	O
0.1	O
µg	O
/	O
ml	O
for	O
1	O
hour	O
at	O
37	O
°	O
C	O
,	O
a	O
2-minute	O
exposure	O
to	O
trypsin	B
/	O
EDTA	O
,	O
hypotonized	O
with	O
0.057	O
M	O
KCl	O
and	O
fixed	O
with	O
3∶1	O
methanol	O
:	O
acetic	O
acid	O
.	O

Slide	O
preparations	O
were	O
made	O
by	O
dropping	O
the	O
fixed	O
cell	O
pellet	O
onto	O
cold	O
,	O
wet	O
slides	O
and	O
air	O
-	O
dried	O
.	O

After	O
incubating	O
the	O
slides	O
at	O
90	O
°	O
C	O
for	O
30	O
minutes	O
,	O
chromosomes	O
were	O
trypsin	B
banded	O
and	O
then	O
Wright	O
/	O
Giemsa	O
stained	O
for	O
G	O
-	O
banding	O
analysis	O
.	O

Twenty	O
metaphase	O
cells	O
were	O
completely	O
analyzed	O
and	O
a	O
normal	O
female	O
chromosome	O
complement	O
was	O
found	O
(	O
46,XX	O
)	O
.	O

Tumorigenicity	O
in	O
nude	O
ratsAll	O
animal	O
experiments	O
were	O
conducted	O
according	O
to	O
the	O
National	O
Institute	O
of	O
Health	O
(	O
NIH	O
)	O
guidelines	O
and	O
approved	O
by	O
the	O
IACUC	O
.	O

Normal	O
adult	O
NIH	O
-	O
Nude	O
rats	O
(	O
n	O
=	O
5	O
,	O
8	O
week	O
-	O
old	O
,	O
Taconic	O
,	O
Germantown	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
were	O
used	O
to	O
test	O
the	O
tumorigenic	O
potential	O
of	O
the	O
SD56	O
hNSCs	O
.	O

Undifferentiated	O
hNSCs	O
from	O
passage	O
9	O
were	O
single	O
cell	O
dissociated	O
using	O
trypsin	B
-	O
EDTA	O
and	O
suspended	O
at	O
the	O
concentration	O
of	O
125,000	O
cell	O
/	O
µl	O
in	O
preparation	O
for	O
cell	O
transplantation	O
.	O

Two	O
µl	O
of	O
the	O
cell	O
suspension	O
were	O
stereotaxically	O
transplanted	O
into	O
4	O
sites	O
within	O
the	O
striatum	O
at	O
the	O
following	O
coordinates	O
:	O
AP	O
:	O
+	O
1.0	O
mm	O
,	O
ML	O
:	O
+	O
3.2	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
+	O
0.5	O
mm	O
,	O
ML	O
:	O
+	O
3.0	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
−0.5	O
mm	O
,	O
ML	O
:	O
+	O
3.0	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
−1.0	O
mm	O
,	O
ML	O
:	O
+	O
3.5	O
mm	O
,	O
DV	O
:	O
−5.0	O
mm	O
with	O
the	O
incisor	O
bar	O
set	O
at	O
3.4	O
mm	O
.	O

The	O
injection	O
rate	O
was	O
1	O
µl	O
/	O
min	O
,	O
and	O
the	O
cannula	O
was	O
left	O
in	O
place	O
for	O
an	O
additional	O
5	O
min	O
before	O
retraction	O
.	O

For	O
the	O
flank	O
tumor	O
assay	O
,	O
2	O
×	O
106	O
cells	O
(	O
125,000	O
cell	O
/	O
µl	O
)	O
were	O
injected	O
subcutaneously	O
to	O
the	O
side	O
of	O
the	O
adult	O
nude	O
rats	O
.	O

To	O
label	O
mitotically	O
active	O
cells	O
in	O
vivo	O
during	O
S	O
-	O
phase	O
,	O
the	O
rats	O
were	O
injected	O
IP	O
with	O
the	O
BrdU	O
(	O
50	O
mg	O
/	O
kg	O
,	O
Sigma	O
)	O
every	O
8	O
hours	O
during	O
the	O
last	O
24	O
hours	O
before	O
euthanasia	O
.	O

After	O
2-month	O
survival	O
time	O
,	O
rats	O
were	O
euthanized	O
and	O
a	O
postmortem	O
examination	O
for	O
tumor	O
formation	O
was	O
performed	O
.	O

Induction	O
of	O
Focal	O
Ischemia	O
and	O
Cell	O
TransplantationAll	O
animal	O
experimentations	O
were	O
conducted	O
according	O
to	O
the	O
National	O
Institute	O
of	O
Health	O
(	O
NIH	O
)	O
guidelines	O
and	O
approved	O
by	O
the	O
IACUC	O
.	O

Sprague	O
Dawley	O
adult	O
male	O
rats	O
(	O
n	O
=	O
17	O
,	O
275g–310	O
g	O
,	O
Charles	O
River	O
Laboratories	O
,	O
Wilmington	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
were	O
subjected	O
to	O
one	O
and	O
a	O
half	O
hour	O
suture	O
occlusion	O
of	O
the	O
middle	O
cerebral	O
artery	O
(	O
MCAO	O
)	O
,	O
as	O
previously	O
described	O
[	O
49	O
]	O
and	O
immunosuppressed	O
2	O
days	O
before	O
cell	O
transplantation	O
and	O
daily	O
thereafter	O
for	O
one	O
week	O
with	O
i.p	O
.	O

injections	O
of	O
cyclosporine	O
A	O
(	O
20	O
mg	O
/	O
ml	O
,	O
Sandimmune	O
,	O
Novartis	O
Pharmaceuticals	O
)	O
.	O

Thereafter	O
oral	O
cyclosporine	O
was	O
used	O
at	O
210	O
µg	O
/	O
ml	O
in	O
drinking	O
water	O
until	O
euthanasia	O
.	O

Undifferentiated	O
SD56	O
hNSCs	O
from	O
passages	O
between	O
P9	O
and	O
P13	O
were	O
single	O
cell	O
dissociated	O
using	O
trypsin	B
-	O
EDTA	O
in	O
preparation	O
for	O
cell	O
transplantation	O
.	O

One	O
week	O
after	O
the	O
stroke	O
lesion	O
,	O
2	O
µl	O
of	O
the	O
hNSCs	O
,	O
at	O
a	O
concentration	O
of	O
50,000	O
cell	O
/	O
µl	O
,	O
were	O
stereotaxically	O
transplanted	O
into	O
4	O
sites	O
within	O
the	O
lesioned	O
striatum	O
(	O
n	O
=	O
10	O
)	O
at	O
the	O
following	O
coordinates	O
:	O
AP	O
:	O
+	O
1.0	O
mm	O
,	O
ML	O
:	O
+	O
3.2	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
+	O
0.5	O
mm	O
,	O
ML	O
:	O
+	O
3.0	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
−0.5	O
mm	O
,	O
ML	O
:	O
+	O
3.0	O
mm	O
,	O
DV	O
:	O
−5.0	O
;	O
AP	O
:	O
−1.0	O
mm	O
,	O
ML	O
:	O
+	O
3.5	O
mm	O
,	O
DV	O
:	O
−5.0	O
mm	O
with	O
the	O
incisor	O
bar	O
set	O
at	O
3.4	O
mm	O
.	O

The	O
injection	O
rate	O
was	O
1	O
µl	O
/	O
min	O
,	O
and	O
the	O
cannula	O
was	O
left	O
in	O
place	O
for	O
an	O
additional	O
5	O
min	O
before	O
retraction	O
.	O

As	O
a	O
control	O
group	O
,	O
we	O
used	O
rats	O
subjected	O
to	O
ischemia	O
and	O
injected	O
with	O
the	O
vehicle	O
(	O
n	O
=	O
7	O
)	O
.	O

All	O
animals	O
underwent	O
baseline	O
motor	O
behavioral	O
assessment	O
before	O
and	O
after	O
the	O
ischemic	O
lesion	O
,	O
and	O
4	O
&	O
8	O
weeks	O
after	O
cell	O
transplantation	O
.	O

The	O
animals	O
were	O
killed	O
after	O
2-month	O
survival	O
time	O
by	O
transcardial	O
perfusion	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
.	O

The	O
brains	O
were	O
cryoprotected	O
in	O
an	O
increasing	O
gradient	O
of	O
10	O
,	O
20	O
and	O
30	O
%	O
sucrose	O
solution	O
and	O
cryostat	O
sectioned	O
at	O
40	O
µm	O
and	O
processed	O
for	O
immunocytochemistry	O
.	O

ImmunocytochemistryCultures	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
for	O
15	O
min	O
.	O

Both	O
cells	O
and	O
brain	O
sections	O
were	O
rinsed	O
in	O
PBS	O
for	O
3	O
×	O
5	O
min	O
then	O
incubated	O
for	O
2	O
hrs	O
(	O
cultures	O
)	O
or	O
overnight	O
(	O
brain	O
sections	O
)	O
with	O
the	O
appropriate	O
primary	O
antibodies	O
for	O
multiple	O
labeling	O
.	O

Secondary	O
antibodies	O
raised	O
in	O
the	O
appropriate	O
hosts	O
and	O
conjugated	O
to	O
FITC	O
,	O
RITC	O
,	O
AMCA	O
,	O
CY3	O
or	O
CY5	O
chromogenes	O
(	O
Jackson	O
ImmunoResearch	O
)	O
were	O
used	O
.	O

Cells	O
and	O
sections	O
were	O
counterstained	O
with	O
the	O
nuclear	O
marker	O
4′,6-diamidine-2′-phenylindole	O
dihydrochloride	O
(	O
DAPI	O
)	O
.	O

Positive	O
and	O
negative	O
controls	O
were	O
included	O
in	O
each	O
run	O
.	O

Immunostained	O
sections	O
were	O
coverslipped	O
using	O
fluorsave	O
(	O
Calbiochem	O
)	O
as	O
the	O
mounting	O
medium	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
:	O
Anti	B
-	I
human	I
Nuclei	I
(	O
hNuc	B
,	O
monoclonal	O
1∶100	O
,	O
Chemicon	O
)	O
,	O
Anti	B
-	I
TuJ1	I
(	O
monoclonal	O
1∶100	O
,	O
Covance	O
;	O
Polyclonal	O
1∶200	O
,	O
Aves	O
Labs	O
)	O
;	O
anti	B
-	I
GAD65	I
/	I
67	I
(	O
polyclonal	O
1∶1000	O
,	O
Chemicon	O
)	O
;	O
Anti	B
-	I
glial	I
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
,	O
monoclonal	O
1∶1000	O
,	O
Chemicon	O
;	O
polyclonal	O
1∶200	O
,	O
Aves	O
Labs	O
)	O
;	O
Anti	B
-	I
galactocerebrocide	I
(	O
GC	B
,	O
monoclonal	O
1∶250	O
,	O
Chemicon	O
)	O
;	O
Anti	B
-	I
CNPase	I
(	O
polyclonal	O
1∶200	O
,	O
Aves	O
Labs	O
)	O
;	O
Anti	B
-	I
Glucose	I
Transporter	I
type	I
1	I
(	O
Glut-1	B
polyclonal	O
,	O
1∶500	O
,	O
Chemicon	O
)	O
;	O
Anti	B
-	I
Nestin	I
(	O
polyclonal	O
1∶1000	O
,	O
Chemicon	O
)	O
;	O
Anti	B
-	I
vimentin	I
(	O
monoclonal	O
1∶500	O
,	O
Calbiochem	O
)	O
;	O
Anti-3CB2	B
(	O
monoclonal	O
1∶500	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
Anti	B
-	I
doublecortin	I
(	O
DCX	B
,	O
polyclonal	O
1∶250	O
,	O
SantaCruz	O
Biotechnology	O
)	O
;	O
Anti	B
-	I
Ki67	I
(	O
polyclonal	O
1∶250	O
,	O
SantaCruz	O
Biotechnology	O
)	O
.	O

Fluorescence	O
was	O
detected	O
,	O
analyzed	O
and	O
photographed	O
with	O
a	O
Zeiss	O
LSM550	O
laser	O
scanning	O
confocal	O
photomicroscope	O
.	O

For	O
each	O
animal	O
,	O
quantitative	O
estimates	O
of	O
the	O
total	O
number	O
of	O
grafted	O
cells	O
were	O
stereologically	O
determined	O
using	O
the	O
optical	O
fractionator	O
procedure	O
[	O
50	O
]	O
.	O

A	O
computer	O
-	O
assisted	O
image	O
analysis	O
system	O
was	O
performed	O
using	O
Stereo	O
Investigator	O
software	O
(	O
MicroBrightField	O
,	O
Inc.	O
)	O
.	O

The	O
rostral	O
and	O
caudal	O
limits	O
of	O
the	O
reference	O
volume	O
were	O
determined	O
by	O
first	O
and	O
last	O
frontal	O
sections	O
containing	O
grafted	O
cells	O
.	O

The	O
striatum	O
and	O
cortex	O
were	O
accurately	O
outlined	O
at	O
low	O
magnification	O
(	O
2.5	O
×	O
objective	O
)	O
.	O

The	O
optical	O
fractionator	O
probe	O
was	O
selected	O
to	O
perform	O
systematic	O
sampling	O
of	O
the	O
immunoreactive	O
cell	O
population	O
distributed	O
within	O
the	O
serial	O
sections	O
to	O
estimate	O
the	O
population	O
number	O
in	O
the	O
volume	O
of	O
tissue	O
.	O

The	O
counting	O
frame	O
of	O
the	O
optical	O
fractionator	O
was	O
defined	O
at	O
50	O
×	O
50	O
µm	O
squares	O
and	O
the	O
systematic	O
sampling	O
was	O
performed	O
by	O
translating	O
a	O
grid	O
with	O
200	O
×	O
200	O
µm	O
squares	O
onto	O
the	O
sections	O
of	O
interest	O
using	O
the	O
Stereo	O
Investigator	O
software	O
.	O

The	O
sample	O
sites	O
were	O
systematically	O
and	O
automatically	O
generated	O
by	O
the	O
computer	O
and	O
examined	O
using	O
a	O
60	O
×	O
objective	O
of	O
a	O
Nikon	O
Eclipse	O
TE	O
300	O
microscope	O
.	O

The	O
counting	O
frame	O
displayed	O
inclusion	O
and	O
exclusion	O
lines	O
and	O
only	O
immunoreactive	O
cell	O
bodies	O
falling	O
within	O
the	O
counting	O
frame	O
with	O
no	O
contact	O
with	O
the	O
exclusion	O
lines	O
were	O
counted	O
.	O

The	O
cell	O
dispersion	O
was	O
measured	O
by	O
counting	O
the	O
number	O
of	O
cells	O
within	O
200	O
µm	O
distance	O
from	O
the	O
graft	O
site	O
.	O

The	O
number	O
and	O
distance	O
in	O
µm	O
of	O
cells	O
dispersed	O
beyond	O
200	O
µm	O
was	O
also	O
measured	O
.	O

An	O
average	O
of	O
2,000	O
cells	O
was	O
counted	O
per	O
animal	O
.	O

Double	O
labeling	O
was	O
determined	O
using	O
the	O
confocal	O
laser	O
scanning	O
microscope	O
by	O
random	O
sampling	O
of	O
100	O
or	O
more	O
cells	O
per	O
marker	O
for	O
each	O
animal	O
,	O
scoring	O
first	O
for	O
hNuc+	O
,	O
followed	O
by	O
DAPI+	O
nuclei	O
and	O
then	O
the	O
marker	O
of	O
choice	O
.	O

The	O
double	O
labeling	O
was	O
always	O
confirmed	O
in	O
x	O
-	O
z	O
and	O
y	O
-	O
z	O
cross	O
-	O
sections	O
produced	O
by	O
the	O
orthogonal	O
projections	O
of	O
z	O
-	O
series	O
.	O

Reverse	O
Transcription	O
-	O
Polymerase	B
Chain	O
Reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysisTotal	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
RNAeasy	O
kit	O
(	O
Quiagen	O
)	O
.	O

Aliquots	O
(	O
1	O
µg	O
)	O
of	O
total	O
RNA	O
from	O
the	O
cells	O
were	O
reverse	O
transcribed	O
in	O
the	O
presence	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8.3	O
,	O
75	O
mM	O
KCl	O
,	O
3	O
mM	O
MgCl2	O
,	O
10	O
mM	O
DTT	O
,	O
0.5	O
µM	O
dNTPs	O
,	O
and	O
0.5	O
µg	O
oligo	O
-	O
dT	O
(	O
12–18	O
)	O
with	O
200	O
U	O
Superscript	O
RNase	B
H	O
-	O
Reverse	O
Transcriptase	B
(	O
Invitrogen	O
)	O
.	O

PCR	O
amplification	O
was	O
performed	O
using	O
standard	O
procedure	O
with	O
Taq	O
Polymerase	O
.	O

Aliquots	O
of	O
cDNA	O
equivalent	O
to	O
50	O
ng	O
of	O
total	O
RNA	O
were	O
amplified	O
in	O
25	O
µl	O
reactions	O
containing	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8.3	O
,	O
50	O
mM	O
KCl	O
,	O
1.5	O
mM	O
MgCl2	O
,	O
50	O
pmol	O
of	O
each	O
primer	O
,	O
400	O
µM	O
dNTPs	O
,	O
and	O
0.5	O
U	O
AmpliTaq	O
DNA	O
polymerase	B
(	O
Perkin	O
-	O
Elmer	O
)	O
.	O

PCR	O
was	O
performed	O
using	O
the	O
following	O
thermal	O
profile	O
:	O
4	O
min	O
at	O
94	O
°	O
C	O
;	O
1	O
min	O
at	O
94	O
°	O
C	O
,	O
1	O
min	O
at	O
60	O
°	O
C	O
,	O
1.5	O
min	O
at	O
72	O
°	O
C	O
,	O
for	O
30–40	O
cycles	O
;	O
7	O
min	O
at	O
72	O
°	O
C	O
,	O
and	O
finally	O
a	O
soak	O
at	O
4	O
°	O
C	O
overnight	O
.	O

The	O
following	O
day	O
,	O
10	O
µl	O
aliquots	O
of	O
the	O
amplified	O
products	O
were	O
run	O
on	O
a	O
2	O
%	O
agarose	O
Tris	O
–	O
acetate	O
gel	O
containing	O
0.5	O
mg	O
/	O
ml	O
ethidium	O
bromide	O
.	O

The	O
products	O
were	O
visualized	O
through	O
a	O
UV	O
transilluminator	O
,	O
captured	O
in	O
a	O
digital	O
format	O
using	O
Quantify	O
One	O
Gel	O
Analysis	O
software	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
on	O
a	O
Macintosh	O
G4	O
computer	O
.	O

The	O
PCR	O
primers	O
specific	O
to	O
each	O
transcript	O
were	O
as	O
follows	O
:	O
GFAP	B
,	O
forward	O
(	O
F	O
)	O
,	O
5′-TCATCGCTCAGGAGGTCCTT–3′	O
Reverse	O
(	O
R	O
)	O
,	O
5′-CTG	O
TTGCCAGAGATGGAGGTT–3′	O
;	O
MAP2	B
(	O
F	O
)	O
5′-GAAGACTCGCATCCGAATGG–3′	O
,	O
(	O
R	O
)	O
5′-CGCAGGATAGGAGGAAGAGACT–3′	O
;	O
MBP	B
(	O
F	O
)	O
5′-TTAGCTGAATTC	O
GCGTGTGG–3′	O
,	O
(	O
R	O
)	O
5′-GAGGAAGTGAATGAGCCGGTTA-3′	O
were	O
deigned	O
using	O
the	O
Primer	O
Designer	O
software	O
,	O
Version	O
2.0	O
(	O
Scientific	O
and	O
Educational	O
Software	O
)	O
[	O
48	O
]	O
.	O

18S	O
,	O
β	B
-	I
tubulin	I
class	I
III	I
,	O
N	B
-	I
CAM	I
,	O
Nestin	B
,	O
NF	B
-	I
M	I
,	O
Notch-1	B
primers	O
[	O
51	O
]	O
.	O

Oct4	B
,	O
Nanog	B
primers	O
[	O
11	O
]	O
.	O

FOXa2	B
(	O
HNF3B	B
)	O
,	O
Brachyury	B
primers	O
[	O
52	O
]	O
.	O

Behavioral	O
testsThe	O
cylinder	O
test	O
was	O
used	O
to	O
assess	O
the	O
spontaneous	O
forelimb	O
use	O
during	O
lateral	O
exploration	O
movement	O
[	O
22	O
]	O
.	O

Rats	O
were	O
placed	O
in	O
a	O
transparent	O
acrylic	O
cylinder	O
(	O
20	O
cm	O
diameter	O
)	O
for	O
5	O
minutes	O
.	O

The	O
cylinder	O
encourages	O
use	O
of	O
the	O
forelimbs	O
for	O
vertical	O
exploration	O
.	O

A	O
mirror	O
was	O
placed	O
behind	O
the	O
cylinder	O
so	O
that	O
the	O
forelimbs	O
could	O
be	O
viewed	O
at	O
all	O
times	O
.	O

Testing	O
sessions	O
were	O
videotaped	O
and	O
forelimb	O
use	O
was	O
scored	O
by	O
a	O
blinded	O
operator	O
.	O

Movements	O
scored	O
were	O
the	O
independent	O
use	O
of	O
the	O
left	O
or	O
right	O
forelimb	O
or	O
simultaneous	O
use	O
of	O
both	O
the	O
left	O
and	O
right	O
forelimb	O
to	O
contact	O
the	O
wall	O
of	O
the	O
cylinder	O
during	O
a	O
full	O
rear	O
,	O
to	O
initiate	O
a	O
weight	O
-	O
shifting	O
movement	O
,	O
or	O
to	O
regain	O
center	O
of	O
gravity	O
while	O
moving	O
laterally	O
in	O
a	O
vertical	O
posture	O
along	O
the	O
wall	O
.	O

Animals	O
were	O
tested	O
for	O
their	O
baselines	O
after	O
stroke	O
and	O
4	O
and	O
8	O
weeks	O
after	O
cell	O
transplantation	O
.	O

Statistical	O
analysisOutcome	O
measurement	O
for	O
each	O
experiment	O
was	O
reported	O
as	O
mean±SEM	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
SPSS	O
11	O
for	O
Mac	O
OS	O
X	O
(	O
SPSS	O
Inc.	O
)	O
.	O

Significance	O
of	O
inter	O
-	O
group	O
differences	O
was	O
performed	O
by	O
applying	O
Student	O
's	O
t	O
-	O
test	O
where	O
appropriate	O
.	O

The	O
One	O
-	O
Way	O
ANOVA	O
analysis	O
was	O
used	O
to	O
compare	O
group	O
differences	O
for	O
the	O
forelimb	O
use	O
as	O
the	O
dependant	O
variable	O
and	O
groups	O
as	O
the	O
single	O
independent	O
factor	O
variable	O
.	O

Differences	O
between	O
the	O
groups	O
were	O
determined	O
using	O
Bonferroni	O
's	O
post	O
hoc	O
test	O
.	O

A	O
P	O
-	O
value	O
of	O
less	O
than	O
0.05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

